<SEC-DOCUMENT>0001824293-22-000072.txt : 20220728
<SEC-HEADER>0001824293-22-000072.hdr.sgml : 20220728
<ACCEPTANCE-DATETIME>20220728080931
ACCESSION NUMBER:		0001824293-22-000072
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220728
DATE AS OF CHANGE:		20220728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vallon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		221112889

	BUSINESS ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		(267) 207-3606

	MAIL ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ck0001824293-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:721867bc-d51d-454c-b3fb-8a0d76704c20,g:cae8d22d-48c3-4397-b0dc-0800bb57f504,d:e30945125f3a415bbe965615270c4a49--><html xmlns:ck0001824293="http://www.vallon-pharma.com/20220630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8yOS0xLTEtMS0zNjkyMw_d44f7ac2-ce86-40c2-81a1-aea3f595a575">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8zMC0xLTEtMS0zNjkyMw_c4752bd5-cbb4-476c-a986-f04a0a8a4734">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8zMS0xLTEtMS0zNjkyMw_bd07e1f9-9509-45a9-a949-bd655fa79a2c">2022</ix:nonNumeric><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8zMi0xLTEtMS0zNjkyMw_072d3224-41b0-4dd6-a1df-36f9066489f9">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8zMy0xLTEtMS0zNjkyMw_27a18a90-cd0a-4584-99a9-241d65f79d97">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i5d1d6f87c92b481ea937ff85d6e87f9f_D20210212-20210212" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80Ni9mcmFnOjg2M2E5YmM4YjlhZjQxZDQ4YzJkOWNmOWExYzI0YmI0L3RhYmxlOjZiNDk2NWZjMzY2NjQ5NzViNjg1ZDk5YmNmOWQwMzY5L3RhYmxlcmFuZ2U6NmI0OTY1ZmMzNjY2NDk3NWI2ODVkOTliY2Y5ZDAzNjlfMS0xLTEtMS0zNjkyMw_96722dea-805d-4207-a11e-62f6b4fc3889">0.025</ix:nonFraction><ix:nonNumeric contextRef="ia9e73432cae24ab4a5dc83c76c8492f7_D20200501-20200531" name="ck0001824293:DebtInstrumentPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwOQ_edb548e1-9964-4ef6-b43d-e162b1ecb626">P1Y6M0D</ix:nonNumeric><ix:nonNumeric contextRef="ice04209849fb435087c6298880b82c73_I20210228" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfODc3_ce620793-2d62-41d1-96a6-0936db85ba5c">P5Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjU5MA_51655d27-6cc7-465e-88ec-29ffbd736c95">P5Y0M0D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia748888e0ae4402c88d60ded2bd69c1f_I20220727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic21ef042a65f42cd84ec887387352371_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i583a5a2c244e481ba66f7dc6f13c40d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079314ede70b418f9e9ba2ac7c5dc17c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2646ebad2e449a09c2a23f7f4b2902f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8edcee8e6aa45a886ecb171a5517013_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b8a0466c4e459f8c722280b3aa0ba3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5043d1cb9aa4ad0afdc1e57a5a95b05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea93e9ac49fe43d9968c3859ed8fbb39_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0791b2a535464c1baf8fef76158971f6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766f19785dcf4de695b5b31c95eb7e37_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd798545154744afa1b5cb0b2f8876de_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4286ecd37f9e4199ae2009b495d787cf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie694c1e0398d496e8ff4f5bfd9a9d95b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c70c7cf434e4b159eca07e21e6a26f1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia636262b34cb415b97e286ebf0087ee6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c8fc66bda34fdda3cd8cdcd6aa7d9b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1007e0fefaa48caa07dc52b020bbc3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c3fee39f1e454d815a147897c9a9d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia29e8203a81641caa143914e81fa5c69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac48792fe36b4e3f951e35aa6b257119_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e836fc1382c488eb49632dc1657d7ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7052bea6a0784d678627df7e577857db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5660a1163c6645df91e98942bd4ba421_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7acb50066099476cbdfe2dab9b1494b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88af9cab6ec44e7f8a4858f9b27704df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0fa2bee71040e69ad3ea864aba74f4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if503def97fcc4164b2c30482e4c2e3ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87d5eda3cf4467e82682535649adf7b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148024954fe941968d8a6d77a82f31a9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e3160bd798c4509b1fdac467dda316a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id894f1a76ecf4d0ab0e13230f7aacd9b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11840acdcca142beb43052c03d2ab29b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd4f70e2c0a4a6ea0840d122b9282fd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8810181f854ea093196a63a43e99d5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11a08a59a9e4ec5bd6becb5683b465b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa3e8f48095e4f31a4b2da281a2c6b83_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ad8d775054940af9d6d777eedda4a9f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="participant"><xbrli:measure>ck0001824293:participant</xbrli:measure></xbrli:unit><xbrli:context id="if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-17</xbrli:startDate><xbrli:endDate>2022-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5eb151e1495417d8ba486b11b22f863_I20220517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d1d6f87c92b481ea937ff85d6e87f9f_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e01297c79d4a238d946c1d8debd442_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1400788042d42598868c075e36cdb98_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1a61e394a9a4f539071373e4b182616_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib436207f2f064e7496a902548a58e399_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea4222aa63154f468853a59705ceb961_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eb1020cc8b9465fba60fc2338a0ddbd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide2992c84c8c4cbb9703a725519f2d52_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idca18b35dfc343a5b432e73aa35dda20_I20220517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90be0efda4140d69daac747399be9da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf955fe5e0a47b98dfd6289d141ce48_I20220517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39261bdabc74d02ab32636701f88ceb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e17459f6e1e4ff88e393694f859f76f_I20220517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica45ce9c7f8e4a4e87dccf62ec9002c2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2268668a2bae461fbd550e2afdedd425_I20220517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c3844471a2415d85a493bb7d1b7ac2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5278a1eaa074dd68b78d80ced668ef6_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca03d411a7545b085d0c47f675a493e_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9e73432cae24ab4a5dc83c76c8492f7_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie893c6ea7cb24a70984639ee82d13224_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf794a259e54b3ba3547350cc2f5ef3_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f18e4fe2f154b23845553ce8b36cbdb_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8b39ceb7ad4164be59942fb7614f0e_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa68683166f845408469b50f0a32b3b5_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice04209849fb435087c6298880b82c73_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719a8a8b7ff446c1bc50f1384cc0de4d_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd279f5e1d8444db25b59b0858f2af5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:WarrantsIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62c32d0200843f38b297b12c7bfa449_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:WarrantsIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e6a1c69d574de78299b71070680019_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:WarrantsIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b4169335d1b4ff29a400e3b99a836a9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:WarrantsIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0242ba0cc646728e31b766046dc508_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:Warrants2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d36a3a0df04368aff26ea0900fa228_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:Warrants2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f3a03eb7104bff89df1b804e710cc1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:Warrants2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e5070e0f094b4c8b1e0ca0d774e78a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:Warrants2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45123774c90a4fa1956d091d5604c46c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59279994119f4d8797134a26b83d8c6a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd9cf59fec149d9a8a643a612719e6e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia17f7b4da78d4e7782a9ae81963a8a71_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c84158c8f14fc088ef909f0eca8c58_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e46d5f45e27451c98c012a1bfb2ff79_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013f7d5cc90144bd84a5bfa54b52c3cb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449ba4759b4e4bf4a5e5c917d68f2bf0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ad6bdf33be419586390b0ac7ab0caf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a3cf62c41b4e068c171f0691bb0bfc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8cd952ddab4185bc4626df7276ebda_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf436d7844974b62a61ac61f27616833_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2d5dff312ff4a6dbd81e861d5714df5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed63d6b4295468c963916e8ee547dd7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8129a30fcf84969a1b747ba20407f23_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie30945125f3a415bbe965615270c4a49_1"></div><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDc4_33232c63-1cb5-4db7-9c1e-aab1b804817a">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6NmMwNTM2Yzc4YjNiNDg0ZGJiZGY4Y2Y4NjE3YTBlOGQvdGFibGVyYW5nZTo2YzA1MzZjNzhiM2I0ODRkYmJkZjhjZjg2MTdhMGU4ZF8wLTAtMS0xLTM2OTIz_3bf92c63-24f7-44e1-bcca-13edb4af3abc">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDY_0e99c7b0-a5ef-4dd1-89da-fe1932d24f05">June 30, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6Mjk5OGMwOTc2YTYxNGE1NzhiMDAyY2E0MzM5Nzk1MGMvdGFibGVyYW5nZToyOTk4YzA5NzZhNjE0YTU3OGIwMDJjYTQzMzk3OTUwY18wLTAtMS0xLTM2OTIz_2e051d8a-1325-4fc8-bf7c-804270de9be7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from_________to_________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDg2_31ab8844-50c8-4007-8504-e46f56cdee2b">001-40034</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="text-align:center"><img src="ck0001824293-20220630_g1.jpg" alt="ck0001824293-20220630_g1.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDc2_8de57b6c-51f4-4b8b-874d-479cf026cfe6">VALLON PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8wLTAtMS0xLTM2OTIz_24a07019-d956-466e-b968-f997dd6428d7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8wLTItMS0xLTM2OTIz_baa061d4-4274-410a-9105-9f5e4dc59bb8">82-4369909</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Identification No.)&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfNQ_f14f0f05-e2f1-4af8-be9a-b32110d2086d">100 N. 18th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfOQ_fcaf41fa-b87b-4a6e-b028-96a1de564114">Suite 300</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfMTQ_c1a68c47-cbbf-43a1-91be-94d219e65154">Philadelphia</ix:nonNumeric>, <ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfMTg_9ffce2e1-60c7-47e0-8f49-c8424f63c6e5">PA</ix:nonNumeric>  <ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfMjI_38c27384-a86a-4cf4-8fc4-22c4e62eb630">19103</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl80NjA_ac63ebee-3237-4f19-969d-43425710415b">267</ix:nonNumeric>)-<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDgy_539f258b-3a22-49b8-bfa9-d4c1f50ee578">607-8255</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6YTRlYTFmMDRlN2E4NDY2NDk0Y2Q2NDJiNzUwNjQ4OGUvdGFibGVyYW5nZTphNGVhMWYwNGU3YTg0NjY0OTRjZDY0MmI3NTA2NDg4ZV8xLTAtMS0xLTM2OTIz_6af057df-45e8-4e83-bb58-5945566fadb0">Common Stock, par value $0.0001<br/>per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6YTRlYTFmMDRlN2E4NDY2NDk0Y2Q2NDJiNzUwNjQ4OGUvdGFibGVyYW5nZTphNGVhMWYwNGU3YTg0NjY0OTRjZDY0MmI3NTA2NDg4ZV8xLTItMS0xLTM2OTIz_9e7b8b6a-72c6-494d-946c-f5507a4d127e">VLON</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6YTRlYTFmMDRlN2E4NDY2NDk0Y2Q2NDJiNzUwNjQ4OGUvdGFibGVyYW5nZTphNGVhMWYwNGU3YTg0NjY0OTRjZDY0MmI3NTA2NDg4ZV8xLTQtMS0xLTM2OTIzL3RleHRyZWdpb246ZjE5ZWE5NjQzNDU3NDcxMGEzYWYxNzRmOWE1MDJiNjVfNA_713fe16f-dbf2-4b85-bc70-6f4807dd5adc">The Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDgz_09994677-c217-43f1-ba18-5ce0aa9747f4">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDgw_19deb4c9-f946-428f-a277-4818762698d1">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6OTI4ZGY4ZmQ5ZmEzNDAxN2IzNTIwMjI3NDhkYjQ5NzUvdGFibGVyYW5nZTo5MjhkZjhmZDlmYTM0MDE3YjM1MjAyMjc0OGRiNDk3NV8xLTAtMS0xLTM2OTIz_bcb5c565-302e-4913-a4ae-4a2b57fc3ea5">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6OTI4ZGY4ZmQ5ZmEzNDAxN2IzNTIwMjI3NDhkYjQ5NzUvdGFibGVyYW5nZTo5MjhkZjhmZDlmYTM0MDE3YjM1MjAyMjc0OGRiNDk3NV8xLTMtMS0xLTM2OTIz_12b7ab7f-0a3b-46e5-975b-dc3914f8d453">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6OTI4ZGY4ZmQ5ZmEzNDAxN2IzNTIwMjI3NDhkYjQ5NzUvdGFibGVyYW5nZTo5MjhkZjhmZDlmYTM0MDE3YjM1MjAyMjc0OGRiNDk3NV8yLTEtMS0xLTM2OTIz_447e3a08-7054-4077-9002-faba071dc820">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDc3_f674cacc-c188-4e10-a188-ad7303ceb285">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDg0_feea83aa-ba7d-4646-84a8-1b1099cc6612">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of July 27, 2022, <ix:nonFraction unitRef="shares" contextRef="ia748888e0ae4402c88d60ded2bd69c1f_I20220727" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDE1_9c3cc9e1-e3f7-4402-abba-1a1fd62567f2">10,512,836</ix:nonFraction> shares of the Registrant&#8217;s Common Stock were outstanding.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_7"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_13">PART&#160;I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_19">Balance Sheets as of</a> June&#160;30, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_19"> (unaudited) and </a>December&#160;31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_25">Statements of Operations </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_25">and Comprehensive Loss </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_25">(unaudited) for the three and six months ended </a>June&#160;30, 2022</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_25"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_25">and</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_25"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_28">Statements of Changes in Stockholders&#8217; Equity (Deficit) (unaudited) for the three and six months ended </a>June&#160;30, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_28"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_31">Statements of Cash Flows (unaudited) for the six months ended </a>June&#160;30, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_31"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_34">Notes to Unaudited Interim Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_34">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_76">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_76">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_100">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_100">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_103">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_103">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_106">PART&#160;II. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_106">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_106">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_109">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_109">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_112">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_112">23</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_127">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_127">29</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_130">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie30945125f3a415bbe965615270c4a49_130">31</a></span></div></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_10"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. Some of the statements in the sections captioned &#8220;Part I&#8212;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this Quarterly Report contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, evaluate and complete any strategic alternative that yields value for our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials and non-clinical studies demonstrating safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of initiation of our future clinical trials, and the reporting of data from our completed, current and future preclinical and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the market opportunity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients in the United States who suffer from ADHD or narcolepsy and the number of patients that will enroll in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of our product candidates, including ADMIR;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties, including MEDICE Arzneimittel Putter GmbH &amp; Co. KG (Medice), which is affiliated with one of our principal stockholders, SALMON Pharma GMbH (Salmon Pharma), and represented by one member of our board of directors, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the United States, the European Union, and other geographic territories;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel, and our ability to attract and retain such personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the COVID-19 pandemic on our operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act or a smaller reporting company under the Exchange Act; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain the listing of our common stock on The Nasdaq Capital Market.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. You should refer to the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K for the year ended December&#160;31, 2021 and this Quarterly Report for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. If the forward-looking statements prove to be inaccurate; the inaccuracy may be material. In light of the significant uncertainties in these forward- looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Quarterly Report represents our views as of the date of this Quarterly Report. We anticipate that subsequent events and developments will cause our views to change, however, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein after we distribute this Quarterly Report, whether as a result of any new information, future events or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report includes trademarks and registered trademarks of Vallon Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Quarterly Report may be trademarks or registered trademarks of their respective owners.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report, unless the context requires otherwise, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Vallon Pharmaceuticals, Inc.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_13"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ie30945125f3a415bbe965615270c4a49_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="ie30945125f3a415bbe965615270c4a49_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMy0xLTEtMS0zNjkyMw_ee0a06bc-2ca8-434a-b47e-e3f00c239b38">5,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMy0zLTEtMS0zNjkyMw_9c83d0d1-5c9c-44bb-8703-73046a425a3d">3,702</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNC0xLTEtMS00OTI0NA_f080f595-18f7-4f61-8510-c5c90d9d029a">1,749</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNC0zLTEtMS00OTMzNA_63d07eff-8521-47a0-adac-c0b7344ea3c5">3,808</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNC0xLTEtMS0zNjkyMw_4bda9a65-8123-474e-9424-0833f8fa83fc">868</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNC0zLTEtMS0zNjkyMw_4f01e89f-4c46-4980-82d6-4d4bd1e30379">619</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNS0xLTEtMS0zNjkyMw_8e8fc1af-db9d-4261-b197-6f6687528d37">7,838</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNS0zLTEtMS0zNjkyMw_55fc7b37-2658-4419-9dff-bdaf55586ddb">8,129</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNi0xLTEtMS0zNjkyMw_8bf3b372-db53-4087-984a-c1afc153c156">169</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNi0zLTEtMS0zNjkyMw_94e41cf9-0e33-42d3-841c-99befdaf727d">206</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfOC0xLTEtMS0zNjkyMw_2b6ef3ad-041f-419b-a152-4cdd0c976826">8,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfOC0zLTEtMS0zNjkyMw_9614730b-ee7f-4f10-a94d-20973b4f6b25">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTItMS0xLTEtMzY5MjM_01b4db99-eb61-438f-867a-df38dd13ae73">1,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTItMy0xLTEtMzY5MjM_2accda93-df48-4509-9417-025ceec37de8">918</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTMtMS0xLTEtMzY5MjM_df206b88-28ac-49b8-85e7-58b6fe88d6a6">854</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTMtMy0xLTEtMzY5MjM_cf64551c-89be-46e6-9b6a-b91a3e66020a">1,430</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTQtMS0xLTEtNTEyMTg_19fdbad8-9899-4240-96dc-d6c4df73b8d3">1,554</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTQtMy0xLTEtNTEyMzA_7f83f378-558a-402f-946a-aff9957fb380">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTUtMS0xLTEtMzY5MjM_83da9201-5f86-4a5f-960b-84b3a51f1602">104</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTUtMy0xLTEtMzY5MjM_019dbf32-3f55-441b-942c-dd8b776b99ae">97</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTYtMS0xLTEtMzY5MjM_184e86d2-0a12-4857-8d3c-4d6158ff7548">4,322</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTYtMy0xLTEtMzY5MjM_fdc1d27a-fc6c-43dd-90d0-0d03a03801c5">2,445</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTgtMS0xLTEtMzY5MjM_40a6c6a6-1ece-412a-9c0a-c5c2adbb995d">19</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTgtMy0xLTEtMzY5MjM_3ea328f7-c8fe-476b-ab1f-36a6c2e3ac87">72</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTktMS0xLTEtMzY5MjM_109f6bd8-ea2c-4ca6-a161-d96e5d21bf1c">4,341</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTktMy0xLTEtMzY5MjM_82eeb856-5c47-4a5b-827b-382aa5dfc9c0">2,517</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjEtMS0xLTEtMzY5MjM_423464e2-3bef-48da-9c67-4e3045db016c"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjEtMy0xLTEtMzY5MjM_80b34638-cc00-4620-ae1b-7f0a20a7ae70"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl8xOA_4cbd90aa-3e13-492a-8812-ce528ebb4a06"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl8xOA_f5d77ba4-db2a-4544-89cc-340de3800dce">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl8zMg_768db6a1-baf0-4141-9a50-f24c98271090"><ix:nonFraction unitRef="shares" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl8zMg_c9febb44-e4c9-4b8a-a861-001ccb22d726">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl83MA_28885867-ffca-469c-baed-c3589a0ed996"><ix:nonFraction unitRef="shares" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl83MA_eb96644c-cf23-46a1-9480-aa6fa6584da8">10,512,836</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl83Nw_8b44d120-be29-470b-941b-59ee343a7593"><ix:nonFraction unitRef="shares" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl83Nw_b55255c2-1fe0-4e0b-815d-14cb8664d797">6,812,836</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMS0xLTEtMzY5MjM_ef15aec5-1789-4197-bce9-b6e12d44e17d">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMy0xLTEtMzY5MjM_f4ece2a7-5cdc-4ce5-b35c-95d6e06b40ff">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjUtMS0xLTEtMzY5MjM_1ed85ec9-799a-42aa-a8a4-9b22d2e2b580">29,978</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjUtMy0xLTEtMzY5MjM_0b3d306d-5942-4d66-8047-a63b0720eaa0">27,722</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMS0xLTEtNDkzMzk_17f4263f-da0a-40c6-a427-11dec2537dd9">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMy0xLTEtNDkzNDE_91e51c8f-b5dd-4635-9f9b-013d2e351f20">2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjYtMS0xLTEtMzY5MjM_b4d99177-1c06-4958-a5f1-2bc1ec829e1c">26,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjYtMy0xLTEtMzY5MjM_0474068c-e145-4c89-abeb-f89d369a0635">21,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjctMS0xLTEtMzY5MjM_ec99e11d-3fb9-4513-8da2-8a2df31aa04a">3,666</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjctMy0xLTEtMzY5MjM_6c60076b-a04a-4027-80e5-c382d4b63654">5,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjgtMS0xLTEtMzY5MjM_967e5115-c09e-4c30-a7d4-a38e1044337c">8,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjgtMy0xLTEtMzY5MjM_25e681b2-42e0-444b-aa5f-eff69799437d">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_25"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNS0xLTEtMS0zNjkyMw_0f28b18c-aaf3-40f1-bb86-300c5189557c">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNS0zLTEtMS0zNjkyMw_03378a99-ba33-424f-b90a-891df5ead5ff">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNS01LTEtMS0zNjkyMw_1d5d952c-65db-4a45-83f0-12ec042a9315">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNS03LTEtMS0zNjkyMw_8fbb91e8-f004-4168-9418-de76b4885dd8">2,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNi0xLTEtMS0zNjkyMw_5f770619-d624-41cd-a4b3-00ea84c53384">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNi0zLTEtMS0zNjkyMw_bbc6cec6-4ab5-4782-b2e5-688b1ae134bf">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNi01LTEtMS0zNjkyMw_f66de7bd-e684-4d6d-8654-c2248d708005">2,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNi03LTEtMS0zNjkyMw_e7d0ee69-4325-4d58-9de1-cb42885b9890">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNy0xLTEtMS0zNjkyMw_2290b243-1846-4a43-975d-2c1563e0a28d">1,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNy0zLTEtMS0zNjkyMw_b0471f9c-8f94-480e-af3b-b1b0130ed1df">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNy01LTEtMS0zNjkyMw_ea134772-dea6-4573-8375-2c89dc14b238">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNy03LTEtMS0zNjkyMw_12b9dd82-075f-4fcb-8942-5b67396a8a68">4,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOC0xLTEtMS0zNjkyMw_d7298fb3-9d85-4415-b015-bdf1cc34e0e6">1,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOC0zLTEtMS0zNjkyMw_62203b62-daf0-45dc-a41f-e9123b2b7abb">2,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOC01LTEtMS0zNjkyMw_a9fafd8c-7bc7-4662-a2af-1da919bb050a">4,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOC03LTEtMS0zNjkyMw_0bc8d309-5435-4d41-9c01-a37966f393b1">4,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOS0xLTEtMS0zNjkyMw_12880a22-d15e-43d3-b319-b03a4dbef224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOS0zLTEtMS0zNjkyMw_02a78342-3908-473c-a455-4a09860cec55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOS01LTEtMS0zNjkyMw_fb08e1d8-c431-44ea-a02f-4b870997c413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOS03LTEtMS0zNjkyMw_63a788f1-e2cd-4060-9562-939f9226f01c">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtMS0xLTEtNTE4OTU_36adadd8-6f28-4a74-949b-a60d6e647598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtMy0xLTEtNTE5MDI_d68c86aa-1f37-4054-8e89-436007b4e38d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtNS0xLTEtNTE5MDk_4b0bbcf4-f030-4727-bb96-67cbc764f5c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtNy0xLTEtNTE4ODg_96587cad-1436-46e5-b8aa-bcb42fa91c10">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtMS0xLTEtMzY5MjM_ba9b1066-1575-4540-8bb7-424720977d4c">266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtMy0xLTEtMzY5MjM_8e4ddeee-16c7-4f7b-a159-d907403804fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtNS0xLTEtMzY5MjM_ce1bc13f-38fa-4bc4-8d54-2e1a3ef0d8bc">266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtNy0xLTEtMzY5MjM_8569437c-d316-4c28-9781-673a88405791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTEtMS0xLTEtMzY5MjM_609881a0-6084-4c2e-a805-4a926453023c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTEtMy0xLTEtMzY5MjM_1343d5dd-00bc-4826-8c25-0ce08475412b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTEtNS0xLTEtMzY5MjM_2ba2a49b-fc1e-43ee-87a2-320b9890d407">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTEtNy0xLTEtMzY5MjM_8944602f-dfbf-4d71-896d-1e1862794fb5">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTItMS0xLTEtMzY5MjM_e9d8b3d0-72b9-4703-a3b2-cbf58db5664c">1,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTItMy0xLTEtMzY5MjM_34af30a2-b980-43b1-b92e-8451b1e8a3a7">2,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTItNS0xLTEtMzY5MjM_8bb7b084-93ca-405d-bd2e-9cf36de90058">4,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTItNy0xLTEtMzY5MjM_a5dc26dd-f163-4aa9-b82c-beac21e863e3">4,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Unrealized gain (loss) on investments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMS0xLTEtNDkzNDg_408fe0b9-9fdd-4824-9ecf-1f4fa9e46c22">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMy0xLTEtNDkzNTA_a9d6c1a8-0b3c-4c4f-a10a-e5825eae5202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNS0xLTEtNDkzNTI_f05b4e1d-cff5-4666-a166-c6b28d52c4a9">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNy0xLTEtNDkzNTQ_c62bbb4e-0cf7-4d82-828c-9633142310ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTUtMS0xLTEtNDkzNDg_f507f504-aa78-4dbd-87fc-9294e258ccbf">1,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTUtMy0xLTEtNDkzNTA_b4a7894c-e7dc-431d-b193-1a3dfa858314">2,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTUtNS0xLTEtNDkzNTI_addd6efd-505e-4ed9-a1e3-756cb478e5c7">4,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTUtNy0xLTEtNDkzNTQ_ae3483e2-62df-4a2f-b2eb-763a3ddaafe3">4,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtMS0xLTEtMzY5MjM_17a4fe75-b2ad-4834-8f43-bdf73625332f"><ix:nonFraction unitRef="usdPerShare" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtMS0xLTEtMzY5MjM_94d2dbc2-19d6-4ef6-bd55-6ebd8bc384dd">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtMy0xLTEtMzY5MjM_aeb9b765-ff30-40e9-9cb1-a95a52c911ed"><ix:nonFraction unitRef="usdPerShare" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtMy0xLTEtMzY5MjM_b971f6b2-210c-4b80-a4dc-52f5d623b3ca">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtNS0xLTEtMzY5MjM_223e122e-d097-403e-87e5-1552ac6bbf07"><ix:nonFraction unitRef="usdPerShare" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtNS0xLTEtMzY5MjM_608f6def-940a-4a78-8b9d-b6eb1e4af42d">0.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtNy0xLTEtMzY5MjM_2b2b9fac-ff64-4ae8-b824-82232215eddd"><ix:nonFraction unitRef="usdPerShare" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtNy0xLTEtMzY5MjM_7181ffab-9831-44bf-b047-42e36f91783a">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMS0xLTEtMzY5MjM_6f8be7d2-4224-4b7f-a36f-9f9bbdd2ad6c"><ix:nonFraction unitRef="shares" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMS0xLTEtMzY5MjM_fb4c7b62-b1a7-4663-8adc-67c9f6dba758">8,683,166</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMy0xLTEtMzY5MjM_515c1e8f-4dfe-4ea2-8d12-f9bd3383b17a"><ix:nonFraction unitRef="shares" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMy0xLTEtMzY5MjM_9f1b7b8a-d80e-4aeb-b0d8-984fd630d5c7">6,812,836</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNS0xLTEtMzY5MjM_95ec6be7-6e94-46bc-af45-91b06192000c"><ix:nonFraction unitRef="shares" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNS0xLTEtMzY5MjM_b30f5f4d-94c0-45ac-8fda-617c765a0d1a">7,753,167</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNy0xLTEtMzY5MjM_15357fa2-4ea1-446b-af56-fb9bd9889bda"><ix:nonFraction unitRef="shares" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNy0xLTEtMzY5MjM_f6ace1cd-1cbc-4fef-8624-fe8e6a64719b">6,264,854</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_28"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.016%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity&#160;(Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i583a5a2c244e481ba66f7dc6f13c40d8_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMi0xLTEtMS0zNjkyMw_8031e662-a5d5-4bb6-be23-92486e4200bf">4,506,216</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079314ede70b418f9e9ba2ac7c5dc17c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMi01LTEtMS0zNjkyMw_6393d105-203f-4a8d-b6d2-04e087cc7fb7">11,145</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2646ebad2e449a09c2a23f7f4b2902f_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMi03LTEtMS0zNjkyMw_9d425e88-5c2d-41a0-99b6-77cfa097d88e">12,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8edcee8e6aa45a886ecb171a5517013_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMi05LTEtMS0zNjkyMw_41e20d57-5645-4b97-a208-207b3b4e97c9">1,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMy0xLTEtMS0zNjkyMw_81447719-49ad-4e36-8b09-676b26cae402">54,906</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMy01LTEtMS0zNjkyMw_233c29c6-14af-47ae-ac8b-e76b4b1f6d24">439</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMy05LTEtMS0zNjkyMw_26e7fe5b-6405-4de4-8faa-525f085668a7">439</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for IPO, net of issuance expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNC0xLTEtMS0zNjkyMw_bbd9a9c3-bff8-4ed3-a4b9-a0fc0cef0619">2,250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNC01LTEtMS0zNjkyMw_a6e59cb1-3d47-4972-ac25-7a6d2f17c77f">15,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNC05LTEtMS0zNjkyMw_cfe7875c-7b1c-4df1-8de8-ec12bfbf8a9c">15,104</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNS0xLTEtMS0zNjkyMw_9bd54395-d6dd-41d8-afc9-1975b3511a87">1,714</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNS01LTEtMS0zNjkyMw_c87cf4de-e009-4c68-9c8e-7930634615b7">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNS05LTEtMS0zNjkyMw_032933c8-8257-40b1-859d-956ebda578a0">9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Underwriters Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNi01LTEtMS0zNjkyMw_7db15bee-d806-4a52-aeeb-fdd15495f6cb">399</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNi05LTEtMS0zNjkyMw_0cc30176-2671-4d9a-bcef-5d14c57d53c1">399</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNy01LTEtMS0zNjkyMw_6cc04b59-0c99-4980-ac08-44cf07db6e29">168</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNy05LTEtMS0zNjkyMw_87a499f6-f692-4f3a-844f-7fb9a0022ad6">168</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0b8a0466c4e459f8c722280b3aa0ba3_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOC03LTEtMS0zNjkyMw_c2b7e46d-b2ac-46c6-85c9-f67b9b5c6194">2,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOC05LTEtMS0zNjkyMw_79b7fc77-abe7-4150-ab53-6dd7ca391b29">2,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31,&#160;2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5043d1cb9aa4ad0afdc1e57a5a95b05_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOS0xLTEtMS0zNjkyMw_f60a51b5-d0f1-43bd-bfec-fbb23ea95c35">6,812,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea93e9ac49fe43d9968c3859ed8fbb39_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOS01LTEtMS0zNjkyMw_bbe5f7fe-61e8-47c2-a2bd-6585c613f92d">27,264</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0791b2a535464c1baf8fef76158971f6_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOS03LTEtMS0zNjkyMw_37365d0f-7816-4054-bc2f-27c8c955a659">15,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766f19785dcf4de695b5b31c95eb7e37_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOS05LTEtMS0zNjkyMw_ce1b9316-f9d6-415b-b47f-221aa31834cb">12,027</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd798545154744afa1b5cb0b2f8876de_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTAtNS0xLTEtMzY5MjM_156a3919-56f4-4d62-b88c-4de29b090afa">138</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTAtOS0xLTEtMzY5MjM_a52ad417-4658-4b42-9d68-476f773e9d3b">138</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4286ecd37f9e4199ae2009b495d787cf_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTEtNy0xLTEtMzY5MjM_e8ebecbc-5dea-4228-8b1c-cdad02a700b6">2,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTEtOS0xLTEtMzY5MjM_0852637c-e835-40f8-80d5-b20afc4a04ba">2,312</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie694c1e0398d496e8ff4f5bfd9a9d95b_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTItMS0xLTEtMzY5MjM_2b8cd524-d601-434e-a0d6-552b4b7db109">6,812,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c70c7cf434e4b159eca07e21e6a26f1_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTItNS0xLTEtMzY5MjM_af242a10-66c2-4566-97af-20c52f998cba">27,402</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia636262b34cb415b97e286ebf0087ee6_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTItNy0xLTEtMzY5MjM_67b10cde-cf37-455b-9f45-4fa7d4d62055">17,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c8fc66bda34fdda3cd8cdcd6aa7d9b_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTItOS0xLTEtMzY5MjM_c40ca4a3-a530-498d-9039-c5edc609fd02">9,853</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.016%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1007e0fefaa48caa07dc52b020bbc3b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi0xLTEtMS01MDU1Mg_6284dd48-b6d2-4dca-add2-4f1d2f36bff4">6,812,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1007e0fefaa48caa07dc52b020bbc3b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi0zLTEtMS01NDI3Mg_3588ea1b-d49d-4fce-9631-f9e5eda70967">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c3fee39f1e454d815a147897c9a9d8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi01LTEtMS01MDU2Mw_1d3fc98d-eac4-4899-85fa-0476809262d1">27,722</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia29e8203a81641caa143914e81fa5c69_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi03LTEtMS01MDU3MA_3f93eb31-8d09-4fba-9c25-2c97de5e069b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac48792fe36b4e3f951e35aa6b257119_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi05LTEtMS01MDY4Mw_bfe14dbf-049a-4295-921b-06f5b45620dd">21,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi0xMS0xLTEtNTQyODU_81e86323-c348-446b-8534-6342acce3d64">5,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e836fc1382c488eb49632dc1657d7ea_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMy01LTEtMS01MDY1OA_150e9d4a-c44b-4abe-b6e3-b1294003d43d">181</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7052bea6a0784d678627df7e577857db_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMy0xMS0xLTEtNTQyODU_ecc6b66d-235b-47c8-a6e9-f44ebb5bc752">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5660a1163c6645df91e98942bd4ba421_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNC03LTEtMS01MDY3Ng_a1154917-3266-46dc-a805-4bede92ffbf2">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7052bea6a0784d678627df7e577857db_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNC0xMS0xLTEtNTQyOTU_9846f096-5dcb-4061-b5a6-fe89501893b3">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7acb50066099476cbdfe2dab9b1494b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNS05LTEtMS01MDY4MA_867442cb-ea2f-4b39-bc75-aa7daf584162">2,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7052bea6a0784d678627df7e577857db_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNS0xMS0xLTEtNTQyOTU_81d1df73-e4c9-4c7f-98d8-3907d2cc4c09">2,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88af9cab6ec44e7f8a4858f9b27704df_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi0xLTEtMS01NDI2Ng_c7c1d9c0-d4b5-4c1a-827c-c2870de113fe">6,812,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88af9cab6ec44e7f8a4858f9b27704df_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi0zLTEtMS01NDI3Ng_2d4d39c8-720e-48b5-8ba6-f78e962cae00">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0fa2bee71040e69ad3ea864aba74f4_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi01LTEtMS01NDI3OQ_ea6c271e-c3eb-4b5e-9336-7d7dda158cc4">27,903</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if503def97fcc4164b2c30482e4c2e3ef_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi03LTEtMS01NDMwMg_14ab6003-7ad5-4112-b9ea-ad66deb95c27">6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id87d5eda3cf4467e82682535649adf7b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi05LTEtMS01NDMwMA_3338e5f4-a282-4d3f-82e2-2a7f234483a1">24,537</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148024954fe941968d8a6d77a82f31a9_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi0xMS0xLTEtNTQyOTc_66307375-2a67-4345-a3a3-9d885e4fbad7">3,360</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e3160bd798c4509b1fdac467dda316a_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNy0xLTEtMS01MDczMg_feac8e24-ad12-4096-9de3-4546ee493d3b">3,700,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3160bd798c4509b1fdac467dda316a_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNy0zLTEtMS01MDczOQ_2c6b18bd-b0de-4f20-9321-b3326b0975d4">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id894f1a76ecf4d0ab0e13230f7aacd9b_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNy01LTEtMS01MDc0Ng_d9b7eefa-6742-49b5-8aab-9ee707d3772c">2,160</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNy0xMS0xLTEtNTQyOTc_663c5700-b5fa-416d-b860-a47bcd9f6444">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id894f1a76ecf4d0ab0e13230f7aacd9b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfOC01LTEtMS01MDc0Ng_62144656-35bb-4566-908e-44059e26b3d4">85</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfOC0xMS0xLTEtNTQyOTc_2d9cf181-53e1-4855-9e8e-7cbac8994e47">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11840acdcca142beb43052c03d2ab29b_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfOS03LTEtMS01MDc2MA_2a329c41-49e3-48b5-a5e1-f4c15c0636e8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfOS0xMS0xLTEtNTQyOTc_a3499817-c36e-4e96-9aff-3dbd10497ce7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cd4f70e2c0a4a6ea0840d122b9282fd_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTAtOS0xLTEtNTA3NTM_faa34071-6b76-4578-9ca5-e64bb9cf2e47">1,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTAtMTEtMS0xLTU0Mjk3_0a77ac41-f152-45b0-a379-55d240c8c7cb">1,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8810181f854ea093196a63a43e99d5_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtMS0xLTEtNTQyNzA_942b6d2c-a3f9-446d-b912-4aa25d204009">10,512,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8810181f854ea093196a63a43e99d5_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtMy0xLTEtNTQyNzQ_6f47e8f8-5e1d-4642-9c03-2de8455cb079">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11a08a59a9e4ec5bd6becb5683b465b_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtNS0xLTEtNTQyODM_3409d2ac-fd7a-47c8-ba3c-ec083b859712">29,978</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3e8f48095e4f31a4b2da281a2c6b83_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtNy0xLTEtNTQzMDU_e403e9a0-a3f9-406f-b088-86123fc2ea44">3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ad8d775054940af9d6d777eedda4a9f_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtOS0xLTEtNTQzMTA_e0dfee57-d103-4f27-98e6-ec35c036f63d">26,310</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtMTEtMS0xLTU0Mjk3_457e2214-a37d-447c-8f8b-56a3097cffa3">3,666</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_31"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMy0xLTEtMS0zNjkyMw_489d1c38-0f63-445e-9155-4b95fe3668ed">4,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMy0zLTEtMS0zNjkyMw_e92c55da-ced6-41d6-a288-78047f34f5e0">4,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of finance lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNS0xLTEtMS0zNjkyMw_66140884-bf80-49ac-9ad9-2e8717202851">37</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNS0zLTEtMS0zNjkyMw_b5ef39b0-17ee-420b-8f51-e2cf20831351">36</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of marketable securities premiums</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNi0xLTEtMS00OTM2Ng_f6048cb1-298f-4c8e-b67c-46c7e9e8042c">27</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNi0zLTEtMS00OTM2OA_8afa95e5-355c-4261-a404-fa11d570728d">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNi0xLTEtMS0zNjkyMw_0eddcd72-200c-4d6f-83ee-f23e3acb3b67">96</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNi0zLTEtMS0zNjkyMw_f5fac545-11ec-4089-b190-22bbf23e5a39">306</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOC0xLTEtMS01MTk3Ng_098c3daa-f805-4b11-bf61-5d2b4fa31031">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOC0zLTEtMS01MTk4Mw_e1cf2b72-ba5f-42e5-9d7b-905eed3e7fa8">89</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOC0xLTEtMS01MTU1Mw_439484de-1040-423a-959f-9cd110c41cda">266</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOC0zLTEtMS01MTU1OA_1d93a835-8513-4f21-85ef-43070637af54">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forgiveness of PPP note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTAtMS0xLTEtNTE5OTI_9559f090-84ed-42b5-be48-02003c889b0d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTAtMy0xLTEtNTE5OTc_274ce060-bf8c-41ee-aa59-dc8981ed09e2">61</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest, depreciation and other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOS0xLTEtMS0zNjkyMw_bf1d65bc-6a44-40cc-a292-1584e39cfb30">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOS0zLTEtMS0zNjkyMw_99c474fc-836d-4144-a6c3-a8fe7fc79fa6">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTEtMS0xLTEtMzY5MjM_6c66f655-1bb6-4b21-87ad-685b9ddc8a59">246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTEtMy0xLTEtMzY5MjM_cbafcffd-d632-473c-b854-e625f5f78258">379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTItMS0xLTEtMzY5MjM_8d395a29-1cd0-47e3-85da-2ca51dc46c71">892</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTItMy0xLTEtMzY5MjM_74460863-572a-4eae-bd95-567883bde912">330</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTMtMS0xLTEtMzY5MjM_04e5267c-05d1-4f5b-b867-a71796aee576">576</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTMtMy0xLTEtMzY5MjM_38ec0fe1-37db-4f40-aff8-42df34f46c98">153</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTQtMS0xLTEtMzY5MjM_2640044a-8295-4973-ba41-7a65d1f269c6">3,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTQtMy0xLTEtMzY5MjM_e92187dc-c99c-4f95-8664-9c83ca51fc5f">5,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTktMS0xLTEtNTQzNTc_afd7e66f-4f0a-4835-bdda-6f31ed86a762">492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTktMy0xLTEtNTQzNjQ_09d36d8c-3e85-42a9-884b-72cc0c2d5892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTgtMS0xLTEtNDkzNzM_920f6cc8-5e36-4bee-946a-c65fedd57c37">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTgtMy0xLTEtNDkzNzY_7ae88b35-4593-4443-85de-ec72b45cf9e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTgtMS0xLTEtMzY5MjM_8bcd7e95-4237-43c0-b322-c4cdcab19a84">2,030</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTgtMy0xLTEtMzY5MjM_3280bf1f-b392-4d0c-bd4c-96f087cf720b">&#8212;</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock and warrants, net of offering expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="ck0001824293:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjItMS0xLTEtMzY5MjM_8bd22843-2ac5-4c02-ae0e-623311448c67">3,447</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="ck0001824293:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjItMy0xLTEtMzY5MjM_1921dd37-e056-4742-a868-aeffac33c97a">15,503</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjQtMS0xLTEtNTIwMTg_970c8c19-98cb-48fe-9bc3-a61bc4ceee02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjQtMy0xLTEtNTIwMjM_a623a83e-74c9-44ec-9810-7ac0bf20c2e5">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjQtMS0xLTEtMzY5MjM_dd2f31a3-4271-41b6-8c41-fe10bbeb1329">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjQtMy0xLTEtMzY5MjM_3009c09c-40d4-43a7-b26a-626a6a02dc5d">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjUtMS0xLTEtMzY5MjM_a128059d-257e-4128-bf58-9ca449519e2d">3,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjUtMy0xLTEtMzY5MjM_36d618d6-6932-48cf-b956-7dced7c5b18a">15,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjctMS0xLTEtMzY5MjM_86e49aa5-3f37-408b-a55b-8908cb0e3be7">1,519</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjctMy0xLTEtMzY5MjM_886ad19c-bfbf-43db-a3f4-25729dfc755d">10,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjgtMS0xLTEtMzY5MjM_f2498b63-faa4-428c-a641-9246c8dd18ed">3,702</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8edcee8e6aa45a886ecb171a5517013_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjgtMy0xLTEtMzY5MjM_81ff64cf-3bff-4d59-91a6-7af3a6d700e5">109</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjktMS0xLTEtMzY5MjM_26b91b74-8191-4f63-a73d-1bdb6edb7a34">5,221</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c8fc66bda34fdda3cd8cdcd6aa7d9b_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjktMy0xLTEtMzY5MjM_edf0bcb3-4193-4cc5-b81f-f69a3212a713">10,460</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flows information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of convertible notes to common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMzItMS0xLTEtMzY5MjM_a784b47a-c450-4765-bbb5-36b6fd5b1557">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMzItMy0xLTEtMzY5MjM_255ad83c-e0cd-4603-bcf5-e7d0b467299c">350</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_34"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div id="ie30945125f3a415bbe965615270c4a49_37"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zNy9mcmFnOjEwYjQwOWY3ZDJiZTRmNzBhNzBmZmM3ZTE5NGY2MTA4L3RleHRyZWdpb246MTBiNDA5ZjdkMmJlNGY3MGE3MGZmYzdlMTk0ZjYxMDhfMjI0Ng_64c616e8-350a-4a5c-9845-26aee3fc575e" continuedAt="ic0f849bef8e64134a5925a963c5929bf" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="ic0f849bef8e64134a5925a963c5929bf"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#8217;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In March 2022, the Company announced that its SEAL study for ADAIR did not reach its primary endpoint, and there is no assurance that ADAIR will receive approval by the U.S. Food and Drug Administration (the FDA). In addition to ADAIR, the Company completed formulation development work and selected the final formulation of its second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tudy to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">buse </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), was the Company&#8217;s pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the FDA. The SEAL study enrolled <ix:nonFraction unitRef="participant" contextRef="i148024954fe941968d8a6d77a82f31a9_I20220331" decimals="INF" name="ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zNy9mcmFnOjEwYjQwOWY3ZDJiZTRmNzBhNzBmZmM3ZTE5NGY2MTA4L3RleHRyZWdpb246MTBiNDA5ZjdkMmJlNGY3MGE3MGZmYzdlMTk0ZjYxMDhfMTA5OTUxMTYzNTM4Mw_e72d3ed5-a147-4b44-8d21-96da0a1ee61a">55</ix:nonFraction> subjects, of whom <ix:nonFraction unitRef="participant" contextRef="i148024954fe941968d8a6d77a82f31a9_I20220331" decimals="INF" name="ck0001824293:ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zNy9mcmFnOjEwYjQwOWY3ZDJiZTRmNzBhNzBmZmM3ZTE5NGY2MTA4L3RleHRyZWdpb246MTBiNDA5ZjdkMmJlNGY3MGE3MGZmYzdlMTk0ZjYxMDhfMTA5OTUxMTYzNTM2OQ_d3efdbfa-a1a4-403e-bd3a-92a6d7efe432">53</ix:nonFraction> completed the study and <ix:nonFraction unitRef="participant" contextRef="i148024954fe941968d8a6d77a82f31a9_I20220331" decimals="INF" name="ck0001824293:ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zNy9mcmFnOjEwYjQwOWY3ZDJiZTRmNzBhNzBmZmM3ZTE5NGY2MTA4L3RleHRyZWdpb246MTBiNDA5ZjdkMmJlNGY3MGE3MGZmYzdlMTk0ZjYxMDhfMTA5OTUxMTYzNTM3Ng_7b54550f-79f7-414c-9289-fefb56637139">52</ix:nonFraction> were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study did not meet its primary endpoint, which was E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking. ADAIR scored similarly to what was observed in an earlier proof-of-concept study, however, reference dextroamphetamine did not score as high as expected and as seen in the previous study, thus driving the lack of statistical significance. The SEAL study did meet all pharmacodynamic secondary endpoints including Overall Drug Liking and willingness to Take Drug Again at 12 and 24 hours post-dosing, demonstrating statistical significance.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is continuing to assess the best path forward for the ADAIR and ADMIR development programs. In addition, the Company has engaged Ladenburg Thalmann &amp; Co. Inc. (Ladenburg) to evaluate its strategic alternatives with the goal of maximizing stockholder value. Ladenburg has been engaged to advise the Company on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. In the meantime, and in conjunction with the exploration of strategic alternatives, the Company is streamlining its operations in order to preserve its capital and cash resources.</span></div></ix:continuation><div id="ie30945125f3a415bbe965615270c4a49_40"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMjMxNA_d2d03f72-9975-4f07-b48c-c50f86024e4d" continuedAt="ie48b6607f0764fcfb1635044601715ce" escape="true">LIQUIDITY</ix:nonNumeric></span></div><ix:continuation id="ie48b6607f0764fcfb1635044601715ce" continuedAt="i9a9f62c3d1d34d69884867d80c1035df"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred an accumulated deficit of  $<ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfNDY4_322c64da-1dc6-4837-8c3b-937a153b2b66">26,310</ix:nonFraction> through June&#160;30, 2022. The Company has financed its working capital requirements to date through the issuance of common stock, warrants, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company completed a $<ix:nonFraction unitRef="usd" contextRef="if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfNzQ2_4b1c65d7-9f0c-43de-a965-89fc831d5fed">350</ix:nonFraction> convertible note financing and in February 2021, the Company completed the initial public offering (IPO), raising net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfODQy_1f4fce47-9f09-4fdc-ad29-e8c8798f3ed1">15,500</ix:nonFraction>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2022, the Company entered into a Securities Purchase Agreement with certain investors (the Securities Purchase Agreement) for the sale of up to <ix:nonFraction unitRef="shares" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE1NQ_6bd7fd64-af96-46f0-954b-07b88bff931d">3,700,000</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE1OQ_7f1b2fcb-e1b3-4d15-9f2b-9eb78e85c5c0">0.0001</ix:nonFraction> per share (the Shares), at a </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><ix:continuation id="i9a9f62c3d1d34d69884867d80c1035df"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE2NQ_9b31483e-bb72-4752-b7e8-d96802a276b7">1.0632</ix:nonFraction> per Share in a registered direct offering (the Offering). In a concurrent private placement also pursuant to the Securities Purchase Agreement (the Private Placement), for each Share of common stock purchased by an investor, such investor was entitled receive from the Company an unregistered warrant (the Warrant and, together with the Shares, the Securities) to purchase one Share of common stock. The gross proceeds from the Offering and Private Placement were approximately $<ix:nonFraction unitRef="usd" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE3MQ_ec6e70ad-bb36-4534-8670-7ffa7051a0fe">3,900</ix:nonFraction>, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE1MA_e7e49937-de99-4df4-9656-00f746544549">572</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="-3" name="ck0001824293:WarrantsIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjM0Nw_8defe780-a107-4821-913b-8951d1a2b713">85</ix:nonFraction> related to the warrants was expensed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2022, the Company had cash, cash equivalents and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjA5Mw_dce1bcba-78ca-46f3-a297-80a742165acc">6,970</ix:nonFraction>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to incur ongoing expenses as it evaluates its plans for the ADAIR and ADMIR programs and strategic alternatives after it announced in March 2022 that the SEAL study of ADAIR for the treatment of ADHD failed to meet statistical significance for its primary endpoint. The Company is currently assessing the best path forward for the ADAIR and ADMIR programs and has no other product candidates undergoing clinical trials. The Company&#8217;s future capital requirements are difficult to forecast and will depend on many factors, including but not limited to the terms and timing of any strategic alternatives including a merger or business combination, asset acquisitions or sales, collaborations or licensing arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing may impose upon it covenants that restrict our operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase its common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to the Company or its stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license to other parties&#8217; rights to develop or commercialize its drug candidates that it would prefer to retain. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company expects to continue to incur expenses and operating losses at least for the foreseeable future as it evaluates future plans for the ADAIR and ADMIR programs as well as its strategic alternatives.</span></div></ix:continuation><div id="ie30945125f3a415bbe965615270c4a49_43"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4Mg_2d491325-eb3b-4351-94e7-d855f66ffe03" continuedAt="i36211a5c6b624e49bf531de763c961ba" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i36211a5c6b624e49bf531de763c961ba" continuedAt="i08adcfc0588343238c8c040e14459027"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4Mw_0309be64-8460-4246-85b7-5fd32fe80a3f" escape="true">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements.</ix:nonNumeric> </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2022, and the results of operations and stockholders&#8217; equity (deficit) for the three and six months ended June&#160;30, 2022 and 2021 and cash flows for the six months ended June&#160;30, 2022 and 2021. Results of operations for the three and six months ended June&#160;30, 2022, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the IPO (Note 7), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4NA_812450d8-f270-4a55-9dd0-02ecd961c6cb" continuedAt="if715a2c84b79469080d35b5a5d2bb570" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made </span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><ix:continuation id="i08adcfc0588343238c8c040e14459027"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if715a2c84b79469080d35b5a5d2bb570">in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</ix:continuation> </span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfMjE5OTAyMzI2MzcxMw_284950f3-cc62-40c0-85ab-d6a5fd0ef094" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfMzI5ODUzNDg5NjYyNQ_cd4d92f0-789f-4ca0-9a5b-2b3aaa755d45" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the warrants issued in connection with the May 2022 registered direct financing (Note 7) in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the Balance Sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with changes in fair value recognized in the Statements of Operations and Comprehensive Loss in the period of change.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4NQ_f7cb588d-c576-41c1-a8df-c2f1ff86a127" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4MQ_e0025f0b-904a-4ac3-ba6e-e9d9920c77a2" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_543"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzIxOTkwMjMyNTc5NTQ_55890182-623c-4198-9ea7-0240ac78005c" continuedAt="ic7fa0494d46748cdade6dbb11760d09d" escape="true">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ic7fa0494d46748cdade6dbb11760d09d" continuedAt="i4ffaecfc5703434e8990a2739ce8d777"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities </span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzIxOTkwMjMyNTc5NTU_36ad1d9d-856e-4fff-9c65-ecfb9cc64747" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale securities as of the dates indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzUtMS0xLTEtNDk0MzA_23a3f068-2728-4e2c-9f88-cacd22759cb9">1,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzUtMy0xLTEtNDk0Mzg_f34be430-477c-4c46-9d38-36254ed46c58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzUtNS0xLTEtNDk0MzQ_9cabc06b-d0e6-4049-9133-c88eeb07477c">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzUtNy0xLTEtNDk0MzY_a2e2b006-5e3c-41f4-84f9-85ddadf88bf6">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzYtMS0xLTEtNDk0MzA_cff05ccc-3104-4256-888d-b8c8f0a3682b">1,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzYtMy0xLTEtNDk0MzI_3c8504a1-8745-49da-9e24-0d3aa59314d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzYtNS0xLTEtNDk0MzQ_b33d2126-562a-4eb2-ae17-98fb90818557">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzYtNy0xLTEtNDk0MzY_955c8026-06b7-4479-95c3-1c1fa3a56547">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e01297c79d4a238d946c1d8debd442_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzQtMS0xLTEtNDk0NDI_ba7429f0-ef4e-45ae-a44d-7d48206f7b4b">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e01297c79d4a238d946c1d8debd442_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzQtMy0xLTEtNDk0NDQ_2eccd419-a57d-4e3b-96e9-6b2bff3e9fce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e01297c79d4a238d946c1d8debd442_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzQtNS0xLTEtNDk0NDY_51103515-008d-43a9-9d82-21827129e059">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e01297c79d4a238d946c1d8debd442_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzQtNy0xLTEtNDk0NDg_cf74c75b-5916-4247-a13a-abad509d3e6e">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzUtMS0xLTEtNDk0NDI_7677a3a4-fd2e-4281-8d2f-91fa1688188b">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzUtMy0xLTEtNDk0NDQ_fdb3418a-eb4a-4827-9082-c6d42611dead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzUtNS0xLTEtNDk0NDY_e088a793-66f4-4125-a2ee-84aff6c20c23">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzUtNy0xLTEtNDk0NDg_be6a6600-54ff-444c-80eb-a72f7a6a1f3e">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzYtMS0xLTEtNDk0NDI_d0cd1c28-ac53-4214-bf2f-0eafef1db6ca">3,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzYtMy0xLTEtNDk0NDQ_5abb2b0e-f44b-4516-82aa-f4d5d9c1256e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzYtNS0xLTEtNDk0NDY_25ff1d26-50af-4333-be34-040e56170e88">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzYtNy0xLTEtNDk0NDg_cb3b10be-bed3-49ee-a400-b65c62e805ab">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company&#8217;s financial instruments included cash and cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses, and the warrant liability. The carrying amounts reported in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2NTk_73fb2431-3e41-4a58-8747-1d3e7eb9f0d6" continuedAt="i81f1421f8ef042bd80552b30cdc9504a" escape="true">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at June&#160;30, 2022:</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><ix:continuation id="i4ffaecfc5703434e8990a2739ce8d777" continuedAt="i2c60a8a5b787442d821358604bd68a22"><div><ix:continuation id="i81f1421f8ef042bd80552b30cdc9504a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1400788042d42598868c075e36cdb98_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzItMi0xLTEtNTE0Njk_393364ec-87e7-42cf-b8e1-05fdcac48855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a61e394a9a4f539071373e4b182616_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzItNC0xLTEtNTE1MDI_db59fcc7-11a6-498b-9aae-f1caf63736b1">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib436207f2f064e7496a902548a58e399_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzItNi0xLTEtNTE0ODg_3d67509b-d474-42d5-a545-880b0905413c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1400788042d42598868c075e36cdb98_I20220630" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzQtMi0xLTEtNTE0NzY_b6e96a7a-6886-495f-b8a3-8062c43f751c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a61e394a9a4f539071373e4b182616_I20220630" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzQtNC0xLTEtNTE1MDk_0af41371-a4d6-4637-a1ec-d9e1a11fb1df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib436207f2f064e7496a902548a58e399_I20220630" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzQtNi0xLTEtNTE0OTU_5b40cc09-35b0-40f3-bca6-834a2ccfcddc">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2MzI_1ccd6fd3-996f-4d17-accc-01b59753b432">3,700,000</ix:nonFraction> shares of common stock pursuant to a securities purchase agreement at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2NTE_b8a013b1-733e-4a2a-b386-24edbcd30621">1.0632</ix:nonFraction> per share in a registered direct offering (Note 7). In connection with the registered direct offering, the Company issued warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzE2NDkyNjc0NDc2MTI_98412202-f526-4872-8aa8-d3ce15c2fcde">3,700,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzE2NDkyNjc0NDc2NjM_69f37f79-9b35-442f-8dd0-932e940d9562">0.9382</ix:nonFraction> per share.  The warrants were classified as a liability in accordance with ASC 815-40 and the fair value of $<ix:nonFraction unitRef="usd" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzE2NDkyNjc0NDc4Mjc_fdf66048-235f-410c-9e5c-0a447b3119aa">1,554</ix:nonFraction> is reflected in warrant liability on the Balance Sheet. The warrant liability was  measured at fair value at inception and is revalued at each financial statement date, with changes in fair value presented within change in fair value of warrant liability in the Statement of Operations and Comprehensive Loss.</span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2MjA_bdcf783b-e709-4cb0-b4db-5d66cd70d2f2" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4222aa63154f468853a59705ceb961_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpkMjc2N2RkMmM4ZDU0NGJmOGQzYTlhMDkwY2I4ZTg4OC90YWJsZXJhbmdlOmQyNzY3ZGQyYzhkNTQ0YmY4ZDNhOWEwOTBjYjhlODg4XzEtMi0xLTEtNTQ0MjM_191d8602-f36c-4056-a545-278687b16389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial measurement on May 17, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1020cc8b9465fba60fc2338a0ddbd_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpkMjc2N2RkMmM4ZDU0NGJmOGQzYTlhMDkwY2I4ZTg4OC90YWJsZXJhbmdlOmQyNzY3ZGQyYzhkNTQ0YmY4ZDNhOWEwOTBjYjhlODg4XzItMi0xLTEtNTQ0MzU_2eda034e-e590-4d44-837d-f831d21261a5">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1020cc8b9465fba60fc2338a0ddbd_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpkMjc2N2RkMmM4ZDU0NGJmOGQzYTlhMDkwY2I4ZTg4OC90YWJsZXJhbmdlOmQyNzY3ZGQyYzhkNTQ0YmY4ZDNhOWEwOTBjYjhlODg4XzMtMi0xLTEtNTQ0MzU_edb490bb-0b3f-4b3d-ad9d-10f356360bbd">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide2992c84c8c4cbb9703a725519f2d52_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpkMjc2N2RkMmM4ZDU0NGJmOGQzYTlhMDkwY2I4ZTg4OC90YWJsZXJhbmdlOmQyNzY3ZGQyYzhkNTQ0YmY4ZDNhOWEwOTBjYjhlODg4XzQtMi0xLTEtNTQ0MzU_c3e8efda-87f3-4c32-9b78-640fe75c3271">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2NjA_35aec96b-4bcd-43bd-b283-95d56932d5d3" continuedAt="icaf0230ccd4943278edebf862762e317" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Initial Measurement)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">May 17, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idca18b35dfc343a5b432e73aa35dda20_I20220517" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzItMS0xLTEtNTE3NDg_0b5e67b0-12bd-47f9-8fa3-3e2c3c5779bd">130.8</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic90be0efda4140d69daac747399be9da_I20220630" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzItMy0xLTEtNTE3NjA_11574b5e-d79b-4545-be59-073c5df1d870">132.3</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cf955fe5e0a47b98dfd6289d141ce48_I20220517" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzMtMS0xLTEtNTE3NDg_6dbe055d-159f-4d6e-b4f3-6c1f9ce54ceb">2.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic39261bdabc74d02ab32636701f88ceb_I20220630" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzMtMy0xLTEtNTE3NjA_d794e299-b77e-4385-a2d2-9caeb507bbce">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e17459f6e1e4ff88e393694f859f76f_I20220517" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzQtMS0xLTEtNTE3NDg_4cabf4d0-0608-4050-bce6-d5488fa0c16c">0.0</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica45ce9c7f8e4a4e87dccf62ec9002c2_I20220630" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzQtMy0xLTEtNTE3NjA_babb8a52-eeae-4dfb-8f40-fb68598c9d48">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2268668a2bae461fbd550e2afdedd425_I20220517" decimals="5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzUtMS0xLTEtNTE3NDg_51a547b3-abe1-4db4-b934-50fbd1206aa7">2.665</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3c3844471a2415d85a493bb7d1b7ac2_I20220630" decimals="5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzUtMy0xLTEtNTE3NjA_86d1f7d3-ff70-40f6-a611-88379c07ff37">2.955</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes (Note 6)  was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id5278a1eaa074dd68b78d80ced668ef6_I20210212" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzEwOTk1MTE2Mjk3OTk_f5224c0b-35f3-444f-9e3b-4875466a700a">8.00</ix:nonFraction> per share upon closing of the IPO. As such, an expense of $<ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzEwOTk1MTE2Mjk4NjE_3ea6dd9f-332c-4c7f-be8d-0fd1e661c964">89</ix:nonFraction> was recorded during the six months ended June&#160;30, 2021.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><ix:continuation id="i2c60a8a5b787442d821358604bd68a22"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzIxOTkwMjMyNTc5NTY_e0e7dde0-2270-49ff-9894-4d68d7316ac8" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our investments in marketable debt securities with stated contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"></td><td style="width:84.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzEtMi0xLTEtNDg5OTY_39b4779e-5af9-4b17-be4d-aa6825d3a8db">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1-5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzItMi0xLTEtNDg5OTY_dff789d6-588d-4020-a28a-cadeb2e66c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 5-10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzMtMi0xLTEtNDg5OTY_f7a841c9-a1e5-49db-8e64-405957b44807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after 10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzQtMi0xLTEtNDg5OTY_7ab4671a-515e-4190-8374-aad28b4c11e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzUtMi0xLTEtNDk0NTI_79f25298-1b60-425a-8b80-e20116512bbf">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie30945125f3a415bbe965615270c4a49_49"></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RleHRyZWdpb246NTJmNGI1ZGQ0YTgyNGI5YTliMmQwYjQ2MTQ2ZWI5NmZfNjg_2b98b27e-8bdd-46d7-980f-b561f4c65f64" continuedAt="ief1369e511d64e52822976aba6a41ffe" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="ief1369e511d64e52822976aba6a41ffe"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RleHRyZWdpb246NTJmNGI1ZGQ0YTgyNGI5YTliMmQwYjQ2MTQ2ZWI5NmZfNjk_08d344a6-9efa-4a8d-9c86-901692baa2d9" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMS0xLTEtMS0zNjkyMw_54346dd8-888d-4c36-b360-6a662ca38097">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMS0zLTEtMS0zNjkyMw_32904f2e-0986-4735-a9a5-0b3bfe442420">894</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMi0xLTEtMS0zNjkyMw_5d6d0d4d-9138-4fed-9b24-ba9311399dab">56</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMi0zLTEtMS0zNjkyMw_5fe4d01d-281b-4560-b444-c22edd6e5df4">183</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMy0xLTEtMS0zNjkyMw_80681d32-1b1d-4eb5-8806-2552f3c98980">277</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMy0zLTEtMS0zNjkyMw_ba9a33f2-db93-407b-a1be-9e66e0865c45">291</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="ck0001824293:AccruedLicensingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfNC0xLTEtMS0zNjkyMw_c1281ac1-268e-4fc6-b284-5a37d8a47510">52</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="ck0001824293:AccruedLicensingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfNC0zLTEtMS0zNjkyMw_b583648b-7c91-4ef3-8ac0-b119996f8b8a">62</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfNi0xLTEtMS0zNjkyMw_7add1060-16b2-40ac-ae8e-e9e0d0f1b50a">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfNi0zLTEtMS0zNjkyMw_3e6ac3a9-7603-472b-88d4-dc13b5a05977">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie30945125f3a415bbe965615270c4a49_52"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwNQ_c9923408-0f70-401a-a607-e5a33663d494" continuedAt="i67eabb5461d1409499f281b30078e22d" escape="true">PPP NOTE AND CONVERTIBLE NOTES</ix:nonNumeric></span></div><ix:continuation id="i67eabb5461d1409499f281b30078e22d"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $<ix:nonFraction unitRef="usd" contextRef="ibca03d411a7545b085d0c47f675a493e_I20200531" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTIx_99c5edac-bd1e-4afb-9677-a6ad9d79f979">61</ix:nonFraction>. The PPP Note had a stated interest rate of <ix:nonFraction unitRef="number" contextRef="ibca03d411a7545b085d0c47f675a493e_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTY4_836779c7-6cd9-4caf-9662-41c09399d530">1</ix:nonFraction>% and had a <ix:nonNumeric contextRef="ia9e73432cae24ab4a5dc83c76c8492f7_D20200501-20200531" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwNg_4609f82c-9adc-4e02-b389-9bda0f6bbf6b">two-year</ix:nonNumeric> maturity. Payments were required to be made over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwOQ_edb548e1-9964-4ef6-b43d-e162b1ecb626">1.5-year</span> period beginning November 1, 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $<ix:nonFraction unitRef="usd" contextRef="if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfNTQy_c5474a30-c987-414a-beeb-6df235141d65">61</ix:nonFraction> included in other income on the accompanying statements of operations and comprehensive loss. The Small Business Administration (SBA) reserves the right to audit any PPP loan, regardless of size. These audits may occur after forgiveness has been granted. In accordance with the CARES Act, all borrowers are required to maintain the PPP loan documentation for six years after the PPP loan was forgiven or repaid in full and to provide that documentation to the SBA upon request.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie893c6ea7cb24a70984639ee82d13224_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfOTIz_52d735cf-45ef-4084-995a-a4c32c75bd8e">350</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="number" contextRef="ifaf794a259e54b3ba3547350cc2f5ef3_I20210131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfOTc3_44c9aef5-2410-4896-a90f-ec37f42a385a">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="i7f18e4fe2f154b23845553ce8b36cbdb_D20210201-20210228" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTA5NQ_a904f8cd-db87-4074-a8ac-607d383d4ea9">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_55"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTI1MA_0a1e50e9-c931-40ad-b094-4c10734bc8b9" continuedAt="i172cb8bb92ae46f0a11e24bff61b45e8" escape="true">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</ix:nonNumeric></span></div><ix:continuation id="i172cb8bb92ae46f0a11e24bff61b45e8"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed the IPO of <ix:nonFraction unitRef="shares" contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfOTI_485beb99-c473-4fcd-ac51-3f9a3e4c7c40">2,250,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9a8b39ceb7ad4164be59942fb7614f0e_I20210228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTQ4_4fd06847-73b7-4a3c-8c77-f434be75d725">8.00</ix:nonFraction> per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $<ix:nonFraction unitRef="usd" contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228" decimals="-3" name="ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMzA1_c44eef2f-3276-4ea2-8d6a-585e0921b813">18,000</ix:nonFraction>. Underwriting discounts and expenses totaled $<ix:nonFraction unitRef="usd" contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228" decimals="-3" name="ck0001824293:StockIssuanceCostsDiscountsAndCommissions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMzUz_b330d364-3898-4b47-ad09-3a21a20d9ef4">1,600</ix:nonFraction> and the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="iaa68683166f845408469b50f0a32b3b5_D20210201-20210228" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMzk1_d29da6f7-5eff-4349-8f31-ff3b8179276a">905</ix:nonFraction> of additional expenses related to completing the IPO for aggregate net proceeds were approximately $<ix:nonFraction unitRef="usd" contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfNjIx_516b2806-484d-42c9-a2df-746740a7b5a8">15,500</ix:nonFraction>. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjUwMQ_733f6605-6051-4cb2-99c7-5a8e93c4ebc2">3,700,000</ix:nonFraction> shares of common stock pursuant to a securities purchase agreement at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjUwNQ_d66752e2-edc9-4ffb-9c15-eabfb8cfe29b">1.0632</ix:nonFraction> per share in a registered direct offering (the Offering). The gross proceeds from the Offering were approximately $<ix:nonFraction unitRef="usd" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjUwOQ_817fc5ee-ccaa-401a-91b6-8327d14e5f0f">3,900</ix:nonFraction>, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMTgzMg_27258185-87b5-4b95-b780-aaedd822b90a">572</ix:nonFraction> of which $<ix:nonFraction unitRef="usd" contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517" decimals="-3" name="ck0001824293:WarrantsIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjY3Mw_f1e55313-7a4b-4755-9df2-876e28ba058e">85</ix:nonFraction> related to the warrants was expensed. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ice04209849fb435087c6298880b82c73_I20210228" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfNzc5_30cf7e29-061e-491a-97e1-f6091d35bc54">112,500</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ice04209849fb435087c6298880b82c73_I20210228" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfODI5_8f548d19-7318-4921-872a-eb70f1be152a">10.00</ix:nonFraction> per share. The Underwriters&#8217; Warrants have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfODc3_ce620793-2d62-41d1-96a6-0936db85ba5c">five</span>-year term and are not exercisable prior to August 12, 2021. All of the Underwriters&#8217; Warrants were outstanding as of June&#160;30, 2022. The warrants were classified as equity and the fair value of $<ix:nonFraction unitRef="usd" contextRef="i719a8a8b7ff446c1bc50f1384cc0de4d_D20210201-20210228" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA2Mg_3efa3966-309c-4f1e-8d4b-330cbccfee59">399</ix:nonFraction> is reflected as additional paid-in capital. <ix:continuation id="icaf0230ccd4943278edebf862762e317" continuedAt="iba9c42f7300543e586900bb73fb9cdc1">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</ix:continuation></span></div><div style="margin-top:8pt"><ix:continuation id="iba9c42f7300543e586900bb73fb9cdc1" continuedAt="i952a7396f5034392a75ca835484b10ec"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd279f5e1d8444db25b59b0858f2af5_I20220630" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOmZhMmFjZjNlMGIxNzQxZDZhMTc0MTVlOWFhNjQ1MTNkL3RhYmxlcmFuZ2U6ZmEyYWNmM2UwYjE3NDFkNmExNzQxNWU5YWE2NDUxM2RfMC0xLTEtMS0zNjkyMw_de2d7675-840a-4dcf-af82-9a373fc20a05">85.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id62c32d0200843f38b297b12c7bfa449_I20220630" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOmZhMmFjZjNlMGIxNzQxZDZhMTc0MTVlOWFhNjQ1MTNkL3RhYmxlcmFuZ2U6ZmEyYWNmM2UwYjE3NDFkNmExNzQxNWU5YWE2NDUxM2RfMS0xLTEtMS0zNjkyMw_5965b3ab-3c38-4c86-b53e-76903fef4aee">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06e6a1c69d574de78299b71070680019_I20220630" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOmZhMmFjZjNlMGIxNzQxZDZhMTc0MTVlOWFhNjQ1MTNkL3RhYmxlcmFuZ2U6ZmEyYWNmM2UwYjE3NDFkNmExNzQxNWU5YWE2NDUxM2RfMi0xLTEtMS0zNjkyMw_32ac96ff-1a47-4734-8e9e-3737f1497473">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b4169335d1b4ff29a400e3b99a836a9_I20220630" decimals="5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOmZhMmFjZjNlMGIxNzQxZDZhMTc0MTVlOWFhNjQ1MTNkL3RhYmxlcmFuZ2U6ZmEyYWNmM2UwYjE3NDFkNmExNzQxNWU5YWE2NDUxM2RfMy0xLTEtMS0zNjkyMw_f611b61c-e03f-42e0-85c0-6c5ad0f10121">0.155</ix:nonFraction>&#160;%</span></td></tr></table></ix:continuation></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering, the Company issued warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMTY2Ng_98412202-f526-4872-8aa8-d3ce15c2fcde">3,700,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMTY3Mg_69f37f79-9b35-442f-8dd0-932e940d9562">0.9382</ix:nonFraction> per share. The warrants have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjU5MA_51655d27-6cc7-465e-88ec-29ffbd736c95">five</span>-year term. All of the warrants were outstanding as of June&#160;30, 2022. The warrants were classified as a liability and the fair value of $<ix:nonFraction unitRef="usd" contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMTgxMQ_fdf66048-235f-410c-9e5c-0a447b3119aa">1,554</ix:nonFraction> is reflected in warrant liability on the balance sheet. <ix:continuation id="i952a7396f5034392a75ca835484b10ec" continuedAt="i6e9efba771764cbfb7072d9e763ac01c">The Black-Scholes option-pricing model was used to estimate the initial fair value of the warrants with the following weighted-average assumptions:</ix:continuation></span></div><div><span><br/></span></div><div><ix:continuation id="i6e9efba771764cbfb7072d9e763ac01c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf0242ba0cc646728e31b766046dc508_I20220630" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOjg3ZjM0MWVlNjkwOTQyNWE5OTIyNzdmNWE3M2VkMjNjL3RhYmxlcmFuZ2U6ODdmMzQxZWU2OTA5NDI1YTk5MjI3N2Y1YTczZWQyM2NfMC0xLTEtMS01MTEyMg_ed431685-76ae-49a5-9bd3-6649ec4f278a">130.8</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i83d36a3a0df04368aff26ea0900fa228_I20220630" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOjg3ZjM0MWVlNjkwOTQyNWE5OTIyNzdmNWE3M2VkMjNjL3RhYmxlcmFuZ2U6ODdmMzQxZWU2OTA5NDI1YTk5MjI3N2Y1YTczZWQyM2NfMS0xLTEtMS01MTEyMg_687a1863-5010-45ba-8d26-da538f4e676a">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1f3a03eb7104bff89df1b804e710cc1_I20220630" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOjg3ZjM0MWVlNjkwOTQyNWE5OTIyNzdmNWE3M2VkMjNjL3RhYmxlcmFuZ2U6ODdmMzQxZWU2OTA5NDI1YTk5MjI3N2Y1YTczZWQyM2NfMi0xLTEtMS01MTEyMg_a3b08c6b-8254-40be-8fe9-f7e699d37d23">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49e5070e0f094b4c8b1e0ca0d774e78a_I20220630" decimals="5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOjg3ZjM0MWVlNjkwOTQyNWE5OTIyNzdmNWE3M2VkMjNjL3RhYmxlcmFuZ2U6ODdmMzQxZWU2OTA5NDI1YTk5MjI3N2Y1YTczZWQyM2NfMy0xLTEtMS01MTEyMg_8c2916d6-ed57-4087-9bad-edc3906d264c">2.665</ix:nonFraction>&#160;%</span></td></tr></table></ix:continuation></div></ix:continuation><div id="ie30945125f3a415bbe965615270c4a49_61"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2Ng_9bb5b852-0ff2-4d10-a1a0-b98d4c7bc855" continuedAt="if933c6af8571446eafb85f6ae3c3eebb" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="if933c6af8571446eafb85f6ae3c3eebb" continuedAt="i33353eb454344665be6dcf92adc4ea4a"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2Nw_4c372271-c846-4098-a048-b9700b8244a4" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options and shares issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2022 and 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45123774c90a4fa1956d091d5604c46c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMi0xLTEtMS0zNjkyMw_3e860a88-f9a1-4ff8-a743-ce34a5133cf4">129</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59279994119f4d8797134a26b83d8c6a_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMi0zLTEtMS0zNjkyMw_cc6262fc-22bd-4a68-9e6c-62019127d6d8">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbd9cf59fec149d9a8a643a612719e6e_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMi01LTEtMS0zNjkyMw_89f65762-ac5c-4947-bc50-6903f0189a40">111</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17f7b4da78d4e7782a9ae81963a8a71_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMi03LTEtMS0zNjkyMw_da933f4a-a0d4-4215-a916-b13efe4d8b6f">39</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c84158c8f14fc088ef909f0eca8c58_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMy0xLTEtMS0zNjkyMw_81e62416-4d06-418a-8604-10275a42f0f2">44</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e46d5f45e27451c98c012a1bfb2ff79_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMy0zLTEtMS0zNjkyMw_f857ea1d-5686-41d1-8f9e-07011f8d75be">120</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013f7d5cc90144bd84a5bfa54b52c3cb_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMy01LTEtMS0zNjkyMw_6eaed79d-44a2-4b61-aed9-5bb50d377eea">207</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449ba4759b4e4bf4a5e5c917d68f2bf0_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMy03LTEtMS0zNjkyMw_913f49fb-9e65-47df-8f01-2ab8eed724ad">267</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfNC0xLTEtMS0zNjkyMw_3d04db94-9684-42a3-951b-62297df329d5">85</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfNC0zLTEtMS0zNjkyMw_321fc2aa-f111-4dff-b32b-e373e6ccb1a5">138</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfNC01LTEtMS0zNjkyMw_85687b18-ff07-419b-9b1e-d4f57579cef4">96</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfNC03LTEtMS0zNjkyMw_960dfcda-bda7-45cc-b3fa-43f54ad02659">306</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><ix:continuation id="i33353eb454344665be6dcf92adc4ea4a" continuedAt="i50ff62c2f74244aebb991c7aa3abf7c3"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018 Plan. Stock options granted by the Company generally have a contractual life of up to <ix:nonNumeric contextRef="ic3ad6bdf33be419586390b0ac7ab0caf_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfNjc0_51b0c135-a996-40bb-a75f-7eb934e8f8d3">10</ix:nonNumeric> years. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2OA_805bd80f-68f2-4a3a-ad10-c5aa9b3df7f3" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMS0xLTEtMS0zNjkyMw_493bc7a5-2112-4260-a125-92ed6606ee20">708,490</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMS0zLTEtMS0zNjkyMw_df19c8e6-c8a1-4cae-bec7-c37eaf193141">3.60</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8a3cf62c41b4e068c171f0691bb0bfc_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMS01LTEtMS0zNjkyMw_5b1ef265-49ca-4dc3-bce5-3367872b65b4">8.64</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMi0xLTEtMS0zNjkyMw_0edf2f77-35ff-4f4d-ba9f-57a8e5dd73cb">204,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMi0zLTEtMS0zNjkyMw_2b1e8b6b-0372-4af7-9d6f-87a5f5ab3331">5.22</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNC0xLTEtMS0zNjkyMw_613ef961-a931-4455-b20d-82a3a77a40d9">182,290</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNS0xLTEtMS0zNjkyMw_dd26403d-043c-44d7-8e07-16e08abce7e6">730,700</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNS0zLTEtMS0zNjkyMw_5a4aa658-8b6e-41c3-a98c-a9fb170ec472">3.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNS01LTEtMS0zNjkyMw_f7f6adc9-36d7-4695-b33a-bd647e237a2a">8.51</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNi0xLTEtMS0zNjkyMw_25b13e95-e5cd-429e-b0cb-990b6d9b01d4">315,888</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNi0zLTEtMS0zNjkyMw_59858d3a-360e-4f35-b575-8f2c01bd54d2">3.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNi01LTEtMS0zNjkyMw_d8c629a2-74a8-4872-8083-6a9510d37ff7">7.88</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2OQ_4c5cc538-6c4b-4864-bc12-adb5eb7ffa28" continuedAt="i9cd02718c3324d6fb42b1325de50049c" escape="true">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="i9cd02718c3324d6fb42b1325de50049c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfMi0xLTEtMS0zNjkyMw_6737010e-7f08-40eb-8eed-0b0a07d0a5cd">90.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfMi0zLTEtMS0zNjkyMw_36a9521d-7282-41fa-8216-a08416d11497">83.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfMy0xLTEtMS0zNjkyMw_421744b7-2a56-40c3-9903-bed3c5480db3">5.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfMy0zLTEtMS0zNjkyMw_b570c10f-ddc2-4962-aa57-ede7951dc175">5.90</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNC0xLTEtMS0zNjkyMw_ad504cff-e864-41e3-945e-feb3469598c9">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNC0zLTEtMS0zNjkyMw_f9c58cf0-7daf-46b8-91a6-a9dae8e85400">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNS0xLTEtMS0zNjkyMw_0d98d50e-1bcc-43ee-a56d-7b498a5a5b5d">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNS0zLTEtMS0zNjkyMw_3559d740-e488-4f73-aa7f-75d0f1ecaa79">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic21ef042a65f42cd84ec887387352371_I20220630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNi0xLTEtMS0zNjkyMw_89dc566f-b130-4894-a079-cfa5ea6c594f">3.86</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i78c8fc66bda34fdda3cd8cdcd6aa7d9b_I20210630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNi0zLTEtMS0zNjkyMw_b10aebfb-5819-4bd8-a14f-c389e9287212">3.87</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="i3d8cd952ddab4185bc4626df7276ebda_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTg1Mg_e5294036-4888-47d6-8013-6ea8f4da0552">1,132</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="ic3ad6bdf33be419586390b0ac7ab0caf_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2Mw_36025d56-1d5b-4115-99cf-4dc0efe23a37">2.71</ix:nonNumeric> years. </span></div></ix:continuation><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><ix:continuation id="i50ff62c2f74244aebb991c7aa3abf7c3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued performance-based restricted stock units (RSUs). Vesting of the performance-based RSUs is subject to the achievement of certain milestones.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMzI5ODUzNDg5MDkyNA_909d5466-9e43-4ed9-81ac-70baaef69eb1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to RSUs granted to employees for the three months ended June&#160;30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf436d7844974b62a61ac61f27616833_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjU5ZGIzNjQ0YjgzNDQ5MGQ4ZTA1NTdhNTNjMDYyMzY1L3RhYmxlcmFuZ2U6NTlkYjM2NDRiODM0NDkwZDhlMDU1N2E1M2MwNjIzNjVfMS0yLTEtMS01MjE2OQ_009077ca-8d5b-4090-aac0-51c631787414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2d5dff312ff4a6dbd81e861d5714df5_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjU5ZGIzNjQ0YjgzNDQ5MGQ4ZTA1NTdhNTNjMDYyMzY1L3RhYmxlcmFuZ2U6NTlkYjM2NDRiODM0NDkwZDhlMDU1N2E1M2MwNjIzNjVfMi0yLTEtMS01MjE2OQ_3af06207-3b03-45f5-a42b-d2f8db51c907">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired/forfeited/canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ed63d6b4295468c963916e8ee547dd7_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjU5ZGIzNjQ0YjgzNDQ5MGQ4ZTA1NTdhNTNjMDYyMzY1L3RhYmxlcmFuZ2U6NTlkYjM2NDRiODM0NDkwZDhlMDU1N2E1M2MwNjIzNjVfNS0yLTEtMS01NDUwOA_e47604b8-26cd-4dc5-a99c-68db5b56337e">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="ib8129a30fcf84969a1b747ba20407f23_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTY0OTI2NzQ0Njk4Mg_fcbd7209-61c5-489d-a4b3-efb6f4086fae">150,000</ix:nonFraction> RSUs at a grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib8129a30fcf84969a1b747ba20407f23_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTY0OTI2NzQ0Njk5Mg_1c6974d5-4f9a-4c11-b841-705c03daa8f6">0.5552</ix:nonFraction>, all of which were performance-based RSUs. As of June&#160;30, 2022, the milestones associated with the performance-based RSUs were not probable of achievement, and accordingly, no stock-based compensation expense has been recognized for these awards. The unrecognized compensation cost related to unvested performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="i9ed63d6b4295468c963916e8ee547dd7_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTY0OTI2NzQ0NzAwMQ_a32984bb-aa70-43e3-a8aa-4105f93ebaa7">83</ix:nonFraction>, which will be recognized commencing in the period in which the performance condition is deemed probable of achievement.</span></div></ix:continuation><div><span><br/></span></div><div id="ie30945125f3a415bbe965615270c4a49_64"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82NC9mcmFnOjZhZmExYTFkZDQzYzQzODg5ZDI4MTE2N2ZiMzdhNjFmL3RleHRyZWdpb246NmFmYTFhMWRkNDNjNDM4ODlkMjgxMTY3ZmIzN2E2MWZfMTQ2Ng_1e82ad5d-18f3-4195-9c8b-e1e70b4d81fd" continuedAt="i2b216cc3e08847c9b6f4777f8e4e797b" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2b216cc3e08847c9b6f4777f8e4e797b">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie893c6ea7cb24a70984639ee82d13224_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82NC9mcmFnOjZhZmExYTFkZDQzYzQzODg5ZDI4MTE2N2ZiMzdhNjFmL3RleHRyZWdpb246NmFmYTFhMWRkNDNjNDM4ODlkMjgxMTY3ZmIzN2E2MWZfMTIyOA_4b8b281c-46c0-422b-b848-3a18adc5f479">350</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="number" contextRef="ifaf794a259e54b3ba3547350cc2f5ef3_I20210131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82NC9mcmFnOjZhZmExYTFkZDQzYzQzODg5ZDI4MTE2N2ZiMzdhNjFmL3RleHRyZWdpb246NmFmYTFhMWRkNDNjNDM4ODlkMjgxMTY3ZmIzN2E2MWZfMTI4Mg_41572d55-e8eb-4f4d-acfb-03481f10d2e7">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="ie893c6ea7cb24a70984639ee82d13224_D20210101-20210131" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82NC9mcmFnOjZhZmExYTFkZDQzYzQzODg5ZDI4MTE2N2ZiMzdhNjFmL3RleHRyZWdpb246NmFmYTFhMWRkNDNjNDM4ODlkMjgxMTY3ZmIzN2E2MWZfMTQwMA_dfdfb698-384b-4cc3-ae98-8d78fa9663da">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO.</ix:continuation></span></div><div id="ie30945125f3a415bbe965615270c4a49_70"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV83MC9mcmFnOjg1ZWQzOWQ5ZDBjODQ5M2E5ZmYwNDUwZDAxYTM0MjE5L3RleHRyZWdpb246ODVlZDM5ZDlkMGM4NDkzYTlmZjA0NTBkMDFhMzQyMTlfMTc1Mg_72335a3f-a51c-41ea-b751-762df4c625fe" continuedAt="i40f17a08591344b6b2a278fa2e48097e" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i40f17a08591344b6b2a278fa2e48097e"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#8217;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of new strains or variants of coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on the Company&#8217;s clinical trial enrollment (including the Company&#8217;s ability to recruit and retain patients), clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 pandemic and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_76"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report, and the audited financial statements (and notes thereto), and management&#8217;s discussion and analysis of financial condition and results of operations for the year ended December 31, 2021, included in our Annual Report on Form 10-K that was filed with the SEC on February 14, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.</span></div><div id="ie30945125f3a415bbe965615270c4a49_79"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. Our lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;), which we were developing for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In March 2022, we announced that our SEAL study for ADAIR did not reach its primary endpoint, and there is no assurance that ADAIR will receive approval by the U.S. Food and Drug Administration (the FDA). In addition to ADAIR, we completed formulation development work and selected the final formulation of our second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tudy to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">buse </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), was our pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the FDA. The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study did not meet its primary endpoint, which was E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking. ADAIR scored similarly to what was observed in an earlier proof-of-concept study, however, reference dextroamphetamine did not score as high as expected and as seen in the previous study, thus driving the lack of statistical significance. The SEAL study did meet all pharmacodynamic secondary endpoints including Overall Drug Liking and willingness to Take Drug Again at 12 and 24 hours post-dosing, demonstrating statistical significance.</span></div><div><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to assess the best path forward for the ADAIR and ADMIR development programs. In addition, we have engaged Ladenburg Thalmann &amp; Co. Inc. (Ladenburg) to evaluate our strategic alternatives with the goal of maximizing stockholder value. Ladenburg has been engaged to advise us on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. In the meantime, and in conjunction with the exploration of strategic alternatives, we are streamlining our operations in order to preserve our capital and cash resources.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we entered into a license agreement with Medice, which grants Medice an exclusive license to develop, use, manufacture, market and sell ADAIR throughout Europe. Under the license agreement, Medice paid us a $0.1 million upfront payment and will pay milestone payments of up to $6.3&#160;million in aggregate upon achieving certain regulatory and sales milestones. We are also entitled to low-double digit tiered royalties on net sales of ADAIR. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to our operations and business plan. We have closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of new strains or variants of the coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. In light of these developments, the full impact of the COVID-19 pandemic on our business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on our clinical trial enrollment (including our ability to recruit and retain patients), clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and with most of our employees and consultants working remotely. We will continue to actively monitor the COVID-19 pandemic and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business.</span></div><div id="ie30945125f3a415bbe965615270c4a49_82"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of in-process research and development expenses, costs related to the development program for ADAIR, commercial manufacturing of ADAIR and formulation development for ADMIR. Research and development costs are expensed as incurred. These expenses include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee -related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead related expenses and travel related expenses for our research and development personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations (CROs), as well as consultants that support the implementation of our clinical and non-clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support an NDA filing as well as manufacturing drug product for commercial launch;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation, research and development expenses related to ADMIR; and other products we may choose to develop; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs for sponsored research.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee, consultant and infrastructure resources across our research and development programs. Although we track certain outsourced development costs by product candidate, we do not allocate personnel costs or other internal costs to specific product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to significantly decrease our research and development expenses as we consider our future plans regarding ADAIR and ADMIR programs as well as strategic alternatives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to our formation and corporate matters.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, legal and accounting costs and investor relations costs. Our general and administrative expenses may increase due to increases in professional and advisory fees as we evaluate our strategic alternatives.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of income recognized as a result of the extinguishment of the promissory note issued to us under the Paycheck Protection Program (PPP) as a result of the forgiveness of the note. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Derivative Instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement pursuant to which we issued $350,000 in convertible promissory notes (the 2021 Convertible Notes). The 2021 Convertible Notes automatically converted into 54,906 shares of our common stock concurrently with the closing of the IPO. We identified the mandatory conversion into shares our common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. We evaluated the fair value of the derivative liability at issuance. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability and Change in Fair Value</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated the warrants issued in connection with the May 2022 registered direct financing in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the Balance Sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with changes in fair value recognized in the Statements of Operations and Comprehensive Loss in the period of change.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, consists of interest earned on our cash, cash equivalents and marketable securities held with institutional banks, the amortization of discounts and accretion of premiums on marketable securities and interest expense on our finance lease of equipment utilized in the commercial scale manufacturing of ADAIR.</span></div><div id="ie30945125f3a415bbe965615270c4a49_85"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2022 and 2021 </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,506)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $0.3 million and $1.2 million for the three months ended June&#160;30, 2022 and 2021, respectively. The $0.9 million decrease in research and development expenses was primarily due to a decrease of $0.8</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million in expenses related to the registration development program of ADAIR and a decrease of&#160; $0.1 million in personnel expenses, including stock-based compensation expense. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.2 million and $1.1 million for the three months ended June&#160;30, 2022 and 2021. The $0.1 million increase in general and administrative expenses was primarily due to a $0.3 million increase in public company expense and consulting fees offset by a $0.2 million decrease in personnel expense, including stock-based compensation, and insurance expenses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we issued 3,700,000 shares of common stock pursuant to a securities purchase agreement at a purchase price of $1.0632 per share in a registered direct offering. In connection with the registered direct offering, we issued warrants to purchase an aggregate of 3,700,000 shares of common stock at an exercise price of $0.9382 per share. The warrants were classified as a liability in accordance with ASC 815-40 and the fair value of $1.3 million was recorded as a liability at inception. The change in fair value of $0.3 million represents the increase in the fair value of the warrant liability from $1.3 million at inception to $1.6 million at June&#160;30, 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2022 and 2021</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,974</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,938</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,912)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,950)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $1.5 million and $3.0 million for the six months ended June&#160;30, 2022 and 2021, respectively. The $1.5 million decrease in research and development expenses was primarily due to a decrease of $1.5 million in expenses related to the registration development program of ADAIR. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $2.6 million and $1.9 million for the six months ended June&#160;30, 2022 and 2021, respectively. The $0.7 million increase was primarily related to increased costs for public company expenses of $0.3 million, consulting fees of $0.2 million, insurance expense of $0.1 million and personnel expense, including non-cash stock compensation, of $0.1 million.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued a promissory note under the PPP totaling $61,000. As of December 31, 2020, the Company had utilized the entire proceeds from such note for payroll costs (greater than 75%), costs related to health care benefits and rent payments and in January 2021, the Company was notified that the note along with accumulated interest had been forgiven. As the PPP note was forgiven, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Derivative Liability</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, pursuant to ASC-815, we revalued the embedded derivative liability associated with the 2021 Convertible Notes, resulting in $89,000 in the fair value of the derivative liability associated with the 2021 Convertible Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we issued 3,700,000 shares of common stock pursuant to a securities purchase agreement at a purchase price of $1.0632 per share in a registered direct offering. In connection with the registered direct offering, we issued warrants to purchase an aggregate of 3,700,000 shares of common stock at an exercise price of $0.9382 per share. The warrants were classified as a liability in accordance with ASC 815-40 and the fair value of $1.3 million was recorded as a liability at inception. The change in fair value of $0.3 million represents the increase in the fair value of the warrant liability from $1.3 million at inception to $1.6 million at June&#160;30, 2022.</span></div><div id="ie30945125f3a415bbe965615270c4a49_88"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $4.4 million and $5.0 million for the six months ended June&#160;30, 2022 and 2021, respectively. As of June&#160;30, 2022, we had an accumulated deficit of $26.3 million.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of common stock, warrants, convertible notes, short-term promissory notes, and a PPP promissory note. As of June&#160;30, 2022, we had $5.2 million in cash and cash equivalents. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,401</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2022 and 2021, $3.9 million and $5.4 million were used in operating activities, respectively. The $1.6 million decrease was primarily due to a $0.6 million decrease in our net loss as well as a decrease in cash used for prepaid expense and other assets and accounts payable of $1.4 million, offset by a $0.4 million increase in cash used for accrued expenses. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $2.0 million for the six months ended June&#160;30, 2022, which was related to purchases and sales of marketable securities. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $3.4 million during the six-month period ended June&#160;30, 2022, which was related to net proceeds of $3.4 million from the sale of common stock and warrants in a registered direct financing in May 2022 offset by payments related to our finance lease of $46,000. Net cash provided by financing activities was $15.8 million for the six months ended June&#160;30, 2021 and was primarily related to the net proceeds from our IPO and 2021 Convertible Notes financings.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Convertible Note Financing</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including SALMON Pharma GmbH (Salmon Pharma), an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we issued convertible promissory notes (the 2021 Convertible Notes) for cash proceeds of $350,000. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a Qualified Financing) and were convertible at a twenty percent discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the initial public offering of our common stock, consummated on February 12, 2021; therefore, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of the IPO, as agreed upon among the parties thereto.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from the sale of any products. Substantially all of our revenue to date has been generated by the Medice license agreement from which we received a $0.1 million license fee in January 2020. We do not know when, or if, we will generate any revenue. In March 2022, we announced that the SEAL study of ADAIR for the treatment of ADHD did not meet statistical significance for its primary endpoint and that we are evaluating our strategic alternatives with the goal of maximizing stockholder value. We are continuing to assess the best path forward for the development of the ADAIR and ADMIR programs and have no other product candidate undergoing clinical trials. We expect to incur ongoing expenses as we assess these programs and evaluate our strategic options. Our future capital requirements are difficult to forecast and will depend on many factors, including but not limited to the terms and timing of any strategic alternatives including a merger or business combination, asset acquisitions or sales, collaborations or licensing arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing may impose upon us covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to other parties&#8217; rights to develop or commercialize our drug candidates that we would prefer to retain. Therefore, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur expenses and operating losses at least for the foreseeable future as we evaluate future plans for the ADAIR and ADMIR programs as well as our strategic alternatives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the &#8220;Risk Factors&#8221; section on this Form 10-Q for additional risks associated with our substantial capital requirements.</span></div><div id="ie30945125f3a415bbe965615270c4a49_91"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div id="ie30945125f3a415bbe965615270c4a49_94"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our unaudited interim financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s critical accounting policies are described in Note 3, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022. There have been no material changes to the significant accounting policies during the six months ended June&#160;30, 2022, except for items mentioned in Note 3 of the unaudited interim financial statements in this Quarterly Report on Form 10-Q.</span></div><div id="ie30945125f3a415bbe965615270c4a49_97"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of the our IPO, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></div><div id="ie30945125f3a415bbe965615270c4a49_100"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div id="ie30945125f3a415bbe965615270c4a49_103"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as of June&#160;30, 2022. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2022, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)) that occurred during the fiscal quarter covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_106"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ie30945125f3a415bbe965615270c4a49_109"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, litigation can have a material adverse effect on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div id="ie30945125f3a415bbe965615270c4a49_112"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, except as set forth below.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute on our business strategy is subject to a number of risks, which are discussed more fully below in this section. You should carefully consider these risks before making an investment in our common stock. These risks include, among others, the following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our activities to evaluate and pursue strategic alternatives may not be successful.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not successfully consummate a strategic transaction, our board of directors may decide to pursue a dissolution and liquidation of the company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on our remaining employees to facilitate the consummation of a strategic transaction. We could lose such key employees, in particular, as a result of the ADAIR data.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our prospects were highly dependent on a single product candidate, ADAIR. As the SEAL study of ADAIR did not meet its predefined clinical endpoint, we are currently assessing the best path forward for ADAIR and have been evaluating other strategic alternatives to maximize stockholder value, which  may not be successful.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have no approved products and a limited operating history, which may make it difficult to evaluate our technology and product development capabilities and predict our future performance.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently assessing the best path forward for ADAIR, and any further development of ADAIR or the development of any new product will require additional capital to fund our operations, which we may not be able to obtain.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative perception of any product candidate that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidate.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock is expected to be volatile. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies.</span></div><div style="margin-top:8pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to Our Evaluation of Strategic Alternatives</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities to evaluate and pursue strategic alternatives may not be successful.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we announced that topline data from our SEAL study of ADAIR for the treatment of ADHD did not meet statistical significance for the primary endpoint of  E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking. We are continuing to assess the best path forward for the ADAIR and ADMIR programs and we have commenced a process of evaluating strategic alternatives to maximize stockholder value. We have engaged a financial advisory firm to help explore our available strategic alternatives, including a possible merger, business combination, asset acquisitions or sales, and collaboration and licensing arrangements. We have significantly reduced our research and development activities to reduce operating expenses while we evaluate these opportunities. We expect to devote significant time and </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources to identifying and evaluating strategic transactions; however, there can be no assurance that such activities will result in any agreements or transactions that will enhance stockholder value. In addition, potential strategic transactions that require stockholder approval may not be approved by our stockholders or a counterparty&#8217;s stockholders. Further, any strategic transaction that is completed ultimately may not deliver the anticipated benefits or enhance stockholder value.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may acquire additional businesses, products or product candidates. Integrating any newly acquired business, product or product candidate could be expensive and time-consuming. We may not be able to integrate any acquired business, product or product candidate successfully. If we do acquire any additional business, products, or product candidates, our future financial performance will depend, in part, on our ability to manage any future growth effectively and our ability to integrate any such acquired businesses, products or product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any strategic transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than anticipated acquisition and/or integration costs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">write downs of assets or goodwill or impairment charges;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to retain our key employees or our other service providers or those of any acquired businesses.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, there can be no assurance that we will undertake or successfully complete any strategic transactions of the nature described above and any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business, financial condition and prospects</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not successfully consummate a strategic transaction, our board of directors may decide to pursue a dissolution and liquidation of the Company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the process to identify a strategic transaction will result in a successfully consummated transaction. If no transaction is completed, our board of directors may decide to pursue a dissolution and liquidation of the Company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution will continue to decrease as we fund our operations while we evaluate our strategic alternatives. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation of the Company, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provisions for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. Our commitments and contingent liabilities may include (i) regulatory and clinical obligations; (ii) obligations under our employment and related agreements with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control; and (iii) potential litigation against us, and other various claims and legal actions arising in the ordinary course of business. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation of the Company. If a dissolution and liquidation were pursued, our board of directors, in consultation with our advisors, would need to evaluate these matters and make a determination about a </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up of the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our prospects were highly dependent on a single product candidate, ADAIR, and while we are assessing the best path forward for ADAIR, we may not complete the development or commercialization of ADAIR</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our long-term prospects were highly dependent on future acceptance and revenues from our lead product candidate, ADAIR. In March 2022, we announced that topline data from our SEAL study of ADAIR for the treatment of ADHD did not meet statistical significance for the primary endpoint of E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Drug Liking and that, given that result, we are currently assessing the best path forward for ADAIR. Any further development of ADAIR would require substantial capital and time to complete, and there is no guarantee that any future clinical trial, if pursued, would be timely or successful, or that ADAIR would be approved or, if approved, that commercialization would be successful. Concurrently, we have been evaluating strategic alternatives to maximize stockholder value, which could involve, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. However, there is no assurance that we will be successful in our pursuit of a strategic alternative, failure of which may have a material adverse impact on our business, financial condition, and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on our remaining employees to facilitate the consummation of a strategic transaction. We could lose such key employees, in particular, as a result of the ADAIR data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash conservation activities may yield unintended consequences, such as attrition and reduced employee morale, which may cause remaining employees to seek alternative employment. Our ability to successfully complete a strategic transaction depends in large part on our ability to retain certain personnel, particularly David Baker, our Chief Executive Officer, and Leanne Kelly, our Chief Financial Officer. Despite our efforts to retain these employees, one or more may terminate their employment on short notice. The loss of the services of any of these employees could potentially harm our ability to evaluate and pursue strategic alternatives, as well as fulfill our reporting obligations as a public company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition among biotechnology companies for qualified employees is intense, and our ability to retain our key employees is critical to our ability to effectively manage our resources and consummate a strategic transaction. If we develop new product candidates, such development would require expertise from a number of different disciplines, some of which are not widely available. The results of the SEAL study of ADAIR will likely make it more challenging to retain qualified personnel and more difficult to recruit personnel in the future, if necessary. If we fail to attract new personnel or fails to retain and motivate our current personnel, our business and future growth prospects and our ability to consummate a strategic transaction would be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to Our Business, Technology and Industry</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no approved products and have a limited operating history, which may make it difficult to evaluate our technology and product development capabilities and predict our future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. Our ability to generate product revenue or profits was dependent on the successful development and eventual commercialization of ADAIR. Given that the topline data from our SEAL study of ADAIR for the treatment of ADHD failed to meet statistical significance for the primary endpoint of  E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking and we are assessing the best path forward for the ADAIR program, we may never be able to develop or commercialize a marketable product.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future programs and product candidates will require additional discovery research, preclinical development, clinical development, regulatory approval to commercialize the product, manufacturing validation, obtaining manufacturing supply, capacity and expertise, building of a commercial and distribution organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. In addition, any drug product candidate must be approved for marketing by the FDA or certain other health regulatory agencies before we may commercialize any product in the respective jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our limited operating history may make it difficult to evaluate our, or any new, technology and industry and predict its future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in evolving fields. If we do not address these risks successfully, our business will suffer. Similarly, we expect that our financial condition and operating results will fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a result, our stockholders should not rely upon the results of any quarterly or annual period as an indicator of future operating performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses in every year since our inception and we anticipate that we will continue to incur net losses in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a limited operating history. Investment in product development in the healthcare industry, including of biopharmaceutical products, is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date. As a result, we are not profitable and have incurred losses in each period since our inception. For the six months ended June&#160;30, 2022, we reported a net loss of $4.4 million. As of June&#160;30, 2022, we had an accumulated deficit of 26.3 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we or any potential future collaborator must develop and eventually commercialize products with significant market potential at an adequate profit margin after cost of goods sold and other expenses. This will require us to be successful in a range of challenging activities, including completing clinical trials, manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional capital will be required to fund our operations, ADAIR product development activities or the development of any new product. If we fail to obtain necessary financing, we will not be able to complete the development and commercialization of product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations have consumed substantial amounts of cash since inception. While we plan to significantly decrease our research and development expenses as we assess the best path forward for ADAIR, we expect to continue to spend a considerable amount of resources on pursuing strategic opportunities. Furthermore, to move forward with the development of ADAIR or any other product candidates, we would be required to spend substantial amounts to conduct clinical trials of such programs, to validate the manufacturing process and specifications for any such product candidate, to seek regulatory approvals for such product candidate and to launch and commercialize any products for which we receive regulatory approval, including potentially building our own commercial organization. As of June&#160;30, 2022, we had $7.0 million of cash, cash equivalents and marketable securities on hand. Our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we currently expect and may change if our business plan changes from our current expected operating plan. Our monthly spending levels will vary based on development and corporate activities. Because of the uncertainty regarding our future development pathway, we are unable to estimate the actual funds we will require for development of any potential product candidate and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options that we pursue;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any collaboration agreements we may choose to initiate or conclude;</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, and other comparable foreign regulatory authorities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure in obtaining the necessary approvals from regulators or institutional review boards (IRBs) in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of third-party contractors, such as contract research organizations (CROs), or investigators to comply with regulatory requirements, including Good Clinical Practices (GCPs);</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governmental or regulatory delays and changes in regulation or policy relating to the development and commercialization of a product candidate by the FDA or other comparable foreign regulatory authorities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">undertaking and completing additional pre-clinical studies to generate data required to support the clinical development of a product candidate;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to enroll sufficient patients to complete clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in having patients complete a trial or return for post-treatment follow-up;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">problems with biopharmaceutical product candidate storage, stability and distribution;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to add new or additional clinical trial sites;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of the data generated from our preclinical or clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to manufacture, or obtain from third parties, adequate supply of biopharmaceutical product candidate sufficient to complete our preclinical studies and clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing, maintaining, and overseeing a quality system compliant with current good manufacturing practice requirements (cGMPs) and a supply chain for the development and manufacture of our product candidate;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing, expanding and scaling manufacturing capabilities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing sales, marketing and distribution capabilities for any product candidate for which we may receive regulatory approval in regions where we choose to commercialize its products on our own; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unforeseen business disruptions or market fluctuations that delay our product development or clinical trials and increase our costs or expenses, such as business or operational disruptions, delays, or system failures due to malware, unauthorized access, terrorism, war, natural disasters, strikes, geopolitical conflicts, restrictions on trade, import or export restrictions, or public health crises, such as the current COVID-19 outbreak.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external source of funds or other support for our development efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance its future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible into or exchangeable for common stock, each existing investors&#8217; ownership interest will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring or licensing intellectual property rights. If we raise additional capital through marketing </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to its product candidate, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourself. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div id="ie30945125f3a415bbe965615270c4a49_115"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Securities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie30945125f3a415bbe965615270c4a49_118"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie30945125f3a415bbe965615270c4a49_121"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie30945125f3a415bbe965615270c4a49_124"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_127"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-1.htm">Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-3.htm">Amended and Restated Bylaws of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-2.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000182429322000039/ex31-amendmentno1toarbylaws.htm">Amendment No. 1 to the Amended and Restated Bylaws of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 18 2022).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000162828022014382/ex101_paavlon-ladenburgmay.htm">Placement Agency Agreement, dated May 13, 2022, between Vallon Pharmaceuticals, Inc. and Ladenburg Thalmann &amp; Co., Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on May 13, 2022).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102_directorcompensation.htm">Non-Employee Director Compensation Program of Vallon Pharmaceuticals, Inc., effective on June 9, 2022. </a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311_ceo302certq222.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302certq222.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906certq222.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906certq222.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Instance Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ie30945125f3a415bbe965615270c4a49_130"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie30945125f3a415bbe965615270c4a49_7"> of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VALLON PHARMACEUTICALS, INC.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: July 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>ex102_directorcompensation.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iacc43001d09f42ecafb0663c8e8613c9_33"></div><div style="min-height:63pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">VALLON PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Non-employee members of the board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) of Vallon Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;). This Program has been adopted under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) and shall be effective on June 9, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;). The cash and equity compensation described in this Program shall be paid or be granted, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) who is entitled to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. This Program shall remain in effect until it is revised or rescinded by further action of the Board. This Program may be amended, modified or terminated by the Board at any time in its sole discretion. The terms and conditions of this Program shall supersede any prior cash and&#47;or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors. No Non-Employee Director shall have any rights hereunder, except with respect to stock options granted pursuant to the Program. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">1.         Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Non-Employee Directors shall be granted the cash compensation described below, effective July 1, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(a)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Each Non-Employee Director shall receive an annual cash retainer of $30,000 for service on the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Additional Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. In addition, each Non-Employee Director shall receive the following additional annual cash retainers, as applicable&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(i) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(iii)     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $10,000 for such service. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(iv)    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">Nominating and Corporate Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $5,000 for such service. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(c)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Payment of Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(d)       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Election to Receive Stock Option in Lieu of Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. After January 1, 2022, Non-Employee Directors shall have the ability to elect to receive the annual retainer set forth in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 1(a) above in an award of a stock option in lieu of cash pursuant to an election form provided by the Company. Non-Employee Directors must complete and deliver the election form to the Company (which shall be irrevocable) at least 15 days prior to the end of the calendar quarter that ends immediately prior to the next annual meeting of the Company&#8217;s stockholders&#59; provided that the election cannot be made during a regular or special blackout period within the meaning of the Company&#8217;s Insider Trading and Securities Law Compliance Policy.  In the event that a Non-Employee Director makes an irrevocable election to receive a stock option in lieu of cash, he or she shall be automatically granted, effective on July 1 immediately following the annual meeting (provided that he or she continues to serve as a Non-Employee Director as of that date), a stock option to purchase that number of shares of the Company&#8217;s common stock determined by dividing (i) the aggregate amount of the annual retainer set forth in Section 1(a) above that would otherwise payable to the Non-Employee Director for the one-year period commencing on July 1 immediately following the annual meeting, by (ii) the per share Black-Scholes valuation as of the grant date, utilizing the same assumptions that the Company uses in preparation of its financial statements, with the resulting quotient rounded down to the nearest whole share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Retainer Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">2.         Annual Retainer for Chairperson of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. A Non-Employee Director serving as Chairperson of the Board as of July 1 of any calendar year shall be automatically granted a restricted stock unit award with a value equal to $20,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Award Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), which amount shall be converted to a number of shares using the average closing per-share price of the Company&#8217;s common stock, as reported on nasdaq.com, rounded to four decimal places, for the 30 trading days immediately preceding the date of grant (with any resulting fractional shares rounded down to the nearest whole share) and shall vest and become payable in substantially equal quarterly installments during the one-year period commencing on July 1 and ending the following June 30 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Service Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), subject to the Non-Employee Director&#8217;s continued service on the Board during the applicable Service Period. A Non-Employee Director who is initially elected or appointed as Chairperson of the Board other than as of July 1 of a calendar year shall be automatically granted a restricted stock unit award as described above on the date of such election or appointment&#59; provided, however, that the Award Value shall be multiplied by a fraction, the numerator of which is the number of days during the period commencing on (and including) the date of the initial election or appointment and ending on (and including) the last day of the applicable Service Period, and the denominator of which is the 365 days. Unless the Board otherwise determines, no portion of the restricted stock unit award granted hereunder which is unvested at the time of a Non-Employee Director&#8217;s termination of service on the Board shall become vested thereafter. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">3.         Equity Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Non-Employee Directors shall be granted the equity awards described below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(a)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Each Non-Employee Director who is initially elected or appointed to the Board on or after the Effective Date shall be automatically granted a stock option to purchase 15,000 shares of the Company&#8217;s common stock on the date of such initial election or appointment. The awards described in this Section 2(a) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;. No Non-Employee Director shall be granted more than one Initial Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.  A Non-Employee Director who (i) is serving on the Board as of the date of any annual meeting of the Company&#8217;s stockholders occurring on or after the Effective Date and has been serving as a Non-Employee Director for at least six months as of the date of such meeting, and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted a stock option to purchase </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">7,500 shares of the Company&#8217;s common stock on the date of such annual meeting. The awards described in this Section 2(b) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;.  For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an annual meeting of the Company&#8217;s stockholders shall only receive an Initial Award in connection with such election and shall not receive any Subsequent Award on the date of such meeting as well.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(c)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Termination of Employment of Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that they are otherwise entitled, will receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(b) above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(d)       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Terms of Awards Granted to Non-Employee Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(i)         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">In General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.  Each restricted stock unit award and each stock option under this Program shall be granted under and shall be subject to the terms and provisions of the Equity Plan, or any other applicable Company equity incentive plan then-maintained by the Company and shall be granted subject to the execution and delivery of award agreements in substantially the forms previously approved by the Board. All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of restricted stock unit awards and stock options hereby are subject in all respects to the terms of the Equity Plan and the applicable award agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(ii)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The per share exercise price of each stock option granted to a Non-Employee Director shall equal the Fair Market Value of a share of common stock on the date the option is granted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(iii)       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Each Initial Award shall vest and become exercisable in substantially equal quarterly installments during the two-year period commencing on the date of grant, and each Retainer Award and each Subsequent Award shall vest and become exercisable in substantially equal quarterly installments during the one-year period commencing on the applicable date of grant, in each case subject to the Non-Employee Director continuing in service on the Board through each such vesting date.  Unless the Board otherwise determines, no portion of a Retainer Award, Initial Award or Subsequent Award which is unvested at the time of a Non-Employee Director&#8217;s termination of service on the Board shall become vested and exercisable thereafter. Upon a Change in Control, all outstanding equity awards granted under the Equity Plan, and any other equity incentive plan maintained by the Company, that are held by a Non-Employee Director shall become fully vested and exercisable, irrespective of any other provisions of the Plan or any award agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(iv)       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The term of each stock option granted to a Non-Employee Director shall be ten years from the date the option is granted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">4.         Compensation Limits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Notwithstanding anything to the contrary in this Program, all compensation payable under this Program will be subject to any limits on the maximum amount of Non-Employee Director compensation set forth in the Equity Plan, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">*  *  *  *  *</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex311_ceo302certq222.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1baaef1d423647cdb72673ed4282f633_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, David Baker, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Vallon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; July&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; David Baker</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Baker</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex312_cfo302certq222.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i411d51e30cdf4689921f77dcd64cfb94_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Vallon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; July&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex321_ceosection906certq222.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9549dfe49cf54e6db3526ca17356491e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, David Baker, President and Chief Executive Officer of Vallon Pharmaceuticals, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2022 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; July&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; David Baker</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Baker</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex322_cfosection906certq222.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i125e46c30bbd46c68184636f0b0a8d2f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly,  Chief Financial Officer of Vallon Pharmaceuticals, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2022 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; July&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ck0001824293-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:721867bc-d51d-454c-b3fb-8a0d76704c20,g:cae8d22d-48c3-4397-b0dc-0800bb57f504-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20220630">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.vallon-pharma.com/role/BalanceSheets">
        <link:definition>1001002 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperationsandComprehensiveLoss" roleURI="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows">
        <link:definition>1005006 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>2103102 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>2404402 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS">
        <link:definition>2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables">
        <link:definition>2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails">
        <link:definition>2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails">
        <link:definition>2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company&#8217;s Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
        <link:definition>2413407 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails">
        <link:definition>2414408 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails">
        <link:definition>2415409 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>2116105 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2317302 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>2418410 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPNOTEANDCONVERTIBLENOTES" roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES">
        <link:definition>2119106 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPNOTEANDCONVERTIBLENOTESDetails" roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails">
        <link:definition>2420411 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT">
        <link:definition>2121107 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables">
        <link:definition>2322303 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails">
        <link:definition>2423412 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>2424413 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2125108 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2326304 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>2427414 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2428415 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails">
        <link:definition>2429416 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>2430417 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails">
        <link:definition>2431418 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2132109 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2433419 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2134110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_Warrants2022Member" abstract="true" name="Warrants2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AccruedLicensingFeesCurrent" abstract="false" name="AccruedLicensingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsDiscountsAndCommissions" abstract="false" name="StockIssuanceCostsDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" abstract="true" name="AffiliateOfMediceAndDavidBakerCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" abstract="true" name="ConvertiblePromissoryNotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" abstract="false" name="ProceedsFromIssuanceInitialPublicOfferingGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" abstract="false" name="ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ck0001824293_WarrantsIPOMember" abstract="true" name="WarrantsIPOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" abstract="false" name="ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ck0001824293_WarrantsIssuanceExpense" abstract="false" name="WarrantsIssuanceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ForgivenessOfDebtInstrument" abstract="false" name="ForgivenessOfDebtInstrument" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentPaymentTerm" abstract="false" name="DebtInstrumentPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" abstract="false" name="ClinicalResearchStudyNumberOfParticipantsEnrolled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ck0001824293-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:721867bc-d51d-454c-b3fb-8a0d76704c20,g:cae8d22d-48c3-4397-b0dc-0800bb57f504-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b8ae45f3-f442-4eeb-b968-666b470d349e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_74447af3-fff2-479c-bd82-0990beea28a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8ae45f3-f442-4eeb-b968-666b470d349e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_74447af3-fff2-479c-bd82-0990beea28a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1e35a09e-8693-4179-aa11-b3b86ff74937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8ae45f3-f442-4eeb-b968-666b470d349e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_1e35a09e-8693-4179-aa11-b3b86ff74937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f48918cc-e53c-4b7d-9e8f-eebd942c0486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8ae45f3-f442-4eeb-b968-666b470d349e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f48918cc-e53c-4b7d-9e8f-eebd942c0486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f379993e-56af-4b82-8429-0814c9979d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8ae45f3-f442-4eeb-b968-666b470d349e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f379993e-56af-4b82-8429-0814c9979d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_788a7ab2-49f8-4939-a63e-bb7c55455a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bec456be-5091-48a7-8070-bc25d71a1695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_788a7ab2-49f8-4939-a63e-bb7c55455a23" xlink:to="loc_us-gaap_Liabilities_bec456be-5091-48a7-8070-bc25d71a1695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ab07b90b-a66a-4fc6-8408-122aa731f57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_788a7ab2-49f8-4939-a63e-bb7c55455a23" xlink:to="loc_us-gaap_StockholdersEquity_ab07b90b-a66a-4fc6-8408-122aa731f57b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8150f46a-83fa-4cb9-9d7b-613d1c54e1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_788a7ab2-49f8-4939-a63e-bb7c55455a23" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8150f46a-83fa-4cb9-9d7b-613d1c54e1f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f0828263-2aed-42bd-958a-f87a99f040d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_192954b1-aa92-4194-80db-f86ea103ef7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0828263-2aed-42bd-958a-f87a99f040d0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_192954b1-aa92-4194-80db-f86ea103ef7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_76ebf9e6-a8ed-4689-8f5c-dc0c7612fe51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0828263-2aed-42bd-958a-f87a99f040d0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_76ebf9e6-a8ed-4689-8f5c-dc0c7612fe51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a68c19ea-2c85-4a2a-a03f-5ef7d20b168c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0828263-2aed-42bd-958a-f87a99f040d0" xlink:to="loc_us-gaap_AccountsPayableCurrent_a68c19ea-2c85-4a2a-a03f-5ef7d20b168c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_35cbc6c9-c3d2-4194-a1b8-66a03bc932c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0828263-2aed-42bd-958a-f87a99f040d0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_35cbc6c9-c3d2-4194-a1b8-66a03bc932c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_84887dc5-cb80-4127-9d54-8277a5c27b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b175350d-19aa-47e5-8b40-e77ead09c9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84887dc5-cb80-4127-9d54-8277a5c27b40" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b175350d-19aa-47e5-8b40-e77ead09c9be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ce861642-38dc-4e6c-b23a-967f951a5be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84887dc5-cb80-4127-9d54-8277a5c27b40" xlink:to="loc_us-gaap_AssetsCurrent_ce861642-38dc-4e6c-b23a-967f951a5be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2c7ad98b-4a91-4372-b8d7-cf524149e8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_89d1edbf-60dd-48ec-9513-cfc9ded15510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c7ad98b-4a91-4372-b8d7-cf524149e8f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_89d1edbf-60dd-48ec-9513-cfc9ded15510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d8d0f587-98cf-407a-9a00-e2bce353b048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c7ad98b-4a91-4372-b8d7-cf524149e8f7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d8d0f587-98cf-407a-9a00-e2bce353b048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_21b8eb94-14b2-49d3-afb0-5491fc2c1cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c7ad98b-4a91-4372-b8d7-cf524149e8f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_21b8eb94-14b2-49d3-afb0-5491fc2c1cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_180d5383-c65e-4293-ac1b-38da46fede55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6cb1e157-2929-43f4-99ef-26d7a54870fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_180d5383-c65e-4293-ac1b-38da46fede55" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6cb1e157-2929-43f4-99ef-26d7a54870fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ab792494-fe87-4928-8f9e-f8efb71a14b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_180d5383-c65e-4293-ac1b-38da46fede55" xlink:to="loc_us-gaap_LiabilitiesCurrent_ab792494-fe87-4928-8f9e-f8efb71a14b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1fef5a4e-0071-4027-950f-e9bbc31aa30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6c2c21a6-e764-43d4-b018-177a7291ce77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1fef5a4e-0071-4027-950f-e9bbc31aa30d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6c2c21a6-e764-43d4-b018-177a7291ce77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_59d3137b-5fa0-488d-ae0c-6230624a9138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1fef5a4e-0071-4027-950f-e9bbc31aa30d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_59d3137b-5fa0-488d-ae0c-6230624a9138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f11b9194-8a19-44c4-a7d2-7ee028dbd54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c21fc1f2-1a3e-44c8-bd8e-5fc800d109d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f11b9194-8a19-44c4-a7d2-7ee028dbd54a" xlink:to="loc_us-gaap_NetIncomeLoss_c21fc1f2-1a3e-44c8-bd8e-5fc800d109d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f0dcbb27-edb4-4098-a0a6-bf48b604b1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f11b9194-8a19-44c4-a7d2-7ee028dbd54a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f0dcbb27-edb4-4098-a0a6-bf48b604b1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1cbb9211-d815-4bb6-b7f9-019b10f8eca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_aa19a545-1745-4d00-9029-d75caef3c402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1cbb9211-d815-4bb6-b7f9-019b10f8eca3" xlink:to="loc_us-gaap_OperatingExpenses_aa19a545-1745-4d00-9029-d75caef3c402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7cadfd0b-ea48-4cb7-8cc6-3f1e6e0bab33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d69d964a-9af5-4537-bfb9-af9c278e1df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cadfd0b-ea48-4cb7-8cc6-3f1e6e0bab33" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d69d964a-9af5-4537-bfb9-af9c278e1df5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_6d6120a2-22e3-489c-8f45-ae5389643b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cadfd0b-ea48-4cb7-8cc6-3f1e6e0bab33" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_6d6120a2-22e3-489c-8f45-ae5389643b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_3ffc6c68-7971-416c-b525-5a208635c368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cadfd0b-ea48-4cb7-8cc6-3f1e6e0bab33" xlink:to="loc_us-gaap_OtherNonoperatingIncome_3ffc6c68-7971-416c-b525-5a208635c368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_ad8f64c1-ec89-42dc-8555-1edb66499c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cadfd0b-ea48-4cb7-8cc6-3f1e6e0bab33" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_ad8f64c1-ec89-42dc-8555-1edb66499c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5eae282c-8e79-406c-8351-221594b75527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cadfd0b-ea48-4cb7-8cc6-3f1e6e0bab33" xlink:to="loc_us-gaap_OperatingIncomeLoss_5eae282c-8e79-406c-8351-221594b75527" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f86421a7-1aba-40e0-85c0-327338434dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f86421a7-1aba-40e0-85c0-327338434dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_01c842f5-e630-44c9-9365-edb7d9c284af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_NetIncomeLoss_01c842f5-e630-44c9-9365-edb7d9c284af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ab33f695-4c68-4655-ac43-11fb7854330e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ab33f695-4c68-4655-ac43-11fb7854330e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3f5d73d9-bada-4246-b78b-b1dced192fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3f5d73d9-bada-4246-b78b-b1dced192fda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a69fe9d4-c121-4233-acb5-ab352f066331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a69fe9d4-c121-4233-acb5-ab352f066331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1ae2767f-8405-437e-9654-849555a9b5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1ae2767f-8405-437e-9654-849555a9b5b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_027bb156-ebd4-4a2b-843f-d2ddb1ad936d" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_027bb156-ebd4-4a2b-843f-d2ddb1ad936d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_db46b7a9-f030-4252-bc62-cb29adf922d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_ShareBasedCompensation_db46b7a9-f030-4252-bc62-cb29adf922d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_56e5fb91-03db-4f71-badd-bdca0148ce2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_OtherNoncashExpense_56e5fb91-03db-4f71-badd-bdca0148ce2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3d80b844-b3d0-4f42-bf68-aaa14448532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3d80b844-b3d0-4f42-bf68-aaa14448532e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_efff20f5-9db4-42b4-ad58-a18fcb495631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daa29afb-93a4-407a-9a03-2f4db3373dc6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_efff20f5-9db4-42b4-ad58-a18fcb495631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb066d88-a83f-4572-8c70-ddffa3eef2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_be84539f-73c8-4041-a268-b6aadf33b528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb066d88-a83f-4572-8c70-ddffa3eef2fe" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_be84539f-73c8-4041-a268-b6aadf33b528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b3687dd0-c028-438e-8309-b4ac528483c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb066d88-a83f-4572-8c70-ddffa3eef2fe" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b3687dd0-c028-438e-8309-b4ac528483c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9823c89a-6aec-4e2f-bcfa-ab9deef7c0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_67758501-2818-471a-ac0c-73b1464aa5f4" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9823c89a-6aec-4e2f-bcfa-ab9deef7c0b9" xlink:to="loc_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_67758501-2818-471a-ac0c-73b1464aa5f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_c1f933b3-9f1c-46a1-a701-9e8959cffea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9823c89a-6aec-4e2f-bcfa-ab9deef7c0b9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_c1f933b3-9f1c-46a1-a701-9e8959cffea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_a2862758-3bc9-4d53-b617-39fb093c6cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9823c89a-6aec-4e2f-bcfa-ab9deef7c0b9" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_a2862758-3bc9-4d53-b617-39fb093c6cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3409ccdb-6577-4f6b-b356-e0d0e8fa47f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f5422e5-f153-42c5-a884-781aca26e485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3409ccdb-6577-4f6b-b356-e0d0e8fa47f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f5422e5-f153-42c5-a884-781aca26e485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_66ecc6d4-f5c0-434f-a6cb-2600da712e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3409ccdb-6577-4f6b-b356-e0d0e8fa47f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_66ecc6d4-f5c0-434f-a6cb-2600da712e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c008c0f0-00ea-42f2-9904-511c7e0139e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3409ccdb-6577-4f6b-b356-e0d0e8fa47f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c008c0f0-00ea-42f2-9904-511c7e0139e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_05ce8a66-e28c-4e3f-b975-6bf2dab9b0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e06d579f-cadd-48a8-9e8d-0b81c591e378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_05ce8a66-e28c-4e3f-b975-6bf2dab9b0e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e06d579f-cadd-48a8-9e8d-0b81c591e378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_506124d6-896a-47a5-95d8-4e2c9808cac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_05ce8a66-e28c-4e3f-b975-6bf2dab9b0e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_506124d6-896a-47a5-95d8-4e2c9808cac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51b16c98-bdaf-46e4-b486-7225a31bff78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_05ce8a66-e28c-4e3f-b975-6bf2dab9b0e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51b16c98-bdaf-46e4-b486-7225a31bff78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9312a29a-bc4c-486f-ba0a-6ee3a140489b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_60d5e266-beff-434c-bb45-a0d51126637e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9312a29a-bc4c-486f-ba0a-6ee3a140489b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_60d5e266-beff-434c-bb45-a0d51126637e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cd53ef60-b249-4c77-b1b4-a2163f4effd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9312a29a-bc4c-486f-ba0a-6ee3a140489b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cd53ef60-b249-4c77-b1b4-a2163f4effd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cd6280c2-45ff-490f-88d6-1036fbcbbeba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9312a29a-bc4c-486f-ba0a-6ee3a140489b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cd6280c2-45ff-490f-88d6-1036fbcbbeba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_2aa6640b-eeb2-4baf-b211-c0f85ee3276d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9312a29a-bc4c-486f-ba0a-6ee3a140489b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_2aa6640b-eeb2-4baf-b211-c0f85ee3276d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1397b024-968b-4adb-8f7b-9cf4d22cfa77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_e235fb5a-5960-4338-ac38-115636aa6a31" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1397b024-968b-4adb-8f7b-9cf4d22cfa77" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_e235fb5a-5960-4338-ac38-115636aa6a31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent_d8143310-c037-4f8a-a3ea-358090c7c0e8" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1397b024-968b-4adb-8f7b-9cf4d22cfa77" xlink:to="loc_ck0001824293_AccruedLicensingFeesCurrent_d8143310-c037-4f8a-a3ea-358090c7c0e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_f3f1ecdf-15cb-4000-903c-0d5ac4036abb" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1397b024-968b-4adb-8f7b-9cf4d22cfa77" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_f3f1ecdf-15cb-4000-903c-0d5ac4036abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_266f7d36-c85c-4674-9236-2eb43cff4053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1397b024-968b-4adb-8f7b-9cf4d22cfa77" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_266f7d36-c85c-4674-9236-2eb43cff4053" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ck0001824293-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:721867bc-d51d-454c-b3fb-8a0d76704c20,g:cae8d22d-48c3-4397-b0dc-0800bb57f504-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#StatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="extended" id="i0144024ca50748cd9b173a0c98125394_StatementsofChangesinStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3ddb070e-4b36-4767-b56d-7ea4038a1638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3ddb070e-4b36-4767-b56d-7ea4038a1638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8a3546e-723d-4717-92bb-29da66a8121f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockholdersEquity_c8a3546e-723d-4717-92bb-29da66a8121f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8784c008-678a-4052-b12f-25183be7c49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8784c008-678a-4052-b12f-25183be7c49c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_47a4df56-7151-452e-bdd0-77ba4a6756d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_47a4df56-7151-452e-bdd0-77ba4a6756d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83cb6f50-ea04-4782-86d3-47452a9920d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83cb6f50-ea04-4782-86d3-47452a9920d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a792d4a-800c-4cae-badf-8b9bca2d5562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a792d4a-800c-4cae-badf-8b9bca2d5562" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9f972d91-d344-476b-a547-e33e0bf57b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9f972d91-d344-476b-a547-e33e0bf57b2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_86b1e789-e953-454c-8caa-694a6bd78ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_86b1e789-e953-454c-8caa-694a6bd78ea8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ea96e836-0532-4304-a11d-590c7bdf02ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ea96e836-0532-4304-a11d-590c7bdf02ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_776732b3-7432-4d86-b0e0-2d8bf1921c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_776732b3-7432-4d86-b0e0-2d8bf1921c74" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f3a8df9-4731-45ab-b45a-c05b4c47413d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f3a8df9-4731-45ab-b45a-c05b4c47413d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0261f277-4aac-4c6c-bdc5-176cb154cf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_NetIncomeLoss_0261f277-4aac-4c6c-bdc5-176cb154cf0f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39c49dad-462c-4317-88b8-217f7d0062c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_17b03a1e-ace1-47a2-8612-da9bee01ffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_473284d9-910e-4700-a0ae-140d1a99b549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StatementTable_473284d9-910e-4700-a0ae-140d1a99b549" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5fa5d2fd-459a-4932-ab02-02095599bc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_473284d9-910e-4700-a0ae-140d1a99b549" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5fa5d2fd-459a-4932-ab02-02095599bc2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5fa5d2fd-459a-4932-ab02-02095599bc2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fa5d2fd-459a-4932-ab02-02095599bc2f" xlink:to="loc_us-gaap_EquityComponentDomain_5fa5d2fd-459a-4932-ab02-02095599bc2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fa5d2fd-459a-4932-ab02-02095599bc2f" xlink:to="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_44b7553c-ebed-431a-8fb0-c96a1705a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:to="loc_us-gaap_CommonStockMember_44b7553c-ebed-431a-8fb0-c96a1705a7e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_53b9a8f2-9786-4089-9136-d79be5fcbebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_53b9a8f2-9786-4089-9136-d79be5fcbebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_337448d8-99f4-47af-a8a6-d679c2f5025b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_337448d8-99f4-47af-a8a6-d679c2f5025b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3ea79c8d-4d4c-407a-a481-23caefb67335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:to="loc_us-gaap_RetainedEarningsMember_3ea79c8d-4d4c-407a-a481-23caefb67335" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended" id="i6957e8420b324848a38f14f42a12377f_LIQUIDITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29d9fb04-da9b-40df-9722-6045c1ac93bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29d9fb04-da9b-40df-9722-6045c1ac93bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1cca4680-c318-474e-adc6-6127d5676c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1cca4680-c318-474e-adc6-6127d5676c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3b359e85-4d53-4d31-b3fe-fbd58f19f407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3b359e85-4d53-4d31-b3fe-fbd58f19f407" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_43eb396c-866e-4f95-a08d-b0928cae41db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_43eb396c-866e-4f95-a08d-b0928cae41db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a7f1ed74-740b-427f-884e-934b9d282e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a7f1ed74-740b-427f-884e-934b9d282e1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3d9a5f52-1683-4f06-9f70-88f233f72b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3d9a5f52-1683-4f06-9f70-88f233f72b99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssuanceExpense_617c3f41-5fd6-4341-b6d5-82b5a399d944" xlink:href="ck0001824293-20220630.xsd#ck0001824293_WarrantsIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_ck0001824293_WarrantsIssuanceExpense_617c3f41-5fd6-4341-b6d5-82b5a399d944" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3c072e1f-7c9b-4b09-8009-f49df9183b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3c072e1f-7c9b-4b09-8009-f49df9183b41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_edd955c5-e015-4786-8d9e-03f873dce8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_edd955c5-e015-4786-8d9e-03f873dce8e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6e801dc6-8d06-4557-bab0-e79894e5bd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_edd955c5-e015-4786-8d9e-03f873dce8e8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6e801dc6-8d06-4557-bab0-e79894e5bd4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e801dc6-8d06-4557-bab0-e79894e5bd4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6e801dc6-8d06-4557-bab0-e79894e5bd4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e801dc6-8d06-4557-bab0-e79894e5bd4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f602606-39ca-44b8-b228-0a7e956cd83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6e801dc6-8d06-4557-bab0-e79894e5bd4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f602606-39ca-44b8-b228-0a7e956cd83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_e7c703f2-6297-4aa9-93a2-9c619677f583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f602606-39ca-44b8-b228-0a7e956cd83a" xlink:to="loc_us-gaap_IPOMember_e7c703f2-6297-4aa9-93a2-9c619677f583" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended" id="id23bbfd2d1824383bdf5273100999f6f_MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4717aca6-c55d-4112-aa09-e48249fab78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4717aca6-c55d-4112-aa09-e48249fab78a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_836d5c79-35a3-4e85-a344-ca32e156ca11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_836d5c79-35a3-4e85-a344-ca32e156ca11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ee0faae4-be9e-4763-952f-cd75f2634e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ee0faae4-be9e-4763-952f-cd75f2634e61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d69c9463-73da-4dea-92b9-d8128f0cdcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d69c9463-73da-4dea-92b9-d8128f0cdcfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_0c8f81a8-df30-4d2c-820e-c10057249c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_0c8f81a8-df30-4d2c-820e-c10057249c55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b4930caf-62e5-4b39-b397-da13fac925a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_0c8f81a8-df30-4d2c-820e-c10057249c55" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b4930caf-62e5-4b39-b397-da13fac925a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b4930caf-62e5-4b39-b397-da13fac925a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b4930caf-62e5-4b39-b397-da13fac925a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b4930caf-62e5-4b39-b397-da13fac925a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be49107f-3628-465f-a459-3101bf9633ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b4930caf-62e5-4b39-b397-da13fac925a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be49107f-3628-465f-a459-3101bf9633ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6c65ef8a-fc20-435b-b7f7-080008020e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be49107f-3628-465f-a459-3101bf9633ca" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6c65ef8a-fc20-435b-b7f7-080008020e65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_e8b92a66-3350-4ef4-9d2a-fe21261cc23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be49107f-3628-465f-a459-3101bf9633ca" xlink:to="loc_us-gaap_MunicipalBondsMember_e8b92a66-3350-4ef4-9d2a-fe21261cc23e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i4e4e132bc62440bdbde83f08b104f28e_MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a1624e-0e19-4d22-a509-cd244d756c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1cbabc1-b9d5-463c-89aa-498c06f74d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a1624e-0e19-4d22-a509-cd244d756c33" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1cbabc1-b9d5-463c-89aa-498c06f74d42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecc90131-8ee7-44a4-916a-1a5223f0bf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1cbabc1-b9d5-463c-89aa-498c06f74d42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecc90131-8ee7-44a4-916a-1a5223f0bf7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fd31129c-6884-452c-ae1c-51d10c0bfc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a1624e-0e19-4d22-a509-cd244d756c33" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fd31129c-6884-452c-ae1c-51d10c0bfc71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_ad3004c4-9bf6-42e9-a0eb-5bee31c20a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fd31129c-6884-452c-ae1c-51d10c0bfc71" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_ad3004c4-9bf6-42e9-a0eb-5bee31c20a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686ad470-b360-4c58-8545-ef8d639a1a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a1624e-0e19-4d22-a509-cd244d756c33" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686ad470-b360-4c58-8545-ef8d639a1a58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_684490c4-4040-40f3-a1bc-b7f265aadad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686ad470-b360-4c58-8545-ef8d639a1a58" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_684490c4-4040-40f3-a1bc-b7f265aadad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_684490c4-4040-40f3-a1bc-b7f265aadad9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_684490c4-4040-40f3-a1bc-b7f265aadad9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_684490c4-4040-40f3-a1bc-b7f265aadad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_684490c4-4040-40f3-a1bc-b7f265aadad9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0686cafd-36e5-4ab8-98d2-e2e3ea3588e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0686cafd-36e5-4ab8-98d2-e2e3ea3588e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_37bb8770-be41-45fb-aaf1-e4ca4fbf43b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_37bb8770-be41-45fb-aaf1-e4ca4fbf43b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_687f7924-05fa-4d0c-b6aa-6f9d64389477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_687f7924-05fa-4d0c-b6aa-6f9d64389477" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended" id="i7f3d6c5925b5411780d903bef67a6636_MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8bece37a-2a3c-4c05-a1f5-1737c3ccea53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8bece37a-2a3c-4c05-a1f5-1737c3ccea53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c43e596d-2b0e-4e17-9b10-206d5306a4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c43e596d-2b0e-4e17-9b10-206d5306a4bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_790f273e-7b2d-4d3a-add1-6b2f25652ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_790f273e-7b2d-4d3a-add1-6b2f25652ead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0adcd1b7-95f1-48c4-b735-ca6fd0f1d590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3d4f9efb-5be6-4676-b61c-0478f816e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3d4f9efb-5be6-4676-b61c-0478f816e9e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_19a5c61b-11fa-4dd1-9b34-a2a383f7579f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3d4f9efb-5be6-4676-b61c-0478f816e9e6" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_19a5c61b-11fa-4dd1-9b34-a2a383f7579f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_19a5c61b-11fa-4dd1-9b34-a2a383f7579f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_19a5c61b-11fa-4dd1-9b34-a2a383f7579f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_19a5c61b-11fa-4dd1-9b34-a2a383f7579f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_49f6d9d9-75b1-43b9-b6f8-bdba78589b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_19a5c61b-11fa-4dd1-9b34-a2a383f7579f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_49f6d9d9-75b1-43b9-b6f8-bdba78589b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_e77703b2-86da-4cfc-8833-bb6a88f204cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_49f6d9d9-75b1-43b9-b6f8-bdba78589b24" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_e77703b2-86da-4cfc-8833-bb6a88f204cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended" id="i56e784186d4d43fb8aa29cffed8b1e02_MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_82dc67f7-81fe-4349-8150-91fa4541f0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_cb910224-6e8b-48b9-a607-e0656dab26a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_82dc67f7-81fe-4349-8150-91fa4541f0e9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_cb910224-6e8b-48b9-a607-e0656dab26a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_118d0f30-e95e-4633-b193-7f7f914cb038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_82dc67f7-81fe-4349-8150-91fa4541f0e9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_118d0f30-e95e-4633-b193-7f7f914cb038" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_11eff0b2-847e-4e22-b3f8-1cbd68d65205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_118d0f30-e95e-4633-b193-7f7f914cb038" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_11eff0b2-847e-4e22-b3f8-1cbd68d65205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_11eff0b2-847e-4e22-b3f8-1cbd68d65205_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_11eff0b2-847e-4e22-b3f8-1cbd68d65205" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_11eff0b2-847e-4e22-b3f8-1cbd68d65205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_11eff0b2-847e-4e22-b3f8-1cbd68d65205" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_02db766e-eb1a-4073-be7a-251c9643e238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_02db766e-eb1a-4073-be7a-251c9643e238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_fa4d8625-404b-4020-816a-f06748300610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_fa4d8625-404b-4020-816a-f06748300610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_698346aa-ad4e-45a5-bd90-b5e3ecc0bebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_698346aa-ad4e-45a5-bd90-b5e3ecc0bebe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3cc1f558-9ea1-492b-a678-0738a87d97ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3cc1f558-9ea1-492b-a678-0738a87d97ca" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#PPPNOTEANDCONVERTIBLENOTESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="extended" id="i780ba8719a6c4f7f80a464cc55187ef6_PPPNOTEANDCONVERTIBLENOTESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0e114ead-cb37-462e-8628-2ebbb3bb4d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0e114ead-cb37-462e-8628-2ebbb3bb4d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55a992d2-becf-41e6-afb8-a6653de1c000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55a992d2-becf-41e6-afb8-a6653de1c000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_9a714075-74dc-4f9b-b2af-54deb3bdddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_DebtInstrumentTerm_9a714075-74dc-4f9b-b2af-54deb3bdddd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm_a541f946-31a5-4f34-9839-4aa35b0b6251" xlink:href="ck0001824293-20220630.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_ck0001824293_DebtInstrumentPaymentTerm_a541f946-31a5-4f34-9839-4aa35b0b6251" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_38614f7a-e854-4862-a472-4cc40136f43c" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_38614f7a-e854-4862-a472-4cc40136f43c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_518a3095-126f-4282-a008-e32ad5c10d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_518a3095-126f-4282-a008-e32ad5c10d51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e48a59a0-f373-463c-85d9-8be03aa713d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e48a59a0-f373-463c-85d9-8be03aa713d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_498e474f-66ab-4ea2-b0ab-0834eaa926ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_498e474f-66ab-4ea2-b0ab-0834eaa926ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_498e474f-66ab-4ea2-b0ab-0834eaa926ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_498e474f-66ab-4ea2-b0ab-0834eaa926ba" xlink:to="loc_us-gaap_RelatedPartyDomain_498e474f-66ab-4ea2-b0ab-0834eaa926ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1b7ba2c9-e11a-4709-8393-9d9e4af9edd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_498e474f-66ab-4ea2-b0ab-0834eaa926ba" xlink:to="loc_us-gaap_RelatedPartyDomain_1b7ba2c9-e11a-4709-8393-9d9e4af9edd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_d9a55c28-5d1b-47e3-9a1b-5c337be34145" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1b7ba2c9-e11a-4709-8393-9d9e4af9edd4" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_d9a55c28-5d1b-47e3-9a1b-5c337be34145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b35e1987-958c-43cf-8676-adc05f174650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b35e1987-958c-43cf-8676-adc05f174650" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b35e1987-958c-43cf-8676-adc05f174650_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b35e1987-958c-43cf-8676-adc05f174650" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b35e1987-958c-43cf-8676-adc05f174650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fde9aab5-27f7-4f24-8057-8b4d386e812e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b35e1987-958c-43cf-8676-adc05f174650" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fde9aab5-27f7-4f24-8057-8b4d386e812e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_9aa355a6-2bfe-47e8-9e3f-fe28fee2827f" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_fde9aab5-27f7-4f24-8057-8b4d386e812e" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_9aa355a6-2bfe-47e8-9e3f-fe28fee2827f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8f125f42-1c9d-43ea-a6ee-8951180a4ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:to="loc_us-gaap_DebtInstrumentAxis_8f125f42-1c9d-43ea-a6ee-8951180a4ee6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8f125f42-1c9d-43ea-a6ee-8951180a4ee6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8f125f42-1c9d-43ea-a6ee-8951180a4ee6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8f125f42-1c9d-43ea-a6ee-8951180a4ee6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbb547df-3a9a-4e4a-9c20-1a6c2ca2f5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8f125f42-1c9d-43ea-a6ee-8951180a4ee6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbb547df-3a9a-4e4a-9c20-1a6c2ca2f5f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_1e1098b7-ce50-473e-8d95-b3abedd41d3d" xlink:href="ck0001824293-20220630.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbb547df-3a9a-4e4a-9c20-1a6c2ca2f5f2" xlink:to="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_1e1098b7-ce50-473e-8d95-b3abedd41d3d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKHOLDERSEQUITYDEFICITNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails" xlink:type="extended" id="i1e8dca9dd18a44c08a6d41d06b1f6611_STOCKHOLDERSEQUITYDEFICITNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f17d3b4e-37bc-429e-bfe5-dffced27bf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f17d3b4e-37bc-429e-bfe5-dffced27bf30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a41277a9-3e09-461a-bf88-5fd5bd62d6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a41277a9-3e09-461a-bf88-5fd5bd62d6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_744f8904-811d-402a-b822-78ce9feefebf" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_744f8904-811d-402a-b822-78ce9feefebf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_af811c64-5db7-4c88-b850-8327cd15e246" xlink:href="ck0001824293-20220630.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_af811c64-5db7-4c88-b850-8327cd15e246" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_590a8a62-a8a7-4928-b363-6b4ce7cfded2" xlink:href="ck0001824293-20220630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_590a8a62-a8a7-4928-b363-6b4ce7cfded2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_594af544-60a5-4d2b-aa5a-b3612a0653b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_594af544-60a5-4d2b-aa5a-b3612a0653b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f19db405-eb3d-48bf-95b9-cdd2fafbab07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f19db405-eb3d-48bf-95b9-cdd2fafbab07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssuanceExpense_cc93b779-d4a1-4ace-8668-85db07c5a38d" xlink:href="ck0001824293-20220630.xsd#ck0001824293_WarrantsIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_ck0001824293_WarrantsIssuanceExpense_cc93b779-d4a1-4ace-8668-85db07c5a38d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3aa494a7-721e-4c5c-bd52-4511b353259a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3aa494a7-721e-4c5c-bd52-4511b353259a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b57f4ac9-1991-4919-a49c-72ef1da54dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b57f4ac9-1991-4919-a49c-72ef1da54dc8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_a7936646-7e61-4b31-b815-6818417e66c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_a7936646-7e61-4b31-b815-6818417e66c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_a9783156-5032-4c68-973e-40a7d73a5b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_a9783156-5032-4c68-973e-40a7d73a5b40" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_ca5edc8b-d8ed-4b9d-8948-30a968d93468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_ca5edc8b-d8ed-4b9d-8948-30a968d93468" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2722e391-c77c-4aa2-a8c9-8ad377db1687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2722e391-c77c-4aa2-a8c9-8ad377db1687" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c84ca99d-69e8-4ce3-b655-32a23a50adeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2722e391-c77c-4aa2-a8c9-8ad377db1687" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c84ca99d-69e8-4ce3-b655-32a23a50adeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c84ca99d-69e8-4ce3-b655-32a23a50adeb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c84ca99d-69e8-4ce3-b655-32a23a50adeb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c84ca99d-69e8-4ce3-b655-32a23a50adeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5919046-babe-40b4-9cb9-9d0a6769786b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c84ca99d-69e8-4ce3-b655-32a23a50adeb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5919046-babe-40b4-9cb9-9d0a6769786b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_d8f0271c-f183-4ef5-b98b-69e92343466f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5919046-babe-40b4-9cb9-9d0a6769786b" xlink:to="loc_us-gaap_IPOMember_d8f0271c-f183-4ef5-b98b-69e92343466f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_b74384fb-2f57-4fdf-a725-2c3150954fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5919046-babe-40b4-9cb9-9d0a6769786b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_b74384fb-2f57-4fdf-a725-2c3150954fd8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended" id="i03ffa868dc864c05be248860783df6ae_STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_fd1a8a98-7e27-44a4-8328-e16fd8cd8d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3ac63cf4-7f1b-43dd-b70d-efb69c071b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fd1a8a98-7e27-44a4-8328-e16fd8cd8d5a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3ac63cf4-7f1b-43dd-b70d-efb69c071b71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_fd1a8a98-7e27-44a4-8328-e16fd8cd8d5a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b4ddcddf-be4c-415a-b35b-cf50e466e37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b4ddcddf-be4c-415a-b35b-cf50e466e37c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b4ddcddf-be4c-415a-b35b-cf50e466e37c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b4ddcddf-be4c-415a-b35b-cf50e466e37c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b4ddcddf-be4c-415a-b35b-cf50e466e37c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b4ddcddf-be4c-415a-b35b-cf50e466e37c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_9011773d-07df-4a2e-9254-fd02d7220278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_9011773d-07df-4a2e-9254-fd02d7220278" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_eaedf424-3e29-46b4-be1a-8774c540435b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_eaedf424-3e29-46b4-be1a-8774c540435b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_cbf0e1ef-daba-4975-aba0-7b41e25f1fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_cbf0e1ef-daba-4975-aba0-7b41e25f1fe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1812d1d3-e3ca-44ea-b41a-8f4c54e0c501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1812d1d3-e3ca-44ea-b41a-8f4c54e0c501" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16f2bd5-e4c7-4402-884b-493b96cba723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16f2bd5-e4c7-4402-884b-493b96cba723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIPOMember_de04a41c-a45f-499b-bcb4-ee37eeb02274" xlink:href="ck0001824293-20220630.xsd#ck0001824293_WarrantsIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16f2bd5-e4c7-4402-884b-493b96cba723" xlink:to="loc_ck0001824293_WarrantsIPOMember_de04a41c-a45f-499b-bcb4-ee37eeb02274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_Warrants2022Member_3613e63c-7bff-4173-bcb1-c5d7b24ae2a7" xlink:href="ck0001824293-20220630.xsd#ck0001824293_Warrants2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16f2bd5-e4c7-4402-884b-493b96cba723" xlink:to="loc_ck0001824293_Warrants2022Member_3613e63c-7bff-4173-bcb1-c5d7b24ae2a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i54761c1fc9e448398c77326cd9393eb9_STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f93fae0-c4d1-4236-89b8-94ff702ca032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2463abcd-9ad6-4900-93c6-d2e0df2aee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f93fae0-c4d1-4236-89b8-94ff702ca032" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2463abcd-9ad6-4900-93c6-d2e0df2aee2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1210410c-f9d6-4ec1-898c-2993608dc692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f93fae0-c4d1-4236-89b8-94ff702ca032" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1210410c-f9d6-4ec1-898c-2993608dc692" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c1624f82-eb16-48f0-a9bc-449fae5098ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1210410c-f9d6-4ec1-898c-2993608dc692" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c1624f82-eb16-48f0-a9bc-449fae5098ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1624f82-eb16-48f0-a9bc-449fae5098ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1624f82-eb16-48f0-a9bc-449fae5098ff" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1624f82-eb16-48f0-a9bc-449fae5098ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7ab5e78a-bba6-45cc-88d0-730f886fd15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1624f82-eb16-48f0-a9bc-449fae5098ff" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7ab5e78a-bba6-45cc-88d0-730f886fd15d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1f480788-f0de-419d-92f5-60573d2bb287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab5e78a-bba6-45cc-88d0-730f886fd15d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1f480788-f0de-419d-92f5-60573d2bb287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_57dfefce-edc7-44aa-b5d2-35f2495fd288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab5e78a-bba6-45cc-88d0-730f886fd15d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_57dfefce-edc7-44aa-b5d2-35f2495fd288" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i32fba03e89884e3c920b3fa3ad057f18_STOCKBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9b23ecfd-1d7c-49e0-8f0e-0c932f1cbcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9b23ecfd-1d7c-49e0-8f0e-0c932f1cbcbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b0c5a897-3576-4990-bb4b-605b94715d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b0c5a897-3576-4990-bb4b-605b94715d1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2fe4e9a9-a7b7-4648-9431-c5393ddda43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2fe4e9a9-a7b7-4648-9431-c5393ddda43e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cdc9a97b-b200-4da8-8cb5-8912dacb97aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cdc9a97b-b200-4da8-8cb5-8912dacb97aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d09dc21-d571-4dfd-b054-f06999321ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d09dc21-d571-4dfd-b054-f06999321ddf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb246436-f107-4e75-adf0-d8d553b4dfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb246436-f107-4e75-adf0-d8d553b4dfa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26156f56-30ab-4e3b-adca-414c9fd84d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb246436-f107-4e75-adf0-d8d553b4dfa5" xlink:to="loc_us-gaap_AwardTypeAxis_26156f56-30ab-4e3b-adca-414c9fd84d5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26156f56-30ab-4e3b-adca-414c9fd84d5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_26156f56-30ab-4e3b-adca-414c9fd84d5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26156f56-30ab-4e3b-adca-414c9fd84d5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2024d88-4ab3-465d-9866-5ca13a0bdc48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_26156f56-30ab-4e3b-adca-414c9fd84d5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2024d88-4ab3-465d-9866-5ca13a0bdc48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_257b26d5-af9b-4ca7-906c-c59a3afbf044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2024d88-4ab3-465d-9866-5ca13a0bdc48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_257b26d5-af9b-4ca7-906c-c59a3afbf044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1537136d-d2a4-4c73-80eb-b8a8489735da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2024d88-4ab3-465d-9866-5ca13a0bdc48" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1537136d-d2a4-4c73-80eb-b8a8489735da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails" xlink:type="extended" id="i23f3370ee2d6464bbe8365f36cb43242_STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcaef71a-0691-421e-ab74-7798f7a6f673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcaef71a-0691-421e-ab74-7798f7a6f673" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b42a8fc-c1fd-4abb-8325-a758d27e65c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b42a8fc-c1fd-4abb-8325-a758d27e65c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7cc6247c-9fe4-43a3-8ad4-78818133d6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7cc6247c-9fe4-43a3-8ad4-78818133d6d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_954db91c-cc27-44f0-b053-ac299ecc8665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41aee20c-12a3-444a-b389-3a5a62bbbe27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcaef71a-0691-421e-ab74-7798f7a6f673" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41aee20c-12a3-444a-b389-3a5a62bbbe27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc0bf175-7dfd-4e62-b67a-cebc29f417ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41aee20c-12a3-444a-b389-3a5a62bbbe27" xlink:to="loc_us-gaap_AwardTypeAxis_cc0bf175-7dfd-4e62-b67a-cebc29f417ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc0bf175-7dfd-4e62-b67a-cebc29f417ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc0bf175-7dfd-4e62-b67a-cebc29f417ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc0bf175-7dfd-4e62-b67a-cebc29f417ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be0c7a8d-ccab-4b50-bbda-306a20645e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc0bf175-7dfd-4e62-b67a-cebc29f417ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be0c7a8d-ccab-4b50-bbda-306a20645e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5805dd2a-d9e5-4f5d-b99e-a19ace893d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be0c7a8d-ccab-4b50-bbda-306a20645e27" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5805dd2a-d9e5-4f5d-b99e-a19ace893d98" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i583a0af456e847128fc6fc96e45779c1_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_775a71a0-b3eb-42ac-a805-0369bd1626c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_775a71a0-b3eb-42ac-a805-0369bd1626c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_301fe621-7a6d-4daa-839d-653f42566666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_301fe621-7a6d-4daa-839d-653f42566666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5589ef3a-2c9d-454b-97e5-a8d09c6225ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5589ef3a-2c9d-454b-97e5-a8d09c6225ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316" xlink:to="loc_us-gaap_RelatedPartyDomain_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_974ccd90-717f-413e-a801-6655f67e46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316" xlink:to="loc_us-gaap_RelatedPartyDomain_974ccd90-717f-413e-a801-6655f67e46d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_4c35236f-3631-4521-8957-5ed9803817aa" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_974ccd90-717f-413e-a801-6655f67e46d6" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_4c35236f-3631-4521-8957-5ed9803817aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7fc02525-2347-4bc9-9af6-e2346dcb0714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7fc02525-2347-4bc9-9af6-e2346dcb0714" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_5444c0c4-3ace-4605-94cd-8dabd6186d14" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7fc02525-2347-4bc9-9af6-e2346dcb0714" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_5444c0c4-3ace-4605-94cd-8dabd6186d14" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ck0001824293-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:721867bc-d51d-454c-b3fb-8a0d76704c20,g:cae8d22d-48c3-4397-b0dc-0800bb57f504-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_98ded506-57d7-4aee-8778-c67a1bfd0909_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 1 year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1a473aef-15f9-43dc-8753-480af1ae43f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_df80c483-168c-4690-95e6-368e2e0d1dda_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e7b9e409-4144-484a-bd1a-8c81e75d55dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3a0edc69-f43a-4904-b7b5-30015904e09e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_379605e2-0ce8-4344-8c6a-3896669e27a6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional&#160;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e185aca9-7b80-4c42-9caa-84fcd747c04a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89f3b9c2-984a-4567-8de8-7d0b6a451a4f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f7177075-3906-4801-840e-799e9c552fff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d7466805-f0eb-45ad-b126-4fea54c2faae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7a992290-35e9-472c-8f30-b047b6655b6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_5d7ccc5a-178d-4341-a1e3-ba30a9f2e442_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 5-10 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0cab03c-5f92-4fb3-a2c9-66e80ea90384_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0caa879d-16cd-4fa3-957f-d0f475536e17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_e6f19755-64b6-4afc-aeee-4d899cc642cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ed688970-1f43-4e2e-baa3-37a36e5dc13d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec7356da-b674-4a6e-bd3e-9e02ab0bad23_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae74f4cd-ea01-446b-8a1a-dec716928c8e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_833d0666-4aa6-46b1-8538-4657d0f26937_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_481a98c3-9f3d-40f8-bc7a-ee4556efb18d_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing related</link:label>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Licensing Fees, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Licensing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedLicensingFeesCurrent" xlink:to="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f4e39126-ad45-4e33-81e6-3792ae8e47bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d96f41af-807a-4c78-8f37-758e0a1c3bc2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79475807-683e-434e-81df-00c65206c47d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6d377c8-8521-4a3d-a2ad-40066ad5ae0b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_59b10c99-6a93-4fae-a3db-56a56cb14dc2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d32259e8-3079-4570-9e93-00f9d0e56756_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Underwriters Warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ad0ed11c-feaf-419a-8cef-1537cdbb86b9_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant issued reflected in additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b60d73c6-7611-4d29-af18-0fa56c130655_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e5153b77-8de0-45ee-962f-38ae89fd50f5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_21ceb46f-d25a-48f3-bc6d-201a3f78a637_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3ac6dc5a-3ed9-46ec-bbc8-d04302458a75_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d9db760f-9ebd-4105-88ab-b5a0988326f5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6c375b60-f495-4800-a63a-579293b7716b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_30328dbd-e9a1-4c75-82cb-7407801a51e9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8f35e8eb-eed2-4b83-a30e-c1b5155bb01f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 1-5 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_11a9d49d-d863-47ee-a6fb-62da59abf3aa_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_32eaa0a8-e4e3-4300-a463-5025bfd19bc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b98c445-17c6-4eba-ad04-158611f5fcaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ee25cc4e-f573-4cef-a101-f33331817b7c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5083fa8d-e11e-42a5-81ff-e3e55cf22880_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d6cf64c1-5b07-4126-a6ae-954c39dc2963_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d7c066ec-a4e9-4524-991e-127d2ce45572_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5e460b7f-876d-4c70-9ff3-fbfe9f90054f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4547f9ed-cfc1-4a74-b0a6-b9ceee430013_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_021de2b4-da27-482d-8617-367fb4b923ef_terseLabel_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_label_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement [Member]</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_documentation_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:to="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0cf61307-0319-422e-9bf7-77517e998f1e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab697b97-3b42-4f4b-9d3c-470520625e3f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_da0028ac-a2ff-4cde-824e-8e332ff470b6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_28a7c5da-444c-45d7-be4e-25d9106c6fe5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_742663c7-de8d-4aef-a791-9660902d32be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e01288d4-ecc5-4c36-8f1c-89b8a2e5b5d7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd148e78-18f4-4a24-94ae-bf76582a50d0_netLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2549c972-eed4-4958-a2cb-aed5aefc01fb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eac4f9d2-77d5-4f21-b34d-443c9f0e0fc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2ecf5714-9c01-4da3-b2e5-b1caa69b5aa1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_8e9c7f18-1f78-4238-9222-011182c7c7eb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_9ecc7526-054e-4c44-bce2-68b5f7c9bc24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bd14a116-08b6-4fc1-a4ff-fce28adcf696_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e22dd4a8-e204-4450-b06c-cc82ef3a17f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2342535f-5734-41ef-9727-a820e69c59a7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4ec00ac0-b5ca-4b95-aaaf-fda66cba13e2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90fcec16-1094-4407-983c-8fcfcf3afaa3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_788d59a7-8d9c-448d-ae9a-a04cba572982_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_511a7318-93ed-4a0a-aa1f-8953783c4701_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8742c5d0-188b-41f4-ad0c-21c457181130_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ba0183c6-198a-427c-8314-ee57a6f914ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_71e1acbc-438c-41b7-99a3-4ac437089039_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ebdd6ccb-0ec8-4a2f-9183-5b457a64161e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_faccc6c7-0a58-40fc-9054-441da86f9d80_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_Warrants2022Member_68459ac1-09d7-4452-9e71-739209472d45_terseLabel_en-US" xlink:label="lab_ck0001824293_Warrants2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2022</link:label>
    <link:label id="lab_ck0001824293_Warrants2022Member_label_en-US" xlink:label="lab_ck0001824293_Warrants2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2022 [Member]</link:label>
    <link:label id="lab_ck0001824293_Warrants2022Member_documentation_en-US" xlink:label="lab_ck0001824293_Warrants2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_Warrants2022Member" xlink:href="ck0001824293-20220630.xsd#ck0001824293_Warrants2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_Warrants2022Member" xlink:to="lab_ck0001824293_Warrants2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_7b198348-2ea8-4a58-80a2-2b76f17a77f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest, depreciation and other expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a665a608-e9db-46a7-93b9-977bfd34991a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_09a98e51-9c63-4d8a-8076-0ff2871ea0fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_82b34f43-6d5a-4b81-9cca-b9f43d7a7e87_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_5ded6f27-bbfa-4adc-90e8-ed756aca1259_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e240faa2-584e-4862-b933-4ad6140a5efe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_97f97e1e-b53b-4381-8bf5-c08edc5a1d08_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3b71c62f-5dd9-453e-b4f7-4b84b60eb85b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_8b7ac27c-2974-4b2f-abca-ca2b8fa6f3ee_terseLabel_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subjects that completed the SEAL study</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_label_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants, Completed the Study</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_documentation_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants, Completed the Study</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:to="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_aebf1f18-837d-49c4-ae4b-db6fddee781d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_22cbe3d6-dc45-4824-819a-86fd8c840b24_terseLabel_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subjects enrolled in the SEAL study</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_label_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants Enrolled</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_documentation_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants Enrolled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:to="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_83b277dd-a05c-4598-bb97-6a85ffbbb284_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_48499694-e59d-4c28-99c5-8a9155374d69_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_418d5716-991b-4746-b33d-799fc107fc5d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b78799e4-7a72-41b0-8d99-e110246310a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_99f15df8-045f-41f8-92b7-613c542b4c44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized on embedded derivative</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_dd782d0f-a309-4602-948d-d42b866c99c4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_3a47a5fa-cddf-42f5-a7e4-18dd05e24b7e_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from stock offering</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Gross</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b824b2da-b668-485e-a237-3e5ef1144bb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1182da9a-fda4-4af0-909b-c1da4dacc168_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1339ff9f-a865-4597-8401-58bdaf76c9f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04a63733-227d-4530-9c86-07948d3ffb59_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_90133e5d-5d2b-411c-a9b0-06a807ed482c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and IPO, net of issuance expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e87694a3-da1a-4043-9f0b-6c80cf387e3f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fc2fd68-348c-4431-be32-5206879e117f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e20c8e9-64dd-4b5f-a6e4-92835dda74be_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_eb4abe83-0433-4c80-a685-eea48168dc5d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a694a911-8b26-48bc-bd57-040d7f4cb6b8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_622f4bd4-3f82-47f8-9a7e-374cda0aa837_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_137287a2-4bd3-4da8-8a56-d82dce447cb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f0b5659a-81a1-4480-9f51-3c64b46eb76f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d600e218-c6d1-487b-8fc7-cc9b9b36eed4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2330e294-6a2b-4319-952f-491a9b967989_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ba290cb3-dae8-41d0-8b8e-0398e20a163e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_62a34f09-c47f-47d9-9177-357e589f7434_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs, discounts and commissions</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Discounts And Commissions</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Discounts And Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:href="ck0001824293-20220630.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:to="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_688f0bfd-85b4-430d-8c40-fa68817c174b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP NOTE AND CONVERTIBLE NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dbbfdcab-b8ec-4480-9e97-4c8dfb4c4af0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_451ce616-13bc-4430-93e2-3b59d4d32ac9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4c680f7-334b-4635-a7e7-cfc60d1fa556_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e7a82e49-6ab6-4089-8b56-23af3b8c7a00_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_514d5fb1-7096-4f9a-92f2-a526a804a8e2_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9c49542d-1355-4d14-bc5b-854fa42288f8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a08867a2-d473-47fd-b39c-fb527c20a74c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_db855f22-3f5d-4407-af1a-0480653ae16c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b91374d4-8be4-4b9c-b3e2-c24fed16ddc2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9604908b-e200-4aba-91fb-4fa107160e6c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6894e1cf-24b5-4dec-9dcc-e92052cf17fe_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_77b3d404-b429-462e-bab0-f71782f88687_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2c7e1602-edb2-43e0-a517-d79bfd1defc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_192e683e-7713-45b3-9835-00d3b58205fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of marketable securities premiums</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_6b4fb78c-daf4-4f94-8e38-182683704537_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_78269d5a-dd6e-4a76-a56d-2f5f1e7cec96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_c57ba3f4-32b4-407b-813c-a4928f2933bf_terseLabel_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subjects included in the final SEAL study analysis</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_label_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants, Included in Final Study Analysis</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_documentation_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants, Included in Final Study Analysis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:to="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17912072-5893-48ed-afe2-99322e697c42_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_690850c4-531e-4816-943b-4bd42b8b44e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d8eaf1e0-a2aa-42c9-80c4-a316f9d445c3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b1a18865-2641-4776-abbe-23089ac3168d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a0c156e-aa2a-4f73-9a4f-7798332d49e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5c27db1-8f0f-494b-bc06-656907734936_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9bbaacea-e25d-4ddc-98c1-86b3112d5946_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_36c4cbc3-c653-47b0-afff-6129a5d5517d_verboseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional offering expense</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20220630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_07dd9b1d-d6db-479b-b677-1cbab6bdec3f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_cc965905-959e-497b-9bf3-47262dc414b5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2c45b15f-d21d-46d9-8dd9-b0c3caf14e80_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4e0f5966-51b5-4828-9bc0-b68406e73f12_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_82fa17a8-965f-4569-aaa3-2430f2b66d2b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bc671cb9-6f10-438e-bd70-157c903e52b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0c2a0af2-285c-48e7-be47-63cc57694350_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_83ef783b-7d73-49ee-8a71-1a2a0459b58e_terseLabel_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:href="ck0001824293-20220630.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:to="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_66c78111-b041-4f4c-a945-500c3108eb62_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_9bf9cddc-9415-4356-bccd-6e6568064762_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_a7d64254-7216-4e8a-9c21-7151d87eeea9_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_9542f847-e17c-42c1-b1a7-aefb979fa834_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_00f48775-4387-4a87-97fb-4efd977d0a20_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_336eda55-81b7-4eaa-9e78-d3aff41c26d3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8601aa40-4765-433e-9046-18b7c1b29e50_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a40e7113-85e7-4f8a-9c4a-504f68508ba4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ad5a0db2-9696-4f7f-a061-94be22763e1f_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5df519a5-0cae-4d00-9a02-7e0a99ac74b7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d978f57-2e21-468f-8446-ee35c2c1bc4b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation, weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_14d2a110-5c57-4e8f-82e2-b3389e6db31e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Balance Ending (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_837a2fb2-5e05-44f4-b937-4c9a3dbddb40_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_640f7cb2-cf51-44f3-8712-45a27866639e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c44e979c-bb1b-4060-b236-a7a1a5691992_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5a8c7e8d-cbce-4cbb-81c0-1cdc631eab17_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a5bb5e77-055f-42c5-8551-5939174992d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_032f02cc-4320-45f6-9d00-f39d99bab28e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4c1d0fd4-e8f2-4780-aba2-7e6613f23a45_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d9a0724f-2bc8-4009-a444-e4fb84d1618a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ab8f58be-9e63-487a-befd-7cafbcb4a8f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ebb3f6cc-836b-4105-814f-39719c7a0703_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and IPO, net of issuance expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c308fa1-21b4-46de-b4e7-4cb30eaadc26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_8c4c8478-c90d-4b99-8c7d-507f7594a44a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c14e676c-a6ca-420b-8161-f561cda8f656_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_8eb4299f-f780-4a57-bcfc-11725168af6c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0d532dbc-db6d-445f-87d4-bdd062bad15d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b9cab1da-6f51-4f3b-90a5-7af8211e63a0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_23d3cfb3-3bc8-4072-aaf3-feb94eade7ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_feaa8170-caca-4198-a261-68bf40d23359_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8a70481b-e473-406d-9fb3-d813993167a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_806defb5-f9af-48e6-ad9a-3941b63d6615_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a04cbdab-f653-41d5-a4e8-b7106876b974_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e9d7e54c-55a9-4c14-88a5-8aafc9dd8d81_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb268936-bf74-4da9-b652-1ee06ba82180_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0ce8434f-1260-49fa-95c6-7f2898061d9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_b1fbd8d3-8e31-4fc2-a485-647457eca741_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_a81dbb7e-59c8-49fc-9e54-ce6a37c817a8_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_97cfc7b8-13b4-4485-8977-00e0525381bb_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cc155f4b-f4ae-415e-a4b0-33ae933c72e9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b65443bc-160c-434b-ac5c-0c36df7de109_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6509f53c-8ab9-4ca1-a023-3e32bae88c9a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_fdda772c-4d79-4d1f-8e84-a93760597903_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, maturity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eb165761-2776-4bdf-8eb3-cdaf27561f7a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c565cb15-754b-4691-bd73-0f6ec6239c31_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_02c87407-9341-4879-80de-96512b536d00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_acc66e92-4dcf-45ee-866c-aa35c28f76f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial measurement on May 17, 2022</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f8300d5-6b15-47eb-a2ca-7922306e0ed4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_be06d3f8-2d82-44c3-af9b-0bca0570e91c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_809a39f3-d9f1-4cf0-8c25-0ebbd4c87ca1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f4e8425a-d36d-475f-80bf-d3b7f7ccd28e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_17f4fc4c-2c08-475c-8606-0db184c162b6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a4d93890-bca9-455f-80a1-a2868c2e2723_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9c532651-9533-49ee-80eb-2dc6f19f0d7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_85618e04-14bf-46f1-9997-27b7e2dc1552_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c4f057c0-975d-4010-908c-d7649c7a1dd6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9b73b6b3-e9dc-497e-a2a8-5bba7f5bf7cb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_9d920057-0c60-4794-a68d-40720f46c263_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_fb75f27b-def5-4d5c-a786-2047c334d0c4_negatedLabel_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP note</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_8bac1861-0571-4a54-909a-1f8821fc9526_terseLabel_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP note</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_label_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Of Debt Instrument</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_documentation_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Of Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ForgivenessOfDebtInstrument" xlink:to="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f0efe1dc-8a50-41c5-82a9-7d73dfcc4431_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7c47ae8f-3014-42d9-b3f0-5c7712bee734_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6ed1803f-e045-4317-8f23-697f11a08f26_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_191cbca2-32d6-4bad-ab20-0bd3f7863120_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_368ad91d-dd13-45dc-ae77-5a64d29971e9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_85750b9d-3949-4519-ad4d-72c2cd3f9802_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_320ca59f-4ccc-404e-9014-d4235bb9fe26_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of June 30, 2022</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_2a6a652b-c79d-4f80-a3d2-d9503afda22f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_792ebdaf-a0d9-4b5c-ae3d-5bebf8b449a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_024ebb3c-b2af-4fb2-a26c-5a2235e548a6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_5b36b848-770c-4191-891a-8767bb2a9a97_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after 10 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_af79e86f-6453-40d0-b983-f5be9c5dc2e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_247a0bc0-8900-46b3-b4ac-c0b2e94a5303_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, payment term</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Term</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm" xlink:href="ck0001824293-20220630.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentPaymentTerm" xlink:to="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c3dd4f49-c982-43f9-9039-6783dcbff03b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_df5f2a1b-9531-46f6-9ceb-8ff13824c0f3_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9141929c-7a97-4efb-892f-dd3fa83647ff_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8c04e065-9e31-4ffb-9899-0fd20fca9fd2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8a8e675a-323d-4f8e-ad49-1697a24d7fcd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock awards, contractual life (up to)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_8b2d24ec-4350-4609-9215-01c41931f01c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_be9146cb-794b-4a8e-82f4-96e1437986d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_28a10ee5-7788-4ff7-a21a-18b15b23e7db_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_db2ce467-ab31-4d54-b1b8-5d5ef7b59605_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_300cfa3a-cacd-4ce6-b018-f75c43ed88ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_8377f0e3-e687-4981-96cf-cdb631f05d73_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' Allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_007c7c9c-924f-455e-8b6f-5d7fa2f655bf_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_38063fcd-01d0-4f25-8cdb-dc1f9822474b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b70ff700-0316-4e09-aac4-0afd8aa8403d_terseLabel_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salmon Pharma, Affiliate of Medice and David Baker, CEO</link:label>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_label_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate of Medice and David Baker, CEO [Member]</link:label>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_documentation_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate of Medice and David Baker, CEO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:to="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f1f26a1a-59af-44af-9c76-30a58864d410_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d10692c-ea22-42ca-b4a3-261222170b5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8aff77b5-6f83-4e0c-856d-b59cd54f92b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6106dcc9-11c4-4b84-a8ab-1bdc8bf08525_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33158567-485a-4cee-bd17-0f2e98286f4b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c1609ffb-310e-4c5e-848a-e50b713f292e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_526dc10c-7df3-48dd-b8e4-90dda8df5f72_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5dd1e376-1657-4d6d-8231-830238e3cdfb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_118caf98-6b3f-45fd-9fcf-ac88540ce788_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_097b9773-7771-405a-962a-424e0b72d0b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8e138c9f-7fa2-4f49-8cea-07a90763959c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_f7867496-a935-4e20-9e00-4c41737a950a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6865f9aa-0ef4-4d5a-850e-3a2851786577_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_a2f7bb0a-718c-49fb-9fff-bfe3f4596ad1_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_30b1f70e-878a-44f9-8a24-65c631cd140e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_53ecbe0f-f427-4520-bf1e-4feb7e9fd2c9_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_79295245-f1c7-4b4b-9caf-b9ed6e930bbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3e479fbe-5d33-4588-bdf6-95cbafa94e6f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_99ff9d8f-f78e-4eb7-b2c7-e5856c30e31f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_66b6cdb1-a06f-4aaa-a536-a9bd5e285348_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_8a5be9b5-ac29-48cd-afe3-d161f761db74_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a1e59989-1337-47c2-88f0-98def6479941_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_aa47ecd8-a9a2-4593-8e86-6f0cd670c841_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5d34e240-2f52-4fd3-9c63-d4d9de1d9537_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_594f355e-bafd-49f1-bb71-911891f4b77f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsIssuanceExpense_08678f07-8cbe-418c-8cc7-82a294960815_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issuance expense</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssuanceExpense_label_en-US" xlink:label="lab_ck0001824293_WarrantsIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issuance Expense</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssuanceExpense_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssuanceExpense" xlink:href="ck0001824293-20220630.xsd#ck0001824293_WarrantsIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsIssuanceExpense" xlink:to="lab_ck0001824293_WarrantsIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4209b220-0dd1-4bd5-bd25-6b6ff438597b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_94cba065-a873-47ad-af29-4aa618fefbb6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62374b40-116c-4e2c-91c5-d443ee1d46d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsIPOMember_022e18c7-0b60-46cf-a390-32b417c40f33_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsIPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants-IPO</link:label>
    <link:label id="lab_ck0001824293_WarrantsIPOMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsIPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants-IPO [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsIPOMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsIPOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants-IPO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIPOMember" xlink:href="ck0001824293-20220630.xsd#ck0001824293_WarrantsIPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsIPOMember" xlink:to="lab_ck0001824293_WarrantsIPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0ee3992c-1a44-47ac-99e9-14fd40bed17c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6868b7b6-5ba5-4bdd-a7d0-bd3143181a02_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8ea8811-980c-4a4f-869c-6cb363569602_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_dd9397f3-224f-42bd-93a5-99f9929a2cd9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_71f40e1f-f34d-438d-b916-714758947dac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_919327dc-422a-456c-ab8c-59f72602905c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a7f485b1-3ec6-4325-9828-f1768a3298ac_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_6864b5b9-6002-4e53-b085-00be059741e2_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_477cee52-da9f-4aed-a4a7-bf92a9f2e70e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_79c0c5c5-cb55-44a7-80f3-cba5572ef45b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f96f84c1-de4b-4432-9b44-3d4540cde2a0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7c12d932-b69f-463b-a6c6-dba3b09cec4f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4c5dc546-d608-4703-af96-2bfe540cf53c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_22de2f20-c644-4140-ba61-6e20c9becd65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_1a41502a-c128-406d-8ce2-faaa76b4fb18_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6017f09b-e57a-41c4-8124-20b0ea3aea44_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b9154560-5469-456e-8bb5-8f1b6126de8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3720b63a-bc71-4124-a24e-18cb28d984c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_cd323e1b-d8d8-442e-b5b6-13f03e855fe9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b72eadda-56bf-49e3-9571-0f9c0541cd3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_46bbafc7-10fa-4384-9e6f-ba95b70c9c58_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e4b5920c-4691-445e-b541-e68ef84cb945_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_c173d288-3816-42b3-a9a4-24ac17c4e808_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e5fad616-3d12-4be0-a13e-cde4765af8c4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f759c645-a190-436b-a88a-3d1e5ace3d3d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d16f617a-bdbc-4f7e-a5d3-e5d4e54432e9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c5f66760-71df-41e3-8db9-2c2c4435d2ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, converted, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_27e988d0-2321-4e67-8a2a-f70cf5e1ff0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6b0bfcd4-993a-43de-a564-aa7a8ff5d5a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f2fb95ef-e866-4228-8ea3-f3cda083f6f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_43b21c31-7664-49d7-bd8c-e0a1d53d7cb4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_c1a28567-27f7-4a79-96c2-fd3f02e428d8_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of offering expenses</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance of Common Stock and Warrants, Net</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance of Common Stock and Warrants, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:to="lab_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ck0001824293-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:721867bc-d51d-454c-b3fb-8a0d76704c20,g:cae8d22d-48c3-4397-b0dc-0800bb57f504-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_da08c5df-dece-4627-85be-02c5d3eb2b67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_DocumentType_da08c5df-dece-4627-85be-02c5d3eb2b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9b0d7c9e-9938-4364-97e4-62265e0677c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_DocumentQuarterlyReport_9b0d7c9e-9938-4364-97e4-62265e0677c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_53a2eec9-f1b5-4d1b-8096-fca52d5c27cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_DocumentPeriodEndDate_53a2eec9-f1b5-4d1b-8096-fca52d5c27cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e238fa2e-c941-4b87-996b-2283a5254b28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_DocumentTransitionReport_e238fa2e-c941-4b87-996b-2283a5254b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_931ce0f8-a165-4353-a39c-b36f2e40afa0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityFileNumber_931ce0f8-a165-4353-a39c-b36f2e40afa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f9aa373a-ea61-4d6c-8544-f160f0760397" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityRegistrantName_f9aa373a-ea61-4d6c-8544-f160f0760397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6f96b437-44e0-4f80-bed9-7f1ad74d5872" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6f96b437-44e0-4f80-bed9-7f1ad74d5872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_71d050d7-4b10-4b7b-acce-66e2289cf139" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityTaxIdentificationNumber_71d050d7-4b10-4b7b-acce-66e2289cf139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7a64ae76-7f96-4aed-ab83-5d34ea0bde30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityAddressAddressLine1_7a64ae76-7f96-4aed-ab83-5d34ea0bde30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_eeb6e585-c7ac-4e43-ad9a-886edc86ac1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityAddressAddressLine2_eeb6e585-c7ac-4e43-ad9a-886edc86ac1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fae26014-5313-41d7-92a2-3de9c95cbfd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityAddressCityOrTown_fae26014-5313-41d7-92a2-3de9c95cbfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_860bf53e-5134-48af-92b0-959cc7eaea71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityAddressStateOrProvince_860bf53e-5134-48af-92b0-959cc7eaea71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_24351b48-6fec-404c-a6e7-4393011665dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityAddressPostalZipCode_24351b48-6fec-404c-a6e7-4393011665dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_71e9dee3-ad25-4cea-86d6-fd14bcb353cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_CityAreaCode_71e9dee3-ad25-4cea-86d6-fd14bcb353cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c42c9066-ddfa-4ef1-b56e-82be20ab9491" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_LocalPhoneNumber_c42c9066-ddfa-4ef1-b56e-82be20ab9491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_04e685c6-2366-4c18-83e7-1c0ff68d6eba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_Security12bTitle_04e685c6-2366-4c18-83e7-1c0ff68d6eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_31f96f6f-97e0-44d4-99c2-ac26a093bac6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_TradingSymbol_31f96f6f-97e0-44d4-99c2-ac26a093bac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_01e4f546-fe46-489a-b0b0-6fd9e7ca1d73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityCurrentReportingStatus_01e4f546-fe46-489a-b0b0-6fd9e7ca1d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_324bc048-3e23-427e-9900-c7c8324ca2c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityInteractiveDataCurrent_324bc048-3e23-427e-9900-c7c8324ca2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_72ed06d6-cfff-437e-8fbe-ca6e188a70ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityFilerCategory_72ed06d6-cfff-437e-8fbe-ca6e188a70ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8b5e7616-7ecc-40ef-925e-c7bb27844483" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntitySmallBusiness_8b5e7616-7ecc-40ef-925e-c7bb27844483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_012b1cc8-1a70-4a19-ae2d-9a50d3816067" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityEmergingGrowthCompany_012b1cc8-1a70-4a19-ae2d-9a50d3816067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_788c85f3-a6ff-4740-94b7-455a03abd877" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityShellCompany_788c85f3-a6ff-4740-94b7-455a03abd877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e9be4ba9-bc92-4ab1-9a76-493311481f0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e9be4ba9-bc92-4ab1-9a76-493311481f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_19480740-ac63-4ea3-87e0-a29df0b94414" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityCentralIndexKey_19480740-ac63-4ea3-87e0-a29df0b94414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1b67c008-b1af-4e36-9d2c-9b9a8ca8f4ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_CurrentFiscalYearEndDate_1b67c008-b1af-4e36-9d2c-9b9a8ca8f4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_964ac89e-f6e9-4361-88bc-13390c0145ab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_DocumentFiscalYearFocus_964ac89e-f6e9-4361-88bc-13390c0145ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_506e59a4-1f53-42d6-a996-0086476aaab5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_506e59a4-1f53-42d6-a996-0086476aaab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_51174c14-e2d4-4091-a47a-9ad0682d898c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_AmendmentFlag_51174c14-e2d4-4091-a47a-9ad0682d898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_13f524f2-3a0c-49c0-9fd2-60187d1892b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_SecurityExchangeName_13f524f2-3a0c-49c0-9fd2-60187d1892b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_38c7e76c-41d2-415b-a22f-ff91a3708572" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e73e1e69-5789-48e1-83a9-d7ae15b57d9d" xlink:to="loc_dei_EntityExTransitionPeriod_38c7e76c-41d2-415b-a22f-ff91a3708572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ab5a6ebe-31e0-42f4-bcc3-21be39447437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_01b84dcd-8ff6-4ec8-baf9-a548be14ece1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ab5a6ebe-31e0-42f4-bcc3-21be39447437" xlink:to="loc_us-gaap_AssetsAbstract_01b84dcd-8ff6-4ec8-baf9-a548be14ece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_67e98c4e-7479-48cf-96e9-d803370c60c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_01b84dcd-8ff6-4ec8-baf9-a548be14ece1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_67e98c4e-7479-48cf-96e9-d803370c60c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51d22357-aa28-4495-8d5d-93f8836d4e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e98c4e-7479-48cf-96e9-d803370c60c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51d22357-aa28-4495-8d5d-93f8836d4e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6e528bc4-9cd1-46fb-a8fa-fb52f3d66b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e98c4e-7479-48cf-96e9-d803370c60c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6e528bc4-9cd1-46fb-a8fa-fb52f3d66b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4dbb2ea0-4154-41ac-814e-140c60078cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e98c4e-7479-48cf-96e9-d803370c60c9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4dbb2ea0-4154-41ac-814e-140c60078cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6b8e39a7-908e-4170-be02-571d2b87c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e98c4e-7479-48cf-96e9-d803370c60c9" xlink:to="loc_us-gaap_AssetsCurrent_6b8e39a7-908e-4170-be02-571d2b87c02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2e1c18f3-904c-456e-bf16-aafcde392ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_01b84dcd-8ff6-4ec8-baf9-a548be14ece1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2e1c18f3-904c-456e-bf16-aafcde392ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4753d3ea-adcf-4879-bbb6-f5093aaa64bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_01b84dcd-8ff6-4ec8-baf9-a548be14ece1" xlink:to="loc_us-gaap_Assets_4753d3ea-adcf-4879-bbb6-f5093aaa64bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83d0c2dd-cf4a-4b66-8e04-0c2d97da6def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ab5a6ebe-31e0-42f4-bcc3-21be39447437" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83d0c2dd-cf4a-4b66-8e04-0c2d97da6def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a8bf4e71-49c2-4bf0-9a3a-63bd8757afe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83d0c2dd-cf4a-4b66-8e04-0c2d97da6def" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a8bf4e71-49c2-4bf0-9a3a-63bd8757afe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f6719763-5868-42ea-9164-822790d76f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bf4e71-49c2-4bf0-9a3a-63bd8757afe3" xlink:to="loc_us-gaap_AccountsPayableCurrent_f6719763-5868-42ea-9164-822790d76f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_306f9fee-cda3-4c64-897d-f5e14211b5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bf4e71-49c2-4bf0-9a3a-63bd8757afe3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_306f9fee-cda3-4c64-897d-f5e14211b5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5ba0793c-d852-4d0e-ab64-06d58e67ee8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bf4e71-49c2-4bf0-9a3a-63bd8757afe3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5ba0793c-d852-4d0e-ab64-06d58e67ee8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5cd2a963-f07b-459d-9627-28bed7cbfcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bf4e71-49c2-4bf0-9a3a-63bd8757afe3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5cd2a963-f07b-459d-9627-28bed7cbfcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_72c295b6-b949-436a-af2b-a2ae3beb62ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bf4e71-49c2-4bf0-9a3a-63bd8757afe3" xlink:to="loc_us-gaap_LiabilitiesCurrent_72c295b6-b949-436a-af2b-a2ae3beb62ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ba1eb8c7-0ca6-43ec-a282-112ac259d71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83d0c2dd-cf4a-4b66-8e04-0c2d97da6def" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ba1eb8c7-0ca6-43ec-a282-112ac259d71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d53f3eff-2080-4b7b-ad51-0f0711ec7ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83d0c2dd-cf4a-4b66-8e04-0c2d97da6def" xlink:to="loc_us-gaap_Liabilities_d53f3eff-2080-4b7b-ad51-0f0711ec7ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9dcab613-9659-4a4e-a1f1-117816204814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83d0c2dd-cf4a-4b66-8e04-0c2d97da6def" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9dcab613-9659-4a4e-a1f1-117816204814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_09a467d4-9712-48f5-b79c-f85336d59e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83d0c2dd-cf4a-4b66-8e04-0c2d97da6def" xlink:to="loc_us-gaap_StockholdersEquityAbstract_09a467d4-9712-48f5-b79c-f85336d59e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_b77f7be6-afbe-4a84-9354-1e9fd269fa41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09a467d4-9712-48f5-b79c-f85336d59e15" xlink:to="loc_us-gaap_CommonStockValueOutstanding_b77f7be6-afbe-4a84-9354-1e9fd269fa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6cd075ab-6a05-4065-bdb9-040175bb2ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09a467d4-9712-48f5-b79c-f85336d59e15" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6cd075ab-6a05-4065-bdb9-040175bb2ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09cb3803-6ebf-4f5c-9751-84487671d05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09a467d4-9712-48f5-b79c-f85336d59e15" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09cb3803-6ebf-4f5c-9751-84487671d05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_289096b0-3441-4990-9d5f-0e5df2358c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09a467d4-9712-48f5-b79c-f85336d59e15" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_289096b0-3441-4990-9d5f-0e5df2358c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_363e2d62-f048-4bfa-a598-4a9a02fc3095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09a467d4-9712-48f5-b79c-f85336d59e15" xlink:to="loc_us-gaap_StockholdersEquity_363e2d62-f048-4bfa-a598-4a9a02fc3095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d257dbb3-54e8-480b-b9bb-30359b097a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09a467d4-9712-48f5-b79c-f85336d59e15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d257dbb3-54e8-480b-b9bb-30359b097a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c498602f-0d89-452d-9365-ca13a4251433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e028563c-58d5-4d86-be85-d1ae72daa823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c498602f-0d89-452d-9365-ca13a4251433" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e028563c-58d5-4d86-be85-d1ae72daa823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c1a0065b-5093-4043-a9f4-920cd4eae543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c498602f-0d89-452d-9365-ca13a4251433" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c1a0065b-5093-4043-a9f4-920cd4eae543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f2065c84-a82b-4cbb-9076-84b96e44e051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c498602f-0d89-452d-9365-ca13a4251433" xlink:to="loc_us-gaap_CommonStockSharesIssued_f2065c84-a82b-4cbb-9076-84b96e44e051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d74f77fa-b2a6-4758-ba74-f5ef8626bd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c498602f-0d89-452d-9365-ca13a4251433" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d74f77fa-b2a6-4758-ba74-f5ef8626bd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d44b327c-1426-4ebe-b0f8-92aea17ea338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d44b327c-1426-4ebe-b0f8-92aea17ea338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c2c5700b-8ed0-49bf-a34d-8e0f56851e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d44b327c-1426-4ebe-b0f8-92aea17ea338" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c2c5700b-8ed0-49bf-a34d-8e0f56851e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3e8b1d9f-7f5d-4266-b20c-9e2fdeb799f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d44b327c-1426-4ebe-b0f8-92aea17ea338" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3e8b1d9f-7f5d-4266-b20c-9e2fdeb799f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1625e9fd-6b94-4780-9020-4004f1053fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d44b327c-1426-4ebe-b0f8-92aea17ea338" xlink:to="loc_us-gaap_OperatingExpenses_1625e9fd-6b94-4780-9020-4004f1053fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_abc9d259-43d8-465b-912a-4b5dd50975d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_OperatingIncomeLoss_abc9d259-43d8-465b-912a-4b5dd50975d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_a14ddf6e-9395-4beb-81d5-c2bfed791ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_OtherNonoperatingIncome_a14ddf6e-9395-4beb-81d5-c2bfed791ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_4d032486-e9b0-459b-91dd-2724963b0fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_4d032486-e9b0-459b-91dd-2724963b0fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_354e4506-cc5b-4040-a1e0-29dbde057efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_354e4506-cc5b-4040-a1e0-29dbde057efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_7ef2b886-fc59-478e-ad62-05615aa4ef84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_7ef2b886-fc59-478e-ad62-05615aa4ef84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_046deb38-4ce8-448f-932f-2c44623d8f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_NetIncomeLoss_046deb38-4ce8-448f-932f-2c44623d8f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_882457ab-46a0-4a5f-b791-d12b29b78b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_882457ab-46a0-4a5f-b791-d12b29b78b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_62f717a5-3fce-4f59-9ebb-7dc48196e030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_882457ab-46a0-4a5f-b791-d12b29b78b86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_62f717a5-3fce-4f59-9ebb-7dc48196e030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8a5879f7-2bdc-442e-90aa-6dd23464f9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8a5879f7-2bdc-442e-90aa-6dd23464f9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d8d13ce5-6e10-4cb4-9569-5fd3b900b979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_EarningsPerShareBasic_d8d13ce5-6e10-4cb4-9569-5fd3b900b979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_174f207d-87a5-457f-8ef3-a2dcd28019fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_EarningsPerShareDiluted_174f207d-87a5-457f-8ef3-a2dcd28019fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_418cfc80-9467-4fc0-b72c-ef4976e77ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_418cfc80-9467-4fc0-b72c-ef4976e77ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e03ad4ac-21d4-4e6d-ba4d-c41b0ae66a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_060dd166-2372-4cc8-92c7-0fe88f0e8826" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e03ad4ac-21d4-4e6d-ba4d-c41b0ae66a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#StatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d9e18843-9c12-4e74-a3f8-f810af40d604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_473284d9-910e-4700-a0ae-140d1a99b549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d9e18843-9c12-4e74-a3f8-f810af40d604" xlink:to="loc_us-gaap_StatementTable_473284d9-910e-4700-a0ae-140d1a99b549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5fa5d2fd-459a-4932-ab02-02095599bc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_473284d9-910e-4700-a0ae-140d1a99b549" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5fa5d2fd-459a-4932-ab02-02095599bc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fa5d2fd-459a-4932-ab02-02095599bc2f" xlink:to="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_44b7553c-ebed-431a-8fb0-c96a1705a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:to="loc_us-gaap_CommonStockMember_44b7553c-ebed-431a-8fb0-c96a1705a7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_53b9a8f2-9786-4089-9136-d79be5fcbebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_53b9a8f2-9786-4089-9136-d79be5fcbebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_337448d8-99f4-47af-a8a6-d679c2f5025b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_337448d8-99f4-47af-a8a6-d679c2f5025b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3ea79c8d-4d4c-407a-a481-23caefb67335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a14c4d48-4a6c-46d4-a600-3b1563b95be7" xlink:to="loc_us-gaap_RetainedEarningsMember_3ea79c8d-4d4c-407a-a481-23caefb67335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_473284d9-910e-4700-a0ae-140d1a99b549" xlink:to="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3ddb070e-4b36-4767-b56d-7ea4038a1638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3ddb070e-4b36-4767-b56d-7ea4038a1638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8a3546e-723d-4717-92bb-29da66a8121f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockholdersEquity_c8a3546e-723d-4717-92bb-29da66a8121f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8784c008-678a-4052-b12f-25183be7c49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8784c008-678a-4052-b12f-25183be7c49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_47a4df56-7151-452e-bdd0-77ba4a6756d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_47a4df56-7151-452e-bdd0-77ba4a6756d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83cb6f50-ea04-4782-86d3-47452a9920d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83cb6f50-ea04-4782-86d3-47452a9920d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a792d4a-800c-4cae-badf-8b9bca2d5562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a792d4a-800c-4cae-badf-8b9bca2d5562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9f972d91-d344-476b-a547-e33e0bf57b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9f972d91-d344-476b-a547-e33e0bf57b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_86b1e789-e953-454c-8caa-694a6bd78ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_86b1e789-e953-454c-8caa-694a6bd78ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ea96e836-0532-4304-a11d-590c7bdf02ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ea96e836-0532-4304-a11d-590c7bdf02ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_776732b3-7432-4d86-b0e0-2d8bf1921c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_776732b3-7432-4d86-b0e0-2d8bf1921c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f3a8df9-4731-45ab-b45a-c05b4c47413d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f3a8df9-4731-45ab-b45a-c05b4c47413d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0261f277-4aac-4c6c-bdc5-176cb154cf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_NetIncomeLoss_0261f277-4aac-4c6c-bdc5-176cb154cf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39c49dad-462c-4317-88b8-217f7d0062c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_39c49dad-462c-4317-88b8-217f7d0062c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_17b03a1e-ace1-47a2-8612-da9bee01ffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c06d5224-3b57-4ac2-bce8-a8d1b86c9001" xlink:to="loc_us-gaap_StockholdersEquity_17b03a1e-ace1-47a2-8612-da9bee01ffc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9dee61b9-ebce-4f22-9f21-1a643b86890b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e58446d4-f087-43e3-9224-ae0c2ae91419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9dee61b9-ebce-4f22-9f21-1a643b86890b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e58446d4-f087-43e3-9224-ae0c2ae91419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7961962c-83a4-4fed-91df-3a633b7edb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e58446d4-f087-43e3-9224-ae0c2ae91419" xlink:to="loc_us-gaap_NetIncomeLoss_7961962c-83a4-4fed-91df-3a633b7edb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e58446d4-f087-43e3-9224-ae0c2ae91419" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e0fc104f-b59d-4501-bd0c-7dcdf3531602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e0fc104f-b59d-4501-bd0c-7dcdf3531602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5fec9163-a82e-49ea-8115-d27aa82d5bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5fec9163-a82e-49ea-8115-d27aa82d5bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bfaaafc8-3b62-444c-8fe0-c2c18ef02c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_us-gaap_ShareBasedCompensation_bfaaafc8-3b62-444c-8fe0-c2c18ef02c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_f4742eb0-6253-4a3c-aa59-491a2625c51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_f4742eb0-6253-4a3c-aa59-491a2625c51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3cc34d2a-e56f-4808-a27f-b57e3b53a72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3cc34d2a-e56f-4808-a27f-b57e3b53a72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_780e2360-4024-4709-b83a-6ea08ed4482e" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_780e2360-4024-4709-b83a-6ea08ed4482e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_6601c59a-8c56-4fdb-b111-def3b64f8269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_us-gaap_OtherNoncashExpense_6601c59a-8c56-4fdb-b111-def3b64f8269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1f7afd39-5a50-4aaa-8153-1d400956faed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1f7afd39-5a50-4aaa-8153-1d400956faed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8c17549f-9e41-4537-b5ba-a54f031cf5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1f7afd39-5a50-4aaa-8153-1d400956faed" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8c17549f-9e41-4537-b5ba-a54f031cf5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8fc03b6f-c2c0-43b2-adda-fed8a5a99148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1f7afd39-5a50-4aaa-8153-1d400956faed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8fc03b6f-c2c0-43b2-adda-fed8a5a99148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6bee6c0b-969d-4004-96a8-8d018d2641b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1f7afd39-5a50-4aaa-8153-1d400956faed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6bee6c0b-969d-4004-96a8-8d018d2641b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c7029c3-381e-4b3e-8b8e-74f916a78c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08b54a62-ac8c-4376-b70c-656c6ce8ddd3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c7029c3-381e-4b3e-8b8e-74f916a78c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d76b7f4a-c36a-497e-9824-ec643dc790f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9dee61b9-ebce-4f22-9f21-1a643b86890b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d76b7f4a-c36a-497e-9824-ec643dc790f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cba46a15-1a2d-4570-96c9-f71dc734a96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d76b7f4a-c36a-497e-9824-ec643dc790f3" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cba46a15-1a2d-4570-96c9-f71dc734a96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_103b2ffc-afb7-43e5-93ad-616e7c04c7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d76b7f4a-c36a-497e-9824-ec643dc790f3" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_103b2ffc-afb7-43e5-93ad-616e7c04c7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4756de96-6110-4031-aa2e-50909a3a579f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d76b7f4a-c36a-497e-9824-ec643dc790f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4756de96-6110-4031-aa2e-50909a3a579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0200b6c-38a9-4f7a-9a9f-433597e38665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9dee61b9-ebce-4f22-9f21-1a643b86890b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0200b6c-38a9-4f7a-9a9f-433597e38665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_4e07f715-31fc-4202-b7cf-977a9aa2a361" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0200b6c-38a9-4f7a-9a9f-433597e38665" xlink:to="loc_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_4e07f715-31fc-4202-b7cf-977a9aa2a361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_47cb0fe3-6530-48b9-b837-15912c140c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0200b6c-38a9-4f7a-9a9f-433597e38665" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_47cb0fe3-6530-48b9-b837-15912c140c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6259b03a-dc8d-4756-ad52-6cd2ffe49e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0200b6c-38a9-4f7a-9a9f-433597e38665" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6259b03a-dc8d-4756-ad52-6cd2ffe49e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c4fe097-62ae-4a93-9ec0-a3656af430b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0200b6c-38a9-4f7a-9a9f-433597e38665" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c4fe097-62ae-4a93-9ec0-a3656af430b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_80357656-518d-4b3a-8f6a-c5a46564bab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9dee61b9-ebce-4f22-9f21-1a643b86890b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_80357656-518d-4b3a-8f6a-c5a46564bab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa9bfee1-94f0-4181-bda2-0175914369c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9dee61b9-ebce-4f22-9f21-1a643b86890b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa9bfee1-94f0-4181-bda2-0175914369c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4cfef29d-bf60-420c-94ce-c723b62c407a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9dee61b9-ebce-4f22-9f21-1a643b86890b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4cfef29d-bf60-420c-94ce-c723b62c407a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_18767cc6-54c1-4e72-88f2-cc985e1e5062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9dee61b9-ebce-4f22-9f21-1a643b86890b" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_18767cc6-54c1-4e72-88f2-cc985e1e5062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_c761ec76-d27b-400d-9725-0609b98cbde3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_18767cc6-54c1-4e72-88f2-cc985e1e5062" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_c761ec76-d27b-400d-9725-0609b98cbde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e2f6e3c-45b1-47d2-9991-b03b4a3862b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_d43284fd-d04e-4602-86b1-8dc04b3b1185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e2f6e3c-45b1-47d2-9991-b03b4a3862b2" xlink:to="loc_us-gaap_NatureOfOperations_d43284fd-d04e-4602-86b1-8dc04b3b1185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18540908-399f-4b50-acd1-2b8813682a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_77052f05-ae2a-4c86-8490-0dce34260293" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18540908-399f-4b50-acd1-2b8813682a8e" xlink:to="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_77052f05-ae2a-4c86-8490-0dce34260293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_3ee31f21-82dd-49ca-9c2d-2ad122c2c6b8" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18540908-399f-4b50-acd1-2b8813682a8e" xlink:to="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_3ee31f21-82dd-49ca-9c2d-2ad122c2c6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_ab073f83-9640-4c61-ba66-8d6435f13904" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18540908-399f-4b50-acd1-2b8813682a8e" xlink:to="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_ab073f83-9640-4c61-ba66-8d6435f13904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_859a8ed8-0151-4eba-bf2b-2521352609ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_2017f4f2-ffa9-4df8-a759-b9278f5217c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_859a8ed8-0151-4eba-bf2b-2521352609ea" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_2017f4f2-ffa9-4df8-a759-b9278f5217c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b20e1d9-a6ba-483c-a5d1-ec6e3b314eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21f569e7-9be2-48a5-8d3b-b14c16447d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b20e1d9-a6ba-483c-a5d1-ec6e3b314eaa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21f569e7-9be2-48a5-8d3b-b14c16447d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_34bbe829-0117-4bbb-8047-74b96c52971b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b20e1d9-a6ba-483c-a5d1-ec6e3b314eaa" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_34bbe829-0117-4bbb-8047-74b96c52971b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_edd955c5-e015-4786-8d9e-03f873dce8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b20e1d9-a6ba-483c-a5d1-ec6e3b314eaa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_edd955c5-e015-4786-8d9e-03f873dce8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6e801dc6-8d06-4557-bab0-e79894e5bd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_edd955c5-e015-4786-8d9e-03f873dce8e8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6e801dc6-8d06-4557-bab0-e79894e5bd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f602606-39ca-44b8-b228-0a7e956cd83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6e801dc6-8d06-4557-bab0-e79894e5bd4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f602606-39ca-44b8-b228-0a7e956cd83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_e7c703f2-6297-4aa9-93a2-9c619677f583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f602606-39ca-44b8-b228-0a7e956cd83a" xlink:to="loc_us-gaap_IPOMember_e7c703f2-6297-4aa9-93a2-9c619677f583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_edd955c5-e015-4786-8d9e-03f873dce8e8" xlink:to="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29d9fb04-da9b-40df-9722-6045c1ac93bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29d9fb04-da9b-40df-9722-6045c1ac93bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1cca4680-c318-474e-adc6-6127d5676c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1cca4680-c318-474e-adc6-6127d5676c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3b359e85-4d53-4d31-b3fe-fbd58f19f407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3b359e85-4d53-4d31-b3fe-fbd58f19f407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_43eb396c-866e-4f95-a08d-b0928cae41db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_43eb396c-866e-4f95-a08d-b0928cae41db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a7f1ed74-740b-427f-884e-934b9d282e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a7f1ed74-740b-427f-884e-934b9d282e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3d9a5f52-1683-4f06-9f70-88f233f72b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3d9a5f52-1683-4f06-9f70-88f233f72b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssuanceExpense_617c3f41-5fd6-4341-b6d5-82b5a399d944" xlink:href="ck0001824293-20220630.xsd#ck0001824293_WarrantsIssuanceExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_ck0001824293_WarrantsIssuanceExpense_617c3f41-5fd6-4341-b6d5-82b5a399d944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3c072e1f-7c9b-4b09-8009-f49df9183b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61c8dd17-1fe1-4b2a-bf7e-66a429a1e21c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3c072e1f-7c9b-4b09-8009-f49df9183b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_657c1eb0-b7fa-4684-8e7a-968c6fcb88cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f90f9a1e-9c1e-454d-893f-db49907ff9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_657c1eb0-b7fa-4684-8e7a-968c6fcb88cb" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f90f9a1e-9c1e-454d-893f-db49907ff9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48c55079-d95f-4378-92cc-cd0ec116e306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ad30fa81-9120-4900-a65b-989c426f9637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55079-d95f-4378-92cc-cd0ec116e306" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ad30fa81-9120-4900-a65b-989c426f9637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1edcad9b-2977-4d16-a7cf-fbe4055b17c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55079-d95f-4378-92cc-cd0ec116e306" xlink:to="loc_us-gaap_UseOfEstimates_1edcad9b-2977-4d16-a7cf-fbe4055b17c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_b59adf75-1a33-40aa-992c-fc1521f4839d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55079-d95f-4378-92cc-cd0ec116e306" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_b59adf75-1a33-40aa-992c-fc1521f4839d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_f3704b3a-fb87-4603-b638-e51182e3f97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55079-d95f-4378-92cc-cd0ec116e306" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_f3704b3a-fb87-4603-b638-e51182e3f97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_34ef75a9-1624-408b-9f71-a65ed8d23ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55079-d95f-4378-92cc-cd0ec116e306" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_34ef75a9-1624-408b-9f71-a65ed8d23ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_60a86461-a180-4ea6-8ee8-2b4e1b5e09d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48c55079-d95f-4378-92cc-cd0ec116e306" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_60a86461-a180-4ea6-8ee8-2b4e1b5e09d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ab7e5a5e-3475-4698-8316-e3c1983fd850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_54956850-86d9-4c06-ac28-e7c4d8b7c0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab7e5a5e-3475-4698-8316-e3c1983fd850" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_54956850-86d9-4c06-ac28-e7c4d8b7c0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7d5d5877-4c19-4621-8518-eef4c7c0fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2248a860-9da5-4cd9-8db3-ba5b28911651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7d5d5877-4c19-4621-8518-eef4c7c0fb0c" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2248a860-9da5-4cd9-8db3-ba5b28911651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f7760fc7-3339-40ba-b754-934ad27bca43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1e2c5ee7-20e7-43d6-87fd-f46503872bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7760fc7-3339-40ba-b754-934ad27bca43" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1e2c5ee7-20e7-43d6-87fd-f46503872bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_714af1e9-ff8c-413f-a7ce-6e88f33ba58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7760fc7-3339-40ba-b754-934ad27bca43" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_714af1e9-ff8c-413f-a7ce-6e88f33ba58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f824dacf-65ea-4fea-a57a-397bb31dac6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7760fc7-3339-40ba-b754-934ad27bca43" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f824dacf-65ea-4fea-a57a-397bb31dac6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2943c044-bd9b-4f29-a8bf-186840c94eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7760fc7-3339-40ba-b754-934ad27bca43" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2943c044-bd9b-4f29-a8bf-186840c94eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_aeefd340-4e0c-469a-a314-1ff7babb6d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7760fc7-3339-40ba-b754-934ad27bca43" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_aeefd340-4e0c-469a-a314-1ff7babb6d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_90d75421-bb33-41e3-a7b5-37329ec8c30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8e279d4-cb55-4fd0-8095-9a7f072bb48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90d75421-bb33-41e3-a7b5-37329ec8c30f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8e279d4-cb55-4fd0-8095-9a7f072bb48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f101116f-250a-43ad-b762-1d057b3accbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90d75421-bb33-41e3-a7b5-37329ec8c30f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f101116f-250a-43ad-b762-1d057b3accbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8174a3ff-cb73-4f78-8b2f-683e905bd601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90d75421-bb33-41e3-a7b5-37329ec8c30f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8174a3ff-cb73-4f78-8b2f-683e905bd601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_35dace14-2d25-4b3c-89c6-94283e2f99f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90d75421-bb33-41e3-a7b5-37329ec8c30f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_35dace14-2d25-4b3c-89c6-94283e2f99f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_d696e4b4-38a7-469b-b943-7052fe4bcb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90d75421-bb33-41e3-a7b5-37329ec8c30f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_d696e4b4-38a7-469b-b943-7052fe4bcb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_9ae9c16a-fa4f-41a4-b664-9940a5014cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90d75421-bb33-41e3-a7b5-37329ec8c30f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_9ae9c16a-fa4f-41a4-b664-9940a5014cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5e7f0486-1949-431c-b20b-fb09ccf20c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90d75421-bb33-41e3-a7b5-37329ec8c30f" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5e7f0486-1949-431c-b20b-fb09ccf20c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a6d4b03c-3673-4626-837a-87fd3da66e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_0c8f81a8-df30-4d2c-820e-c10057249c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a6d4b03c-3673-4626-837a-87fd3da66e57" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_0c8f81a8-df30-4d2c-820e-c10057249c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b4930caf-62e5-4b39-b397-da13fac925a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_0c8f81a8-df30-4d2c-820e-c10057249c55" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b4930caf-62e5-4b39-b397-da13fac925a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be49107f-3628-465f-a459-3101bf9633ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b4930caf-62e5-4b39-b397-da13fac925a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be49107f-3628-465f-a459-3101bf9633ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6c65ef8a-fc20-435b-b7f7-080008020e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be49107f-3628-465f-a459-3101bf9633ca" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6c65ef8a-fc20-435b-b7f7-080008020e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_e8b92a66-3350-4ef4-9d2a-fe21261cc23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be49107f-3628-465f-a459-3101bf9633ca" xlink:to="loc_us-gaap_MunicipalBondsMember_e8b92a66-3350-4ef4-9d2a-fe21261cc23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_0c8f81a8-df30-4d2c-820e-c10057249c55" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4717aca6-c55d-4112-aa09-e48249fab78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4717aca6-c55d-4112-aa09-e48249fab78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_836d5c79-35a3-4e85-a344-ca32e156ca11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_836d5c79-35a3-4e85-a344-ca32e156ca11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ee0faae4-be9e-4763-952f-cd75f2634e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ee0faae4-be9e-4763-952f-cd75f2634e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d69c9463-73da-4dea-92b9-d8128f0cdcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_63204e70-7b21-443b-937c-eec78b80fd2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d69c9463-73da-4dea-92b9-d8128f0cdcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cd36d71c-14ee-4c85-846f-2ed84fc8c989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686ad470-b360-4c58-8545-ef8d639a1a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cd36d71c-14ee-4c85-846f-2ed84fc8c989" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686ad470-b360-4c58-8545-ef8d639a1a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_684490c4-4040-40f3-a1bc-b7f265aadad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686ad470-b360-4c58-8545-ef8d639a1a58" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_684490c4-4040-40f3-a1bc-b7f265aadad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_684490c4-4040-40f3-a1bc-b7f265aadad9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0686cafd-36e5-4ab8-98d2-e2e3ea3588e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0686cafd-36e5-4ab8-98d2-e2e3ea3588e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_37bb8770-be41-45fb-aaf1-e4ca4fbf43b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_37bb8770-be41-45fb-aaf1-e4ca4fbf43b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_687f7924-05fa-4d0c-b6aa-6f9d64389477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_997ee273-3e3b-4a83-928a-6af6d769ffa8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_687f7924-05fa-4d0c-b6aa-6f9d64389477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a1624e-0e19-4d22-a509-cd244d756c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686ad470-b360-4c58-8545-ef8d639a1a58" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a1624e-0e19-4d22-a509-cd244d756c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1cbabc1-b9d5-463c-89aa-498c06f74d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a1624e-0e19-4d22-a509-cd244d756c33" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1cbabc1-b9d5-463c-89aa-498c06f74d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecc90131-8ee7-44a4-916a-1a5223f0bf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1cbabc1-b9d5-463c-89aa-498c06f74d42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecc90131-8ee7-44a4-916a-1a5223f0bf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fd31129c-6884-452c-ae1c-51d10c0bfc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a1624e-0e19-4d22-a509-cd244d756c33" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fd31129c-6884-452c-ae1c-51d10c0bfc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_ad3004c4-9bf6-42e9-a0eb-5bee31c20a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fd31129c-6884-452c-ae1c-51d10c0bfc71" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_ad3004c4-9bf6-42e9-a0eb-5bee31c20a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a81e8373-d567-4a8f-b065-4fb9c734bd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3d4f9efb-5be6-4676-b61c-0478f816e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a81e8373-d567-4a8f-b065-4fb9c734bd88" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3d4f9efb-5be6-4676-b61c-0478f816e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_19a5c61b-11fa-4dd1-9b34-a2a383f7579f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3d4f9efb-5be6-4676-b61c-0478f816e9e6" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_19a5c61b-11fa-4dd1-9b34-a2a383f7579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_49f6d9d9-75b1-43b9-b6f8-bdba78589b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_19a5c61b-11fa-4dd1-9b34-a2a383f7579f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_49f6d9d9-75b1-43b9-b6f8-bdba78589b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_e77703b2-86da-4cfc-8833-bb6a88f204cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_49f6d9d9-75b1-43b9-b6f8-bdba78589b24" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_e77703b2-86da-4cfc-8833-bb6a88f204cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3d4f9efb-5be6-4676-b61c-0478f816e9e6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8bece37a-2a3c-4c05-a1f5-1737c3ccea53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8bece37a-2a3c-4c05-a1f5-1737c3ccea53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c43e596d-2b0e-4e17-9b10-206d5306a4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c43e596d-2b0e-4e17-9b10-206d5306a4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_790f273e-7b2d-4d3a-add1-6b2f25652ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_790f273e-7b2d-4d3a-add1-6b2f25652ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0adcd1b7-95f1-48c4-b735-ca6fd0f1d590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2b9e0b48-03c0-4821-9b4e-5b3b7d30ce4e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0adcd1b7-95f1-48c4-b735-ca6fd0f1d590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f8b635fe-3394-421e-a6f4-a67b48452fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_118d0f30-e95e-4633-b193-7f7f914cb038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f8b635fe-3394-421e-a6f4-a67b48452fed" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_118d0f30-e95e-4633-b193-7f7f914cb038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_11eff0b2-847e-4e22-b3f8-1cbd68d65205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_118d0f30-e95e-4633-b193-7f7f914cb038" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_11eff0b2-847e-4e22-b3f8-1cbd68d65205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_11eff0b2-847e-4e22-b3f8-1cbd68d65205" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_02db766e-eb1a-4073-be7a-251c9643e238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_02db766e-eb1a-4073-be7a-251c9643e238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_fa4d8625-404b-4020-816a-f06748300610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_fa4d8625-404b-4020-816a-f06748300610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_698346aa-ad4e-45a5-bd90-b5e3ecc0bebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_698346aa-ad4e-45a5-bd90-b5e3ecc0bebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3cc1f558-9ea1-492b-a678-0738a87d97ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9330bee0-fbb0-4044-a4bc-0a00d9a1fa88" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3cc1f558-9ea1-492b-a678-0738a87d97ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_82dc67f7-81fe-4349-8150-91fa4541f0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_118d0f30-e95e-4633-b193-7f7f914cb038" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_82dc67f7-81fe-4349-8150-91fa4541f0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_cb910224-6e8b-48b9-a607-e0656dab26a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_82dc67f7-81fe-4349-8150-91fa4541f0e9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_cb910224-6e8b-48b9-a607-e0656dab26a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f44b5073-91b2-454e-86e1-c3f14c313b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd6e61a2-2f6d-4822-8547-fbd10c879236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44b5073-91b2-454e-86e1-c3f14c313b93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd6e61a2-2f6d-4822-8547-fbd10c879236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b6616578-0830-40e0-8c3a-7e990ef18790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44b5073-91b2-454e-86e1-c3f14c313b93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b6616578-0830-40e0-8c3a-7e990ef18790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_02a8eb5d-c706-4e9e-bda9-1aa52840005d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44b5073-91b2-454e-86e1-c3f14c313b93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_02a8eb5d-c706-4e9e-bda9-1aa52840005d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_06a7d34b-d8ce-4285-91c3-2061ee72bf33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44b5073-91b2-454e-86e1-c3f14c313b93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_06a7d34b-d8ce-4285-91c3-2061ee72bf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a4ca7853-fa51-4b89-9f16-a74c0f25ba18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44b5073-91b2-454e-86e1-c3f14c313b93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a4ca7853-fa51-4b89-9f16-a74c0f25ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_267b2bc3-7793-4950-837c-d76903a798d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_11ba28db-0b36-4924-91c4-334e260e98fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_267b2bc3-7793-4950-837c-d76903a798d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_11ba28db-0b36-4924-91c4-334e260e98fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6f3b021a-5bc2-4af8-bfd4-070fffa75c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c85bb310-1b47-4eab-be88-e150cd0c5b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6f3b021a-5bc2-4af8-bfd4-070fffa75c67" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c85bb310-1b47-4eab-be88-e150cd0c5b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c13a6126-074b-45a4-8410-ccebf9a34951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_c5332aaa-837a-442e-a5b8-0a67d139f58a" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c13a6126-074b-45a4-8410-ccebf9a34951" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_c5332aaa-837a-442e-a5b8-0a67d139f58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_b3c65695-6710-44ec-9feb-0f72d031c81e" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c13a6126-074b-45a4-8410-ccebf9a34951" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_b3c65695-6710-44ec-9feb-0f72d031c81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ca5586fa-31dd-4c36-a28a-b901f7fa24bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c13a6126-074b-45a4-8410-ccebf9a34951" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ca5586fa-31dd-4c36-a28a-b901f7fa24bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent_82bddda4-2bf3-4f4b-8722-28c06ce2e3ea" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c13a6126-074b-45a4-8410-ccebf9a34951" xlink:to="loc_ck0001824293_AccruedLicensingFeesCurrent_82bddda4-2bf3-4f4b-8722-28c06ce2e3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ed7e17b6-1788-4cde-a2ed-8c49813a630d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c13a6126-074b-45a4-8410-ccebf9a34951" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ed7e17b6-1788-4cde-a2ed-8c49813a630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#PPPNOTEANDCONVERTIBLENOTES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_778ca7fe-7470-40e6-92a2-a002e4c68c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d01f2ebb-3b21-4fe4-9366-3c22d5004f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_778ca7fe-7470-40e6-92a2-a002e4c68c3b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d01f2ebb-3b21-4fe4-9366-3c22d5004f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#PPPNOTEANDCONVERTIBLENOTESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9db8c292-961b-4c6c-a611-6de0b638f2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9db8c292-961b-4c6c-a611-6de0b638f2d7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_498e474f-66ab-4ea2-b0ab-0834eaa926ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_498e474f-66ab-4ea2-b0ab-0834eaa926ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1b7ba2c9-e11a-4709-8393-9d9e4af9edd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_498e474f-66ab-4ea2-b0ab-0834eaa926ba" xlink:to="loc_us-gaap_RelatedPartyDomain_1b7ba2c9-e11a-4709-8393-9d9e4af9edd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_d9a55c28-5d1b-47e3-9a1b-5c337be34145" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1b7ba2c9-e11a-4709-8393-9d9e4af9edd4" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_d9a55c28-5d1b-47e3-9a1b-5c337be34145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b35e1987-958c-43cf-8676-adc05f174650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b35e1987-958c-43cf-8676-adc05f174650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fde9aab5-27f7-4f24-8057-8b4d386e812e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b35e1987-958c-43cf-8676-adc05f174650" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fde9aab5-27f7-4f24-8057-8b4d386e812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_9aa355a6-2bfe-47e8-9e3f-fe28fee2827f" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_fde9aab5-27f7-4f24-8057-8b4d386e812e" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_9aa355a6-2bfe-47e8-9e3f-fe28fee2827f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8f125f42-1c9d-43ea-a6ee-8951180a4ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:to="loc_us-gaap_DebtInstrumentAxis_8f125f42-1c9d-43ea-a6ee-8951180a4ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbb547df-3a9a-4e4a-9c20-1a6c2ca2f5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8f125f42-1c9d-43ea-a6ee-8951180a4ee6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbb547df-3a9a-4e4a-9c20-1a6c2ca2f5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_1e1098b7-ce50-473e-8d95-b3abedd41d3d" xlink:href="ck0001824293-20220630.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbb547df-3a9a-4e4a-9c20-1a6c2ca2f5f2" xlink:to="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_1e1098b7-ce50-473e-8d95-b3abedd41d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3e548e7e-dd90-408c-b47b-da73b5a36a56" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0e114ead-cb37-462e-8628-2ebbb3bb4d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0e114ead-cb37-462e-8628-2ebbb3bb4d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55a992d2-becf-41e6-afb8-a6653de1c000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55a992d2-becf-41e6-afb8-a6653de1c000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_9a714075-74dc-4f9b-b2af-54deb3bdddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_DebtInstrumentTerm_9a714075-74dc-4f9b-b2af-54deb3bdddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm_a541f946-31a5-4f34-9839-4aa35b0b6251" xlink:href="ck0001824293-20220630.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_ck0001824293_DebtInstrumentPaymentTerm_a541f946-31a5-4f34-9839-4aa35b0b6251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_38614f7a-e854-4862-a472-4cc40136f43c" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_38614f7a-e854-4862-a472-4cc40136f43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_518a3095-126f-4282-a008-e32ad5c10d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_518a3095-126f-4282-a008-e32ad5c10d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e48a59a0-f373-463c-85d9-8be03aa713d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f84c6661-9279-4969-9324-179933d697ae" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e48a59a0-f373-463c-85d9-8be03aa713d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c2bda129-dce5-4905-8859-ecda0738c441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9f9e20bc-b589-4393-8a02-6246639a87ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2bda129-dce5-4905-8859-ecda0738c441" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9f9e20bc-b589-4393-8a02-6246639a87ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f2fd019f-98ae-4acc-b56b-134a9eb77ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b0f8e4b7-eca4-48e6-8456-f9cdfe299ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2fd019f-98ae-4acc-b56b-134a9eb77ab3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b0f8e4b7-eca4-48e6-8456-f9cdfe299ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKHOLDERSEQUITYDEFICITNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_36dc434d-8bf0-4cbc-9d0e-ceb72e7d1fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2722e391-c77c-4aa2-a8c9-8ad377db1687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_36dc434d-8bf0-4cbc-9d0e-ceb72e7d1fc8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2722e391-c77c-4aa2-a8c9-8ad377db1687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c84ca99d-69e8-4ce3-b655-32a23a50adeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2722e391-c77c-4aa2-a8c9-8ad377db1687" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c84ca99d-69e8-4ce3-b655-32a23a50adeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5919046-babe-40b4-9cb9-9d0a6769786b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c84ca99d-69e8-4ce3-b655-32a23a50adeb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5919046-babe-40b4-9cb9-9d0a6769786b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_d8f0271c-f183-4ef5-b98b-69e92343466f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5919046-babe-40b4-9cb9-9d0a6769786b" xlink:to="loc_us-gaap_IPOMember_d8f0271c-f183-4ef5-b98b-69e92343466f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_b74384fb-2f57-4fdf-a725-2c3150954fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5919046-babe-40b4-9cb9-9d0a6769786b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_b74384fb-2f57-4fdf-a725-2c3150954fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2722e391-c77c-4aa2-a8c9-8ad377db1687" xlink:to="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f17d3b4e-37bc-429e-bfe5-dffced27bf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f17d3b4e-37bc-429e-bfe5-dffced27bf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a41277a9-3e09-461a-bf88-5fd5bd62d6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a41277a9-3e09-461a-bf88-5fd5bd62d6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_744f8904-811d-402a-b822-78ce9feefebf" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_744f8904-811d-402a-b822-78ce9feefebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_af811c64-5db7-4c88-b850-8327cd15e246" xlink:href="ck0001824293-20220630.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_af811c64-5db7-4c88-b850-8327cd15e246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_590a8a62-a8a7-4928-b363-6b4ce7cfded2" xlink:href="ck0001824293-20220630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_590a8a62-a8a7-4928-b363-6b4ce7cfded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_594af544-60a5-4d2b-aa5a-b3612a0653b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_594af544-60a5-4d2b-aa5a-b3612a0653b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f19db405-eb3d-48bf-95b9-cdd2fafbab07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f19db405-eb3d-48bf-95b9-cdd2fafbab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssuanceExpense_cc93b779-d4a1-4ace-8668-85db07c5a38d" xlink:href="ck0001824293-20220630.xsd#ck0001824293_WarrantsIssuanceExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_ck0001824293_WarrantsIssuanceExpense_cc93b779-d4a1-4ace-8668-85db07c5a38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3aa494a7-721e-4c5c-bd52-4511b353259a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3aa494a7-721e-4c5c-bd52-4511b353259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b57f4ac9-1991-4919-a49c-72ef1da54dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b57f4ac9-1991-4919-a49c-72ef1da54dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_a7936646-7e61-4b31-b815-6818417e66c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_a7936646-7e61-4b31-b815-6818417e66c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_a9783156-5032-4c68-973e-40a7d73a5b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_a9783156-5032-4c68-973e-40a7d73a5b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_ca5edc8b-d8ed-4b9d-8948-30a968d93468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89c836be-e73a-418c-8d52-5fd555521f94" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_ca5edc8b-d8ed-4b9d-8948-30a968d93468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6044ffe8-5d9b-4e20-8edf-d0e689e555f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6044ffe8-5d9b-4e20-8edf-d0e689e555f0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b4ddcddf-be4c-415a-b35b-cf50e466e37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b4ddcddf-be4c-415a-b35b-cf50e466e37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b4ddcddf-be4c-415a-b35b-cf50e466e37c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_9011773d-07df-4a2e-9254-fd02d7220278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_9011773d-07df-4a2e-9254-fd02d7220278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_eaedf424-3e29-46b4-be1a-8774c540435b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_eaedf424-3e29-46b4-be1a-8774c540435b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_cbf0e1ef-daba-4975-aba0-7b41e25f1fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_cbf0e1ef-daba-4975-aba0-7b41e25f1fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1812d1d3-e3ca-44ea-b41a-8f4c54e0c501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_05769322-eff2-42f2-9c49-0840039bc7d1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1812d1d3-e3ca-44ea-b41a-8f4c54e0c501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16f2bd5-e4c7-4402-884b-493b96cba723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c1e2544-b6f2-4d52-9f9f-cf44518bddbc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16f2bd5-e4c7-4402-884b-493b96cba723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIPOMember_de04a41c-a45f-499b-bcb4-ee37eeb02274" xlink:href="ck0001824293-20220630.xsd#ck0001824293_WarrantsIPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16f2bd5-e4c7-4402-884b-493b96cba723" xlink:to="loc_ck0001824293_WarrantsIPOMember_de04a41c-a45f-499b-bcb4-ee37eeb02274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_Warrants2022Member_3613e63c-7bff-4173-bcb1-c5d7b24ae2a7" xlink:href="ck0001824293-20220630.xsd#ck0001824293_Warrants2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16f2bd5-e4c7-4402-884b-493b96cba723" xlink:to="loc_ck0001824293_Warrants2022Member_3613e63c-7bff-4173-bcb1-c5d7b24ae2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_fd1a8a98-7e27-44a4-8328-e16fd8cd8d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_206677ad-f396-4439-aba5-74da71f97d99" xlink:to="loc_us-gaap_ClassOfStockLineItems_fd1a8a98-7e27-44a4-8328-e16fd8cd8d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3ac63cf4-7f1b-43dd-b70d-efb69c071b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fd1a8a98-7e27-44a4-8328-e16fd8cd8d5a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3ac63cf4-7f1b-43dd-b70d-efb69c071b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a079a40-d797-487b-b232-7adc24b83843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d6bc2778-9ed1-441d-923c-552fa4b439ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a079a40-d797-487b-b232-7adc24b83843" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d6bc2778-9ed1-441d-923c-552fa4b439ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75c54642-0f30-497a-be9f-8392cab995e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02e3005b-0b14-455a-8561-07df3c44dba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75c54642-0f30-497a-be9f-8392cab995e8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02e3005b-0b14-455a-8561-07df3c44dba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_2b2b67aa-34f2-41f0-9b26-320b752849eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75c54642-0f30-497a-be9f-8392cab995e8" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_2b2b67aa-34f2-41f0-9b26-320b752849eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d5fe427d-f9f9-470d-a1bb-189969e429b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75c54642-0f30-497a-be9f-8392cab995e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d5fe427d-f9f9-470d-a1bb-189969e429b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_27f7335e-c752-4052-bea0-d60f5f643c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75c54642-0f30-497a-be9f-8392cab995e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_27f7335e-c752-4052-bea0-d60f5f643c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ba021b9-c689-41d1-bd7e-6d2df5906f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1210410c-f9d6-4ec1-898c-2993608dc692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ba021b9-c689-41d1-bd7e-6d2df5906f40" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1210410c-f9d6-4ec1-898c-2993608dc692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c1624f82-eb16-48f0-a9bc-449fae5098ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1210410c-f9d6-4ec1-898c-2993608dc692" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c1624f82-eb16-48f0-a9bc-449fae5098ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7ab5e78a-bba6-45cc-88d0-730f886fd15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1624f82-eb16-48f0-a9bc-449fae5098ff" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7ab5e78a-bba6-45cc-88d0-730f886fd15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1f480788-f0de-419d-92f5-60573d2bb287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab5e78a-bba6-45cc-88d0-730f886fd15d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1f480788-f0de-419d-92f5-60573d2bb287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_57dfefce-edc7-44aa-b5d2-35f2495fd288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab5e78a-bba6-45cc-88d0-730f886fd15d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_57dfefce-edc7-44aa-b5d2-35f2495fd288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f93fae0-c4d1-4236-89b8-94ff702ca032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1210410c-f9d6-4ec1-898c-2993608dc692" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f93fae0-c4d1-4236-89b8-94ff702ca032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2463abcd-9ad6-4900-93c6-d2e0df2aee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f93fae0-c4d1-4236-89b8-94ff702ca032" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2463abcd-9ad6-4900-93c6-d2e0df2aee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcaece66-71f3-42ee-8b3c-6067008a2a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb246436-f107-4e75-adf0-d8d553b4dfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcaece66-71f3-42ee-8b3c-6067008a2a00" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb246436-f107-4e75-adf0-d8d553b4dfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26156f56-30ab-4e3b-adca-414c9fd84d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb246436-f107-4e75-adf0-d8d553b4dfa5" xlink:to="loc_us-gaap_AwardTypeAxis_26156f56-30ab-4e3b-adca-414c9fd84d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2024d88-4ab3-465d-9866-5ca13a0bdc48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_26156f56-30ab-4e3b-adca-414c9fd84d5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2024d88-4ab3-465d-9866-5ca13a0bdc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_257b26d5-af9b-4ca7-906c-c59a3afbf044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2024d88-4ab3-465d-9866-5ca13a0bdc48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_257b26d5-af9b-4ca7-906c-c59a3afbf044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1537136d-d2a4-4c73-80eb-b8a8489735da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2024d88-4ab3-465d-9866-5ca13a0bdc48" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1537136d-d2a4-4c73-80eb-b8a8489735da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb246436-f107-4e75-adf0-d8d553b4dfa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9b23ecfd-1d7c-49e0-8f0e-0c932f1cbcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9b23ecfd-1d7c-49e0-8f0e-0c932f1cbcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b0c5a897-3576-4990-bb4b-605b94715d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b0c5a897-3576-4990-bb4b-605b94715d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2fe4e9a9-a7b7-4648-9431-c5393ddda43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2fe4e9a9-a7b7-4648-9431-c5393ddda43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cdc9a97b-b200-4da8-8cb5-8912dacb97aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cdc9a97b-b200-4da8-8cb5-8912dacb97aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d09dc21-d571-4dfd-b054-f06999321ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ccfc30e-b39b-4400-adb7-824ea0b3c0b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d09dc21-d571-4dfd-b054-f06999321ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c1cb58-75c2-4360-9194-664948edda21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_28f9dffa-4117-4b2c-89f9-f19eb24e3ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c1cb58-75c2-4360-9194-664948edda21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_28f9dffa-4117-4b2c-89f9-f19eb24e3ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_adb16bae-890e-4964-926d-fd536775c2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_28f9dffa-4117-4b2c-89f9-f19eb24e3ee0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_adb16bae-890e-4964-926d-fd536775c2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d252c8a6-f02e-4c58-9cc6-2234a77ef50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_28f9dffa-4117-4b2c-89f9-f19eb24e3ee0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d252c8a6-f02e-4c58-9cc6-2234a77ef50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_402e75d2-14b0-4728-8be4-eb0d129922e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_28f9dffa-4117-4b2c-89f9-f19eb24e3ee0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_402e75d2-14b0-4728-8be4-eb0d129922e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5aa29a1-a995-4dd5-9b6c-33e29b241bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_28f9dffa-4117-4b2c-89f9-f19eb24e3ee0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5aa29a1-a995-4dd5-9b6c-33e29b241bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3fe6f40a-0b16-4f56-b5e5-85dc597ec5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_28f9dffa-4117-4b2c-89f9-f19eb24e3ee0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3fe6f40a-0b16-4f56-b5e5-85dc597ec5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ec348269-48a7-400e-94f6-d2468244d0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c1cb58-75c2-4360-9194-664948edda21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ec348269-48a7-400e-94f6-d2468244d0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1ca17330-9d2a-4f6b-8f4a-3ac1a4901d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ec348269-48a7-400e-94f6-d2468244d0fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1ca17330-9d2a-4f6b-8f4a-3ac1a4901d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0362a0e3-fd5b-4a82-b115-aa150840ae3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ec348269-48a7-400e-94f6-d2468244d0fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0362a0e3-fd5b-4a82-b115-aa150840ae3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_803512f4-b98d-4d0f-959b-176d498f7f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ec348269-48a7-400e-94f6-d2468244d0fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_803512f4-b98d-4d0f-959b-176d498f7f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d3f41f5c-8e96-4c75-9f5b-3594495686e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ec348269-48a7-400e-94f6-d2468244d0fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d3f41f5c-8e96-4c75-9f5b-3594495686e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0c750885-3a30-48d2-a0e0-4b071aba818f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c1cb58-75c2-4360-9194-664948edda21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0c750885-3a30-48d2-a0e0-4b071aba818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5dfc50b7-7f17-44e8-a183-0eab6d07847e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0c750885-3a30-48d2-a0e0-4b071aba818f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5dfc50b7-7f17-44e8-a183-0eab6d07847e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b0d60463-b170-4bec-b020-8a87f63c3cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0c750885-3a30-48d2-a0e0-4b071aba818f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b0d60463-b170-4bec-b020-8a87f63c3cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61b0d431-2117-4fa9-bbe9-1e96d91b589e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0c750885-3a30-48d2-a0e0-4b071aba818f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61b0d431-2117-4fa9-bbe9-1e96d91b589e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664336b9-a74a-4aec-ba1b-71a517348bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5c84dc52-5ac7-442d-805d-1b6910c6830c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664336b9-a74a-4aec-ba1b-71a517348bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5c84dc52-5ac7-442d-805d-1b6910c6830c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29776ae2-3661-4904-88ff-263e10c4e78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664336b9-a74a-4aec-ba1b-71a517348bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29776ae2-3661-4904-88ff-263e10c4e78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_148302a6-7a2a-4bac-8fc9-a234997b0d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664336b9-a74a-4aec-ba1b-71a517348bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_148302a6-7a2a-4bac-8fc9-a234997b0d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_67d8fc12-4089-42d2-932b-7642a8c4b794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664336b9-a74a-4aec-ba1b-71a517348bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_67d8fc12-4089-42d2-932b-7642a8c4b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_22ec9075-eb59-4f08-8878-a285255d4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664336b9-a74a-4aec-ba1b-71a517348bf4" xlink:to="loc_us-gaap_SharePrice_22ec9075-eb59-4f08-8878-a285255d4cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1842db37-a521-4d1b-a9bd-6f1db579016d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41aee20c-12a3-444a-b389-3a5a62bbbe27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1842db37-a521-4d1b-a9bd-6f1db579016d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41aee20c-12a3-444a-b389-3a5a62bbbe27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc0bf175-7dfd-4e62-b67a-cebc29f417ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41aee20c-12a3-444a-b389-3a5a62bbbe27" xlink:to="loc_us-gaap_AwardTypeAxis_cc0bf175-7dfd-4e62-b67a-cebc29f417ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be0c7a8d-ccab-4b50-bbda-306a20645e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc0bf175-7dfd-4e62-b67a-cebc29f417ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be0c7a8d-ccab-4b50-bbda-306a20645e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5805dd2a-d9e5-4f5d-b99e-a19ace893d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be0c7a8d-ccab-4b50-bbda-306a20645e27" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5805dd2a-d9e5-4f5d-b99e-a19ace893d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcaef71a-0691-421e-ab74-7798f7a6f673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41aee20c-12a3-444a-b389-3a5a62bbbe27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcaef71a-0691-421e-ab74-7798f7a6f673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcaef71a-0691-421e-ab74-7798f7a6f673" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b42a8fc-c1fd-4abb-8325-a758d27e65c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b42a8fc-c1fd-4abb-8325-a758d27e65c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7cc6247c-9fe4-43a3-8ad4-78818133d6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7cc6247c-9fe4-43a3-8ad4-78818133d6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_954db91c-cc27-44f0-b053-ac299ecc8665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b6cdd8a-6ef2-4269-b5d1-e1798156720d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_954db91c-cc27-44f0-b053-ac299ecc8665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_342cf3c3-6d37-4f4d-8d14-da91dd4fb17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_027b70f2-7c11-4202-a26d-c5024b99be0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_342cf3c3-6d37-4f4d-8d14-da91dd4fb17a" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_027b70f2-7c11-4202-a26d-c5024b99be0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_43b948ef-64bf-4a71-92f3-a6e54f6ba131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_43b948ef-64bf-4a71-92f3-a6e54f6ba131" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_974ccd90-717f-413e-a801-6655f67e46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e4896dd-e82a-4ba9-bc5a-ad0ca62d2316" xlink:to="loc_us-gaap_RelatedPartyDomain_974ccd90-717f-413e-a801-6655f67e46d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_4c35236f-3631-4521-8957-5ed9803817aa" xlink:href="ck0001824293-20220630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_974ccd90-717f-413e-a801-6655f67e46d6" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_4c35236f-3631-4521-8957-5ed9803817aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7fc02525-2347-4bc9-9af6-e2346dcb0714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_e541d0ea-2e5d-4d50-8db8-8cd026c9ac78" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7fc02525-2347-4bc9-9af6-e2346dcb0714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_5444c0c4-3ace-4605-94cd-8dabd6186d14" xlink:href="ck0001824293-20220630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7fc02525-2347-4bc9-9af6-e2346dcb0714" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_5444c0c4-3ace-4605-94cd-8dabd6186d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d351747-7d49-4926-8423-3af665f72fa0" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_775a71a0-b3eb-42ac-a805-0369bd1626c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_775a71a0-b3eb-42ac-a805-0369bd1626c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_301fe621-7a6d-4daa-839d-653f42566666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_301fe621-7a6d-4daa-839d-653f42566666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5589ef3a-2c9d-454b-97e5-a8d09c6225ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd5b98f0-0042-44b1-9417-54c98c28cf34" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5589ef3a-2c9d-454b-97e5-a8d09c6225ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20220630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_93531bf1-bf9f-4424-96bf-bbc6ed25edf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6ab91090-56f3-4b32-a363-d0d8f7e1fe1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_93531bf1-bf9f-4424-96bf-bbc6ed25edf1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6ab91090-56f3-4b32-a363-d0d8f7e1fe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ck0001824293-20220630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ck0001824293-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .PU$2
M  0    !   .PP       8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( <4%D@,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7OP/_P!A^P_]*(Z_M5'2OS/C[^+1]'^:/ILA^"?J@HHHK\_/>"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M':Z'>'Q3\/II3)?>$=2G(M'+'+26\F&:VE//S("K9RR/@8_IB_8*_;E\%_\
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M?S3T5[%/@; 1^.4G\TOT_4XY9Y7>R2^__,_HR_XB\?V;/^A(^.'_ ()]+_\
MEC79^ /^#J+]E'QE;12:CJ'C[PFTF=T>J^'6D:+#$<_97G'( /!/!'0Y _F:
MHK:?!.6M67,O1_YIF<<ZQ"WM]Q_8;^SI_P %._V?OVLKJWM?A_\ %KP9KNI7
M:"2'36O?L>HR#VM9Q'/QD9^3COBO=Z_A[K[6_8*_X+W_ +07["VIV-G'XFN/
MB!X)M\))X<\2SO=1I'E?^/>X.9H"%4A0K&,;B3&W%>%C^!9Q7-A)\WE+1_?M
M^"]3NP^>1;M6C;S7^1_5=17S'_P36_X*P_"W_@IU\/Y+_P &WS:7XHTV)7UC
MPQ?NHU#3<X&\8XFA+$ 2IQD@$*WRU].5\)7P]2C4=*JG&2W3/>A4C./-%W04
M445B4%?A7_P>2_\ (W_L_P#_ %YZ[_Z'I]?NI7X5_P#!Y+_R-_[/_P#UYZ[_
M .AZ?7TG"/\ R-:7_;W_ *2SSLV_W67R_-'XGT445^T'Q@5_:%^R1_R:G\,O
M^Q4TO_TCBK^+VO[0OV2/^34_AE_V*FE_^D<5?GO'WP4?67Z'T.0[S^7ZGH5%
M%%?FI]&%?SF_\'>7_*27P1_V32Q_].FJU_1E7\YO_!WE_P I)?!'_9-+'_TZ
M:K7UG!?_ ",E_A9Y6<_[L_5'Y6T445^P'R!U_P"S[_R7OP/_ -A^P_\ 2B.O
M[51TK^*K]GW_ )+WX'_[#]A_Z41U_:J.E?F?'W\6CZ/\T?39#\$_5!1117Y^
M>\%%%% !117R[_P48_X*\_!W_@FCX<_XK35Y-4\67</FZ?X7TK;-J5V.SN"0
ML$1/\<A&>=H<C%;8?#U*TU2I1<I/HB:E2,(\TW9'U%7F_P =OVPOA3^S#;+)
M\1/B+X,\&F3_ %<6K:M#;33<9^2-FWOQS\H-?SD?MS?\')/[0W[75[=Z?X;U
M;_A4/@^96C73/#<Y%]*C ?ZZ_($K,/F&81"I#8*GK7P)K6MWOB35KC4-1O+K
M4+Z\D,L]S<RM+-,YZLS,26)]2<U]Q@>!:TUS8J:CY+5_?M]USPZ^>03M25_-
MZ?U^!_4!\0?^#F+]D/P-=W%O;>/=8\236TAC8:3X=O61B" =KRQQHPZD,K$$
M D$Y&?*[K_@[L_9JM[F2-?!OQMG6-BJR)HVF!9 #]X;M0!P>O(!]A7\Y-%>]
M3X(RZ*]YR?JU^B1PRSO$/:R^7_!/Z2/"7_!VA^S#XDOFAO-&^+?A^-0")K_0
M[1XVYQ@""[E;CKRHX'KQ7N'PC_X."/V1OC'=?9[3XOZ7HEUQF/7[&ZTI1G_I
MK/&L/Y/QW[5_*/14UN!\!+X)2C\T_P U^HXYY77Q)/\ KU/[:O 'Q*\.?%CP
MU;ZUX5\0:+XFT>[4/!?Z5?17EM,I&05DC9E8$$$$'H:VJ_BK^"O[0GCK]F_Q
M;'KW@'Q?XC\':LC(QN=(U"6T:4*=P6380)$SU1P5.2""":_5O_@GU_P=B>,O
M E[8^'OV@M#B\8Z+E(3XFT:W2UU:V&<%YX!B&< ?\\Q$P )^<G%?,YAP3BJ*
M<\._:+ML_NV?W_(]+#YU2GI47*_P/WYHKA?V<OVFO ?[6_PKT_QK\.?$VF^*
MO#>I#]W=6CG=$^ 3'+&P#Q2KD9CD577/(%=U7QLHRA)QDK-=#V%)-704445(
MQLTZ6T+22,L<<:EF9CA5 ZDGTKF?^%W>"_\ H;O"_P#X-8/_ (JCXW?\D8\7
M?]@6\_\ 1#U_%'7TO#_#ZS-3;GR\MNE[WOYKL>;F&8?5N7W;WOUMM;R/[7/^
M%W>"_P#H;O"__@U@_P#BJL:7\6?"NN:A%:67B;P_>74[;8X8-1ADDD/H%#9)
M^E?Q-UZ-^R#\;9/V;?VJ?ASX^266%?!_B2PU:8QC+-##.CRKCN&C#*1W#$5[
M]3@+E@Y1K7=M%R[_ /DQPQSZ\DG#\?\ @']GU%1VMS'>VT<T+K)#,H='4Y5U
M(R"#Z&OSH_X*T?\ !Q!\/_V KK4O!/@>&S^(?Q7MP8I[193_ &7H,G3_ $N5
M3EI!_P \(R&_O-'QGX7!X&OBJJHT(\S_ *W[(]RM6A2CSU'9'Z)ZIJMKHFG3
M7E[<6]G:6Z&26>>01QQ*.I9CP /4U\G?';_@NU^RC^SU=R6NL?&'P_JU]&S(
M;;P]'-K3!EX*E[5)(U(/'SL.:_FH_;)_X*4?&K]O77Y+KXE^.M6UC3_.:6WT
M:!OLNDV7S$J([:/"94':'<-(0!EV/->%U]]@N XVOBZFO:/^;_R/!K9Z[VI1
M^_\ R_X)_2+XJ_X.U?V8O#VJ_9[/0?B]KT.W=]JL=#LTB)R1C$]Y$^>,_=QR
M.<Y ?X/_ .#M']F'Q-K M;W1?BYX=A*Y^UZAH=H\(.X#&+>[E?."3]S&%/?
M/\V]%>M_J3EO+;WO6_\ P+''_;6(O?3[C^MO]GC_ (+:?LN?M.WT%EX9^+_A
MNVU2XD$,=CKGFZ+<22'HB"Z6,2$]O++9/'7BOJ:WN([NWCEBD22*10Z.AW*Z
MGD$'N#ZU_#]7U-^P3_P6,^.G_!/35[.+PAXLN=5\)0R*9_"VLNUWI<R \K&K
M'=;DC^*%D.<9W 8KQL?P):+E@ZE_*7^:_P OF=N'SR[M6C\U_D?UO45\C?\
M!+'_ (+&?#7_ (*B^")%T1F\,^/])@676?"M[,'GMQP#-;R8 N(-W&\!67(W
MHFY<_7-? 8C#U:%1TJT>62W3/>IU(SCS0=T%%%%8EA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#;1^$%_P"!_B1X<LO$6@7PW*DR[9K*7!"SP2#YHI5R<.I!P2#D$@_S7_\
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M,?PK-HULUIXP^+-];^9IWAN*;Y+,-]V>]=<F*/G<$X>3&%P,NOSM_P %K/\
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M,-V 0@C!;=^@'C[Q_H?PK\%ZGXC\2ZMI^@Z#HMNUW?ZA?3K!;VD2C+.[L0%
M]ZXW]K#]KKX?_L2_!O4/'7Q'\06N@Z#8_(F\[KB^F()6""/[TLK8.%7L"3@
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M.!6#PD,.NBU]=W^)\'BZ[K5I5._Y= J6RLIM3O8;>WAEN+BX=8XHHT+/(Y.
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M6W1!114ME93:G>PV]O#+<7%PZQQ11H6>1R<!5 Y)). !UKV3C(J*_1?]B_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#A_CW^S/\/?VI?"4.A?$;P;X=\::3:W NX+;5[%+I;>8
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M2["> X4J3QG-?GKP>(5+V[@^3O9V^_8^@]M#FY+J_:^I^&G_  =I:MXPN/\
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M2/\ DU/X9?\ 8J:7_P"D<5?GO'WP4?67Z'T.0[S^7ZGH5%%%?FI]&%?SF_\
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M_P#8;U?_ -*WK]":_/;_ (-?_P#E$7X1_P"PWJ__ *5O7Z$U^#YU_P C"O\
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M *5O7Z$5^>__  ; ?\HBO"/_ &&M7_\ 2MZ_0BOP?.O^1A7_ ,<OS9]W@_\
M=X>B_(****\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKQ7_ (* _MC:3^PS^S#KWCK4#;S:A$GV/1+*
M1L?VC?R*WDQ8ZE1AG?'(2-SVKIP>$K8JO##4%S3FTDN[9CB<13P]*5>L[1BF
MV^R1\%_\'#W_  49_L/2_P#A0O@^_P 7E\B7/BZY@EPT,)P\5CD<@OQ)(./D
MV+R'8#\_/^":_P"W#J7[!7[3NE>+8OM%SX=O<:?XAL(V_P"/NR=AN91T,D9
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MU;'JG+X:FGSZ?CI\SR\VP_M*',MXZ_YG\]-%%%?L1\>?5G_!%/\ ;&'[$/\
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M>A^9M%%%?LQ\:%?UA?\ ! ;P2WP__P""0'P1L6:1S<:7=:EEUVG%W?W5T!]
M)@ >X -?R?PPO<3+'&K222$*JJ,LQ/0 5_9W^Q[\&O\ AG;]D_X:> _F,G@_
MPQIVD2LP^:22"VCC=C[LZL3CC)KX+CVM;#TJ7>3?W*WZGO9##]Y*?E;[_P#A
MC?\ C=_R1CQ=_P!@6\_]$/7\4=?VN?&[_DC'B[_L"WG_ *(>OXHZPX ^&O\
M]N_^W&F??8^?Z!1117Z(?.G[8?\ !FU_R.'[0'_7GH/_ *'J%?NI7X5_\&;7
M_(X?M ?]>>@_^AZA7[J5^+\6_P#(UJ_]N_\ I*/LLI_W6/S_ #84445\V>D%
M%%% 'P9_P<N_\H=/B9_U^:-_Z=+6OY;J_J1_X.7?^4.GQ,_Z_-&_].EK7\MU
M?K' O^X3_P ;_P#28GRF>?[PO1?FPHHHK[0\8_I\_P"#8#_E$5X1_P"PUJ__
M *5O7Z$5^>__  ; ?\HBO"/_ &&M7_\ 2MZ_0BOP?.O^1A7_ ,<OS9]W@_\
M=X>B_(****\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'9.S\[-!1117.;!1110 4444 %%%% !1110 4444 %<E\>O@QHO[1?P4\5^
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M**BO))?D*=24W>3;]0HHJ;3]/N-7OX+6U@FNKJZD6*&&)"\DKL<*JJ.2Q)
M'))K4@AK]5?^#=__ ((G7'[6?CO2_C9\3-,*?"WPW=^=HVGW"X_X2B]A<8+*
M?O6D3CYL\2.NSE1(*[3_ (([_P#!LYKGQ3U'2/B1^T5I]WX>\*KLN[#P;+F'
M4=6Z,IO1]ZWA]8CB5NA\L#YOWOT#P_8^%-$M-,TNRM=.TVPB6"VM;:)8H;>-
M1A41% "J ,  8%?GW$O%48Q>$P3NWHY+IY+S\^G37;Z#+<K;:JUEZ+_,N*NU
M< 8 X ':BBBOS0^D.7^-W_)&/%W_ &!;S_T0]?Q1U_:Y\;O^2,>+O^P+>?\
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MPG^T;\,]5\&^.-!T[Q+X9UJ(PW=A>Q[XY!V8'JKJ>5=2&4@$$$9K\._V_O\
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M_P"7RL<F*P5*NOWBU[]3^,WXP?L/_&3]G^YO(_&OPM\?>&5L=WG3W^A7,5L
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M]S+.(L7@*3HT+6;OJKZV2_0X<3E]&O+GJ7OL?S2_\0IG[5'_ %3;_P *!_\
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MV]0 /E45_2!\2/!R?$3X=Z]X?DF:WCUS3KC3VE4?-&)8FC+#W&[-?RV_M!_
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MLTH9=A98S$WY(VO97>K27XL_0^BOQU_X)]?\%O\ XW_M+?ME^ ? OB1_"/\
M8?B/4&MKS[+I1BFV"*1_E;S#@Y4=J_8JNOB3AC&Y'B(X;&VYI1YERNZM=KLN
MQS9'GV%S:B\1A+\J=G=6ULG^H4445\Z>T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_L$_L1>)OV\OC[I_@_08Y+?3XR+G6]5*9ATFT!PTC=B[?=1.K,1T 8C^D/\
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MN>(O^_5O_P#&Z/\ A\/^TQ_T5SQ%_P!^K?\ ^-U^FW_$,O\  ?\ Z&WXN?\
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MX$A/'W8O,/2OBG4=/N-(U">TNX)K6ZM9&BFAF0I)$ZG#*RGD,"""#R"*Z*O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU9^C3MY6ZG].\&Y]4S;+EB*RM.+<7V;23NO6_P!]PHHHKX<^K"BBB@ HHHH
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M+E(EBG?N%5HBF>@,X!ZBOQ0K^GO!S*\)2RAXZG9U:C:D^J2>D?+2TO.Z[(_
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M !1110!_*'\8O^2N^*O^PQ=_^CGK]F/^#8[_ ),Z\=?]CE)_Z0VE?C/\8O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT.,N,L+D&$]I/WJLO@AW?=]HKJ_DM3AX5X7Q&<XCEC[M./Q2[>2[M_ANR_\
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M%OX!\!^)/%4T9VI=:G/'I=J_^TH ED(]F5"?;K7T64\)9QF6N"P\I+O:T?\
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M8-N-6NF^T?>?X72^;1^RM%?SS^//^"]?[3?C6XW6_C;3_#L/_/#2]$M%4_\
M I8Y'_\ 'N_TKS[4?^"LO[2&JW'F2?&#QBK8VXAN%A7_ +Y10/QQFOK:/@KG
M,E>I5IQ\KR?_ +;;\3YNIXJ95%VA3J/SM%?G*_X']+-%?S4Z1_P5J_:1T2\\
M^'XP>+G<#&+B9+A.H/W9%9>WIZCN:]K^"G_!Q5\?OAQ<VL?B9_#/CZQC;$PO
M].6SNI$]%EMMBJW3YFC;IR">:SQ7@OG=.'-1G3GY)M/\8I?BB\/XI934ERU(
MSCYM)K\&W^!^]=%?#O[&/_!>GX/?M0WMIHOB.27X9^*KHK'';:O.KZ?<R''R
MQ78"KG/ $JQD\ 9)Q7W"CB1 RD,K#((Z$5^:9KDN.RVM[#'4G3EYK?T>S7FF
MS[O+\TPN.I>VPE13CY=/5;I^3%HHHKS#N"BBB@ HHHH **** "BBB@ HHHH
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MZ6M_V[>_ROT/5****_G<_:@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNWR[9$/X#;CZ"OYCZ_3[]H+_ (*(W'P;_P""*GP5^'_A?5"GBCX@Z+/9WES
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MJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML_AK]+/V=/V</!_[*7PIT_P9X'TB'1]#T\%@H.Z6YD/WI97/,DC8Y8^@ P
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M.B?"K3;G?;VO,=QKKH?EGN>?N@C<D71<@ME@-OJ7_!R+^TQXKUW]IG3?A?\
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MY.4^&_\ V+,O_I4]?I'A/_R4E'TG_P"DL^'\1?\ D0U?6/\ Z4CYO_X(F_\
M*4/X4?\ 7W>_^F^ZK^CBOYQ_^")O_*4/X4?]?=[_ .F^ZK^CBO:\;/\ D=4?
M^O2_]+F>3X4_\BJI_P!?'_Z3 ****_'3]."BN2^-'QW\&_LZ^"+CQ)XX\2:5
MX9T6WX:YOI@F]O[B+]Z1SV1 6/85^:'[5'_!S+INCW5UIGP>\%_VP4+)'K?B
M)FAMV/9DM8R)&4\X+R1G@97M7T61\*YKG$K8"BY+K+:*]9.R^2U\CQ<VX@R_
M+(WQE11?1;R?HEK\]O,_5RBOYPOC#_P6<_:1^,UQ<_:OB5JF@V=QD+:>'XX]
M+6!3V62)1-^+2,>>M>):AX[^(WQ^U$V-UK/C;QM=R ,;>6[NM2D;#  [26)^
M9@.G4CUK]*PO@GCG'FQF)A#O9.5OOY5_6Y\+B/%7!\W+A:$YOI>RO]W,_P /
MD?U.3>)]-MY6CDU"QCDC)5E:=05(Z@C-26.MV>IR,MM=VMPRC)6*57('KP:_
MEQMOV-OB_>P++#\*?B1-'(,JZ>&;UE8>Q$=%Y^QS\7M/MFFN/A7\2((4QN>3
MPU>JJY.!DF/'6NC_ (@[@MO[2C?_  +_ .6'/_Q$S%_] $O_  )__(']3%%?
MRUP_'GXQ_ _4_L<?C3XF>#[Q!N\A=7OM/E49*YV[U/52/JN.U>Q_#+_@MS^T
MO\,;B'9\1KG7;6/[UMK5C;WJR_[TC)YOY.*Y,3X*9BH\V$Q$)^MXW]+<R.JC
MXJ8'FY,31G#[G]^J9XY^VG_R>/\ %K_L<]8_]+IJ_5[_ (-A/^3:?B1_V,T?
M_I+'7XX?$KQ[??%7XC>(/%&I+;IJ7B34KC5+I8%*Q++/*TKA 22%W,< DD#N
M:_8__@V$_P"3:?B1_P!C-'_Z2QU^A^)U*5+A-TI;Q]FG\FD?%\ U%4XB]I'9
M\[^^Y^FU%%%?RF?T,%9_BS_D5=3_ .O27_T UH5G^+/^15U/_KTE_P#0#54_
MB0I;'\E]?MA_P;#^#H+']E?XA>(%B5;G5/%8T^23^)TM[2&15_ W3G_@1K\3
MZ_>O_@W(LX;7_@G:TD<,<;W'BF_DE95 ,K;(%W,>YVJHR>R@=A7]6^,%9PX>
ME%?:G%?F_P!#^=O#&ESYUS?RPD_R7ZGWK1117\H']%!1110 4444 %> _P#!
M4_\ Y1U_&+_L6;K^0KWZO ?^"I__ "CK^,7_ &+-U_(5ZN1?\C+#_P#7R'_I
M2.'-/]RK?X9?DS^9VOZ1O^".'A&+P5_P3/\ A+:Q1B/[1I<E^V#NW-<7,TY)
M/_;3IVZ=J_FYK^F+_@E?_P HZ?@[_P!BS:_RK^@_&Z;65T(='4_*,O\ ,_%O
M">*^OUI=>3\Y+_(]^HHHK^9S]W"BBB@ HHHH *_"/_@Y/_Y2 :1_V)MC_P"E
M-Y7[N5^$?_!R?_RD TC_ +$VQ_\ 2F\K]2\'_P#DH5_@E^A^?^)G_(D?^*/Z
MGFO_  0I\)MXJ_X*@?#EC&LD&EKJ-_-DCY0EA<!" >I$C1].>_:OZ)J_G[_X
M-\/^4EWAW_L#ZE_Z3FOZ!*ZO&BHY9["+Z4X_^E39S^%M-1R>376<G^$5^@44
M45^1GZ0%%%% !1110!P_[3O_ ";7\0O^Q9U+_P!)9*_E7K^JC]IW_DVOXA?]
MBSJ7_I+)7\J]?T1X&_P,7ZP_*1^*^+GQX7TG_P"VG]%'_!"?_E%7\+/^XM_Z
M=[VOKBOD?_@A/_RBK^%G_<6_].][7UQ7XOQ9_P CS&?]?:G_ *7(_4.&_P#D
M4X7_ *]P_P#24%%%%?/GM!17R!^VE_P6P^#7['EW>:.FH3>.?&%J6C?2-#=7
M6VD&?EGN#^[CY&"!O=?[E?F[^T#_ ,'&/QR^*$TT'@^W\/\ PYTYN$-I;+J%
M\!W#33J4/IE8E/X]/NLB\.<\S2*JTJ7)![2F^5>J6LFO-*Q\GG'&V4Y=)TZM
M3FFOLQU?SZ)^3:/WAJ&^U*WTR-6N;B&W5C@-*X0$^G-?R^_$7]N[XT?%FYFD
M\0?%3Q[J*SY#P'6[B.WP>"!"C"-0?0**P]*_9^^*'Q1F;4+'P3X\\1270\QK
MF#1[N\:;@?,7"'/!'.>XK[BGX*SA'FQF-C#TC=?>Y1_(^2EXJ0F[83"RG\[?
MDI']2G_"6Z5_T$M/_P# A/\ &KZ.)$#*0RL,@CH17\MG_#%GQD_Z)+\3/_"7
MOO\ XU47_"M?BY\!_M%Y_P (_P#$?P;Y8#SS_8;W3MH52P+-M7HI8Y/0$FJ?
M@YAI:4<QBY=N5?I4?Y"CXG8A.]7 R2[\S_6"_,_J9K\V_P#@YQ_Y,X\"_P#8
MYQ_^D-W7Y:?#G_@I=\?_ (52EM'^+WCL+\I$5[JDFH0KCIB.X,B#KS@<\9S@
M5J_M4_\ !3_XM?MI?"+2?!WQ$U+2=:L]&U%=4AO(]-CM;MY5BDB^8Q;8RI65
ML@(.0.>H/?P_X4YEE6<4,:ZL)TX2N[74K6?1JWXG%G7B)@,PRRMA5"49R5E>
MS6_=._X'F?[+_P#R<M\._P#L9M-_]*HJ_JFK^5G]E_\ Y.6^'?\ V,VF_P#I
M5%7]4U</CC_O6$_PR_-'7X2_[MB/\4?R84445^%'ZX%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <?\>?@'X3_
M &F?A?J7@WQMH]OKGA_5% E@ERK1L.5DC<89)%/(92"/SK^?O_@IE_P2M\7?
M\$^/&QNE^U>(OAWJDS#2]=2'_4DD[;>ZP,1S!>AX63!*XPRK_1I6+\1/AUH7
MQ;\%:CX;\3:38ZYH6K1&"\L;R(20SH><$'T(!!'((!&" :^WX+XXQ>05_=]Z
MC)^]#]8]I?@]GTM\KQ1PGALYH^_[M2*]V7;R?=?ET/Y.:*_4;]JS_@VJ\9:?
M\0+J\^$'B'0]2\+WDADAT[7+E[>]TX'_ )9^8$9)E'.&.QL8!#'+'W__ ()C
M_P#!!K1?V:=4M?&OQ:;2/%OC6TF$VG:=;YFTO2&4Y20[U7SIAP02H5". Q >
MOZ%QGBCD-' _7*57GDUI!:2OV:>UNK>G:^E_Q7"^'N<5<7]6J0Y(K>;UC;NK
M;WZ+?O;6WSQ_P28_X(6WGQ7ETOXD?&BPN-.\+@K<Z7X9F4QW&L<Y62Y'6.#T
MCX:3.3M7[_[/6=G#IUI%;V\4<%O @CCCC4*D:@8"@#@ #@ 4V_U"#2K":ZNI
MH;:UMHVEFFE<)'$BC+,S'@  $DG@ 5^1W_!5C_@O6UZNH_#OX$:EMA8&WU/Q
MC WS/V:.Q/8=C/UY/EXXDK\(J3SSC?,]%HOE"G%_J_G*5NRLOV"$<IX4R^[Z
M_.<W_7HD?K"WCO0TUO\ LQM9TE=2WB/[(;N/S]QY"[,[L^V*T;VRAU*RFM[B
M*.>WN$:.6.1=RR*1@J0>H(.,5_)5<:C<7>H27<L\TEU)(9GF=RTCN3DL6ZEB
M><]<U^EO_!*W_@N_JWP;N-/\ _&J^O-<\(L5@L/$<I:>^T8= D_5IX!QAN9$
M&?OKA5^AS_P<QN"POUG 5?;..KCR\K]8ZN_IH^UWH>'DWB=A,7B/88NG[)/:
M5[KYZ*WKJN]MSD_^"K__  1-UK]D^;5/B!\-XKSQ!\-6=[F\LP/,O/#2G).[
M',ELO:3&47 ?.#(?SXK^M#PYXDTOQWX:M=4TJ]LM6TG5(1-;W5M*LT%S$PX9
M6&0RD>E?EI_P56_X(*P^)?[0^(7P+TZ&UU##7&I^$85"Q71ZM)9=D?KF'[K?
MP;3\K?1<">*:ERY;GDK26D:CT^4^S_O?^!6W?B\7^'K5\=E*NMW!?G'_ .1^
M[L?CU14VI:;<:-J-Q9WEO-:7=K(T,\$T9CDA=20RLIY5@000>017TO\ \$Z/
M^"6OCS_@H+XP62QBD\/^!;&7;J?B.YB)A4CK#;KQYTQ]!\J]6(RH;]JS#-,+
M@<-+%XN:C".[?Z=V^B6KZ'Y3@<OQ.,KK#8:#E-]%^O9+JWHCRS]E?]DKQU^V
M7\5+7PCX#TA]1U"7#W-Q)E+/38LX,T\F"$0?0DGA0Q(!_H2_X)R?\$]/#7_!
M/#X+R>'])N7UC7]8D2YUW6)(_+;4)E!"*J9.R) S!5R3\S$DEC7:_LF?L?\
M@7]BOX56_A+P)I*6%FN)+R[DQ)>:I-CF:>3 +L><#A5'RJ%4 5XE_P %,O\
M@KEX,_8#T"71[/[/XH^)5Y%FTT.*7Y+ ,,K/=L/]6G0A!\[Y& %)<?S1Q1QA
MF7%N+65953?LF](]96^U-[)+>U[+=MNUOWKA_AG \.89YAF$U[2VLND;](K=
MM[7M=]$EH?57B?QEI'@FP^U:UJNFZ1:\CSKVY2WCX&3\SD#IS5K2]6M=<L8[
MJRNK>\MI>4F@D$D;_1AP:_EE_:._:<\;_M8?$J\\5>.M>O-:U2Z=FC21R+>Q
M0](H(L[8HQ@?*HYQDY))/I'[ G_!2KXA?\$_/'/VOP[='5O"]Y(&U3PY>3,+
M.^'=D//DS8Z2*#T&X.HVUZN(\$\9#!>UI8A2K6OR6M%OLI7^YM)/K;<\VCXK
M866*]G4HN-*_Q7N_5QM^3;]3]N/^"EW_  2Y\(_\%$/!$,EQ*OA_QYHL)CTC
M78X]V%R6^SW"]9(2Q) !#(Q)4\LK?@#^TM^S#XU_9'^*=YX/\=:--I&KVN7C
M/WH+V')"SPR=)(VP<$<C!! ((']'W[&'[='P_P#VZ_AHOB'P1JGF7%NJC4M)
MN<)?Z3(?X)8\G@X.UU)1L'!R"!8_;'_8J\"?MR?"F?PMXVTT3;0SZ=J4 "WN
MD3$#]["Y!QT&5.58## UX_!_'F.X<KO+,SC)TD[.+^*#[J_3JX[/=6Z^IQ-P
M?A,\H_7L#)*HU=27PS72_P"CW6SOT_EYK>^&7PP\0?&;QWIGACPKI%[KFO:Q
M.MO:65K'NDE<G\E4=2S$*H!)( )K[X\2?\&T_P :K7XAW%AI/B+P'>>'?./V
M?5;F\G@D,.>"\(B8J^.JJ67/1CUK]+?^"<'_  2Z\$_\$\_!DC6)7Q!XXU2(
M1ZKXAGA\N21<Y\F!,GRH00#@$LY +$X4+^M<0>*F3X+">UP-15JDOABKV7G)
M]$NV[V[M?F^2^'>98K$^SQD'2IK=NUWY1[W[[?D^&_X)1?\ !(;0?V$/#L/B
MCQ(+77?BIJ5OMN;L8>VT5&^]!:Y&<D'#R]6P0-JY#?:U%%?R_FV;XO,\5+&8
MR?-.7X+HDNB71'[]EV78? X>.&PL>6,?ZN^[?5A1117FG<%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?RA_&+_DKOBK_L,7?_ *.>OV8_
MX-CO^3.O'7_8Y2?^D-I7XS_&+_DKOBK_ +#%W_Z.>OV8_P"#8[_DSKQU_P!C
ME)_Z0VE?U7XI?\DM\Z?YG\]\ ?\ )1/TF?I)1117\J']"!1110 4444 %%%%
M !1110 4444 %?C;_P '1'_)6OA+_P!@B_\ _1T5?LE7XV_\'1'_ "5KX2_]
M@B__ /1T5?HOA3_R4U#TG_Z1(^*\0_\ D05_^W/_ $N)\C_\$>?^4E_PC_["
M[_\ I/-7])5?S:_\$>?^4E_PC_["[_\ I/-7])5?0>-G_(XH_P#7I?\ I4CQ
M?"G_ )%=7_KX_P#TF(4445^-'Z>%%%% !1110 5^*_\ P<^?\G*?#?\ [%F7
M_P!*GK]J*_%?_@Y\_P"3E/AO_P!BS+_Z5/7Z1X3_ /)24?2?_I+/A_$7_D0U
M?6/_ *4CYO\ ^")O_*4/X4?]?=[_ .F^ZK^CBOYQ_P#@B;_RE#^%'_7W>_\
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MJ4I<(\TG=OV=_O1^!\!Q4>)'&.B7/^I^FU%%%?RL?T(%9_BS_D5=3_Z])?\
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M*_%^+/\ D>8S_K[4_P#2Y'ZAPW_R*<+_ ->X?^DH;-,MO$TDC+''&"S,QP%
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MEM\G.P?,F3MW#"5^U7P?^.'@_P#: \'0^(/!/B31_$VCS_=N=/N5F5#_ '7
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MJUN5=^Y^>\*\!O)L8\7[?GO%QMRVW:=[\S[=B:BBBORD_0@HHHH **** "O
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MBL>Z?M/=:M?EW\[/\CY_B;(O[7P3P?/R:IWM?;RNOS/P%_X-\/\ E)=X=_[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834435232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VALLON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 N. 18th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">607-8255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VLON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,512,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506833549248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,221<span></span>
</td>
<td class="nump">$ 3,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,838<span></span>
</td>
<td class="nump">8,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,007<span></span>
</td>
<td class="nump">8,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,322<span></span>
</td>
<td class="nump">2,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,341<span></span>
</td>
<td class="nump">2,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">29,978<span></span>
</td>
<td class="nump">27,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(26,310)<span></span>
</td>
<td class="num">(21,902)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,666<span></span>
</td>
<td class="nump">5,818<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 8,007<span></span>
</td>
<td class="nump">$ 8,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506828754208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">10,512,836<span></span>
</td>
<td class="nump">10,512,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506828570016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 1,548<span></span>
</td>
<td class="nump">$ 2,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,506)<span></span>
</td>
<td class="num">(2,310)<span></span>
</td>
<td class="num">(4,140)<span></span>
</td>
<td class="num">(4,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Revaluation of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(266)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,773)<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
<td class="num">(4,408)<span></span>
</td>
<td class="num">(4,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (1,770)<span></span>
</td>
<td class="num">$ (2,312)<span></span>
</td>
<td class="num">$ (4,409)<span></span>
</td>
<td class="num">$ (4,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">8,683,166<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">7,753,167<span></span>
</td>
<td class="nump">6,264,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">8,683,166<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">7,753,167<span></span>
</td>
<td class="nump">6,264,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506827905696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional&#160;Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">$ (1,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes</a></td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and IPO, net of issuance expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and IPO, net of issuance expenses</a></td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Underwriters Warrants</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,638)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">(1,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">9,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,549)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2021</a></td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 9,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,549)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2021</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 5,818<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27,722<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(21,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,635)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 3,360<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27,903<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(24,537)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2021</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 5,818<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27,722<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(21,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Jun. 30, 2022</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">10,512,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 3,666<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">29,978<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(26,310)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2022</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27,903<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(24,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and IPO, net of issuance expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and IPO, net of issuance expenses</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,773)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Jun. 30, 2022</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">10,512,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 3,666<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 29,978<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (26,310)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834188464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (4,408)<span></span>
</td>
<td class="num">$ (4,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use asset</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of marketable securities premiums</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Revaluation of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ForgivenessOfDebtInstrument', window );">Forgiveness of PPP note</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest, depreciation and other expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(246)<span></span>
</td>
<td class="num">(379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">892<span></span>
</td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(576)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(3,912)<span></span>
</td>
<td class="num">(5,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(492)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of marketable securities</a></td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by investing activities</a></td>
<td class="nump">2,030<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet', window );">Proceeds from issuance of common stock and warrants, net of offering expenses</a></td>
<td class="nump">3,447<span></span>
</td>
<td class="nump">15,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liability</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">3,401<span></span>
</td>
<td class="nump">15,791<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">1,519<span></span>
</td>
<td class="nump">10,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">3,702<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">5,221<span></span>
</td>
<td class="nump">10,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes to common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ForgivenessOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ForgivenessOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock and Warrants, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506829398880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#8217;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In March 2022, the Company announced that its SEAL study for ADAIR did not reach its primary endpoint, and there is no assurance that ADAIR will receive approval by the U.S. Food and Drug Administration (the FDA). In addition to ADAIR, the Company completed formulation development work and selected the final formulation of its second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tudy to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">buse </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), was the Company&#8217;s pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the FDA. The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study did not meet its primary endpoint, which was E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking. ADAIR scored similarly to what was observed in an earlier proof-of-concept study, however, reference dextroamphetamine did not score as high as expected and as seen in the previous study, thus driving the lack of statistical significance. The SEAL study did meet all pharmacodynamic secondary endpoints including Overall Drug Liking and willingness to Take Drug Again at 12 and 24 hours post-dosing, demonstrating statistical significance.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is continuing to assess the best path forward for the ADAIR and ADMIR development programs. In addition, the Company has engaged Ladenburg Thalmann &amp; Co. Inc. (Ladenburg) to evaluate its strategic alternatives with the goal of maximizing stockholder value. Ladenburg has been engaged to advise the Company on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. In the meantime, and in conjunction with the exploration of strategic alternatives, the Company is streamlining its operations in order to preserve its capital and cash resources.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506830198880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITY<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred an accumulated deficit of  $26,310 through June&#160;30, 2022. The Company has financed its working capital requirements to date through the issuance of common stock, warrants, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company completed a $350 convertible note financing and in February 2021, the Company completed the initial public offering (IPO), raising net proceeds of $15,500. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2022, the Company entered into a Securities Purchase Agreement with certain investors (the Securities Purchase Agreement) for the sale of up to 3,700,000 shares of the Company&#8217;s common stock, par value $0.0001 per share (the Shares), at a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase price of $1.0632 per Share in a registered direct offering (the Offering). In a concurrent private placement also pursuant to the Securities Purchase Agreement (the Private Placement), for each Share of common stock purchased by an investor, such investor was entitled receive from the Company an unregistered warrant (the Warrant and, together with the Shares, the Securities) to purchase one Share of common stock. The gross proceeds from the Offering and Private Placement were approximately $3,900, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company of approximately $572, of which $85 related to the warrants was expensed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2022, the Company had cash, cash equivalents and marketable securities of approximately $6,970. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to incur ongoing expenses as it evaluates its plans for the ADAIR and ADMIR programs and strategic alternatives after it announced in March 2022 that the SEAL study of ADAIR for the treatment of ADHD failed to meet statistical significance for its primary endpoint. The Company is currently assessing the best path forward for the ADAIR and ADMIR programs and has no other product candidates undergoing clinical trials. The Company&#8217;s future capital requirements are difficult to forecast and will depend on many factors, including but not limited to the terms and timing of any strategic alternatives including a merger or business combination, asset acquisitions or sales, collaborations or licensing arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing may impose upon it covenants that restrict our operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase its common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to the Company or its stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license to other parties&#8217; rights to develop or commercialize its drug candidates that it would prefer to retain. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company expects to continue to incur expenses and operating losses at least for the foreseeable future as it evaluates future plans for the ADAIR and ADMIR programs as well as its strategic alternatives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506832088096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2022, and the results of operations and stockholders&#8217; equity (deficit) for the three and six months ended June&#160;30, 2022 and 2021 and cash flows for the six months ended June&#160;30, 2022 and 2021. Results of operations for the three and six months ended June&#160;30, 2022, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the IPO (Note 7), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the warrants issued in connection with the May 2022 registered direct financing (Note 7) in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the Balance Sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with changes in fair value recognized in the Statements of Operations and Comprehensive Loss in the period of change.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506934605120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale securities as of the dates indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company&#8217;s financial instruments included cash and cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses, and the warrant liability. The carrying amounts reported in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at June&#160;30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2022, the Company issued 3,700,000 shares of common stock pursuant to a securities purchase agreement at a purchase price of $1.0632 per share in a registered direct offering (Note 7). In connection with the registered direct offering, the Company issued warrants to purchase an aggregate of 3,700,000 shares of common stock at an exercise price of $0.9382 per share.  The warrants were classified as a liability in accordance with ASC 815-40 and the fair value of $1,554 is reflected in warrant liability on the Balance Sheet. The warrant liability was  measured at fair value at inception and is revalued at each financial statement date, with changes in fair value presented within change in fair value of warrant liability in the Statement of Operations and Comprehensive Loss.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial measurement on May 17, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Initial Measurement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">May 17, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130.8&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.3&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.665&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.955&#160;%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes (Note 6)  was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $8.00 per share upon closing of the IPO. As such, an expense of $89 was recorded during the six months ended June&#160;30, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our investments in marketable debt securities with stated contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"/><td style="width:84.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1-5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 5-10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after 10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506833180624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506829430592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PPP NOTE AND CONVERTIBLE NOTES</a></td>
<td class="text">PPP NOTE AND CONVERTIBLE NOTES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $61. The PPP Note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwOQ_edb548e1-9964-4ef6-b43d-e162b1ecb626">1.5-year</span> period beginning November 1, 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $61 included in other income on the accompanying statements of operations and comprehensive loss. The Small Business Administration (SBA) reserves the right to audit any PPP loan, regardless of size. These audits may occur after forgiveness has been granted. In accordance with the CARES Act, all borrowers are required to maintain the PPP loan documentation for six years after the PPP loan was forgiven or repaid in full and to provide that documentation to the SBA upon request.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506829430592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY (DEFICIT)<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed the IPO of 2,250,000 shares of common stock at a public offering price of $8.00 per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $18,000. Underwriting discounts and expenses totaled $1,600 and the Company incurred approximately $905 of additional expenses related to completing the IPO for aggregate net proceeds were approximately $15,500. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2022, the Company sold 3,700,000 shares of common stock pursuant to a securities purchase agreement at a purchase price of $1.0632 per share in a registered direct offering (the Offering). The gross proceeds from the Offering were approximately $3,900, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company of approximately $572 of which $85 related to the warrants was expensed. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share. The Underwriters&#8217; Warrants have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfODc3_ce620793-2d62-41d1-96a6-0936db85ba5c">five</span>-year term and are not exercisable prior to August 12, 2021. All of the Underwriters&#8217; Warrants were outstanding as of June&#160;30, 2022. The warrants were classified as equity and the fair value of $399 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.155&#160;%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering, the Company issued warrants to purchase an aggregate of 3,700,000 shares of common stock at an exercise price of $0.9382 per share. The warrants have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjU5MA_51655d27-6cc7-465e-88ec-29ffbd736c95">five</span>-year term. All of the warrants were outstanding as of June&#160;30, 2022. The warrants were classified as a liability and the fair value of $1,554 is reflected in warrant liability on the balance sheet. The Black-Scholes option-pricing model was used to estimate the initial fair value of the warrants with the following weighted-average assumptions:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.665&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506833120912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options and shares issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2022 and 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018 Plan. Stock options granted by the Company generally have a contractual life of up to 10 years. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,290</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,700</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,888</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.88</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the unrecognized compensation cost related to unvested stock options expected to vest was $1,132. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 2.71 years. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued performance-based restricted stock units (RSUs). Vesting of the performance-based RSUs is subject to the achievement of certain milestones.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to RSUs granted to employees for the three months ended June&#160;30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired/forfeited/canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, the Company granted 150,000 RSUs at a grant date fair value of $0.5552, all of which were performance-based RSUs. As of June&#160;30, 2022, the milestones associated with the performance-based RSUs were not probable of achievement, and accordingly, no stock-based compensation expense has been recognized for these awards. The unrecognized compensation cost related to unvested performance-based RSUs was $83, which will be recognized commencing in the period in which the performance condition is deemed probable of achievement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506833120912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSIn January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506833180624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#8217;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of new strains or variants of coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on the Company&#8217;s clinical trial enrollment (including the Company&#8217;s ability to recruit and retain patients), clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 pandemic and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506828683792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made </span></div>in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the warrants issued in connection with the May 2022 registered direct financing (Note 7) in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the Balance Sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with changes in fair value recognized in the Statements of Operations and Comprehensive Loss in the period of change.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506823188176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available for Sale Securities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale securities as of the dates indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at June&#160;30, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial measurement on May 17, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Initial Measurement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">May 17, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130.8&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.3&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.665&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.955&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.155&#160;%</span></td></tr></table>The Black-Scholes option-pricing model was used to estimate the initial fair value of the warrants with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.665&#160;%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our investments in marketable debt securities with stated contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"/><td style="width:84.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1-5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 5-10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after 10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506915218080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506833180624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Initial Measurement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">May 17, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130.8&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.3&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.665&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.955&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.155&#160;%</span></td></tr></table>The Black-Scholes option-pricing model was used to estimate the initial fair value of the warrants with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.665&#160;%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834914384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options and shares issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2022 and 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Activity of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,290</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,700</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,888</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.88</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to RSUs granted to employees for the three months ended June&#160;30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired/forfeited/canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506828763616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>participant</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled', window );">Number of subjects enrolled in the SEAL study</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy', window );">Number of subjects that completed the SEAL study</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis', window );">Number of subjects included in the final SEAL study analysis</a></td>
<td class="nump">52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Research Study, Number of Participants, Completed the Study</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Research Study, Number of Participants Enrolled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Research Study, Number of Participants, Included in Final Study Analysis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834821040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 1.0632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,221<span></span>
</td>
<td class="nump">$ 10,460<span></span>
</td>
<td class="nump">$ 3,702<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_WarrantsIssuanceExpense', window );">Warrants issuance expense</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantsIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issuance Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantsIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506830189008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506827863152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 1.0632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 0.9382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Expense recognized on embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI https://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834808800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company&#8217;s Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">$ 1,752<span></span>
</td>
<td class="nump">$ 3,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">1,752<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506827850336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Other Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834513040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details) - Embedded Derivative Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial measurement on May 17, 2022</a></td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in valuation</a></td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of June 30, 2022</a></td>
<td class="nump">$ 1,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834795264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 17, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.323<span></span>
</td>
<td class="nump">1.308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.02955<span></span>
</td>
<td class="nump">0.02665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834539808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in 1 year</a></td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in 1-5 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due in 5-10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="nump">$ 3,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506824198784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedLicensingFeesCurrent', window );">Licensing related</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedLicensingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Licensing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedLicensingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834749664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ForgivenessOfDebtInstrument', window );">Forgiveness of PPP note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_DebtInstrumentPaymentTerm', window );">Debt instrument, payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember', window );">Salmon Pharma, Affiliate of Medice and David Baker, CEO | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ForgivenessOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ForgivenessOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506827653056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 1.0632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Additional offering expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_WarrantsIssuanceExpense', window );">Warrants issuance expense</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 0.9382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issued reflected in additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds from stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions', window );">Stock issuance costs, discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issued reflected in additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance Initial Public Offering, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantsIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issuance Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantsIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506827680144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 17, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.323<span></span>
</td>
<td class="nump">1.308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Warrants-IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Warrants 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years | Warrants-IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years | Warrants 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate | Warrants-IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate | Warrants 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.02955<span></span>
</td>
<td class="nump">0.02665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants-IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.00155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.02665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ck0001824293_WarrantsIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ck0001824293_WarrantsIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ck0001824293_Warrants2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ck0001824293_Warrants2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834565408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="num">$ (85)<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="num">(129)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506834582144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,132<span></span>
</td>
<td class="nump">$ 1,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506828808016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">708,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">204,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">182,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">730,700<span></span>
</td>
<td class="nump">708,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending Balance (in shares)</a></td>
<td class="nump">315,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">5.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance (in usd per share)</a></td>
<td class="nump">3.92<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending Balance (in usd per share)</a></td>
<td class="nump">$ 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Beginning Balance (years)</a></td>
<td class="text">8 years 6 months 3 days<span></span>
</td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Ending Balance (years)</a></td>
<td class="text">8 years 6 months 3 days<span></span>
</td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Balance Ending (years)</a></td>
<td class="text">7 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506824212352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">90.39%<span></span>
</td>
<td class="nump">83.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in dollars per share)</a></td>
<td class="nump">$ 3.86<span></span>
</td>
<td class="nump">$ 3.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506832082032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Outstanding (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140506827748352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember', window );">Salmon Pharma, Affiliate of Medice and David Baker, CEO | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>ck0001824293-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20220630.xsd" xlink:type="simple"/>
    <context id="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia748888e0ae4402c88d60ded2bd69c1f_I20220727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="ic21ef042a65f42cd84ec887387352371_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3fdede838e6d478099d6431eb6ed4bd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i583a5a2c244e481ba66f7dc6f13c40d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i079314ede70b418f9e9ba2ac7c5dc17c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2646ebad2e449a09c2a23f7f4b2902f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8edcee8e6aa45a886ecb171a5517013_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0b8a0466c4e459f8c722280b3aa0ba3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id5043d1cb9aa4ad0afdc1e57a5a95b05_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iea93e9ac49fe43d9968c3859ed8fbb39_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0791b2a535464c1baf8fef76158971f6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i766f19785dcf4de695b5b31c95eb7e37_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idd798545154744afa1b5cb0b2f8876de_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4286ecd37f9e4199ae2009b495d787cf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie694c1e0398d496e8ff4f5bfd9a9d95b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8c70c7cf434e4b159eca07e21e6a26f1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia636262b34cb415b97e286ebf0087ee6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i78c8fc66bda34fdda3cd8cdcd6aa7d9b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib1007e0fefaa48caa07dc52b020bbc3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4c3fee39f1e454d815a147897c9a9d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia29e8203a81641caa143914e81fa5c69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac48792fe36b4e3f951e35aa6b257119_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e836fc1382c488eb49632dc1657d7ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7052bea6a0784d678627df7e577857db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5660a1163c6645df91e98942bd4ba421_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7acb50066099476cbdfe2dab9b1494b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88af9cab6ec44e7f8a4858f9b27704df_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0b0fa2bee71040e69ad3ea864aba74f4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if503def97fcc4164b2c30482e4c2e3ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id87d5eda3cf4467e82682535649adf7b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i148024954fe941968d8a6d77a82f31a9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2e3160bd798c4509b1fdac467dda316a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id894f1a76ecf4d0ab0e13230f7aacd9b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11840acdcca142beb43052c03d2ab29b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4cd4f70e2c0a4a6ea0840d122b9282fd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1f8810181f854ea093196a63a43e99d5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie11a08a59a9e4ec5bd6becb5683b465b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifa3e8f48095e4f31a4b2da281a2c6b83_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ad8d775054940af9d6d777eedda4a9f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ie9a508657df54d2a89439c9203c94580_D20220517-20220517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-05-17</startDate>
            <endDate>2022-05-17</endDate>
        </period>
    </context>
    <context id="ia5eb151e1495417d8ba486b11b22f863_I20220517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="i5d1d6f87c92b481ea937ff85d6e87f9f_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id0e01297c79d4a238d946c1d8debd442_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1400788042d42598868c075e36cdb98_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib1a61e394a9a4f539071373e4b182616_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib436207f2f064e7496a902548a58e399_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iea4222aa63154f468853a59705ceb961_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1eb1020cc8b9465fba60fc2338a0ddbd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide2992c84c8c4cbb9703a725519f2d52_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idca18b35dfc343a5b432e73aa35dda20_I20220517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="ic90be0efda4140d69daac747399be9da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3cf955fe5e0a47b98dfd6289d141ce48_I20220517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="ic39261bdabc74d02ab32636701f88ceb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1e17459f6e1e4ff88e393694f859f76f_I20220517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="ica45ce9c7f8e4a4e87dccf62ec9002c2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2268668a2bae461fbd550e2afdedd425_I20220517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="ie3c3844471a2415d85a493bb7d1b7ac2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id5278a1eaa074dd68b78d80ced668ef6_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="ibca03d411a7545b085d0c47f675a493e_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ia9e73432cae24ab4a5dc83c76c8492f7_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ie893c6ea7cb24a70984639ee82d13224_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ifaf794a259e54b3ba3547350cc2f5ef3_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i7f18e4fe2f154b23845553ce8b36cbdb_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i9a8b39ceb7ad4164be59942fb7614f0e_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="iaa68683166f845408469b50f0a32b3b5_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ice04209849fb435087c6298880b82c73_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i719a8a8b7ff446c1bc50f1384cc0de4d_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i0dd279f5e1d8444db25b59b0858f2af5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:WarrantsIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id62c32d0200843f38b297b12c7bfa449_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:WarrantsIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i06e6a1c69d574de78299b71070680019_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:WarrantsIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1b4169335d1b4ff29a400e3b99a836a9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:WarrantsIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icf0242ba0cc646728e31b766046dc508_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:Warrants2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i83d36a3a0df04368aff26ea0900fa228_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:Warrants2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia1f3a03eb7104bff89df1b804e710cc1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:Warrants2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i49e5070e0f094b4c8b1e0ca0d774e78a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ck0001824293:Warrants2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i45123774c90a4fa1956d091d5604c46c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i59279994119f4d8797134a26b83d8c6a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idbd9cf59fec149d9a8a643a612719e6e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia17f7b4da78d4e7782a9ae81963a8a71_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if0c84158c8f14fc088ef909f0eca8c58_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5e46d5f45e27451c98c012a1bfb2ff79_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i013f7d5cc90144bd84a5bfa54b52c3cb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i449ba4759b4e4bf4a5e5c917d68f2bf0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3ad6bdf33be419586390b0ac7ab0caf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if8a3cf62c41b4e068c171f0691bb0bfc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3d8cd952ddab4185bc4626df7276ebda_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icf436d7844974b62a61ac61f27616833_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2d5dff312ff4a6dbd81e861d5714df5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9ed63d6b4295468c963916e8ee547dd7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib8129a30fcf84969a1b747ba20407f23_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="participant">
        <measure>ck0001824293:participant</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8yOS0xLTEtMS0zNjkyMw_d44f7ac2-ce86-40c2-81a1-aea3f595a575">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8zMC0xLTEtMS0zNjkyMw_c4752bd5-cbb4-476c-a986-f04a0a8a4734">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8zMS0xLTEtMS0zNjkyMw_bd07e1f9-9509-45a9-a949-bd655fa79a2c">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8zMi0xLTEtMS0zNjkyMw_072d3224-41b0-4dd6-a1df-36f9066489f9">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80L2ZyYWc6NDUwZDU5NmY5ZjNmNDM0MmJlYWVhNGQ0Njc3NGQyYzAvdGFibGU6NDkxNDBmOTM3MjJlNDQyN2I1MGRmOTMxNTBkYWRhZTkvdGFibGVyYW5nZTo0OTE0MGY5MzcyMmU0NDI3YjUwZGY5MzE1MGRhZGFlOV8zMy0xLTEtMS0zNjkyMw_27a18a90-cd0a-4584-99a9-241d65f79d97">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i5d1d6f87c92b481ea937ff85d6e87f9f_D20210212-20210212"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80Ni9mcmFnOjg2M2E5YmM4YjlhZjQxZDQ4YzJkOWNmOWExYzI0YmI0L3RhYmxlOjZiNDk2NWZjMzY2NjQ5NzViNjg1ZDk5YmNmOWQwMzY5L3RhYmxlcmFuZ2U6NmI0OTY1ZmMzNjY2NDk3NWI2ODVkOTliY2Y5ZDAzNjlfMS0xLTEtMS0zNjkyMw_96722dea-805d-4207-a11e-62f6b4fc3889"
      unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <ck0001824293:DebtInstrumentPaymentTerm
      contextRef="ia9e73432cae24ab4a5dc83c76c8492f7_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwOQ_edb548e1-9964-4ef6-b43d-e162b1ecb626">P1Y6M0D</ck0001824293:DebtInstrumentPaymentTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ice04209849fb435087c6298880b82c73_I20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfODc3_ce620793-2d62-41d1-96a6-0936db85ba5c">P5Y0M0D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjU5MA_51655d27-6cc7-465e-88ec-29ffbd736c95">P5Y0M0D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDc4_33232c63-1cb5-4db7-9c1e-aab1b804817a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6NmMwNTM2Yzc4YjNiNDg0ZGJiZGY4Y2Y4NjE3YTBlOGQvdGFibGVyYW5nZTo2YzA1MzZjNzhiM2I0ODRkYmJkZjhjZjg2MTdhMGU4ZF8wLTAtMS0xLTM2OTIz_3bf92c63-24f7-44e1-bcca-13edb4af3abc">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDY_0e99c7b0-a5ef-4dd1-89da-fe1932d24f05">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6Mjk5OGMwOTc2YTYxNGE1NzhiMDAyY2E0MzM5Nzk1MGMvdGFibGVyYW5nZToyOTk4YzA5NzZhNjE0YTU3OGIwMDJjYTQzMzk3OTUwY18wLTAtMS0xLTM2OTIz_2e051d8a-1325-4fc8-bf7c-804270de9be7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDg2_31ab8844-50c8-4007-8504-e46f56cdee2b">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDc2_8de57b6c-51f4-4b8b-874d-479cf026cfe6">VALLON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8wLTAtMS0xLTM2OTIz_24a07019-d956-466e-b968-f997dd6428d7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8wLTItMS0xLTM2OTIz_baa061d4-4274-410a-9105-9f5e4dc59bb8">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfNQ_f14f0f05-e2f1-4af8-be9a-b32110d2086d">100 N. 18th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfOQ_fcaf41fa-b87b-4a6e-b028-96a1de564114">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfMTQ_c1a68c47-cbbf-43a1-91be-94d219e65154">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfMTg_9ffce2e1-60c7-47e0-8f49-c8424f63c6e5">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6MTJiZjlmZTczYjYxNDBlOGE1OTNhY2E5ZTFmYjY0OWEvdGFibGVyYW5nZToxMmJmOWZlNzNiNjE0MGU4YTU5M2FjYTllMWZiNjQ5YV8zLTAtMS0xLTM2OTIzL3RleHRyZWdpb246MzZlNGQyNzJmMDJmNGRmM2IzY2M5N2MwODgwZGMwNjNfMjI_38c27384-a86a-4cf4-8fc4-22c4e62eb630">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl80NjA_ac63ebee-3237-4f19-969d-43425710415b">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDgy_539f258b-3a22-49b8-bfa9-d4c1f50ee578">607-8255</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6YTRlYTFmMDRlN2E4NDY2NDk0Y2Q2NDJiNzUwNjQ4OGUvdGFibGVyYW5nZTphNGVhMWYwNGU3YTg0NjY0OTRjZDY0MmI3NTA2NDg4ZV8xLTAtMS0xLTM2OTIz_6af057df-45e8-4e83-bb58-5945566fadb0">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6YTRlYTFmMDRlN2E4NDY2NDk0Y2Q2NDJiNzUwNjQ4OGUvdGFibGVyYW5nZTphNGVhMWYwNGU3YTg0NjY0OTRjZDY0MmI3NTA2NDg4ZV8xLTItMS0xLTM2OTIz_9e7b8b6a-72c6-494d-946c-f5507a4d127e">VLON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6YTRlYTFmMDRlN2E4NDY2NDk0Y2Q2NDJiNzUwNjQ4OGUvdGFibGVyYW5nZTphNGVhMWYwNGU3YTg0NjY0OTRjZDY0MmI3NTA2NDg4ZV8xLTQtMS0xLTM2OTIzL3RleHRyZWdpb246ZjE5ZWE5NjQzNDU3NDcxMGEzYWYxNzRmOWE1MDJiNjVfNA_713fe16f-dbf2-4b85-bc70-6f4807dd5adc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDgz_09994677-c217-43f1-ba18-5ce0aa9747f4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDgw_19deb4c9-f946-428f-a277-4818762698d1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6OTI4ZGY4ZmQ5ZmEzNDAxN2IzNTIwMjI3NDhkYjQ5NzUvdGFibGVyYW5nZTo5MjhkZjhmZDlmYTM0MDE3YjM1MjAyMjc0OGRiNDk3NV8xLTAtMS0xLTM2OTIz_bcb5c565-302e-4913-a4ae-4a2b57fc3ea5">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6OTI4ZGY4ZmQ5ZmEzNDAxN2IzNTIwMjI3NDhkYjQ5NzUvdGFibGVyYW5nZTo5MjhkZjhmZDlmYTM0MDE3YjM1MjAyMjc0OGRiNDk3NV8xLTMtMS0xLTM2OTIz_12b7ab7f-0a3b-46e5-975b-dc3914f8d453">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGFibGU6OTI4ZGY4ZmQ5ZmEzNDAxN2IzNTIwMjI3NDhkYjQ5NzUvdGFibGVyYW5nZTo5MjhkZjhmZDlmYTM0MDE3YjM1MjAyMjc0OGRiNDk3NV8yLTEtMS0xLTM2OTIz_447e3a08-7054-4077-9002-faba071dc820">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDc3_f674cacc-c188-4e10-a188-ad7303ceb285">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDg0_feea83aa-ba7d-4646-84a8-1b1099cc6612">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia748888e0ae4402c88d60ded2bd69c1f_I20220727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xL2ZyYWc6MTlmOWQyOWUzMmFiNGZmYjk3ZDFmODFmY2U3ZjJlYmIvdGV4dHJlZ2lvbjoxOWY5ZDI5ZTMyYWI0ZmZiOTdkMWY4MWZjZTdmMmViYl8yMDE1_9c3cc9e1-e3f7-4402-abba-1a1fd62567f2"
      unitRef="shares">10512836</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMy0xLTEtMS0zNjkyMw_ee0a06bc-2ca8-434a-b47e-e3f00c239b38"
      unitRef="usd">5221000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMy0zLTEtMS0zNjkyMw_9c83d0d1-5c9c-44bb-8703-73046a425a3d"
      unitRef="usd">3702000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNC0xLTEtMS00OTI0NA_f080f595-18f7-4f61-8510-c5c90d9d029a"
      unitRef="usd">1749000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNC0zLTEtMS00OTMzNA_63d07eff-8521-47a0-adac-c0b7344ea3c5"
      unitRef="usd">3808000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNC0xLTEtMS0zNjkyMw_4bda9a65-8123-474e-9424-0833f8fa83fc"
      unitRef="usd">868000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNC0zLTEtMS0zNjkyMw_4f01e89f-4c46-4980-82d6-4d4bd1e30379"
      unitRef="usd">619000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNS0xLTEtMS0zNjkyMw_8e8fc1af-db9d-4261-b197-6f6687528d37"
      unitRef="usd">7838000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNS0zLTEtMS0zNjkyMw_55fc7b37-2658-4419-9dff-bdaf55586ddb"
      unitRef="usd">8129000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNi0xLTEtMS0zNjkyMw_8bf3b372-db53-4087-984a-c1afc153c156"
      unitRef="usd">169000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfNi0zLTEtMS0zNjkyMw_94e41cf9-0e33-42d3-841c-99befdaf727d"
      unitRef="usd">206000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfOC0xLTEtMS0zNjkyMw_2b6ef3ad-041f-419b-a152-4cdd0c976826"
      unitRef="usd">8007000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfOC0zLTEtMS0zNjkyMw_9614730b-ee7f-4f10-a94d-20973b4f6b25"
      unitRef="usd">8335000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTItMS0xLTEtMzY5MjM_01b4db99-eb61-438f-867a-df38dd13ae73"
      unitRef="usd">1810000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTItMy0xLTEtMzY5MjM_2accda93-df48-4509-9417-025ceec37de8"
      unitRef="usd">918000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTMtMS0xLTEtMzY5MjM_df206b88-28ac-49b8-85e7-58b6fe88d6a6"
      unitRef="usd">854000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTMtMy0xLTEtMzY5MjM_cf64551c-89be-46e6-9b6a-b91a3e66020a"
      unitRef="usd">1430000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTQtMS0xLTEtNTEyMTg_19fdbad8-9899-4240-96dc-d6c4df73b8d3"
      unitRef="usd">1554000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTQtMy0xLTEtNTEyMzA_7f83f378-558a-402f-946a-aff9957fb380"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTUtMS0xLTEtMzY5MjM_83da9201-5f86-4a5f-960b-84b3a51f1602"
      unitRef="usd">104000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTUtMy0xLTEtMzY5MjM_019dbf32-3f55-441b-942c-dd8b776b99ae"
      unitRef="usd">97000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTYtMS0xLTEtMzY5MjM_184e86d2-0a12-4857-8d3c-4d6158ff7548"
      unitRef="usd">4322000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTYtMy0xLTEtMzY5MjM_fdc1d27a-fc6c-43dd-90d0-0d03a03801c5"
      unitRef="usd">2445000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTgtMS0xLTEtMzY5MjM_40a6c6a6-1ece-412a-9c0a-c5c2adbb995d"
      unitRef="usd">19000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTgtMy0xLTEtMzY5MjM_3ea328f7-c8fe-476b-ab1f-36a6c2e3ac87"
      unitRef="usd">72000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTktMS0xLTEtMzY5MjM_109f6bd8-ea2c-4ca6-a161-d96e5d21bf1c"
      unitRef="usd">4341000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMTktMy0xLTEtMzY5MjM_82eeb856-5c47-4a5b-827b-382aa5dfc9c0"
      unitRef="usd">2517000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjEtMS0xLTEtMzY5MjM_423464e2-3bef-48da-9c67-4e3045db016c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjEtMy0xLTEtMzY5MjM_80b34638-cc00-4620-ae1b-7f0a20a7ae70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl8xOA_4cbd90aa-3e13-492a-8812-ce528ebb4a06"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl8xOA_f5d77ba4-db2a-4544-89cc-340de3800dce"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl8zMg_768db6a1-baf0-4141-9a50-f24c98271090"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl8zMg_c9febb44-e4c9-4b8a-a861-001ccb22d726"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl83MA_28885867-ffca-469c-baed-c3589a0ed996"
      unitRef="shares">10512836</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl83MA_eb96644c-cf23-46a1-9480-aa6fa6584da8"
      unitRef="shares">10512836</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl83Nw_8b44d120-be29-470b-941b-59ee343a7593"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMC0xLTEtMzY5MjMvdGV4dHJlZ2lvbjo2OGI5ZTI1MTQ5MTE0YTczYjE0NWYzY2Q5YzI5MjFiMl83Nw_b55255c2-1fe0-4e0b-815d-14cb8664d797"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMS0xLTEtMzY5MjM_ef15aec5-1789-4197-bce9-b6e12d44e17d"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMy0xLTEtMzY5MjM_f4ece2a7-5cdc-4ce5-b35c-95d6e06b40ff"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjUtMS0xLTEtMzY5MjM_1ed85ec9-799a-42aa-a8a4-9b22d2e2b580"
      unitRef="usd">29978000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjUtMy0xLTEtMzY5MjM_0b3d306d-5942-4d66-8047-a63b0720eaa0"
      unitRef="usd">27722000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMS0xLTEtNDkzMzk_17f4263f-da0a-40c6-a427-11dec2537dd9"
      unitRef="usd">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjQtMy0xLTEtNDkzNDE_91e51c8f-b5dd-4635-9f9b-013d2e351f20"
      unitRef="usd">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjYtMS0xLTEtMzY5MjM_b4d99177-1c06-4958-a5f1-2bc1ec829e1c"
      unitRef="usd">-26310000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjYtMy0xLTEtMzY5MjM_0474068c-e145-4c89-abeb-f89d369a0635"
      unitRef="usd">-21902000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjctMS0xLTEtMzY5MjM_ec99e11d-3fb9-4513-8da2-8a2df31aa04a"
      unitRef="usd">3666000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjctMy0xLTEtMzY5MjM_6c60076b-a04a-4027-80e5-c382d4b63654"
      unitRef="usd">5818000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjgtMS0xLTEtMzY5MjM_967e5115-c09e-4c30-a7d4-a38e1044337c"
      unitRef="usd">8007000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8xOS9mcmFnOjYyMWNhNjdmYTlkYjRjNTg5NDk0OTIxZDExMWNkMTdjL3RhYmxlOjNkNzcyNzhjMDQ5NjRlNzRhNTAxZWMzMWQxMTMxMDU0L3RhYmxlcmFuZ2U6M2Q3NzI3OGMwNDk2NGU3NGE1MDFlYzMxZDExMzEwNTRfMjgtMy0xLTEtMzY5MjM_25e681b2-42e0-444b-aa5f-eff69799437d"
      unitRef="usd">8335000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNS0xLTEtMS0zNjkyMw_0f28b18c-aaf3-40f1-bb86-300c5189557c"
      unitRef="usd">278000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNS0zLTEtMS0zNjkyMw_03378a99-ba33-424f-b90a-891df5ead5ff"
      unitRef="usd">1202000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNS01LTEtMS0zNjkyMw_1d5d952c-65db-4a45-83f0-12ec042a9315"
      unitRef="usd">1548000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNS03LTEtMS0zNjkyMw_8fbb91e8-f004-4168-9418-de76b4885dd8"
      unitRef="usd">2974000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNi0xLTEtMS0zNjkyMw_5f770619-d624-41cd-a4b3-00ea84c53384"
      unitRef="usd">1228000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNi0zLTEtMS0zNjkyMw_bbc6cec6-4ab5-4782-b2e5-688b1ae134bf"
      unitRef="usd">1108000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNi01LTEtMS0zNjkyMw_f66de7bd-e684-4d6d-8654-c2248d708005"
      unitRef="usd">2592000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNi03LTEtMS0zNjkyMw_e7d0ee69-4325-4d58-9de1-cb42885b9890"
      unitRef="usd">1938000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNy0xLTEtMS0zNjkyMw_2290b243-1846-4a43-975d-2c1563e0a28d"
      unitRef="usd">1506000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNy0zLTEtMS0zNjkyMw_b0471f9c-8f94-480e-af3b-b1b0130ed1df"
      unitRef="usd">2310000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNy01LTEtMS0zNjkyMw_ea134772-dea6-4573-8375-2c89dc14b238"
      unitRef="usd">4140000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfNy03LTEtMS0zNjkyMw_12b9dd82-075f-4fcb-8942-5b67396a8a68"
      unitRef="usd">4912000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOC0xLTEtMS0zNjkyMw_d7298fb3-9d85-4415-b015-bdf1cc34e0e6"
      unitRef="usd">-1506000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOC0zLTEtMS0zNjkyMw_62203b62-daf0-45dc-a41f-e9123b2b7abb"
      unitRef="usd">-2310000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOC01LTEtMS0zNjkyMw_a9fafd8c-7bc7-4662-a2af-1da919bb050a"
      unitRef="usd">-4140000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOC03LTEtMS0zNjkyMw_0bc8d309-5435-4d41-9c01-a37966f393b1"
      unitRef="usd">-4912000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOS0xLTEtMS0zNjkyMw_12880a22-d15e-43d3-b319-b03a4dbef224"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOS0zLTEtMS0zNjkyMw_02a78342-3908-473c-a455-4a09860cec55"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOS01LTEtMS0zNjkyMw_fb08e1d8-c431-44ea-a02f-4b870997c413"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfOS03LTEtMS0zNjkyMw_63a788f1-e2cd-4060-9562-939f9226f01c"
      unitRef="usd">61000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtMS0xLTEtNTE4OTU_36adadd8-6f28-4a74-949b-a60d6e647598"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtMy0xLTEtNTE5MDI_d68c86aa-1f37-4054-8e89-436007b4e38d"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtNS0xLTEtNTE5MDk_4b0bbcf4-f030-4727-bb96-67cbc764f5c6"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtNy0xLTEtNTE4ODg_96587cad-1436-46e5-b8aa-bcb42fa91c10"
      unitRef="usd">-89000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtMS0xLTEtMzY5MjM_ba9b1066-1575-4540-8bb7-424720977d4c"
      unitRef="usd">266000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtMy0xLTEtMzY5MjM_8e4ddeee-16c7-4f7b-a159-d907403804fd"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtNS0xLTEtMzY5MjM_ce1bc13f-38fa-4bc4-8d54-2e1a3ef0d8bc"
      unitRef="usd">266000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTAtNy0xLTEtMzY5MjM_8569437c-d316-4c28-9781-673a88405791"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTEtMS0xLTEtMzY5MjM_609881a0-6084-4c2e-a805-4a926453023c"
      unitRef="usd">-1000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTEtMy0xLTEtMzY5MjM_1343d5dd-00bc-4826-8c25-0ce08475412b"
      unitRef="usd">-2000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTEtNS0xLTEtMzY5MjM_2ba2a49b-fc1e-43ee-87a2-320b9890d407"
      unitRef="usd">-2000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTEtNy0xLTEtMzY5MjM_8944602f-dfbf-4d71-896d-1e1862794fb5"
      unitRef="usd">-10000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTItMS0xLTEtMzY5MjM_e9d8b3d0-72b9-4703-a3b2-cbf58db5664c"
      unitRef="usd">-1773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTItMy0xLTEtMzY5MjM_34af30a2-b980-43b1-b92e-8451b1e8a3a7"
      unitRef="usd">-2312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTItNS0xLTEtMzY5MjM_8bb7b084-93ca-405d-bd2e-9cf36de90058"
      unitRef="usd">-4408000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTItNy0xLTEtMzY5MjM_a5dc26dd-f163-4aa9-b82c-beac21e863e3"
      unitRef="usd">-4950000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMS0xLTEtNDkzNDg_408fe0b9-9fdd-4824-9ecf-1f4fa9e46c22"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMy0xLTEtNDkzNTA_a9d6c1a8-0b3c-4c4f-a10a-e5825eae5202"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNS0xLTEtNDkzNTI_f05b4e1d-cff5-4666-a166-c6b28d52c4a9"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNy0xLTEtNDkzNTQ_c62bbb4e-0cf7-4d82-828c-9633142310ef"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTUtMS0xLTEtNDkzNDg_f507f504-aa78-4dbd-87fc-9294e258ccbf"
      unitRef="usd">-1770000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTUtMy0xLTEtNDkzNTA_b4a7894c-e7dc-431d-b193-1a3dfa858314"
      unitRef="usd">-2312000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTUtNS0xLTEtNDkzNTI_addd6efd-505e-4ed9-a1e3-756cb478e5c7"
      unitRef="usd">-4409000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTUtNy0xLTEtNDkzNTQ_ae3483e2-62df-4a2f-b2eb-763a3ddaafe3"
      unitRef="usd">-4950000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtMS0xLTEtMzY5MjM_17a4fe75-b2ad-4834-8f43-bdf73625332f"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtMS0xLTEtMzY5MjM_94d2dbc2-19d6-4ef6-bd55-6ebd8bc384dd"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtMy0xLTEtMzY5MjM_aeb9b765-ff30-40e9-9cb1-a95a52c911ed"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtMy0xLTEtMzY5MjM_b971f6b2-210c-4b80-a4dc-52f5d623b3ca"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtNS0xLTEtMzY5MjM_223e122e-d097-403e-87e5-1552ac6bbf07"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtNS0xLTEtMzY5MjM_608f6def-940a-4a78-8b9d-b6eb1e4af42d"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtNy0xLTEtMzY5MjM_2b2b9fac-ff64-4ae8-b824-82232215eddd"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTMtNy0xLTEtMzY5MjM_7181ffab-9831-44bf-b047-42e36f91783a"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMS0xLTEtMzY5MjM_6f8be7d2-4224-4b7f-a36f-9f9bbdd2ad6c"
      unitRef="shares">8683166</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMS0xLTEtMzY5MjM_fb4c7b62-b1a7-4663-8adc-67c9f6dba758"
      unitRef="shares">8683166</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMy0xLTEtMzY5MjM_515c1e8f-4dfe-4ea2-8d12-f9bd3383b17a"
      unitRef="shares">6812836</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtMy0xLTEtMzY5MjM_9f1b7b8a-d80e-4aeb-b0d8-984fd630d5c7"
      unitRef="shares">6812836</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNS0xLTEtMzY5MjM_95ec6be7-6e94-46bc-af45-91b06192000c"
      unitRef="shares">7753167</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNS0xLTEtMzY5MjM_b30f5f4d-94c0-45ac-8fda-617c765a0d1a"
      unitRef="shares">7753167</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNy0xLTEtMzY5MjM_15357fa2-4ea1-446b-af56-fb9bd9889bda"
      unitRef="shares">6264854</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yNS9mcmFnOjM1NjUwNmJkMmE3NjQyMWQ4MWIwYjA4YjFhMWYwNDI4L3RhYmxlOjYwNWNiNTFjNzdiNDQ3N2Q4NjQ0ZmNhZWRhYzYzODI5L3RhYmxlcmFuZ2U6NjA1Y2I1MWM3N2I0NDc3ZDg2NDRmY2FlZGFjNjM4MjlfMTQtNy0xLTEtMzY5MjM_f6ace1cd-1cbc-4fef-8624-fe8e6a64719b"
      unitRef="shares">6264854</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i583a5a2c244e481ba66f7dc6f13c40d8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMi0xLTEtMS0zNjkyMw_8031e662-a5d5-4bb6-be23-92486e4200bf"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i079314ede70b418f9e9ba2ac7c5dc17c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMi01LTEtMS0zNjkyMw_6393d105-203f-4a8d-b6d2-04e087cc7fb7"
      unitRef="usd">11145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id2646ebad2e449a09c2a23f7f4b2902f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMi03LTEtMS0zNjkyMw_9d425e88-5c2d-41a0-99b6-77cfa097d88e"
      unitRef="usd">-12599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8edcee8e6aa45a886ecb171a5517013_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMi05LTEtMS0zNjkyMw_41e20d57-5645-4b97-a208-207b3b4e97c9"
      unitRef="usd">-1454000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMy0xLTEtMS0zNjkyMw_81447719-49ad-4e36-8b09-676b26cae402"
      unitRef="shares">54906</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMy01LTEtMS0zNjkyMw_233c29c6-14af-47ae-ac8b-e76b4b1f6d24"
      unitRef="usd">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMy05LTEtMS0zNjkyMw_26e7fe5b-6405-4de4-8faa-525f085668a7"
      unitRef="usd">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNC0xLTEtMS0zNjkyMw_bbd9a9c3-bff8-4ed3-a4b9-a0fc0cef0619"
      unitRef="shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNC01LTEtMS0zNjkyMw_a6e59cb1-3d47-4972-ac25-7a6d2f17c77f"
      unitRef="usd">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNC05LTEtMS0zNjkyMw_cfe7875c-7b1c-4df1-8de8-ec12bfbf8a9c"
      unitRef="usd">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNS0xLTEtMS0zNjkyMw_9bd54395-d6dd-41d8-afc9-1975b3511a87"
      unitRef="shares">1714</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNS01LTEtMS0zNjkyMw_c87cf4de-e009-4c68-9c8e-7930634615b7"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNS05LTEtMS0zNjkyMw_032933c8-8257-40b1-859d-956ebda578a0"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNi01LTEtMS0zNjkyMw_7db15bee-d806-4a52-aeeb-fdd15495f6cb"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNi05LTEtMS0zNjkyMw_0cc30176-2671-4d9a-bcef-5d14c57d53c1"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6e7f6d18773848ea9ceb95ea222080d2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNy01LTEtMS0zNjkyMw_6cc04b59-0c99-4980-ac08-44cf07db6e29"
      unitRef="usd">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfNy05LTEtMS0zNjkyMw_87a499f6-f692-4f3a-844f-7fb9a0022ad6"
      unitRef="usd">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="if0b8a0466c4e459f8c722280b3aa0ba3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOC03LTEtMS0zNjkyMw_c2b7e46d-b2ac-46c6-85c9-f67b9b5c6194"
      unitRef="usd">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia366d1da22be47e7a5b2746dd92f4b18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOC05LTEtMS0zNjkyMw_79b7fc77-abe7-4150-ab53-6dd7ca391b29"
      unitRef="usd">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5043d1cb9aa4ad0afdc1e57a5a95b05_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOS0xLTEtMS0zNjkyMw_f60a51b5-d0f1-43bd-bfec-fbb23ea95c35"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iea93e9ac49fe43d9968c3859ed8fbb39_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOS01LTEtMS0zNjkyMw_bbe5f7fe-61e8-47c2-a2bd-6585c613f92d"
      unitRef="usd">27264000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0791b2a535464c1baf8fef76158971f6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOS03LTEtMS0zNjkyMw_37365d0f-7816-4054-bc2f-27c8c955a659"
      unitRef="usd">-15237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i766f19785dcf4de695b5b31c95eb7e37_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfOS05LTEtMS0zNjkyMw_ce1b9316-f9d6-415b-b47f-221aa31834cb"
      unitRef="usd">12027000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idd798545154744afa1b5cb0b2f8876de_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTAtNS0xLTEtMzY5MjM_156a3919-56f4-4d62-b88c-4de29b090afa"
      unitRef="usd">138000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTAtOS0xLTEtMzY5MjM_a52ad417-4658-4b42-9d68-476f773e9d3b"
      unitRef="usd">138000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i4286ecd37f9e4199ae2009b495d787cf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTEtNy0xLTEtMzY5MjM_e8ebecbc-5dea-4228-8b1c-cdad02a700b6"
      unitRef="usd">-2312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTEtOS0xLTEtMzY5MjM_0852637c-e835-40f8-80d5-b20afc4a04ba"
      unitRef="usd">-2312000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie694c1e0398d496e8ff4f5bfd9a9d95b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTItMS0xLTEtMzY5MjM_2b8cd524-d601-434e-a0d6-552b4b7db109"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8c70c7cf434e4b159eca07e21e6a26f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTItNS0xLTEtMzY5MjM_af242a10-66c2-4566-97af-20c52f998cba"
      unitRef="usd">27402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia636262b34cb415b97e286ebf0087ee6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTItNy0xLTEtMzY5MjM_67b10cde-cf37-455b-9f45-4fa7d4d62055"
      unitRef="usd">-17549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78c8fc66bda34fdda3cd8cdcd6aa7d9b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOjM0ZDA0ODhlZmJmYzQwNzliMDBiZDBmMDUwNGZmOTYwL3RhYmxlcmFuZ2U6MzRkMDQ4OGVmYmZjNDA3OWIwMGJkMGYwNTA0ZmY5NjBfMTItOS0xLTEtMzY5MjM_c40ca4a3-a530-498d-9039-c5edc609fd02"
      unitRef="usd">9853000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib1007e0fefaa48caa07dc52b020bbc3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi0xLTEtMS01MDU1Mg_6284dd48-b6d2-4dca-add2-4f1d2f36bff4"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib1007e0fefaa48caa07dc52b020bbc3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi0zLTEtMS01NDI3Mg_3588ea1b-d49d-4fce-9631-f9e5eda70967"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4c3fee39f1e454d815a147897c9a9d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi01LTEtMS01MDU2Mw_1d3fc98d-eac4-4899-85fa-0476809262d1"
      unitRef="usd">27722000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia29e8203a81641caa143914e81fa5c69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi03LTEtMS01MDU3MA_3f93eb31-8d09-4fba-9c25-2c97de5e069b"
      unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac48792fe36b4e3f951e35aa6b257119_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi05LTEtMS01MDY4Mw_bfe14dbf-049a-4295-921b-06f5b45620dd"
      unitRef="usd">-21902000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMi0xMS0xLTEtNTQyODU_81e86323-c348-446b-8534-6342acce3d64"
      unitRef="usd">5818000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e836fc1382c488eb49632dc1657d7ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMy01LTEtMS01MDY1OA_150e9d4a-c44b-4abe-b6e3-b1294003d43d"
      unitRef="usd">181000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7052bea6a0784d678627df7e577857db_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMy0xMS0xLTEtNTQyODU_ecc6b66d-235b-47c8-a6e9-f44ebb5bc752"
      unitRef="usd">181000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5660a1163c6645df91e98942bd4ba421_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNC03LTEtMS01MDY3Ng_a1154917-3266-46dc-a805-4bede92ffbf2"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7052bea6a0784d678627df7e577857db_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNC0xMS0xLTEtNTQyOTU_9846f096-5dcb-4061-b5a6-fe89501893b3"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i7acb50066099476cbdfe2dab9b1494b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNS05LTEtMS01MDY4MA_867442cb-ea2f-4b39-bc75-aa7daf584162"
      unitRef="usd">-2635000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7052bea6a0784d678627df7e577857db_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNS0xMS0xLTEtNTQyOTU_81d1df73-e4c9-4c7f-98d8-3907d2cc4c09"
      unitRef="usd">-2635000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i88af9cab6ec44e7f8a4858f9b27704df_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi0xLTEtMS01NDI2Ng_c7c1d9c0-d4b5-4c1a-827c-c2870de113fe"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i88af9cab6ec44e7f8a4858f9b27704df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi0zLTEtMS01NDI3Ng_2d4d39c8-720e-48b5-8ba6-f78e962cae00"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b0fa2bee71040e69ad3ea864aba74f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi01LTEtMS01NDI3OQ_ea6c271e-c3eb-4b5e-9336-7d7dda158cc4"
      unitRef="usd">27903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if503def97fcc4164b2c30482e4c2e3ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi03LTEtMS01NDMwMg_14ab6003-7ad5-4112-b9ea-ad66deb95c27"
      unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id87d5eda3cf4467e82682535649adf7b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi05LTEtMS01NDMwMA_3338e5f4-a282-4d3f-82e2-2a7f234483a1"
      unitRef="usd">-24537000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i148024954fe941968d8a6d77a82f31a9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNi0xMS0xLTEtNTQyOTc_66307375-2a67-4345-a3a3-9d885e4fbad7"
      unitRef="usd">3360000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2e3160bd798c4509b1fdac467dda316a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNy0xLTEtMS01MDczMg_feac8e24-ad12-4096-9de3-4546ee493d3b"
      unitRef="shares">3700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2e3160bd798c4509b1fdac467dda316a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNy0zLTEtMS01MDczOQ_2c6b18bd-b0de-4f20-9321-b3326b0975d4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id894f1a76ecf4d0ab0e13230f7aacd9b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNy01LTEtMS01MDc0Ng_d9b7eefa-6742-49b5-8aab-9ee707d3772c"
      unitRef="usd">2160000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfNy0xMS0xLTEtNTQyOTc_663c5700-b5fa-416d-b860-a47bcd9f6444"
      unitRef="usd">2161000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id894f1a76ecf4d0ab0e13230f7aacd9b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfOC01LTEtMS01MDc0Ng_62144656-35bb-4566-908e-44059e26b3d4"
      unitRef="usd">-85000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfOC0xMS0xLTEtNTQyOTc_2d9cf181-53e1-4855-9e8e-7cbac8994e47"
      unitRef="usd">-85000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i11840acdcca142beb43052c03d2ab29b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfOS03LTEtMS01MDc2MA_2a329c41-49e3-48b5-a5e1-f4c15c0636e8"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfOS0xMS0xLTEtNTQyOTc_a3499817-c36e-4e96-9aff-3dbd10497ce7"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i4cd4f70e2c0a4a6ea0840d122b9282fd_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTAtOS0xLTEtNTA3NTM_faa34071-6b76-4578-9ca5-e64bb9cf2e47"
      unitRef="usd">-1773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTAtMTEtMS0xLTU0Mjk3_0a77ac41-f152-45b0-a379-55d240c8c7cb"
      unitRef="usd">-1773000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1f8810181f854ea093196a63a43e99d5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtMS0xLTEtNTQyNzA_942b6d2c-a3f9-446d-b912-4aa25d204009"
      unitRef="shares">10512836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1f8810181f854ea093196a63a43e99d5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtMy0xLTEtNTQyNzQ_6f47e8f8-5e1d-4642-9c03-2de8455cb079"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie11a08a59a9e4ec5bd6becb5683b465b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtNS0xLTEtNTQyODM_3409d2ac-fd7a-47c8-ba3c-ec083b859712"
      unitRef="usd">29978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa3e8f48095e4f31a4b2da281a2c6b83_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtNy0xLTEtNTQzMDU_e403e9a0-a3f9-406f-b088-86123fc2ea44"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ad8d775054940af9d6d777eedda4a9f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtOS0xLTEtNTQzMTA_e0dfee57-d103-4f27-98e6-ec35c036f63d"
      unitRef="usd">-26310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8yOC9mcmFnOmFlYmE1MjZjNDZjNjQzM2JiMDc4ZDUxZDc2MGNlZGZjL3RhYmxlOmZmNjYzYjE3MDA0MDQ0YjM5N2E0NTIxNTVkODk5M2FlL3RhYmxlcmFuZ2U6ZmY2NjNiMTcwMDQwNDRiMzk3YTQ1MjE1NWQ4OTkzYWVfMTEtMTEtMS0xLTU0Mjk3_457e2214-a37d-447c-8f8b-56a3097cffa3"
      unitRef="usd">3666000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMy0xLTEtMS0zNjkyMw_489d1c38-0f63-445e-9155-4b95fe3668ed"
      unitRef="usd">-4408000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMy0zLTEtMS0zNjkyMw_e92c55da-ced6-41d6-a288-78047f34f5e0"
      unitRef="usd">-4950000</us-gaap:NetIncomeLoss>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNS0xLTEtMS0zNjkyMw_66140884-bf80-49ac-9ad9-2e8717202851"
      unitRef="usd">37000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNS0zLTEtMS0zNjkyMw_b5ef39b0-17ee-420b-8f51-e2cf20831351"
      unitRef="usd">36000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNi0xLTEtMS00OTM2Ng_f6048cb1-298f-4c8e-b67c-46c7e9e8042c"
      unitRef="usd">-27000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNi0zLTEtMS00OTM2OA_8afa95e5-355c-4261-a404-fa11d570728d"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNi0xLTEtMS0zNjkyMw_0eddcd72-200c-4d6f-83ee-f23e3acb3b67"
      unitRef="usd">96000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfNi0zLTEtMS0zNjkyMw_f5fac545-11ec-4089-b190-22bbf23e5a39"
      unitRef="usd">306000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOC0xLTEtMS01MTk3Ng_098c3daa-f805-4b11-bf61-5d2b4fa31031"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOC0zLTEtMS01MTk4Mw_e1cf2b72-ba5f-42e5-9d7b-905eed3e7fa8"
      unitRef="usd">-89000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOC0xLTEtMS01MTU1Mw_439484de-1040-423a-959f-9cd110c41cda"
      unitRef="usd">266000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOC0zLTEtMS01MTU1OA_1d93a835-8513-4f21-85ef-43070637af54"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTAtMS0xLTEtNTE5OTI_9559f090-84ed-42b5-be48-02003c889b0d"
      unitRef="usd">0</ck0001824293:ForgivenessOfDebtInstrument>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTAtMy0xLTEtNTE5OTc_274ce060-bf8c-41ee-aa59-dc8981ed09e2"
      unitRef="usd">61000</ck0001824293:ForgivenessOfDebtInstrument>
    <us-gaap:OtherNoncashExpense
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOS0xLTEtMS0zNjkyMw_bf1d65bc-6a44-40cc-a292-1584e39cfb30"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfOS0zLTEtMS0zNjkyMw_99c474fc-836d-4144-a6c3-a8fe7fc79fa6"
      unitRef="usd">2000</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTEtMS0xLTEtMzY5MjM_6c66f655-1bb6-4b21-87ad-685b9ddc8a59"
      unitRef="usd">246000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTEtMy0xLTEtMzY5MjM_cbafcffd-d632-473c-b854-e625f5f78258"
      unitRef="usd">379000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTItMS0xLTEtMzY5MjM_8d395a29-1cd0-47e3-85da-2ca51dc46c71"
      unitRef="usd">892000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTItMy0xLTEtMzY5MjM_74460863-572a-4eae-bd95-567883bde912"
      unitRef="usd">-330000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTMtMS0xLTEtMzY5MjM_04e5267c-05d1-4f5b-b867-a71796aee576"
      unitRef="usd">-576000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTMtMy0xLTEtMzY5MjM_38ec0fe1-37db-4f40-aff8-42df34f46c98"
      unitRef="usd">-153000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTQtMS0xLTEtMzY5MjM_2640044a-8295-4973-ba41-7a65d1f269c6"
      unitRef="usd">-3912000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTQtMy0xLTEtMzY5MjM_e92187dc-c99c-4f95-8664-9c83ca51fc5f"
      unitRef="usd">-5440000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTktMS0xLTEtNTQzNTc_afd7e66f-4f0a-4835-bdda-6f31ed86a762"
      unitRef="usd">492000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTktMy0xLTEtNTQzNjQ_09d36d8c-3e85-42a9-884b-72cc0c2d5892"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTgtMS0xLTEtNDkzNzM_920f6cc8-5e36-4bee-946a-c65fedd57c37"
      unitRef="usd">2522000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTgtMy0xLTEtNDkzNzY_7ae88b35-4593-4443-85de-ec72b45cf9e1"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTgtMS0xLTEtMzY5MjM_8bcd7e95-4237-43c0-b322-c4cdcab19a84"
      unitRef="usd">2030000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMTgtMy0xLTEtMzY5MjM_3280bf1f-b392-4d0c-bd4c-96f087cf720b"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ck0001824293:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjItMS0xLTEtMzY5MjM_8bd22843-2ac5-4c02-ae0e-623311448c67"
      unitRef="usd">3447000</ck0001824293:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <ck0001824293:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjItMy0xLTEtMzY5MjM_1921dd37-e056-4742-a868-aeffac33c97a"
      unitRef="usd">15503000</ck0001824293:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjQtMS0xLTEtNTIwMTg_970c8c19-98cb-48fe-9bc3-a61bc4ceee02"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjQtMy0xLTEtNTIwMjM_a623a83e-74c9-44ec-9810-7ac0bf20c2e5"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjQtMS0xLTEtMzY5MjM_dd2f31a3-4271-41b6-8c41-fe10bbeb1329"
      unitRef="usd">46000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjQtMy0xLTEtMzY5MjM_3009c09c-40d4-43a7-b26a-626a6a02dc5d"
      unitRef="usd">62000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjUtMS0xLTEtMzY5MjM_a128059d-257e-4128-bf58-9ca449519e2d"
      unitRef="usd">3401000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjUtMy0xLTEtMzY5MjM_36d618d6-6932-48cf-b956-7dced7c5b18a"
      unitRef="usd">15791000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjctMS0xLTEtMzY5MjM_86e49aa5-3f37-408b-a55b-8908cb0e3be7"
      unitRef="usd">1519000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjctMy0xLTEtMzY5MjM_886ad19c-bfbf-43db-a3f4-25729dfc755d"
      unitRef="usd">10351000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjgtMS0xLTEtMzY5MjM_f2498b63-faa4-428c-a641-9246c8dd18ed"
      unitRef="usd">3702000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib8edcee8e6aa45a886ecb171a5517013_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjgtMy0xLTEtMzY5MjM_81ff64cf-3bff-4d59-91a6-7af3a6d700e5"
      unitRef="usd">109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjktMS0xLTEtMzY5MjM_26b91b74-8191-4f63-a73d-1bdb6edb7a34"
      unitRef="usd">5221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i78c8fc66bda34fdda3cd8cdcd6aa7d9b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMjktMy0xLTEtMzY5MjM_edf0bcb3-4193-4cc5-b81f-f69a3212a713"
      unitRef="usd">10460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMzItMS0xLTEtMzY5MjM_a784b47a-c450-4765-bbb5-36b6fd5b1557"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zMS9mcmFnOjhlZjEyMGFkMzY1YjQzMjNiZGQwYThlMGIzNDg0OTkyL3RhYmxlOjk2MWQ2MmJkMTQ4ZDRmMWZhYzlmZmMyYzI1Njk3MWRmL3RhYmxlcmFuZ2U6OTYxZDYyYmQxNDhkNGYxZmFjOWZmYzJjMjU2OTcxZGZfMzItMy0xLTEtMzY5MjM_255ad83c-e0cd-4603-bcf5-e7d0b467299c"
      unitRef="usd">350000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NatureOfOperations
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zNy9mcmFnOjEwYjQwOWY3ZDJiZTRmNzBhNzBmZmM3ZTE5NGY2MTA4L3RleHRyZWdpb246MTBiNDA5ZjdkMmJlNGY3MGE3MGZmYzdlMTk0ZjYxMDhfMjI0Ng_64c616e8-350a-4a5c-9845-26aee3fc575e">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#x2019;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#xae;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In March 2022, the Company announced that its SEAL study for ADAIR did not reach its primary endpoint, and there is no assurance that ADAIR will receive approval by the U.S. Food and Drug Administration (the FDA). In addition to ADAIR, the Company completed formulation development work and selected the final formulation of its second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#xae;), for the treatment of ADHD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SEAL study (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tudy to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;valuate the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;buse &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;L&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), was the Company&#x2019;s pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the FDA. The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SEAL study did not meet its primary endpoint, which was E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;max&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Drug Liking. ADAIR scored similarly to what was observed in an earlier proof-of-concept study, however, reference dextroamphetamine did not score as high as expected and as seen in the previous study, thus driving the lack of statistical significance. The SEAL study did meet all pharmacodynamic secondary endpoints including Overall Drug Liking and willingness to Take Drug Again at 12 and 24 hours post-dosing, demonstrating statistical significance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is continuing to assess the best path forward for the ADAIR and ADMIR development programs. In addition, the Company has engaged Ladenburg Thalmann &amp;amp; Co. Inc. (Ladenburg) to evaluate its strategic alternatives with the goal of maximizing stockholder value. Ladenburg has been engaged to advise the Company on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. In the meantime, and in conjunction with the exploration of strategic alternatives, the Company is streamlining its operations in order to preserve its capital and cash resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled
      contextRef="i148024954fe941968d8a6d77a82f31a9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zNy9mcmFnOjEwYjQwOWY3ZDJiZTRmNzBhNzBmZmM3ZTE5NGY2MTA4L3RleHRyZWdpb246MTBiNDA5ZjdkMmJlNGY3MGE3MGZmYzdlMTk0ZjYxMDhfMTA5OTUxMTYzNTM4Mw_e72d3ed5-a147-4b44-8d21-96da0a1ee61a"
      unitRef="participant">55</ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled>
    <ck0001824293:ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy
      contextRef="i148024954fe941968d8a6d77a82f31a9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zNy9mcmFnOjEwYjQwOWY3ZDJiZTRmNzBhNzBmZmM3ZTE5NGY2MTA4L3RleHRyZWdpb246MTBiNDA5ZjdkMmJlNGY3MGE3MGZmYzdlMTk0ZjYxMDhfMTA5OTUxMTYzNTM2OQ_d3efdbfa-a1a4-403e-bd3a-92a6d7efe432"
      unitRef="participant">53</ck0001824293:ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy>
    <ck0001824293:ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis
      contextRef="i148024954fe941968d8a6d77a82f31a9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV8zNy9mcmFnOjEwYjQwOWY3ZDJiZTRmNzBhNzBmZmM3ZTE5NGY2MTA4L3RleHRyZWdpb246MTBiNDA5ZjdkMmJlNGY3MGE3MGZmYzdlMTk0ZjYxMDhfMTA5OTUxMTYzNTM3Ng_7b54550f-79f7-414c-9289-fefb56637139"
      unitRef="participant">52</ck0001824293:ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMjMxNA_d2d03f72-9975-4f07-b48c-c50f86024e4d">LIQUIDITY&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred an accumulated deficit of  $26,310 through June&#160;30, 2022. The Company has financed its working capital requirements to date through the issuance of common stock, warrants, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company completed a $350 convertible note financing and in February 2021, the Company completed the initial public offering (IPO), raising net proceeds of $15,500. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 17, 2022, the Company entered into a Securities Purchase Agreement with certain investors (the Securities Purchase Agreement) for the sale of up to 3,700,000 shares of the Company&#x2019;s common stock, par value $0.0001 per share (the Shares), at a &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;purchase price of $1.0632 per Share in a registered direct offering (the Offering). In a concurrent private placement also pursuant to the Securities Purchase Agreement (the Private Placement), for each Share of common stock purchased by an investor, such investor was entitled receive from the Company an unregistered warrant (the Warrant and, together with the Shares, the Securities) to purchase one Share of common stock. The gross proceeds from the Offering and Private Placement were approximately $3,900, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company of approximately $572, of which $85 related to the warrants was expensed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of June&#160;30, 2022, the Company had cash, cash equivalents and marketable securities of approximately $6,970. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects to incur ongoing expenses as it evaluates its plans for the ADAIR and ADMIR programs and strategic alternatives after it announced in March 2022 that the SEAL study of ADAIR for the treatment of ADHD failed to meet statistical significance for its primary endpoint. The Company is currently assessing the best path forward for the ADAIR and ADMIR programs and has no other product candidates undergoing clinical trials. The Company&#x2019;s future capital requirements are difficult to forecast and will depend on many factors, including but not limited to the terms and timing of any strategic alternatives including a merger or business combination, asset acquisitions or sales, collaborations or licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing may impose upon it covenants that restrict our operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase its common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to the Company or its stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license to other parties&#x2019; rights to develop or commercialize its drug candidates that it would prefer to retain. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company expects to continue to incur expenses and operating losses at least for the foreseeable future as it evaluates future plans for the ADAIR and ADMIR programs as well as its strategic alternatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfNDY4_322c64da-1dc6-4837-8c3b-937a153b2b66"
      unitRef="usd">-26310000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfNzQ2_4b1c65d7-9f0c-43de-a965-89fc831d5fed"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfODQy_1f4fce47-9f09-4fdc-ad29-e8c8798f3ed1"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE1NQ_6bd7fd64-af96-46f0-954b-07b88bff931d"
      unitRef="shares">3700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE1OQ_7f1b2fcb-e1b3-4d15-9f2b-9eb78e85c5c0"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE2NQ_9b31483e-bb72-4752-b7e8-d96802a276b7"
      unitRef="usdPerShare">1.0632</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE3MQ_ec6e70ad-bb36-4534-8670-7ffa7051a0fe"
      unitRef="usd">3900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjE1MA_e7e49937-de99-4df4-9656-00f746544549"
      unitRef="usd">572000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ck0001824293:WarrantsIssuanceExpense
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjM0Nw_8defe780-a107-4821-913b-8951d1a2b713"
      unitRef="usd">85000</ck0001824293:WarrantsIssuanceExpense>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80MC9mcmFnOmM3NmE5YTgyMjQ1NTRjNTY5MTZkZDIxM2ZhOGFmNTQzL3RleHRyZWdpb246Yzc2YTlhODIyNDU1NGM1NjkxNmRkMjEzZmE4YWY1NDNfMTA5OTUxMTY0MjA5Mw_dce1bcba-78ca-46f3-a297-80a742165acc"
      unitRef="usd">6970000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4Mg_2d491325-eb3b-4351-94e7-d855f66ffe03">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of June&#160;30, 2022, and the results of operations and stockholders&#x2019; equity (deficit) for the three and six months ended June&#160;30, 2022 and 2021 and cash flows for the six months ended June&#160;30, 2022 and 2021. Results of operations for the three and six months ended June&#160;30, 2022, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recapitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the closing of the IPO (Note 7), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the warrants issued in connection with the May 2022 registered direct financing (Note 7) in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the Balance Sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with changes in fair value recognized in the Statements of Operations and Comprehensive Loss in the period of change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4Mw_0309be64-8460-4246-85b7-5fd32fe80a3f">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4NA_812450d8-f270-4a55-9dd0-02ecd961c6cb">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made &lt;/span&gt;&lt;/div&gt;in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</us-gaap:UseOfEstimates>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfMjE5OTAyMzI2MzcxMw_284950f3-cc62-40c0-85ab-d6a5fd0ef094">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfMzI5ODUzNDg5NjYyNQ_cd4d92f0-789f-4ca0-9a5b-2b3aaa755d45">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the warrants issued in connection with the May 2022 registered direct financing (Note 7) in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the Balance Sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with changes in fair value recognized in the Statements of Operations and Comprehensive Loss in the period of change.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4NQ_f7cb588d-c576-41c1-a8df-c2f1ff86a127">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80My9mcmFnOmQxYWVlMjkyNTdmMzQwZjE5ZTNlZTE5ZjJiYzIwNmFkL3RleHRyZWdpb246ZDFhZWUyOTI1N2YzNDBmMTllM2VlMTlmMmJjMjA2YWRfNTQ4MQ_e0025f0b-904a-4ac3-ba6e-e9d9920c77a2">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzIxOTkwMjMyNTc5NTQ_55890182-623c-4198-9ea7-0240ac78005c">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available for sale securities as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company&#x2019;s financial instruments included cash and cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses, and the warrant liability. The carrying amounts reported in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 17, 2022, the Company issued 3,700,000 shares of common stock pursuant to a securities purchase agreement at a purchase price of $1.0632 per share in a registered direct offering (Note 7). In connection with the registered direct offering, the Company issued warrants to purchase an aggregate of 3,700,000 shares of common stock at an exercise price of $0.9382 per share.  The warrants were classified as a liability in accordance with ASC 815-40 and the fair value of $1,554 is reflected in warrant liability on the Balance Sheet. The warrant liability was  measured at fair value at inception and is revalued at each financial statement date, with changes in fair value presented within change in fair value of warrant liability in the Statement of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes is the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Initial measurement on May 17, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Initial Measurement)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;May 17, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130.8&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132.3&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.665&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.955&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the embedded derivative liability identified in the 2021 Convertible Notes (Note 6)  was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $8.00 per share upon closing of the IPO. As such, an expense of $89 was recorded during the six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our investments in marketable debt securities with stated contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1-5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 5-10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after 10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzIxOTkwMjMyNTc5NTU_36ad1d9d-856e-4fff-9c65-ecfb9cc64747">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available for sale securities as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzUtMS0xLTEtNDk0MzA_23a3f068-2728-4e2c-9f88-cacd22759cb9"
      unitRef="usd">1752000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzUtMy0xLTEtNDk0Mzg_f34be430-477c-4c46-9d38-36254ed46c58"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzUtNS0xLTEtNDk0MzQ_9cabc06b-d0e6-4049-9133-c88eeb07477c"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfbd00df61d44caab13c70f7d93bc5c7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzUtNy0xLTEtNDk0MzY_a2e2b006-5e3c-41f4-84f9-85ddadf88bf6"
      unitRef="usd">1749000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzYtMS0xLTEtNDk0MzA_cff05ccc-3104-4256-888d-b8c8f0a3682b"
      unitRef="usd">1752000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzYtMy0xLTEtNDk0MzI_3c8504a1-8745-49da-9e24-0d3aa59314d3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzYtNS0xLTEtNDk0MzQ_b33d2126-562a-4eb2-ae17-98fb90818557"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxNGVjZjEyZTAzMzc0YzNkYTZjMDNmN2E2OGE0ZDUwNC90YWJsZXJhbmdlOjE0ZWNmMTJlMDMzNzRjM2RhNmMwM2Y3YTY4YTRkNTA0XzYtNy0xLTEtNDk0MzY_955c8026-06b7-4479-95c3-1c1fa3a56547"
      unitRef="usd">1749000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id0e01297c79d4a238d946c1d8debd442_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzQtMS0xLTEtNDk0NDI_ba7429f0-ef4e-45ae-a44d-7d48206f7b4b"
      unitRef="usd">1153000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id0e01297c79d4a238d946c1d8debd442_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzQtMy0xLTEtNDk0NDQ_2eccd419-a57d-4e3b-96e9-6b2bff3e9fce"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id0e01297c79d4a238d946c1d8debd442_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzQtNS0xLTEtNDk0NDY_51103515-008d-43a9-9d82-21827129e059"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0e01297c79d4a238d946c1d8debd442_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzQtNy0xLTEtNDk0NDg_cf74c75b-5916-4247-a13a-abad509d3e6e"
      unitRef="usd">1152000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzUtMS0xLTEtNDk0NDI_7677a3a4-fd2e-4281-8d2f-91fa1688188b"
      unitRef="usd">2657000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzUtMy0xLTEtNDk0NDQ_fdb3418a-eb4a-4827-9082-c6d42611dead"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzUtNS0xLTEtNDk0NDY_e088a793-66f4-4125-a2ee-84aff6c20c23"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic97df5a8e00e4d33bb2daa6f5d1afd27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzUtNy0xLTEtNDk0NDg_be6a6600-54ff-444c-80eb-a72f7a6a1f3e"
      unitRef="usd">2656000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzYtMS0xLTEtNDk0NDI_d0cd1c28-ac53-4214-bf2f-0eafef1db6ca"
      unitRef="usd">3810000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzYtMy0xLTEtNDk0NDQ_5abb2b0e-f44b-4516-82aa-f4d5d9c1256e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzYtNS0xLTEtNDk0NDY_25ff1d26-50af-4333-be34-040e56170e88"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZToxYmExNDkwOTE2Zjg0NGIxYWFkMDRkYmY2ZGQwMTBlNC90YWJsZXJhbmdlOjFiYTE0OTA5MTZmODQ0YjFhYWQwNGRiZjZkZDAxMGU0XzYtNy0xLTEtNDk0NDg_cb3b10be-bed3-49ee-a400-b65c62e805ab"
      unitRef="usd">3808000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2NTk_73fb2431-3e41-4a58-8747-1d3e7eb9f0d6">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at June&#160;30, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1400788042d42598868c075e36cdb98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzItMi0xLTEtNTE0Njk_393364ec-87e7-42cf-b8e1-05fdcac48855"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1a61e394a9a4f539071373e4b182616_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzItNC0xLTEtNTE1MDI_db59fcc7-11a6-498b-9aae-f1caf63736b1"
      unitRef="usd">1749000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib436207f2f064e7496a902548a58e399_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzItNi0xLTEtNTE0ODg_3d67509b-d474-42d5-a545-880b0905413c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="if1400788042d42598868c075e36cdb98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzQtMi0xLTEtNTE0NzY_b6e96a7a-6886-495f-b8a3-8062c43f751c"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ib1a61e394a9a4f539071373e4b182616_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzQtNC0xLTEtNTE1MDk_0af41371-a4d6-4637-a1ec-d9e1a11fb1df"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ib436207f2f064e7496a902548a58e399_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTphZDFlNDQxMDBlNjY0Nzg3YWNhYzQ3ZmQyN2VhZDg3My90YWJsZXJhbmdlOmFkMWU0NDEwMGU2NjQ3ODdhY2FjNDdmZDI3ZWFkODczXzQtNi0xLTEtNTE0OTU_5b40cc09-35b0-40f3-bca6-834a2ccfcddc"
      unitRef="usd">1554000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2MzI_1ccd6fd3-996f-4d17-accc-01b59753b432"
      unitRef="shares">3700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2NTE_b8a013b1-733e-4a2a-b386-24edbcd30621"
      unitRef="usdPerShare">1.0632</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzE2NDkyNjc0NDc2MTI_98412202-f526-4872-8aa8-d3ce15c2fcde"
      unitRef="shares">3700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzE2NDkyNjc0NDc2NjM_69f37f79-9b35-442f-8dd0-932e940d9562"
      unitRef="usdPerShare">0.9382</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzE2NDkyNjc0NDc4Mjc_fdf66048-235f-410c-9e5c-0a447b3119aa"
      unitRef="usd">1554000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2MjA_bdcf783b-e709-4cb0-b4db-5d66cd70d2f2">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes is the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Initial measurement on May 17, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iea4222aa63154f468853a59705ceb961_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpkMjc2N2RkMmM4ZDU0NGJmOGQzYTlhMDkwY2I4ZTg4OC90YWJsZXJhbmdlOmQyNzY3ZGQyYzhkNTQ0YmY4ZDNhOWEwOTBjYjhlODg4XzEtMi0xLTEtNTQ0MjM_191d8602-f36c-4056-a545-278687b16389"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i1eb1020cc8b9465fba60fc2338a0ddbd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpkMjc2N2RkMmM4ZDU0NGJmOGQzYTlhMDkwY2I4ZTg4OC90YWJsZXJhbmdlOmQyNzY3ZGQyYzhkNTQ0YmY4ZDNhOWEwOTBjYjhlODg4XzItMi0xLTEtNTQ0MzU_2eda034e-e590-4d44-837d-f831d21261a5"
      unitRef="usd">1288000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i1eb1020cc8b9465fba60fc2338a0ddbd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpkMjc2N2RkMmM4ZDU0NGJmOGQzYTlhMDkwY2I4ZTg4OC90YWJsZXJhbmdlOmQyNzY3ZGQyYzhkNTQ0YmY4ZDNhOWEwOTBjYjhlODg4XzMtMi0xLTEtNTQ0MzU_edb490bb-0b3f-4b3d-ad9d-10f356360bbd"
      unitRef="usd">-266000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ide2992c84c8c4cbb9703a725519f2d52_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpkMjc2N2RkMmM4ZDU0NGJmOGQzYTlhMDkwY2I4ZTg4OC90YWJsZXJhbmdlOmQyNzY3ZGQyYzhkNTQ0YmY4ZDNhOWEwOTBjYjhlODg4XzQtMi0xLTEtNTQ0MzU_c3e8efda-87f3-4c32-9b78-640fe75c3271"
      unitRef="usd">1554000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzMyOTg1MzQ4OTE2NjA_35aec96b-4bcd-43bd-b283-95d56932d5d3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Initial Measurement)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;May 17, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130.8&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132.3&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.665&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.955&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.155&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;The Black-Scholes option-pricing model was used to estimate the initial fair value of the warrants with the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.665&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="idca18b35dfc343a5b432e73aa35dda20_I20220517"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzItMS0xLTEtNTE3NDg_0b5e67b0-12bd-47f9-8fa3-3e2c3c5779bd"
      unitRef="number">1.308</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic90be0efda4140d69daac747399be9da_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzItMy0xLTEtNTE3NjA_11574b5e-d79b-4545-be59-073c5df1d870"
      unitRef="number">1.323</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i3cf955fe5e0a47b98dfd6289d141ce48_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzMtMS0xLTEtNTE3NDg_6dbe055d-159f-4d6e-b4f3-6c1f9ce54ceb"
      unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic39261bdabc74d02ab32636701f88ceb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzMtMy0xLTEtNTE3NjA_d794e299-b77e-4385-a2d2-9caeb507bbce"
      unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i1e17459f6e1e4ff88e393694f859f76f_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzQtMS0xLTEtNTE3NDg_4cabf4d0-0608-4050-bce6-d5488fa0c16c"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ica45ce9c7f8e4a4e87dccf62ec9002c2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzQtMy0xLTEtNTE3NjA_babb8a52-eeae-4dfb-8f40-fb68598c9d48"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i2268668a2bae461fbd550e2afdedd425_I20220517"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzUtMS0xLTEtNTE3NDg_51a547b3-abe1-4db4-b934-50fbd1206aa7"
      unitRef="number">0.02665</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ie3c3844471a2415d85a493bb7d1b7ac2_I20220630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTplMDVhMGZiMGYzZTk0NjcwOTRhNWUwODY4YTZkYTRkMy90YWJsZXJhbmdlOmUwNWEwZmIwZjNlOTQ2NzA5NGE1ZTA4NjhhNmRhNGQzXzUtMy0xLTEtNTE3NjA_86d1f7d3-ff70-40f6-a611-88379c07ff37"
      unitRef="number">0.02955</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="id5278a1eaa074dd68b78d80ced668ef6_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzEwOTk1MTE2Mjk3OTk_f5224c0b-35f3-444f-9e3b-4875466a700a"
      unitRef="usdPerShare">8.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzEwOTk1MTE2Mjk4NjE_3ea6dd9f-332c-4c7f-be8d-0fd1e661c964"
      unitRef="usd">-89000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90ZXh0cmVnaW9uOmExNzc3YWQ3NTFkMjQ3ZGZhMzMzMGQ1ODJlODhkNjNlXzIxOTkwMjMyNTc5NTY_e0e7dde0-2270-49ff-9894-4d68d7316ac8">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our investments in marketable debt securities with stated contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1-5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 5-10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after 10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzEtMi0xLTEtNDg5OTY_39b4779e-5af9-4b17-be4d-aa6825d3a8db"
      unitRef="usd">1749000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzItMi0xLTEtNDg5OTY_dff789d6-588d-4020-a28a-cadeb2e66c12"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzMtMi0xLTEtNDg5OTY_f7a841c9-a1e5-49db-8e64-405957b44807"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzQtMi0xLTEtNDg5OTY_7ab4671a-515e-4190-8374-aad28b4c11e8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NDMvZnJhZzphMTc3N2FkNzUxZDI0N2RmYTMzMzBkNTgyZTg4ZDYzZS90YWJsZTpjNDYyYjNiOTg4MGI0ZDY1YjZhMjgwMDU2NTdkMTQwMC90YWJsZXJhbmdlOmM0NjJiM2I5ODgwYjRkNjViNmEyODAwNTY1N2QxNDAwXzUtMi0xLTEtNDk0NTI_79f25298-1b60-425a-8b80-e20116512bbf"
      unitRef="usd">1749000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RleHRyZWdpb246NTJmNGI1ZGQ0YTgyNGI5YTliMmQwYjQ2MTQ2ZWI5NmZfNjg_2b98b27e-8bdd-46d7-980f-b561f4c65f64">ACCRUED EXPENSES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RleHRyZWdpb246NTJmNGI1ZGQ0YTgyNGI5YTliMmQwYjQ2MTQ2ZWI5NmZfNjk_08d344a6-9efa-4a8d-9c86-901692baa2d9">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMS0xLTEtMS0zNjkyMw_54346dd8-888d-4c36-b360-6a662ca38097"
      unitRef="usd">469000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMS0zLTEtMS0zNjkyMw_32904f2e-0986-4735-a9a5-0b3bfe442420"
      unitRef="usd">894000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMi0xLTEtMS0zNjkyMw_5d6d0d4d-9138-4fed-9b24-ba9311399dab"
      unitRef="usd">56000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMi0zLTEtMS0zNjkyMw_5fe4d01d-281b-4560-b444-c22edd6e5df4"
      unitRef="usd">183000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMy0xLTEtMS0zNjkyMw_80681d32-1b1d-4eb5-8806-2552f3c98980"
      unitRef="usd">277000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfMy0zLTEtMS0zNjkyMw_ba9a33f2-db93-407b-a1be-9e66e0865c45"
      unitRef="usd">291000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ck0001824293:AccruedLicensingFeesCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfNC0xLTEtMS0zNjkyMw_c1281ac1-268e-4fc6-b284-5a37d8a47510"
      unitRef="usd">52000</ck0001824293:AccruedLicensingFeesCurrent>
    <ck0001824293:AccruedLicensingFeesCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfNC0zLTEtMS0zNjkyMw_b583648b-7c91-4ef3-8ac0-b119996f8b8a"
      unitRef="usd">62000</ck0001824293:AccruedLicensingFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfNi0xLTEtMS0zNjkyMw_7add1060-16b2-40ac-ae8e-e9e0d0f1b50a"
      unitRef="usd">854000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV80OS9mcmFnOjUyZjRiNWRkNGE4MjRiOWE5YjJkMGI0NjE0NmViOTZmL3RhYmxlOmJlNDA0YmRmMzc3ZjQ1YTM4Njc2YzIxMDZmMTYzMDFkL3RhYmxlcmFuZ2U6YmU0MDRiZGYzNzdmNDVhMzg2NzZjMjEwNmYxNjMwMWRfNi0zLTEtMS0zNjkyMw_3e6ac3a9-7603-472b-88d4-dc13b5a05977"
      unitRef="usd">1430000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwNQ_c9923408-0f70-401a-a607-e5a33663d494">PPP NOTE AND CONVERTIBLE NOTES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $61. The PPP Note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwOQ_edb548e1-9964-4ef6-b43d-e162b1ecb626"&gt;1.5-year&lt;/span&gt; period beginning November 1, 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $61 included in other income on the accompanying statements of operations and comprehensive loss. The Small Business Administration (SBA) reserves the right to audit any PPP loan, regardless of size. These audits may occur after forgiveness has been granted. In accordance with the CARES Act, all borrowers are required to maintain the PPP loan documentation for six years after the PPP loan was forgiven or repaid in full and to provide that documentation to the SBA upon request.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#x2019;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibca03d411a7545b085d0c47f675a493e_I20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTIx_99c5edac-bd1e-4afb-9677-a6ad9d79f979"
      unitRef="usd">61000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibca03d411a7545b085d0c47f675a493e_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTY4_836779c7-6cd9-4caf-9662-41c09399d530"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="ia9e73432cae24ab4a5dc83c76c8492f7_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTcwNg_4609f82c-9adc-4e02-b389-9bda0f6bbf6b">P2Y</us-gaap:DebtInstrumentTerm>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfNTQy_c5474a30-c987-414a-beeb-6df235141d65"
      unitRef="usd">61000</ck0001824293:ForgivenessOfDebtInstrument>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie893c6ea7cb24a70984639ee82d13224_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfOTIz_52d735cf-45ef-4084-995a-a4c32c75bd8e"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifaf794a259e54b3ba3547350cc2f5ef3_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfOTc3_44c9aef5-2410-4896-a90f-ec37f42a385a"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i7f18e4fe2f154b23845553ce8b36cbdb_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81Mi9mcmFnOjU1YjQ1MzNiNDBhNTRjZjBiY2IzYWViODE0ZTUzOWM0L3RleHRyZWdpb246NTViNDUzM2I0MGE1NGNmMGJjYjNhZWI4MTRlNTM5YzRfMTA5NQ_a904f8cd-db87-4074-a8ac-607d383d4ea9"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTI1MA_0a1e50e9-c931-40ad-b094-4c10734bc8b9">STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company completed the IPO of 2,250,000 shares of common stock at a public offering price of $8.00 per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $18,000. Underwriting discounts and expenses totaled $1,600 and the Company incurred approximately $905 of additional expenses related to completing the IPO for aggregate net proceeds were approximately $15,500. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 17, 2022, the Company sold 3,700,000 shares of common stock pursuant to a securities purchase agreement at a purchase price of $1.0632 per share in a registered direct offering (the Offering). The gross proceeds from the Offering were approximately $3,900, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company of approximately $572 of which $85 related to the warrants was expensed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share. The Underwriters&#x2019; Warrants have a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfODc3_ce620793-2d62-41d1-96a6-0936db85ba5c"&gt;five&lt;/span&gt;-year term and are not exercisable prior to August 12, 2021. All of the Underwriters&#x2019; Warrants were outstanding as of June&#160;30, 2022. The warrants were classified as equity and the fair value of $399 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.155&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering, the Company issued warrants to purchase an aggregate of 3,700,000 shares of common stock at an exercise price of $0.9382 per share. The warrants have a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjU5MA_51655d27-6cc7-465e-88ec-29ffbd736c95"&gt;five&lt;/span&gt;-year term. All of the warrants were outstanding as of June&#160;30, 2022. The warrants were classified as a liability and the fair value of $1,554 is reflected in warrant liability on the balance sheet. The Black-Scholes option-pricing model was used to estimate the initial fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.665&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfOTI_485beb99-c473-4fcd-ac51-3f9a3e4c7c40"
      unitRef="shares">2250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9a8b39ceb7ad4164be59942fb7614f0e_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTQ4_4fd06847-73b7-4a3c-8c77-f434be75d725"
      unitRef="usdPerShare">8.00</us-gaap:SaleOfStockPricePerShare>
    <ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMzA1_c44eef2f-3276-4ea2-8d6a-585e0921b813"
      unitRef="usd">18000000</ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross>
    <ck0001824293:StockIssuanceCostsDiscountsAndCommissions
      contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMzUz_b330d364-3898-4b47-ad09-3a21a20d9ef4"
      unitRef="usd">1600000</ck0001824293:StockIssuanceCostsDiscountsAndCommissions>
    <ck0001824293:StockIssuanceCostsOfferingExpenses
      contextRef="iaa68683166f845408469b50f0a32b3b5_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMzk1_d29da6f7-5eff-4349-8f31-ff3b8179276a"
      unitRef="usd">905000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7eaf870dd33a4352b9244747796c25f9_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfNjIx_516b2806-484d-42c9-a2df-746740a7b5a8"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjUwMQ_733f6605-6051-4cb2-99c7-5a8e93c4ebc2"
      unitRef="shares">3700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjUwNQ_d66752e2-edc9-4ffb-9c15-eabfb8cfe29b"
      unitRef="usdPerShare">1.0632</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjUwOQ_817fc5ee-ccaa-401a-91b6-8327d14e5f0f"
      unitRef="usd">3900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMTgzMg_27258185-87b5-4b95-b780-aaedd822b90a"
      unitRef="usd">572000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ck0001824293:WarrantsIssuanceExpense
      contextRef="ie9a508657df54d2a89439c9203c94580_D20220517-20220517"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMjY3Mw_f1e55313-7a4b-4755-9df2-876e28ba058e"
      unitRef="usd">85000</ck0001824293:WarrantsIssuanceExpense>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ice04209849fb435087c6298880b82c73_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfNzc5_30cf7e29-061e-491a-97e1-f6091d35bc54"
      unitRef="shares">112500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ice04209849fb435087c6298880b82c73_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfODI5_8f548d19-7318-4921-872a-eb70f1be152a"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i719a8a8b7ff446c1bc50f1384cc0de4d_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA2Mg_3efa3966-309c-4f1e-8d4b-330cbccfee59"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i0dd279f5e1d8444db25b59b0858f2af5_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOmZhMmFjZjNlMGIxNzQxZDZhMTc0MTVlOWFhNjQ1MTNkL3RhYmxlcmFuZ2U6ZmEyYWNmM2UwYjE3NDFkNmExNzQxNWU5YWE2NDUxM2RfMC0xLTEtMS0zNjkyMw_de2d7675-840a-4dcf-af82-9a373fc20a05"
      unitRef="number">0.850</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id62c32d0200843f38b297b12c7bfa449_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOmZhMmFjZjNlMGIxNzQxZDZhMTc0MTVlOWFhNjQ1MTNkL3RhYmxlcmFuZ2U6ZmEyYWNmM2UwYjE3NDFkNmExNzQxNWU5YWE2NDUxM2RfMS0xLTEtMS0zNjkyMw_5965b3ab-3c38-4c86-b53e-76903fef4aee"
      unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i06e6a1c69d574de78299b71070680019_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOmZhMmFjZjNlMGIxNzQxZDZhMTc0MTVlOWFhNjQ1MTNkL3RhYmxlcmFuZ2U6ZmEyYWNmM2UwYjE3NDFkNmExNzQxNWU5YWE2NDUxM2RfMi0xLTEtMS0zNjkyMw_32ac96ff-1a47-4734-8e9e-3737f1497473"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i1b4169335d1b4ff29a400e3b99a836a9_I20220630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOmZhMmFjZjNlMGIxNzQxZDZhMTc0MTVlOWFhNjQ1MTNkL3RhYmxlcmFuZ2U6ZmEyYWNmM2UwYjE3NDFkNmExNzQxNWU5YWE2NDUxM2RfMy0xLTEtMS0zNjkyMw_f611b61c-e03f-42e0-85c0-6c5ad0f10121"
      unitRef="number">0.00155</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMTY2Ng_98412202-f526-4872-8aa8-d3ce15c2fcde"
      unitRef="shares">3700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMTY3Mg_69f37f79-9b35-442f-8dd0-932e940d9562"
      unitRef="usdPerShare">0.9382</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ia5eb151e1495417d8ba486b11b22f863_I20220517"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RleHRyZWdpb246M2U1ZjA1YTM4OTM3NGZmZThlZjMwNDBiNDI1YTA2MzRfMTA5OTUxMTYzMTgxMQ_fdf66048-235f-410c-9e5c-0a447b3119aa"
      unitRef="usd">1554000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="icf0242ba0cc646728e31b766046dc508_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOjg3ZjM0MWVlNjkwOTQyNWE5OTIyNzdmNWE3M2VkMjNjL3RhYmxlcmFuZ2U6ODdmMzQxZWU2OTA5NDI1YTk5MjI3N2Y1YTczZWQyM2NfMC0xLTEtMS01MTEyMg_ed431685-76ae-49a5-9bd3-6649ec4f278a"
      unitRef="number">1.308</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i83d36a3a0df04368aff26ea0900fa228_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOjg3ZjM0MWVlNjkwOTQyNWE5OTIyNzdmNWE3M2VkMjNjL3RhYmxlcmFuZ2U6ODdmMzQxZWU2OTA5NDI1YTk5MjI3N2Y1YTczZWQyM2NfMS0xLTEtMS01MTEyMg_687a1863-5010-45ba-8d26-da538f4e676a"
      unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia1f3a03eb7104bff89df1b804e710cc1_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOjg3ZjM0MWVlNjkwOTQyNWE5OTIyNzdmNWE3M2VkMjNjL3RhYmxlcmFuZ2U6ODdmMzQxZWU2OTA5NDI1YTk5MjI3N2Y1YTczZWQyM2NfMi0xLTEtMS01MTEyMg_a3b08c6b-8254-40be-8fe9-f7e699d37d23"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i49e5070e0f094b4c8b1e0ca0d774e78a_I20220630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV81NS9mcmFnOjNlNWYwNWEzODkzNzRmZmU4ZWYzMDQwYjQyNWEwNjM0L3RhYmxlOjg3ZjM0MWVlNjkwOTQyNWE5OTIyNzdmNWE3M2VkMjNjL3RhYmxlcmFuZ2U6ODdmMzQxZWU2OTA5NDI1YTk5MjI3N2Y1YTczZWQyM2NfMy0xLTEtMS01MTEyMg_8c2916d6-ed57-4087-9bad-edc3906d264c"
      unitRef="number">0.02665</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2Ng_9bb5b852-0ff2-4d10-a1a0-b98d4c7bc855">STOCK-BASED COMPENSATION&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to stock options and shares issued under the Company&#x2019;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018 Plan. Stock options granted by the Company generally have a contractual life of up to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,290&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022, the unrecognized compensation cost related to unvested stock options expected to vest was $1,132. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 2.71 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued performance-based restricted stock units (RSUs). Vesting of the performance-based RSUs is subject to the achievement of certain milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to RSUs granted to employees for the three months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired/forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022, the Company granted 150,000 RSUs at a grant date fair value of $0.5552, all of which were performance-based RSUs. As of June&#160;30, 2022, the milestones associated with the performance-based RSUs were not probable of achievement, and accordingly, no stock-based compensation expense has been recognized for these awards. The unrecognized compensation cost related to unvested performance-based RSUs was $83, which will be recognized commencing in the period in which the performance condition is deemed probable of achievement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2Nw_4c372271-c846-4098-a048-b9700b8244a4">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to stock options and shares issued under the Company&#x2019;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45123774c90a4fa1956d091d5604c46c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMi0xLTEtMS0zNjkyMw_3e860a88-f9a1-4ff8-a743-ce34a5133cf4"
      unitRef="usd">-129000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i59279994119f4d8797134a26b83d8c6a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMi0zLTEtMS0zNjkyMw_cc6262fc-22bd-4a68-9e6c-62019127d6d8"
      unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idbd9cf59fec149d9a8a643a612719e6e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMi01LTEtMS0zNjkyMw_89f65762-ac5c-4947-bc50-6903f0189a40"
      unitRef="usd">-111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia17f7b4da78d4e7782a9ae81963a8a71_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMi03LTEtMS0zNjkyMw_da933f4a-a0d4-4215-a916-b13efe4d8b6f"
      unitRef="usd">39000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if0c84158c8f14fc088ef909f0eca8c58_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMy0xLTEtMS0zNjkyMw_81e62416-4d06-418a-8604-10275a42f0f2"
      unitRef="usd">44000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e46d5f45e27451c98c012a1bfb2ff79_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMy0zLTEtMS0zNjkyMw_f857ea1d-5686-41d1-8f9e-07011f8d75be"
      unitRef="usd">120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i013f7d5cc90144bd84a5bfa54b52c3cb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMy01LTEtMS0zNjkyMw_6eaed79d-44a2-4b61-aed9-5bb50d377eea"
      unitRef="usd">207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i449ba4759b4e4bf4a5e5c917d68f2bf0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfMy03LTEtMS0zNjkyMw_913f49fb-9e65-47df-8f01-2ab8eed724ad"
      unitRef="usd">267000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfNC0xLTEtMS0zNjkyMw_3d04db94-9684-42a3-951b-62297df329d5"
      unitRef="usd">-85000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i97a3e7ac29ef4a258561cb60bbc6a037_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfNC0zLTEtMS0zNjkyMw_321fc2aa-f111-4dff-b32b-e373e6ccb1a5"
      unitRef="usd">138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfNC01LTEtMS0zNjkyMw_85687b18-ff07-419b-9b1e-d4f57579cef4"
      unitRef="usd">96000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjYyZjNmNDJhZDY2ODQ0YjQ5YzQ3MWNlMzJlMTg5NDlmL3RhYmxlcmFuZ2U6NjJmM2Y0MmFkNjY4NDRiNDljNDcxY2UzMmUxODk0OWZfNC03LTEtMS0zNjkyMw_960dfcda-bda7-45cc-b3fa-43f54ad02659"
      unitRef="usd">306000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic3ad6bdf33be419586390b0ac7ab0caf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfNjc0_51b0c135-a996-40bb-a75f-7eb934e8f8d3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2OA_805bd80f-68f2-4a3a-ad10-c5aa9b3df7f3">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,290&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMS0xLTEtMS0zNjkyMw_493bc7a5-2112-4260-a125-92ed6606ee20"
      unitRef="shares">708490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3fdede838e6d478099d6431eb6ed4bd9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMS0zLTEtMS0zNjkyMw_df19c8e6-c8a1-4cae-bec7-c37eaf193141"
      unitRef="usdPerShare">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if8a3cf62c41b4e068c171f0691bb0bfc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMS01LTEtMS0zNjkyMw_5b1ef265-49ca-4dc3-bce5-3367872b65b4">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMi0xLTEtMS0zNjkyMw_0edf2f77-35ff-4f4d-ba9f-57a8e5dd73cb"
      unitRef="shares">204500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfMi0zLTEtMS0zNjkyMw_2b1e8b6b-0372-4af7-9d6f-87a5f5ab3331"
      unitRef="usdPerShare">5.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNC0xLTEtMS0zNjkyMw_613ef961-a931-4455-b20d-82a3a77a40d9"
      unitRef="shares">182290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNS0xLTEtMS0zNjkyMw_dd26403d-043c-44d7-8e07-16e08abce7e6"
      unitRef="shares">730700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNS0zLTEtMS0zNjkyMw_5a4aa658-8b6e-41c3-a98c-a9fb170ec472"
      unitRef="usdPerShare">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNS01LTEtMS0zNjkyMw_f7f6adc9-36d7-4695-b33a-bd647e237a2a">P8Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNi0xLTEtMS0zNjkyMw_25b13e95-e5cd-429e-b0cb-990b6d9b01d4"
      unitRef="shares">315888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNi0zLTEtMS0zNjkyMw_59858d3a-360e-4f35-b575-8f2c01bd54d2"
      unitRef="usdPerShare">3.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOmFhM2Q0Y2E2ZjVlYTRlZDA4ZTc0YmM1YmIyODU0OGUzL3RhYmxlcmFuZ2U6YWEzZDRjYTZmNWVhNGVkMDhlNzRiYzViYjI4NTQ4ZTNfNi01LTEtMS0zNjkyMw_d8c629a2-74a8-4872-8083-6a9510d37ff7">P7Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2OQ_4c5cc538-6c4b-4864-bc12-adb5eb7ffa28">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfMi0xLTEtMS0zNjkyMw_6737010e-7f08-40eb-8eed-0b0a07d0a5cd"
      unitRef="number">0.9039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfMi0zLTEtMS0zNjkyMw_36a9521d-7282-41fa-8216-a08416d11497"
      unitRef="number">0.8350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfMy0xLTEtMS0zNjkyMw_421744b7-2a56-40c3-9903-bed3c5480db3">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfMy0zLTEtMS0zNjkyMw_b570c10f-ddc2-4962-aa57-ede7951dc175">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNC0xLTEtMS0zNjkyMw_ad504cff-e864-41e3-945e-feb3469598c9"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNC0zLTEtMS0zNjkyMw_f9c58cf0-7daf-46b8-91a6-a9dae8e85400"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNS0xLTEtMS0zNjkyMw_0d98d50e-1bcc-43ee-a56d-7b498a5a5b5d"
      unitRef="number">0.0200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i764a87eb1bfb49b68e774924e1edbf2d_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNS0zLTEtMS0zNjkyMw_3559d740-e488-4f73-aa7f-75d0f1ecaa79"
      unitRef="number">0.0099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="ic21ef042a65f42cd84ec887387352371_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNi0xLTEtMS0zNjkyMw_89dc566f-b130-4894-a079-cfa5ea6c594f"
      unitRef="usdPerShare">3.86</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i78c8fc66bda34fdda3cd8cdcd6aa7d9b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjY4NDVjNGJmYzI2ZjQ4MTZiZjZlMDQyM2Y0YzYwNWFkL3RhYmxlcmFuZ2U6Njg0NWM0YmZjMjZmNDgxNmJmNmUwNDIzZjRjNjA1YWRfNi0zLTEtMS0zNjkyMw_b10aebfb-5819-4bd8-a14f-c389e9287212"
      unitRef="usdPerShare">3.87</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i3d8cd952ddab4185bc4626df7276ebda_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTg1Mg_e5294036-4888-47d6-8013-6ea8f4da0552"
      unitRef="usd">1132000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic3ad6bdf33be419586390b0ac7ab0caf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTk2Mw_36025d56-1d5b-4115-99cf-4dc0efe23a37">P2Y8M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMzI5ODUzNDg5MDkyNA_909d5466-9e43-4ed9-81ac-70baaef69eb1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to RSUs granted to employees for the three months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired/forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icf436d7844974b62a61ac61f27616833_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjU5ZGIzNjQ0YjgzNDQ5MGQ4ZTA1NTdhNTNjMDYyMzY1L3RhYmxlcmFuZ2U6NTlkYjM2NDRiODM0NDkwZDhlMDU1N2E1M2MwNjIzNjVfMS0yLTEtMS01MjE2OQ_009077ca-8d5b-4090-aac0-51c631787414"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id2d5dff312ff4a6dbd81e861d5714df5_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjU5ZGIzNjQ0YjgzNDQ5MGQ4ZTA1NTdhNTNjMDYyMzY1L3RhYmxlcmFuZ2U6NTlkYjM2NDRiODM0NDkwZDhlMDU1N2E1M2MwNjIzNjVfMi0yLTEtMS01MjE2OQ_3af06207-3b03-45f5-a42b-d2f8db51c907"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9ed63d6b4295468c963916e8ee547dd7_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RhYmxlOjU5ZGIzNjQ0YjgzNDQ5MGQ4ZTA1NTdhNTNjMDYyMzY1L3RhYmxlcmFuZ2U6NTlkYjM2NDRiODM0NDkwZDhlMDU1N2E1M2MwNjIzNjVfNS0yLTEtMS01NDUwOA_e47604b8-26cd-4dc5-a99c-68db5b56337e"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib8129a30fcf84969a1b747ba20407f23_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTY0OTI2NzQ0Njk4Mg_fcbd7209-61c5-489d-a4b3-efb6f4086fae"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib8129a30fcf84969a1b747ba20407f23_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTY0OTI2NzQ0Njk5Mg_1c6974d5-4f9a-4c11-b841-705c03daa8f6"
      unitRef="usdPerShare">0.5552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i9ed63d6b4295468c963916e8ee547dd7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82MS9mcmFnOjlkNjUzMGI0MzZhYTQ3ZjdhYzk2YjkwM2NjMTQ0ODFmL3RleHRyZWdpb246OWQ2NTMwYjQzNmFhNDdmN2FjOTZiOTAzY2MxNDQ4MWZfMTY0OTI2NzQ0NzAwMQ_a32984bb-aa70-43e3-a8aa-4105f93ebaa7"
      unitRef="usd">83000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82NC9mcmFnOjZhZmExYTFkZDQzYzQzODg5ZDI4MTE2N2ZiMzdhNjFmL3RleHRyZWdpb246NmFmYTFhMWRkNDNjNDM4ODlkMjgxMTY3ZmIzN2E2MWZfMTQ2Ng_1e82ad5d-18f3-4195-9c8b-e1e70b4d81fd">RELATED PARTY TRANSACTIONSIn January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie893c6ea7cb24a70984639ee82d13224_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82NC9mcmFnOjZhZmExYTFkZDQzYzQzODg5ZDI4MTE2N2ZiMzdhNjFmL3RleHRyZWdpb246NmFmYTFhMWRkNDNjNDM4ODlkMjgxMTY3ZmIzN2E2MWZfMTIyOA_4b8b281c-46c0-422b-b848-3a18adc5f479"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifaf794a259e54b3ba3547350cc2f5ef3_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82NC9mcmFnOjZhZmExYTFkZDQzYzQzODg5ZDI4MTE2N2ZiMzdhNjFmL3RleHRyZWdpb246NmFmYTFhMWRkNDNjNDM4ODlkMjgxMTY3ZmIzN2E2MWZfMTI4Mg_41572d55-e8eb-4f4d-acfb-03481f10d2e7"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ie893c6ea7cb24a70984639ee82d13224_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV82NC9mcmFnOjZhZmExYTFkZDQzYzQzODg5ZDI4MTE2N2ZiMzdhNjFmL3RleHRyZWdpb246NmFmYTFhMWRkNDNjNDM4ODlkMjgxMTY3ZmIzN2E2MWZfMTQwMA_dfdfb698-384b-4cc3-ae98-8d78fa9663da"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMDk0NTEyNWYzYTQxNWJiZTk2NTYxNTI3MGM0YTQ5L3NlYzplMzA5NDUxMjVmM2E0MTViYmU5NjU2MTUyNzBjNGE0OV83MC9mcmFnOjg1ZWQzOWQ5ZDBjODQ5M2E5ZmYwNDUwZDAxYTM0MjE5L3RleHRyZWdpb246ODVlZDM5ZDlkMGM4NDkzYTlmZjA0NTBkMDFhMzQyMTlfMTc1Mg_72335a3f-a51c-41ea-b751-762df4c625fe">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Impact&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#x2019;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of new strains or variants of coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#x2019;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#x2019;s future impact on the Company&#x2019;s clinical trial enrollment (including the Company&#x2019;s ability to recruit and retain patients), clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 pandemic and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MK(-!:-CV,/:@V#>QJ"QYDIQT^_6[DEV3M&[3PO(0ZU[=<WR.)%]-ME+=Z1+
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M4K*BT@C [VL!7JE?S 3-#=/T?U!+ P04    "  M0?Q44G)DP"8(  !/$@
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M,!X<0T3'*1$:M#Y$- VWD!'A'35A&X(7M:U)TP=$;%5,!2"B&M"Z8CJ[$),
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MKWH>J'8<M(:1C9/@1AH2M-N6-$%160>ZSZ4T!\,FZ&;RY ]02P,$%     @
M+4'\5 YPVL!B!   # H  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
MI59M;R(W$/XKH[T7M1+':TC2'" !R:DY-0D*N>N'JA_,[BQKQ6OOV5X(_[XS
MWH6 CB"U_0)K>^;Q\\R,QQZLC7UV&:*'EUQI-XPR[XNK5LO%&>;"-4V!FE92
M8W/A:6B7+5=8%$EPRE6KVVZ?MW(A=30:A+F9'0U,Z974.+/@RCP7=C-!9=;#
MJ!-M)Q[E,O,\T1H-"K'$.?IOQ<S2J+5#262.VDFCP6(ZC,:=J\D9VP>#[Q+7
M;N\;6,G"F&<>W";#J,V$4&'L&4'0WPJGJ!0#$8T?-6:TVY(=][^WZ%^"=M*R
M$ ZG1OTI$Y\-H\L($DQ%J?RC6?^.M9X^X\5&N? +Z\JV1SO&I?,FKYUIG$M=
M_8N7.@Y[#I?M-QRZM4,W\*XV"BROA1>C@35KL&Q-:/P1I 9O(B<U)V7N+:U*
M\O.CV6P&]P]/-S"^OX;IP_WWF\>GV\D?-V%R/FAYVH,M6W&--ZGPNF_@G<.=
MT3YS<*,33 []6\1M1["[)3CIG@3\6NHF]-H-Z+:[W1-XO9W@7L#KO8%WC0L/
MU]+%RKC2(OPU7CAOJ3C^/B:VPCH[CL4'YLH5(L9A1"?"H5UA-/KXKG/>_GR"
MZ=F.Z=DI]/^0FO^#![<:[L2&PTS!]AG"U.2%T!N0SI68@(#"FIP&QFY &X]0
M4HIM,&7H7[8?][3V*WCC!3%8POOS3A.>]M8@$XSFO/ $*[5'BIT'2T,P*70^
M@-!);>37YM,&A:62]Z65?M.$F=A04_ .UN1'?>%'*2WA> ,+)+.$0%9$2T"G
MV:]\2=E7H4OJ.:RN<Z@.P_Z!AR&GJ='D[>5"$>%7O8'WK+1Q1AT QDN+R"3H
ML/H,8G*@]@?X(IUGR71JX^?,* J/:Q!RK,J$Y^="Y=2)9IF@?M(@F2#25"I9
M*[_#1,;8"/*OQ4HF,!'/: _X?GQWV>U<?'8PS22F</."<<E]#1X(*6;CHK2N
M%,2-]*PS&6?'DLE3'(L#O2R2^%*GAUBXC/,=(R:.N;WO]=M5&H^[P<)0-DC1
M3_F\:+8_0,$9T;K,&U0Z^E-,; R5#P6EL9?M;9(AJ7WG6'C,%^1<=X#.20YQ
M-;/-9O^L\5O['!R%&X.(8W$D*IR3D#(H"_ID<@K#G5'[W,X>JGUW44PH^3*5
M=21SDB \UTG%(-Q8@<*_V%LXB@!5(N9%V#M%C@:50Y7$NM IT#*E.A25#57H
MB5R&T'JZJT-(?+4%%:5<B5 S5'D+*C\*>'64Q_,I7';Z;,>@/Y.!-2W1V8=8
MT<%2F[ !=U*D;XLJ;$2RV3NA1GL8-5P)558F-)L*:8%G<!N>8\R:\(USPLM[
ML:T=WE!-! XCZRM_XLFG\#6IU<GB DOHLCH>&59LZ; +OBV2()B&U&*2U^@O
MA!(Z1@C7</-8ZV_MW= YVF5XAW !E-I7E_5N=O?4&5<W_*MY]4ZZ$W8IM0.%
M*;FVFQ?]"&SU]J@&WA3AOE\83Z^'\)G1<PTM&]!Z:BA*]8 WV#T 1_\ 4$L#
M!!0    ( "U!_%0LIBRQ< 0  !$+   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;*U6;6_C-@S^*X*ONUV!S+&=.DU[28"^I+AL*]KUY0[#L ^*S=A"
M;<DGR77S[T?)L>/<DMRP[8MM2>1#\A%)<UP)^:)2 $W>\HRKB9-J79SW^RI*
M(:?*%05P/%D*F5.-2YGT52&!QE8IS_J!YPW[.67<F8[MWKV<CD6I,\;A7A)5
MYCF5JTO(1#5Q?*?9>&!)JLU&?SHN: */H)^+>XFK?HL2LQRX8H(3"<N)<^&?
M7YX8>2OPF4&E.M_$1+(0XL4LYO'$\8Q#D$&D#0+%URM<0989('3CZQK3:4T:
MQ>YW@WYC8\=8%E3!E<B^L%BG$V?DD!B6M,ST@Z@^P3J>T.!%(E/V2:I:=H 6
MHU)ID:^5<9TS7K_IVYJ'CL+(VZ,0K!4"ZW=MR'IY336=CJ6HB#32B&8^;*A6
M&YUCW%S*HY9XRE!/3Q^?[JY^^73WZ_7LX?']NU'@GWXDL]^>YT^_DP_7LYOY
MU?SI>-S7:,G(]Z,UZF6-&NQ!'9);P76JR(S'$&_K]]'#ULV@<?,R. CX<\E=
M,O!Z)/""X #>H U[8/$&>_!F7TNF5^2/BX72$C/CSUTQUA GNR%,M9RK@D8P
M<; <%,A7<*;OW_E#[^,!!T]:!T\.H?_K>_GOJ.1*Y#G6RZ,6T0N9<W(#"UEB
MP1KN_1[1*1B1@O(5B?"=@8;8[L[O[XA8DJ 7A%[/\SRB4HK,F+VHQE06DVI"
M25$N,A;AV1(DXPDI)(O B!Z-7%0M0-;J+GE"Z$0*I5!&1 "Q(DLI\L9DCRP
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ME+4JI\NEX/"N@AM@?:Z4K6[00/TM[?(?4$L#!!0    ( "U!_%0*@2@'/@,
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M:W-H965T<R]S:&5E=#$V+GAM;*5776_;-A3]*X0*%!W@QHZ3M%V;&$B<K/.
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M+LGQ!JR7%GWO7CC \&_&[%]02P,$%     @ +4'\5*H2%F/C"0  U!D  !D
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MLVEG= M/^%%!]%$-ERSN3Q%W';5(B^[$91UTZ.CM0'%*['!!,Q"E6[2V3L0
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MT:N><O$WA'@3[$R^VZ.8@BWE<DH:<>8%>#^V(.+IAA6T/^2<_A=02P,$%
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MS0X^)S\VV*8;P%1&)G8[2B2>-<VN_;O!7/$I.M">6^UF&[<DOW.FGALK24W
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M<XO_7T"1 <ZOI31EAP)4_XBF_P!02P,$%     @ +4'\5/8MC.A] @  I04
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M.'UEU*J]%-H 9>T:<2/1M+4;EN8>!647F.^%E'@?V-[N;^;D%U!+ P04
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M':H*2L^':1],\@!6DYAC.]#NU\].TI30D(%D/H#M^+[\V+?M8 _VE+WR#8!
M;U$8\Z&Q$6)[:YK<WT"$>8-N(99/5I1%6,@L6YM\RP 'J2@*3<>R.F:$26R,
M!FG9$QL-:")"$L,30SR)(LS>[R"D^Z%A&Q\%,[+>"%5@C@9;O(8YB,7VB<F<
M65 "$D',"8T1@]70&-NWGFTI05KCA<">'Z21ZLJ2TE>5>0B&AJ4B@A!\H1!8
M_NS@'L)0D60</W.H4;2IA(?I#[J7=EYV9HDYW-/P!PG$9FCT#!3 "B>AF-']
M'Y!WJ*UX/@UY^HWV>5W+0'["!8URL8P@(G'VB]_R@3@0V,T3 B<7.,>"]@E!
M,Q<TCP6M$X)6+FB=*VCG@O:Y@DXNZ*1CGPU6.M(3+/!HP.@>,55;TE0BM2M5
MRP$FL9I9<\'D4R)U8C0=S_YRG\=WWUTT=^\7LX?G!W>.QH\3Y(T?9NAE_'WA
MHJD[GB]F[M1]?)ZCW] C9@RK"8&N)B P"?FU+%W,)^CJVS7ZADS$-Y@!1R1&
MBY@(?B,+9?IY0Q..XX /3"%#5P&8?A[F?1:F<R+,#IK26&PX<N, @K+>E%TN
M^NU\]/O.J05.\3NRNS?(L1RG*IQZ]9])W$!-*Y7;%?+)^?*JUMUZ^01\*;=/
MMN[5RSU8-I#M5,E+0]DLIE SY35/\3!AZ 6'": )X7Y(>:+,_WN\Y(+)G>.?
MBA#O,F2K&JFVTUN^Q3X,#;E?<F [,$:__F)WK-^KS-()F^B$N3IAGB98R>16
M87*KCCZ:XQ 072&Y(?FOZ$JNYFR-7U>9FZ':*4J]VG:C9M=2GX&Y._2MMLE+
M?=,)<W7"/$VPDF_MPK?V^;[=H"TC/J ML,R^U,B$!Y\EE7YF370/_+0;5J?I
M'-E9&\FE=NJ$N3IAGB98R<Y.86>GULX?ZM4;"_EJY3R!X/\68N?,A5C;Z*7.
MZ82Y.F&>)EC)N6[A7/<<YQ"\ ?,)AWPIGK< NU\6H-7H-WO'"[ V@DMMU ES
M=<(\3;"2C;W"QMY9-H8$+TE(Q'N571FB<[A?MMNM([-JV[G4K'-:=+]6.MH'
M/$TQE4:V7XQLOW9D[VF\ Y:>6"]9&K702_](ZH1-=,)<G3"O_V4B](J)4/+.
MMCZ/D5:M>^[;%F*YJS'PZ3HF_\IWDS02HB4$\L FS_J,[-(S8Y6']>Q+3<QI
MI>[URQ-]HK5%5RO-TT7+G#0/[@8B8.OT%H<CGR:QR*X)BM+BIFB<WH^8G]6S
M:Z8I9FL2<Q3"2DJM1E?^L6#9S4V6$72;WC0LJ1 T2I,;P-)[54$^7U$J/C*J
M@>+^;/0?4$L#!!0    ( "U!_%3G@U/JUP,  *\0   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;+5877/:.!3]*QJWTVEGMK%E\^&DP P!TF4W=#(X
M9!]V]D'@2_#6MKR2#.W^^KTVQ& P2CU+7X)DWW-\SK5\=97.AHNO<@6@R+<H
MC&776"F5W)BF7*P@8O**)Q#CG247$5,X%<^F3 0P/P=%H6E;5LN,6! ;O4Y^
M[4'T.CQ581##@R RC2(FOM]"R#==@QHO%Z;!\TIE%\Q>)V'/X(&:)0\"9V;!
MX@<1Q#+@,1&P[!I]>C.@;@;((YX"V,B#,<FLS#G_FDW&?M>P,D40PD)E% Q_
MUC" ,,R84,<_.U*C>&8&/!R_L-_EYM',G$D8\/"/P%>KKN$:Q(<E2T,UY9M?
M86>HF?$M>"CSOV2SB[4,LDBEXM$.C JB(-[^LF^[1!P :.,,P-X![!\%.#N
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MP0O"]07J_)(Q^;*COQUD'Y=Z_P%02P,$%     @ +4'\5"S1F:D$ P  Z@8
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M5=N(EV5G+2=:;%PW6PIM>J,;9N9GA-(>,/LK(?1A8A-4O[?>7U!+ P04
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M:(:/ F2>ID2L;Y'Q5<OQG=>!/IW-E1EPP^:"S'" :K1X%+KGEBY3FF(F*<]
M8-)R(O^FW3#Q-N")XDINM<&0C#E_-IWNM.5X)B%D.%'&@>C'$MO(F#'2:?S>
M>#KEDD:XW7YUO[/LFF5,)+8Y^T&G:MYRKAV88D)RIOI\]14W/#7C-^%,VE]8
M;6(]!R:Y5#S=B'4&*<V*)WG9U&%+X%?W"(*-(#A64-D(*A:TR,QB=8@B85/P
M%0@3K=U,P];&JC4-S<PN#I30LU3K5-B+^M_C871['\,@;H_ZW6$W'D#TT(&[
MJ-N'I^A^%$,OC@:C?MR+'X8#N(1!L>/ $XBEHKJ6.(4[0@4\$9:C&>]F2Y1*
M[[:2T&9$2II0'31>0YMG2NC-RPF#'E&YH&H-.G6$\PXJ0IF\T$N,!ATX/[N
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M;QW;G.OO A0F0,\GG*O7CKEZRB^-\ ]02P,$%     @ +4'\5"!Y[7RY @
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MSX1SDEX#JI1*$D8B+;U;N.CURS?H)3*06!-.!0H3=)>$4IRI0K5]NV9;09)
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M]ZDY&K4[T&AH<L6E2DE(!PXF T7EFCK#GW_RN]XO=7H/!+:CL5UJ;%OTUKZ
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M4*:^HDV52=0=#OM,D\MNO;?9-TULZM)V*>CZ^'GG^&GJX]]02P,$%     @
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M%ZAW\4Z]0[S4/CQZ[FN\_SNICM=K_>/VM^5]$Y\7Q0UG!_\/EK]02P,$%
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M5F5S]&?=[XGY)U!+ 0(4 Q0    ( "U!_%0'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ +4'\5+L<
M)++O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ +4'\5)E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  M0?Q4WFZ9S0L&  "D
M(   &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ +4'\5.F'01BR!   @!,  !@              ("!3PX
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "U!_%1-O6D2
MEP(  %<'   8              " @3<3  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  M0?Q40X;<;3L%  !#%P  &
M@($$%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ +4'\
M5'6"!Z8K"0  W5$  !@              ("!=1L  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( "U!_%1>W;+;108  &T:   8
M      " @=8D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  M0?Q44G)DP"8(  !/$@  &               @(%1*P  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ +4'\5 -8 ,M<"   Y!,  !@
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M970Q,BYX;6Q02P$"% ,4    "  M0?Q4+*8LL7 $   1"P  &0
M    @(%)60  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M "U!_%1I'6%:7@<  %<3   9              " @?!=  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ +4'\5 J!* <^ P  !0<  !D
M             ("!A64  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  M0?Q4@5"E5'$%  !R#   &0              @('Z:   >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "U!_%2J$A9CXPD
M -09   9              " @:)N  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ +4'\5,R.R]T#!@  S!   !D              ("!
MO'@  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  M0?Q4
MM%@=G9\"  "C!0  &0              @('V?@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "U!_%0S157F"@,  +@&   9
M      " @<R!  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ +4'\5-I]MVA4!0  '0T  !D              ("!#84  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  M0?Q4]BV,Z'T"  "E!0
M&0              @(&8B@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( "U!_%2%W83U[ 4  !\N   9              " @4R-  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ +4'\5,Z-Q/<I
M @  -00  !D              ("!;Y,  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  M0?Q495N-ZOP#  !+$P  &0
M@('/E0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "U!
M_%3G@U/JUP,  *\0   9              " @0*:  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ +4'\5 "$7]TY!   :!H  !D
M         ("!$)X  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    "  M0?Q4+-&9J00#  #J!@  &0              @(& H@  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "U!_%2?MK;J6@,  *X.
M   9              " @;NE  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ +4'\5.EXU/C8 @  =0@  !D              ("!3*D
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  M0?Q4('GM
M?+D"  !X!P  &0              @(%;K   >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( "U!_%3MBY52^@0  ,,>   9
M  " @4NO  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M+4'\5&7]8*=8!@  'S(  !D              ("!?+0  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    "  M0?Q4QT:&O^H$   #)0  &0
M            @($+NP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( "U!_%2O$@]AH@,  *@0   9              " @2S   !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ +4'\5"&"[Q_! P
MJ0T  !D              ("!!<0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    "  M0?Q4/"+* P$$  "X$0  &0              @(']
MQP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "U!_%0/
M$H==-@,  -D(   9              " @37,  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ +4'\5,AW=@.5 @  @ <  !D
M     ("!HL\  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M"  M0?Q43P Y8:T#  ###P  &0              @(%NT@  >&PO=V]R:W-H
M965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "U!_%0;ED$]3P,  )85   -
M              "  5+6  !X;"]S='EL97,N>&UL4$L! A0#%     @ +4'\
M5)>*NQS     $P(   L              ( !S-D  %]R96QS+RYR96QS4$L!
M A0#%     @ +4'\5(0SP6C+ P  'AL   \              ( !M=H  'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "U!_%0\8?4:C0$  $\8   :
M          "  :W>  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( "U!_%28Q"$EH@$  *88   3              "  7+@  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     P #  !PT  $7B      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>101</ContextCount>
  <ElementCount>183</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2317302 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2326304 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company???s Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company???s Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ck0001824293-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ck0001824293-20220630.htm">ck0001824293-20220630.htm</File>
    <File>ck0001824293-20220630.xsd</File>
    <File>ck0001824293-20220630_cal.xml</File>
    <File>ck0001824293-20220630_def.xml</File>
    <File>ck0001824293-20220630_lab.xml</File>
    <File>ck0001824293-20220630_pre.xml</File>
    <File>ex102_directorcompensation.htm</File>
    <File>ex311_ceo302certq222.htm</File>
    <File>ex312_cfo302certq222.htm</File>
    <File>ex321_ceosection906certq222.htm</File>
    <File>ex322_cfosection906certq222.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="380">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ck0001824293-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "contextCount": 101,
   "dts": {
    "calculationLink": {
     "local": [
      "ck0001824293-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ck0001824293-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 281,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://www.vallon-pharma.com/20220630": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 9
   },
   "keyCustom": 13,
   "keyStandard": 170,
   "memberCustom": 5,
   "memberStandard": 20,
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.vallon-pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES",
     "role": "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317302 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Balance Sheets",
     "role": "http://www.vallon-pharma.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326304 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "i148024954fe941968d8a6d77a82f31a9_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "participant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "i148024954fe941968d8a6d77a82f31a9_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "participant",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - LIQUIDITY (Details)",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "shortName": "LIQUIDITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ia5eb151e1495417d8ba486b11b22f863_I20220517",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ie9a508657df54d2a89439c9203c94580_D20220517-20220517",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "id5278a1eaa074dd68b78d80ced668ef6_I20210212",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company\u2019s Available for Sale Securities (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company\u2019s Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "if1400788042d42598868c075e36cdb98_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "iea4222aa63154f468853a59705ceb961_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "iea4222aa63154f468853a59705ceb961_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic90be0efda4140d69daac747399be9da_I20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - ACCRUED EXPENSES (Details)",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic21ef042a65f42cd84ec887387352371_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ForgivenessOfDebtInstrument",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "role": "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ForgivenessOfDebtInstrument",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ie9a508657df54d2a89439c9203c94580_D20220517-20220517",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "iaa68683166f845408469b50f0a32b3b5_D20210201-20210228",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ck0001824293:StockIssuanceCostsOfferingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic90be0efda4140d69daac747399be9da_I20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "i0dd279f5e1d8444db25b59b0858f2af5_I20220630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic3ad6bdf33be419586390b0ac7ab0caf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ic3ad6bdf33be419586390b0ac7ab0caf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "i3fdede838e6d478099d6431eb6ed4bd9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "icf436d7844974b62a61ac61f27616833_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails",
     "shortName": "STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "icf436d7844974b62a61ac61f27616833_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "icd5e1ea773f74f228cd0dcd9b78f52b8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "if8886d05b4bf4743a0ec7f5e64f3620a_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "i583a5a2c244e481ba66f7dc6f13c40d8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)",
     "role": "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ib22a3ec9f57c472e9b4b81732634c2fe_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Statements of Cash Flows",
     "role": "http://www.vallon-pharma.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - LIQUIDITY",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "shortName": "LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220630.htm",
      "contextRef": "ief01e294b18b40129a1dea6fb2622a96_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 25,
   "tag": {
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued General and Administrative Expenses, Current",
        "label": "Accrued General and Administrative Expenses, Current",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedLicensingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Licensing Fees, Current",
        "label": "Accrued Licensing Fees, Current",
        "terseLabel": "Licensing related"
       }
      }
     },
     "localname": "AccruedLicensingFeesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Costs, Current",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliate of Medice and David Baker, CEO",
        "label": "Affiliate of Medice and David Baker, CEO [Member]",
        "terseLabel": "Salmon Pharma, Affiliate of Medice and David Baker, CEO"
       }
      }
     },
     "localname": "AffiliateOfMediceAndDavidBakerCEOMember",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Research Study, Number of Participants, Completed the Study",
        "label": "Clinical Research Study, Number of Participants, Completed the Study",
        "terseLabel": "Number of subjects that completed the SEAL study"
       }
      }
     },
     "localname": "ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Research Study, Number of Participants Enrolled",
        "label": "Clinical Research Study, Number of Participants Enrolled",
        "terseLabel": "Number of subjects enrolled in the SEAL study"
       }
      }
     },
     "localname": "ClinicalResearchStudyNumberOfParticipantsEnrolled",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Research Study, Number of Participants, Included in Final Study Analysis",
        "label": "Clinical Research Study, Number of Participants, Included in Final Study Analysis",
        "terseLabel": "Number of subjects included in the final SEAL study analysis"
       }
      }
     },
     "localname": "ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Note Purchase Agreement",
        "label": "Convertible Promissory Note Purchase Agreement [Member]",
        "terseLabel": "Convertible Promissory Note Purchase Agreement"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotePurchaseAgreementMember",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_DebtInstrumentPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Term",
        "label": "Debt Instrument, Payment Term",
        "terseLabel": "Debt instrument, payment term"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTerm",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_ForgivenessOfDebtInstrument": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness Of Debt Instrument",
        "label": "Forgiveness Of Debt Instrument",
        "negatedLabel": "Forgiveness of PPP note",
        "terseLabel": "Forgiveness of PPP note"
       }
      }
     },
     "localname": "ForgivenessOfDebtInstrument",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance Initial Public Offering, Gross",
        "label": "Proceeds from Issuance Initial Public Offering, Gross",
        "terseLabel": "Gross proceeds from stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_ProceedsFromIssuanceOfCommonStockAndWarrantsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance of Common Stock and Warrants, Net",
        "label": "Proceeds From Issuance of Common Stock and Warrants, Net",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net of offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNet",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuanceCostsDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Discounts And Commissions",
        "label": "Stock Issuance Costs, Discounts And Commissions",
        "terseLabel": "Stock issuance costs, discounts and commissions"
       }
      }
     },
     "localname": "StockIssuanceCostsDiscountsAndCommissions",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Offering Expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "verboseLabel": "Additional offering expense"
       }
      }
     },
     "localname": "StockIssuanceCostsOfferingExpenses",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_Warrants2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants 2022",
        "label": "Warrants 2022 [Member]",
        "terseLabel": "Warrants 2022"
       }
      }
     },
     "localname": "Warrants2022Member",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsIPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants-IPO",
        "label": "Warrants-IPO [Member]",
        "terseLabel": "Warrants-IPO"
       }
      }
     },
     "localname": "WarrantsIPOMember",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issuance Expense",
        "label": "Warrants Issuance Expense",
        "terseLabel": "Warrants issuance expense"
       }
      }
     },
     "localname": "WarrantsIssuanceExpense",
     "nsuri": "http://www.vallon-pharma.com/20220630",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r22",
      "r344"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of marketable securities premiums"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r35",
      "r36",
      "r37",
      "r406",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r34",
      "r37",
      "r43",
      "r44",
      "r45",
      "r74",
      "r75",
      "r76",
      "r293",
      "r333",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r280",
      "r281",
      "r282",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional\u00a0Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r239",
      "r285",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r164",
      "r219",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of Underwriters Warrants",
        "verboseLabel": "Warrant issued reflected in additional paid-in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r8",
      "r70",
      "r108",
      "r110",
      "r114",
      "r135",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r291",
      "r294",
      "r317",
      "r342",
      "r344",
      "r389",
      "r405"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r21",
      "r70",
      "r135",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r291",
      "r294",
      "r317",
      "r342",
      "r344"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r120",
      "r142"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Adjusted Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r124",
      "r127",
      "r401"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due in 5-10 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r124",
      "r126",
      "r400"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due in 1-5 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r124",
      "r128",
      "r402"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after 10 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r124",
      "r125",
      "r399"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r117",
      "r121",
      "r142",
      "r393"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "netLabel": "Marketable securities, available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r119",
      "r142"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r6",
      "r62"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r57",
      "r62",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents, at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r57",
      "r318"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants granted (in shares)",
        "verboseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r394",
      "r409"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares (in shares)",
        "periodStartLabel": "Beginning Balance, shares (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r42",
      "r47",
      "r396",
      "r411"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible notes to common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Convertible notes, converted, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r182",
      "r189",
      "r190",
      "r192",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "PPP NOTE AND CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r69",
      "r72",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r194",
      "r195",
      "r196",
      "r197",
      "r326",
      "r390",
      "r391",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r167",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r165",
      "r194",
      "r195",
      "r325",
      "r326",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r27",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Convertible notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r28",
      "r69",
      "r72",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r194",
      "r195",
      "r196",
      "r197",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, maturity"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Available for Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Embedded Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r242",
      "r243",
      "r275",
      "r276",
      "r278",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r241",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Activity of Stock Options Granted"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r48",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r87",
      "r89",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r306",
      "r307",
      "r397",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r48",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r89",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r306",
      "r307",
      "r397",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "negatedTerseLabel": "Expense recognized on embedded derivative"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation, weighted average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r43",
      "r44",
      "r45",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r96",
      "r136",
      "r219",
      "r226",
      "r280",
      "r281",
      "r282",
      "r289",
      "r290",
      "r305",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r333",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r60",
      "r199"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows",
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r308",
      "r309",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r180",
      "r194",
      "r195",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r309",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r180",
      "r229",
      "r230",
      "r235",
      "r237",
      "r309",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r180",
      "r194",
      "r195",
      "r229",
      "r230",
      "r235",
      "r237",
      "r309",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r180",
      "r194",
      "r195",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r309",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Other Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r312",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r312",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in valuation"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Initial measurement on May 17, 2022"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of June 30, 2022",
        "periodStartLabel": "Fair value as of December 31, 2021"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r180",
      "r194",
      "r195",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r329",
      "r331"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease liability"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r328",
      "r330",
      "r332"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of finance lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r191",
      "r217",
      "r303",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedTerseLabel": "Revaluation of derivative liability",
        "terseLabel": "Revaluation of derivative liability"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows",
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r24",
      "r70",
      "r111",
      "r135",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r292",
      "r294",
      "r295",
      "r317",
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r70",
      "r135",
      "r317",
      "r344",
      "r392",
      "r408"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r26",
      "r70",
      "r135",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r292",
      "r294",
      "r295",
      "r317",
      "r342",
      "r343",
      "r344"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r99",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r57",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r38",
      "r40",
      "r45",
      "r46",
      "r61",
      "r70",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r90",
      "r108",
      "r109",
      "r112",
      "r113",
      "r115",
      "r135",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r307",
      "r317",
      "r395",
      "r410"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r108",
      "r109",
      "r112",
      "r113",
      "r115"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r33",
      "r35"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r344"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest, depreciation and other expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' Allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r52",
      "r54",
      "r118"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r52",
      "r53",
      "r118"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r236",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r236",
      "r336",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r236",
      "r336",
      "r339",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r334",
      "r335",
      "r337",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r288",
      "r375",
      "r421"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r226",
      "r344",
      "r407",
      "r416",
      "r418"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r136",
      "r280",
      "r281",
      "r282",
      "r289",
      "r290",
      "r305",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r273",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r238",
      "r240",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r67",
      "r97",
      "r98",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r212",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance, Outstanding (in shares)",
        "periodStartLabel": "Beginning Balance, Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term\u00a0(years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable, Ending Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance (in usd per share)",
        "periodStartLabel": "Outstanding, Beginning Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r272",
      "r283",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of option on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock awards, contractual life (up to)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Balance Ending (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Beginning Balance (years)",
        "verboseLabel": "Outstanding, Ending Balance (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r32",
      "r43",
      "r44",
      "r45",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r96",
      "r136",
      "r219",
      "r226",
      "r280",
      "r281",
      "r282",
      "r289",
      "r290",
      "r305",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r333",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r96",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r31",
      "r183",
      "r219",
      "r220",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r219",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock and IPO, net of issuance expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r32",
      "r219",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r219",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock and IPO, net of issuance expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r70",
      "r116",
      "r135",
      "r317",
      "r344"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r226",
      "r228",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "LIQUIDITY"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r133",
      "r134",
      "r191",
      "r217",
      "r303",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants outstanding, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r88",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r87",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "https://asc.fasb.org/subtopic&trid=2229187"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r425": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r426": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r427": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r428": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r429": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r430": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r431": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r432": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r433": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r434": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r435": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001824293-22-000072-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-22-000072-xbrl.zip
M4$L#!!0    ( "U!_%0*6?1LCD ! #4(#  9    8VLP,# Q.#(T,CDS+3(P
M,C(P-C,P+FAT;>Q]:U<;.;/N]_TK^O#NL_?,6C31O24RPUE,( RS8Y. DVSX
MDJ4K-/C"V[8#YM>?4K?-'4(2 S;I69/$=G>K)5754Q>52G_\O]-.._GJBW[>
MZ_ZY@)?00O+_5O[X/VGZOW]MOTO6>G;8\=U!\J;P>N!=<I(/#I+/SO>/DE#T
M.LGG7G&4?]5I6C[SIG<\*O+]@T%"$"'7+A;+&<%29,:FCF.7,LYL:F@PJ=3(
M92)#S!*TN+]LM9>.$+A#6IHRJK+4(&=3)!$RAF>!([;HECU%BG%,>*":86Z,
M5X(+S$F&+--,Q=<>#&!T,,)N?]D>(82P)(PH^N?"P6!PO/SJU<G)R=)7W6[W
MNNGQ@2XZ>LGV.J]BYY&@,!75HZ?MO'MTY9D3NM0K]E]AI=2K\NKYK?W\MAL)
MO/K5_S;>[=@#W]%IWNT/=-?Z\Z=,T787#\:OD\?$J^KB^-:[>Q&'.FDO[_<8
MP=F5FR\W2E^-[SA_X'1P^\UY%T;G(R^\&A2ZVP\]F*0!\$J<))0BDF(R:638
M3_>U/CYO*.B^*1L97RCG=7+SC2F]VK]XV>C^^0PY?VUZ^MXN[?>^OH(+5]J%
MD:1P[4K3DWOO&PSFP%\IQ1?MW-4[3"\U=)F"^7WS?9GBRVW=W?]SP7?3CSL+
MP*1>NY4_.GZ@D_A\ZO\]S+_^N?"FUQV Z*6MT3$\9JMO?RX,_.G@54GL5RO_
M\1__\<<@'[3]RF7N3B?\^\>KZN(?KZI7F)X;K?SA\J])?S!J^S\77-X_;NO1
M<K?7]="1_'0YWNB+ZF/NG.^6'^%Z$W"@R&W5C]/!M@]_+N0^(.R)8@9+PQ F
M2F/GM0B&"$*T$E_6RJY@A-,+F>KJ3GRUSY?7N]"_T1L85J';FUWG3__'CQ:2
MW$'3CGX:F;7>UW=D^^LN;0S=X?K7O0UUN-7Y>-98.T+-UOJH^7GW;+?UX;3Y
M^9]\KW5$FJW=TV9KDS8V&@A^Y^]HL[U[=MQNG*WRYMK'T\;AITZ#K*-&ZU.^
MV_G(FX<?2:/U<=0\^^NPN;&.MCY)]([LC78_6P'WG^RMP3V=7;YWV.PTUQJH
MT?FGO?OYTT%SXP-J'EH*_XYVSU:_NHVWN=GX",\<G3;7_NILM1JT<?A/N[GV
M8=0DF[BQL1U_@[[]=;3[>?L ^CI^YA.\BW?W6CVTU8)^;>SRQID=-3H?47-M
MD^X>0A_*W]9C&P=[&V_;T,?1U@XZ?==:'S1VT%GS\&C4./GB& N9MB2U7HJ4
M(?@DL<:I]IH&KKCF&5]8N>"1/UY=(>MC4OG-L"B Q&_SOM7M7:^+]:Y; V52
M$_I;A#YKO+E!:,LR3HSCJ36&I2P3-M4*2!X0TTA+S3+*%E92@&4 LR>D\L12
MN"#S6_BE7Q/YVT2^*<W&H<SCH%+%D0)#22L@,E@TQ@G.@\Z4)G9A)9+AV2C\
M'MKON9K&#Z1Q?H/&*"..$@(RC U*F7,B!7J$E(J@D!!,JJ 65CX\)857@;RN
M)'%;[R\DE7D$S9X.ED-^ZET:=+M?X_8#R#VZ06Z2:2RU0JEU2(-(2Y8J!7)-
M& :A#IER*EM8>;OZ;F?]#HJ_+;2-QFHR[.85O;O#CO'%PE4>X X:##*SBA@F
ML=>*9B%([H2765"AY $,_Y-T\F$A<=[F'2#NGPMTPA!CHWUY9]"S1P>]-IB%
M_76P3 >C9F_@RU]WCMOY ,S4L?NX'6UI,* C/$ #Z)D9I9FKCNV\[6X=[A.X
ME^]V&FSWL'VP=_CA=&_M ]L]^^=HZW.SL_5Y_73W;!/M=C;1.[I]L-LY;6\=
M[N7 +*3Y>>^P<;9+FH<?>//L4]X\W,=[:T?05GSNPPE<XY-GX%W#/0),!NUL
MM7;Q7J<!Q(=GUXYH\_,FV5K[=+35:N>[!!AV;16NM<,MV*]$!KZOUZE$'%Q@
M@C+ !>Q308(P+%@J)> "6D*$3QAEPAGW8H-6'DP#2L"[)DP;IKFSDEHP("13
M)&0E7R#$*VR #]$7JECALG.QO.;-8!.\F:)4!N_U*/[3\D7G><F-&^?D_HAW
M#S]@F'P@X5\'S=;VX=[A7S#MFV> #?G6VCK::WT\V_K<B.1N^[^W1WN?W;$A
M3#2A?7C?68-L@JROX^9&L]/8^.=P][!YL/=YDS5:V^UFJ\%WS[9#HV5/MCY\
M\<YP)CT&:1: Y3Z(U##J4H\%,=A;(XA86'F/=T4#K7T/EEN/@/@*B!.@08Y
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M>V .I^W<9ZSQ:D[P"HC&:[R::[RB^ 9>Z?Y!\K;=.^G?"D4O%(#B/-0 -&<
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M-<K]%)]M%+U]]^1XFQ2P6*&=C^G>YTNF0%0?N>K2%1CZ)Y"H\\5VZX?ESGN
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M$=%A0"C[V22][Q*&QT[?^T9\H(:S&LX>*0Q2P]D4X>R&62<PRR@RJ?<9P%G
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MS6YEJL< LIJIYHBIK I1$;+4 Q.ES$B=:BEP"F!FK2'$9;&.*N%H$? M_GD
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M?B,:P$.6(8%5Z@2)*&5=JIFA*4)>2V8YI9*5#@3Y::/C5RQR,1<^Q-3C ;5
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M7&]+7.?8 F&<!1$"PMAYQ#652'LJ$/81Y%<)3FCN3_!0XOH8@W6/0U;OKL]
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M_,'XXRAV!]<T>)=,T*,'DU4P>.$5RZ7&L+TU6-E^O6#8.A<,T'Z&7$H:#-O
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MP..BI0EL1V90]F2CW%C.)J$YD32?3"*9>)I'##52?&<67"/%=R7%"S:9)H'
MHC$4N3>(>Y60T4$C9K *U'ON\R$@*R3&SR R->FFL67[_J#B/8RL53]D46J:
M:EROJ8;6-AEOG8R>\ZB2MEP+G8RC2F$>4LE&7@"JIJG&0^'53%.-[8U-NKV_
MYY4GP7B, G<"X(I8I*GRR%.M<(B$L!3ONZE&(WV7.?+D6J+7M):X/U$[TUH"
M1(T&'ICQ&BF*(^(:Y$V[[*U5.AI)O8T8WV]KB4;0+B%HV.%D@9='E<_VC-+8
MP*+5DEMG%4_\M@2M(>(WDC8R*VT[[_? CO)4D8@\BP[,:1&184PB%50(E@@-
M5+PT6##X)RV_&V&[1QLX"<Q"3$8E6!\BN:.>8:XI6%,TLGB!6FM:#]R19+&I
M9&T=;^WO$4 ^B3%#R@:@C(10Y$S,S=BD#-$9 7('E/'GUFTC5?<E54&KD-M7
M,9\XERIJ*C453$@.VBPI=RM2U2BS6Q,Y<4;DUO<88SJ*Q)&E.K<^9 FLM$@1
MM2I1QKEF-G<+XFN"J4;N5H8Z$JXQY4;P% TG1NJ@K0Q*64T3(]8TU'$EI&W.
MA^OWI&18,25 OJ3*!SD+9)EER 2M1<S-=@)H.+;&)+[$:3%/.^=E<S 89>=J
MJY=RE?1A+P\ MNM:JQN'^9>]E&+._6K%'[E0)CZ[[)BKN52!Y1*)75!&>RZP
M<20%ZT%IY\.FB!P7L_)Q$.CG!\(7],C+%,-L%E[E9X57+)<N&15JO*R70)23
MV=;%_A0H<XK6ZTA!?P=@RSRG[)D0&>*"RQBY88&Y#"@*XS78BTW9ZGT7D-](
MYLY1V(LB5\K_9B2N4=-7$:K36:':>;]'O71$NX <#A'Q1#$RC!+D&*/28:-$
MX"]>-37@]RQ,01N>B%4R@K$9L'4X$D893LI:GX](O"-A:@CQK4G:3+\%C[?W
M]V#5%%AR%DG%07V9'+FPUB$3H\(J,*6HSSD-Y&=\N$D9:M(SFU5J5FD5]98/
M(I)HE6)) 9F@V@<<LL)2.@GJ=*.W5EYO+7/D> %&%7*YMSHG$LBBEAA9KAPL
M;9*<\TIQ-;TB'F]OO:8BOVEFT$S=G84.;VS.G1-#;/HLK9#VW'F]8/5)2CB7
M0B(FG$-<2(D,UA%QCH6)5#J6_2OZ$FGL3:'_W5@3*]P6HEFE9I4>@7:[!:.O
MT6Z/0KLMV(8T&)^()DBP2!#70B 30;TI#[*@C>&1J\NIMZ9[QFWW#]RW[>[=
M]P]\Q/&8IFU$,W5/<^J>NQN:$,TQ6-;>6\*IBXXS+*C'+%#KZ#7"ITWWKE4@
M(!]GNP;".-;WJ&74> [4P^1,H%P.9H&,HL0]$1[654;]XM5B;4H3<5II46_B
M@H]AE1XR+M@ \FH \H)%:!DW1A.%/& OXC%G:=J4$ LN$,R-\E&M%B(_@TCA
MC7HJ/N(831/>:J;N:4[=DW0Z-Z&!Q[!*5PD-<!]X4CB"[6VYE=%B,,P#H=09
MJFD*UP\---W8[N:HH-WUX<Z$TJVS[=VMO62!U&%%D'1*(BZ41L9;@:+DSAF?
M:''RDS5@]ZOAYV_$^-%$^!HQOC,QWJI<92#*G_#6UV]L#\,"VNPL2T10D&.'
MD67*("$"Y=AKK[Q;*3E^!O&Z25?%?X^ZL<7P6NO:K13KEZ\;!50O]3N#J0^]
M40[^E68!SZ2-P-*J8)*T)IAH^*_@0$4,(T9:R2QGT9@@ZDX"/R\&;AHMW@^&
MC?&K\BYMGZ[OY2.@9* >@"N9? )\0,[D:F!K*: 8:*#<&);@-7&;K19_XN6]
M#XE<RBE6#<S^^]S9O83_^S9QZPJ*9I50:TD@\UJ0=;GF)PV=NAH4G<Q"T?L]
MF;B*.FD$U#@@+CD%JP@S1$/47 COL#+W53G=(%"#0'>$0)$0B[45QIK(HQ<N
M2!>]$U(SQZ5P-T&@QMJ[/7C:/G.^\]8>X]@$:CU*0=GJ?&=GF4?18U@Y+8PB
M^20,LV:4;C"JP:B5PZ@K-3RU#%0QU]CDSF*,6.YHL%03F_N;:'8^2#4-3^\,
MD*9\">;CTU[D&#BKQ;7IAF5"#FN-M"24)4^CS67$E_ \-6#4@-$J@Y&Q00>E
M!!;<<&R3";E=I8HQ!,NM2;<"1@UUNCVDFL:[8%R[ZWL1AQ2C4"@0L.=XH@H9
M'250)R; PI-)L@#42:XQLMBJIX&K!JX>?)JN$MJC)";,J94B<>J#!B-/:\7@
M_X(R11K[;C5 :B&:QX6*E!*>8W@!<;#PD$[:(2$MPT;Y!*0XM\.4\B=>\!)E
M^ZT4B,%_0_O[JW_!7^,=>VC[^^UN)1;T+#CX"/NH?]L[G.#Q%B]W_#W7>+;]
MQ9N>EG8H,;:LSXU0;/<D]\KM]H;PO&$/MK\=A?8PAE8[C[A]V$KMKNWZMNW
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M+AB!A%1:,Q>BR6?M,?:SKDC/RK;/9:&C.+7MGUV@9#5Z.BY%A[PP?T^]:0U
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MFV/RT/I0DX>W4TT!>B 3R^$29G/4_M[+*26@<D&YV@'\># ZG"B>28>]&L1
M"<?!(+M,\\UJJM8+)V"/P:NT?GFW <\ZFGM#^/7_A5\/IJ\YG'O-0;?7+X=I
M@2Y,^0&%8'6LRRRXUS]!,*+V47X;T*F5YF>X=;@/[#=V*XK8S]JVU_+]T>
M?@QHEC8-ZEDJ=G@'R*7K9;K4+^6"-9T+F1_ .V<.6),+FWE)K.Z=%>EDF$ P
M[/@U@4W UTJR10LF?-@&Q1:/6L/H#[KM_QW5=.4 "*2+<<(7JI9$]KP7+B.U
M0.W@<Z,CT/4UI0&N4C'4&<42N_U>IP,?/#>4 V\ Z]"&A1_.A70(UYAR(WB*
MAA,C== Y\UY97=K0F3KWEYTMI-C<?KNT?_EKV/>9M'^(@Y@9XL<\/C  7>SO
MI'?300S>U$.>!';P<S/8=]?%SBZ,;??SZ?;N%M\ZWHN*!A:#0)9PA;CC'.E
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M#W V^$!CEH3MP]C?ST+KLO&8UP<XFVMWZYM4P8;#RJ\/(YX9ZEJKNM$(Z!-
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M66?'9JQ)DGH62& \2*,UUU(%C3W!3(15#+"#8AO$I4F8 .S?8X7L$R==#>+
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M;(Z92Y/DC:KM:M4G",3_NVUW\FV*>R#GB+QLS=Q[_B[Y!AGU^AEO;>6-K4N
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M!WNE,95_R>L \YHO6:@FIZ0S/7<'%T"I8V$ QM\_8W<02^NJ5V@H7-0O%J*
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M<_M7@8>#2P#Q]?6 ?"(L7)W"PI"2TB9()+0.B&.*D:7:(F_!X:-12D_H0_>
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MI*W5*# ?B? T^1#ODF[YD&>)CRM4]5GBS:2%-7=WI$E@/:E,H<H$XIPFI$/
MR# :#<?!"$DSU!JFKTJPG#AGJH\1+TTI%,VEG.4O1*"9C=B#)2M%1%K#[%"3
MD@N*26_$)8>*8V>$)X]P'FA'.&7N?RAX-T6?/@N\RORJ,UEOD&/XN[F^DT+.
MP^<:42; K"+8(Q.%1]ARKAPCQ-B<1; @9K0_&C\A;'>',C0B+17]T3C)T"6G
MA=>>9TWV-@!'+SFK%%&2>Y><PHH&$Y5DUF/B[W]:V"X+:9_XU+ T+3_\V_7_
MG/7F[#8+U\Y%?198GP769X%W"!;XA"FGSF+O)9>*ZLB(4QDT9? "Z_HL\+)@
MP?XN@UT(-W_\W0$G_F1ML[@&=J#5TZ+9U(\5UJ1_'S3W6_N3P8*UY7#8S,&%
M']_I6B92+':Q ]'<7V4MN@6_^[/M'^NG3=H:/0LD39@'L&!CX(Q(+9"2-F=.
M6I'; 3 D)3?1\T15;HI*&%[4;RTP6!\&7J'KF@4F+;,X),R9U#8E*J/%!N-D
M*;U$U^O#P"=3]6]3JBZUL@2\!B1P)O@5SH*S2B4*5C"=>)1% 7Y]&%@?!MX*
M"2Q)  ,LY@/ S JG34C$:<PCO.#])5U[Z\/ IX."]A046.:P]M(A305''+N(
M=(H&)16E,8&I0.O#P/HP<$+3P2(46.&($S;<<:\=B=B#": 4*+NV]6'@<VOZ
MZ92F:T\-D4&B&$0F5=<*['L;,B, ,UC"_L]]WO2E?,##P/LT=Y7DQ39WU<_6
MW/6<17<MY3/+V!U4U 1%36M1#EX<%'VT@QB&1>,OA'&7-L\UIW, [Y_E]LS-
ML^T]N!]H1=C;.CN@6Z 5(,'[S<UUO+;\^7 R=KOV8QW&TLS:==8Z_+S7 JUH
MT<_[:YO;;="*LRW:_-U:7N?-']NIF<>]NV.<$TX+BC"X)H@'L'DML1@YHP/W
MRGDMQ&2@-!G&O+1)"T4X!W\FP1T2>,;,LQB=F\FXBSXN?5O)/6";7U=:WY8V
M5]=:=V#9O?ZKQX?*&!-@=''!&5PNA8LR^&2H#9Y'R^TYN#\:X;/?B^$X<V:L
M'/[L]$YC_!;[O]H^7DCBJ*PN=4 4B]_6TD;TO=TN:%X^X6SW2@%^T^)ZLL,]
M4Y0J@KSF$H#::&3S:8,S $9.4P[H."E^+R[K8K0/Q'D+P.( '+DL$ 5/VU B
M1DORRT/R\LRAY(*LSM&KU(R+OL&3W35 2'6C)!QOK'9SSX/<V>%K!Q[^G\5[
M^=<_AHT"+\X>JIK_!LADW.WUV^69?6[.=K-N<IE>+M_Q:"];B\6(V[\;AS!%
M>X,&N(XPZ.D#Q.*Z7+_W_N854'-S&L'%HI#RX4\CR*(F=[OMU>\Q(>K!SM5@
MZ<T&=$-_%&?_;.1^YY>:F[BN97>5I_'F]'7F::&PGRM$VBP0J5DBT<HY$C4
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M&;C2V)@@.2/1R1BX"V7K:$(H(]=T*;W6AK[,A*XB:B,KW*IH[>>@&>[]#H'
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MEI83YL'(9(EWU1BF;U@@^7^,[$]8U<BG:58< .^>U1T"N2\ CVC/UKY;X6R
M&@:NJY1\0H3/A7_@:H!UX6JVP 7Z-? P>%BTI#$\T>'!='@P'1Y,AP?3X<%T
M>##?*=V)9 ^(YYL([])PX>V5.3F6]SMLF$? AMEJ>K#X0 $JT>00^)K$XA\T
M=6>74G".UBL<_:KL\(VDF'7TMDUKVSOQC]>I/O^&]/8S".PW8'_G]S#H'[Q
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M+^?JOR%*HWD 8\(\P3 .S7I=?"&Y_;PA!-%S^0[^$MBA7*04T9UX"86B0*+
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M=#PVQ^)_B*UO:[T8M!-'MYE9IDQX'&4S'&BJXCD*D1C#1J0K&']L\]O=)/3
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M<TLG>-Y$&!B1"S^M/D,)P N?F/@HDOQOH\:A)R>*0\F<"5RN1W 8;LI+FDU
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M'!GG[NLN<4V0!GA71G% OP.6BKT:F5MQ*UV9E;T9S;:I)I<5=]3>HRX!V4U
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M>IR/1MAL!3T8LL^KA#LVX6#8&E]"O]V7\&28A@OXS[28Q7_[_U!+ P04
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MBAI!.*FC(8P\>E>*_+\BZ.$A1BYCVD.<R[4&J=L4AB-$6W""R!0Z*&\?[S\
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M.:FZJEY*28TU .R#M(Y_@H46\#'6<ZHCU81DW/""E\,'Y0I!3M6EJE[)J6)
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M "D"":2A3IZ.0R?<74#RV?:JFMU5WT7-R<ZP&=?R<T#<R&.Y3_S*B/]25_Q
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M.#(T,CDS+3(P,C(P-C,P7V-A;"YX;6S=75M3&\F2?I]?P7I?MTS=+X[QG,"
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MPN)GY5T5Y?5&K7EG1>G]OYX5B@6F$20)J;PK%A-$$J35Q'"NO& AY[4QAK>
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M$X2(3"UO' S3]R_<^&3/F\P@&4F,I+@S<I.)M;C$.2&#2]QR8+[VTK$)X.?
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M.=-B2DI34I6<E\:@EK 8DK9)*TYK7\FS#,O.PXP[)\OM^U9J**T#A_0N7//
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MG0A.Q^ -%S\<4Q_P]_>>J.LHM:N+)KZ=-+NN4P JO621>*G0%76EG5Q$9P-
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MU--%R/U;[&>)4-"R_.Z=:9PG"<6,-.B_2$>DXYI8R041/FNMLN'9T\X"NVL
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M!M;1.J<%5@&EX-?)]'6:"S<_.FV6,_7S.P#4YWZ(2$C8.OW^6MJ."$%4R+1
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MU@"-ES^%<N%S]3G(?:?]21E-_C=\!QB\ W=,*LII/,M^TXMN#Q!+4Y2[+CX
M$E(( *(IJVI**>8U\0[AGG>:)FI(RG:?LWE.(-5!'1W]@S&ETJS[DM=9G<^)
MYUOS.HMF[DNN\G*MW \M/DIV1E0<DVM/4D./K 72IMR(-?X=_9"*HNT"K#:9
MGI>@8J9;I/AU_CM$OT*Q01!;&.G"/^LH0,<V-5WXA\OU][3C-;=>>CZR*SC+
MOV#8IT41:5@C)$^/2[ZU[CPB]%V9R["?>'8_VNZ!8'Z5=-/OE(!]Y:GLF]RR
M[C/@S'6F,N 3TL$#@SJ'?._3 4.D]EA=^KQ %W=#A^M/38ZK/YB[E_E2>@TZ
M8R?#!)J@-..SV'Z-D"RM\Y.^^W'UQ_=)=81Z$BNK;,?(YUGNG3:'30KP%VH(
MU!WJ=7\7>1%-K]2E$4VR=1I"A:'>?D;84X<'27/L(]D7!WL$RQ/WGB=/&0WT
M?LBSET(&(-<CCQA(O_U %DG+2OHFCPJWIG/J/)CNLN[?Z\;=G75(<MW>EUYF
MT)E1DCQ#SU28KSJ^9T,0A;>CV!%O]"/'X/1XI_GI E^SZJO#G6=[K!0OOK6O
M_DPLT6K(CH^Z_%($LN%.IO_;<ZT7@ZH])W<^@;)@1A_]SH?!= N=CC?XGO\>
M$8^YC.YZLOS"#!/.JRQV:8'JA>0^7#']0W2VP-6^C22363+2:W5X7=8\80Z)
MV=]=>C_>BIK4G_=J1[*9;\S=P#MC(#R.E0^*7'SS\>^'R MG836&NC8O#:]?
MO[/(/;7.?RLMM+Q3RH-@X21PTYB]Q<6%+>;R9P\3$X!JZVH?]\E6]J7/%H/"
MI,35!0B1QX;, ANM$UUDY?(3):6-/90E:-:EZ(SY.;F>=^!Y]>7'X#KN6T (
M+?P/9I7)QO+U9_)%?'QK35)4W1V?/"?^X*."7$<CA;;9Y:7M6VTC^6X#8E%Z
M<ARZ8G&Z1<-0_+55(EM9!ZP4W0;A\[/#WE-2OX9_NL"LY>_T>.]S%V+>1R(V
M*\'^MKK3L]YWO7(5CR:OW_:!RN0=%0JD!X2PZ]/:>Q2>HG,1RU4VBW)7$V:?
MY/G56G1*_L!KXD+;H #YXCK\&M:Z/M?;OC59JMGWEH;^MQ9YZ1E;3T-9OD<F
MGS_=H8E862MZ;V!H66KZ &/H, L9="&R4P RRP,L:MN"E(0]7O28<@DDB]TW
M'.LP[PS2P0E\HZ5)E2X\CRLF;P_,7C73NH4B,_SMB43P?WL(R=*45D5GW@_P
M*^V9/3CQA.*X6_<N-\8<L1D_N-'XB?WB//RE >AX:9XG1HY>Q=/3+=)M;2WY
MKIK\/#Z"WV@?JXC%?Z S)]> >82<8FW=!2M/DY(Z-\B>SXN.7, MIR;B9C5_
MV6\73X<O$R[JUZ[L/QGO9!)8H7G>\&ST)(G=KJ3;L4/@0YKHFQG4\O+L+47U
M%)G6.DLA_HVC39(GE-=/&D2K./(@&-T<T@>S-JT4@-D#S2(0G<3?5T!JFQ:[
M-7?3G>GU=DQ8;] M,Q:G(P29?A8T+O7?6J,1K/VD&FL&J:JURB!XI$X_YVI?
MKB,=M23J?,0UY8CK>3,[KTM.K1L,P< &NPCUZR2P,F+2R)?QX1@+QILH=O.9
M*0>LI57;ZIV?C.'W8 ZVG2S&G[@@2;Z%=_CH6EKMGX8X7'YN+Q.>99?A?'S3
M 8/%&V]D55:A=U1=\)=EB%P48%Z)R&D_?WR$:F5VM3"K"T^[C]T.>%IA918#
M]>+1FMAO2NC^9SWN+6LWI&27*"2'E3F*Q7]UGG?A>446P9NZYD"3['(<]UM<
MLVJ_ 7']'\^;Q;U]JE9'G63T ?'=)1*<9:()C@(LJ.<M[/([3:6%U^D5]-K7
MC\BLR/;)"0=)!)N<9X@XD_LA%P!8'!L&F!OQ9G^6BRZMG!9P'%C!?4^$;SW8
MR_N.J9_K.*9E6G=GZ!*0BNU,3_B\;";\$7+?$Z$,P]X;P"N;/B5%I.GA;7#P
MS<<XNF832>?L#66GR%UZ&8"66D8A WEB*]L)'5VBXB.'$QD7"P06O((\4.S>
M7L8E8^72CE,W>Q@)*HE.OM56&F)AFRU7: 0C\(+H2ZUVASY7"X0',L%>:U;X
MB)-/GUWXE<OH.X5?&1%[C_[YORWJ$!(*:J<'F78Y4L8'89L)7::X)_%2BG+=
M*8E#AS>D\R<Z"?$_7FMIW195&R\V,#?*N>IN<B'ST>8HY^4<"=XR:!B*&V_Q
M&*L4X2G-^Z0\N<5D<">KI+[R\PL]GPRW.*V6T:<ZZ@MEFP>^9!8?4N3XD=W?
MYXD/%Z5EQSNQZ'9&H\)68RI^1_:$F-,;'8;M5V+<^\:M6_9#4'X]N-BVY^EA
MR"G3DT.81#K6.^):PE,C_S.H.RC,5-JT!)G/B<R@G;'&'[PPC7=9:(5@HZSI
M!:6<WO4U=#]"1/8+ZQS]=B2>Y)GS_/:9CWXS8#B\\[)L1/YD:&5J@6=:C"/S
MK+:AZO5GYVZ%94(^QDBRJJD=Q56=0.-'KA]^OQJ1L3:PO1&!0^,E=K=-[0G.
M\/8T5KB$N4)U4AO_/4-T"^,;"XNE7M/'00''$KI<;V6!6YL3>5C5\N5';[X=
M.(!<<5=47.Q')4CWRB[_);_:GM%\7X)-^,12@:(E/3+#,>%YU787B!OT^/#%
M/-],SW_\Z]95J5@;;F1/D5=X]#7CG1X&$(T4$/?06&O$-(1\OH5,G[U88-B]
M98Z/;V='-%])7S 2#/2ML(N[)\+!+^FJ]@\%>*_ QW<6]5F5! EP(TE$Q9$W
MB.AU?-K-U!?J_)*CY !-+M.U[/[4<((XO+^F:MN%\, ;,E\8_MN3E<\1ZY#Q
MN+:AAU/1[EO,)M>=)=%!9H0M@DE=\!7(]> "KX0YL*0,LS5KON%_ALH)GNNT
M=3?R78LPN9+8%C+SWR=&\U?Q>8M%,5-9#9M0AF8_F?3$)B-?5;$J0Q99?F4F
M'18MS6'/;<(D+!Y7^7R[Q(E9**>H;?=8$BXQ9EL-OZ\^N"O3>;F0[N@?4A91
M@@#Q8Q@GBWHOK)P.-)/YP\7KDX>Z+;J,U<(YJ 0=+9(\^91-^LT^T$.0L H8
M4?C,TS>OU1F(UZ8_]?"4+#+&A"K3/)VNRA;Y>IIJ&@/WE>G"?4$?>UN]GNOR
MFT2'M1MF$K5MCEFJ=R,AY= /<&H'69CW8CN9'>O_[39/BOGH]A:;[0>5A/$X
M'<!+C K6O;LM!'JJE90#=5BMB;3$5RQ(0QY4OP;[%6_/),TJ3?**<[/.YK;H
M[UM=10F'T2_W6U6SVH[2/=W]?3U6= NOB3O8?44^>?E"CW/CH?\;W@\;]:[<
MAGOW*4!DU8:/B?N:S'P[N0;QE61&? QF< #4%AK,*_QPM?TAQ+A:I?E5LO_*
MK^SS%"#QTUU<3&8>TWY,J/#-11A>=?K(%%M^;4P2)]D:E9_+^?"/:/0W]KB6
M;;GFZZJ"G]S_L/<AY ],2_0#BMGQRQ+[>@>D1RKV"7-=,BCBP%H/^2*.E )=
MT\'/@RGI+P/>7V$23TUFR2!]]K-SYDJ.25_<I2__.BN<-S\6F]'"/C!I[=H)
M8/5I/%2H3Y(S*M-HE@N>NLMHDQV^=JBV2F\?0R9<MM;!B;I)2D,Y2>;YPD(I
M $\=7^&&Z2NQT(=.Z)(-65:GIZWNN-BT^!A\D5?1_$[#&"D0A:FG .6\6](Y
M$Y,="T[(,&'ZJF;=^0&._F.#'SXP_'&U2O(9;IW'^38"X3>JN.=M\#RNEA.Z
M^SYZVL?;>!FC6M94S=HGT77C)Y!13^Y]")'3@LS0@JTB,WABR7I@V4,K)BU$
M*XK[V[3P[F0^'G8/J+,)3Y>ZS9'-)\)6L#<^G(!-P!Y>'O'(S>:3'KZU9ARU
MV,?KP66@^>*QZ3P87. M1!%;?W?@6+_?)8=FC^]D_<N=/OX2YRA YU@2"33G
M1UE_'VK6;H\XB$\#DVZ;KIWVW_>GD5/D/RA;Y(D"- 1V=-4!<:K-#??M0--"
MGL)#_RS='%@^30T&+U[)'@Q&J*"P7DG$'TE-D*.'4HB#]=SQ SM8OPM1:)D"
M7!'':I/B]2 D5<>*PV]@A1<5)_/X/!T@E!UJ+SMS&<"*(2*>%*!LEYB$HJ8
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MNK,,JWPA&-?Q-,,2QM?_&Y,2O82Z^RSXH9R:?"7#1)6YIXYF4[G!I#=QI*^
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MT?"$;T6G\IZ3D]"'EM9INV=%5#X)]XJ6&#!A*N+=B>3=&NIV>TAG,X61UHY
M$@&/:[:G$%OV59B6GU!'Z*&:212$;+V62D77L[1 "=;@\8GF^Z[EY,5YUF@(
M\5!^2X])]$)DA^_!];!!'S2?[]V/L'SS QX1G<=498P?]!]->>!DH/3?0K"
MK3)CO_L$:.2S8?F7I4G^L);UTVU2I[\?@=+J:S8?.3-5%G5*2]*]!W0T%9C
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M?V7?7<,MN-&^0=?[M8] O_;8:,/8=F2#\5(YSVK/$>A[]F&JW4>Y9[8[U#_
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M+W03@$2IW6C"?U4D+Y'>&9&?%A]\2B) [N \H.M]Z'8(H3F58 J&(*_][-E
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M($]>""W4NU8\,VFIA^% QLH83JRY<Z J\:+-8)P@%*_P,!"FB5(FV\V!(XY
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M9W:*6OFK\A>8H0/7ZIF7&1JEQ/6==G)(CYRQ6>P!Q;4@^D;B*<*X_)?0H^&
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MXK8USME:Q.$1LQQ_3&CGE&5I26W&ZJP#G& :)"_%?JLC&'CW.)5PI6#[#**
M<*V@*R^@U_GJ5&-2N\')FG[6VOV.K%6[]-4?J]S).4-<'4\J.H7H'N*G.JX@
M[I!?PZ[JX>*.Z@E@[%!.UL)B-^7Z6%"8ZV,>%Y.(KR77C$4 _UQ(OW6, /)%
MEUQ3N?LTT<P<<J>E--"\6MQ&,>,7XCOEI^R>(>4\EIQ51D@BBA$DL:4%OJ[O
M,!TU1S<S8@>R7> K'_PUG_OQM)RG E 'PS"DK0H^ \,;1]$A2>-YHR.M'PF5
M81:Y'YB6;ERD<5SN:MK=)G;<YQ_6<3*=G%]Y"%FV*:%:5@JR6^U1JO#G1U]R
M91JE+:- V.C$$R4*<QB-$4OX.-(%X%'.1!L/EO&Z[P%+602"=;-42[?&[HG/
M4\-_GOPNOQ9E_G>%CZ\C #&/(R0&_:EHR,-.CNM<+-&X;<8U?]8SU*3_,O)9
MI"&DRN-F:4GAQI1\Q^Q)]\IVC<\<O:O8;3XS)C[ZIZ9NH_8-N?6B/N9;N04D
M;O#1BZF#Q=J%R&#"MS#W5V$70J<MTK5<A .'4UZDED35TFQ" \E] HC9LJVL
M]IINB?VX!&78N!DQ'.$_;AHB!O7Q5U-*_]XEYR"P#(AP0]W8W$ 0KASWKI_F
M;W79Z9S=&/^V/!"$51Y%1BZ&4Z2O646V[4V+A ?\.&<:QM=T_OUGE2(S:37>
MNBW$B>#;FV/6Z.63HI-9A ZYG IP S)29A;/M.GCU@8N^WLY"^+%:V-=_XBW
MQK1H8*&8=#7FC9Z/SDM7V\\EDE0OO!$KXW5K-)P;E*Y4(I!I:BCM-.&X[?1&
M;YS\$1')B]VTNZ[<6IJ^U#.[99[FB;"+[?X:5_CUPZ?TJR$& RUUFI%$\"^U
M[48B>Z3VOU(4V3IP[+T^ EZ7GPRO_9KOC6P=EEC^APN[<(\KG35MWL[8AK5*
ME^()1W^"X^X@DH1QIF!N9R]>&UZ=&X0G>^R?"4@04N+29 *+X&\7B5GSSK^H
MX%_\3BG6<$<,1;+D56)1?&0CD"D\[&_4 EC\K:M_X=\_F\)?"3]H7DB-5H9E
M5X?Z5(< (98-W#/;7_YA8ZKX+31PLUG.]\H(@W>\'GOG]&C^N7_-,9XL8%=V
M_3Q.T0RE0 (O67Y:9+M[7Q%T,O221H'XXW7 .D!8?M3Q\'.#+/PRLW,Y\/L8
M3X4>VB=<:1ZF0*.1&<H#FCI5[Q!:OZ36ZV31C[$3K[O\>^K(O_R'GNX%,9^)
M%-LR0=GN3X4UR<Q6V7)2GQ!BV<O2$V_FE^<.F:7*&\@Z2[:HZ*DIIIJ:FN('
M'V/%Y,5J!I@KBM+_M^( "T;(H2V%;9&V54E'V!1,<XRB&GEOG#E2#C>_F%?D
M><R22K@K_\@O>A!V6&RFXXT7K?EA923;0/M[3=KNZG/7^K0-C0AI1'W/8Y@0
MKF*K]3/.NSG.?+)%\=WH<37F,!YKLQ[Y60>Z0*;K.=+A'I53'KX^.&TV[GWU
M@5RU3^&#C\AD QY.;D %H!/PT';MMTF?^2OG"_0["RDF9>G[^W_&G3IBY ;G
MO*I=UU'?OU0V/CT'0)^9I7%AF+U8 _X_DDY%%OV/?*K(G?\_R//_=,D^)U=J
M\03A98^<"!F8.>GD]E44QL?2-/I^R2M_4\]K7C/T%Z([T9Q.ASS5S&,E%BHN
M;?:0Y1UWF]QR!C,'%6@;Q>AAM$GYF%1:<;H!<WQ1@((6@,$?<G*-' UC#(52
MF&CFGGX+V8:OGNQ(4*DN"DWMFZXIR=4LMP[@8&;1-.AP9*Y,_][V#[@@FL9W
M($%\>)S&L(=:/I!J#W\]-/S%S>631E0.DT-$^AB?\M=I4;8]Q7NWOO8^T.+,
MCZ&<UR4WSSG@KV?CY'NF%]?#P=F5H<6]BYO7+_DV-3YFOZ.W6O=:5_&V/S,G
M>)3D]"K2]"W&GY45%3Q6:5Z3YO4G_->)L_D63+0G%'0(ITOXX>='QOJ^O[ Q
M7O]7M=WG(BP1U@O&W5^,$T8>QP55[IZ9]S)6B]NAYYVZG-<R-]]=Y3"8[54?
M(_#N4CE;/N,5HZL=9VGB<9I$_)[B#<9UM%UYM"^9#<$2/42)/2]BB73C*RDT
M^.LX5W^9=*HT0V"S-\NVQ(F@=9AJ_7Z-<C#PT;2W*!!/0R-7A![ODSQN?XU+
MS56A1[^&%P_+6^*F!T9>/IUW:"K @IA"6TW/O_B4-7>_(5_GA5#%UQF1$_1T
M_UJ8#XQAQ-/ELUHF4T@$HO$<\=!L/K]:Z<_>^RBA:X,RCQ2"K5W:6X#URJV!
MX<<.RG IE:W%SW%;EECH'.KHV7@D[P>QK*-(Q\W+'U,#[4W?BFA5;PQ<,0_(
M<J-[GJ[SGEP.1"_"7\$ND NA#8NQX=Q"XCBALI!5S_ WN25M#&;/Y\C6@X,;
MQ,)O9],<PC^)KHHS;$R3+D"/Z'_"T07P^D-D[-:KFW$)0;>1^5<G,\V@.TU+
M7NYIK"XR20-\C]4TW0_R9?":\MTK7DUV%BJR5LX;IFK\.\LM*K]V3NS7NI_N
M I9D5\_G/S+MSU3;U7Y3/29?$67_*VSF4/[7,5HX%N@F_^*RY'.2<%E-WH?U
M^V$WRNS$78:&1.'<*;WU:OX@W>?@,Z>6$HAN1L+KCGOM.@1($G&&DUJFI:\@
MN>U;;MC%>Z\/FA+.G%FERW8;++V->1=\6C<9/0[OLG0A)U'XD=&1?%$LD??Q
M^K5,5U57<>3*)_Q9@B6^=VX= #7HI=@(5\(B5(O"5/IZZT!^3U>-7=.2M%Z9
MF7"%B>4;J^ 6!)[R'KW/#WI?XV&,Y)$E;N]*A]C.M4ZN-Y[L:"P);Q&J$-<B
MZXV=*B,JBVW=H<T^E>-')A0F=YKOM#$!TXBT:"3 \45$=A!J*N_1J,JFD6F5
MI2/7/W..$G<K-21=:D9;F0V_L\%*;/> 8!K:OP,FR+9$!HTI4P$O@%R'MSI4
MQ[&<'O:-$\_@T#M%_S!HN:WP?M10E!I98 C.%P_U8U46@KRY_1,LP O:U0^F
MN(Y'(;P)["GB\=E',%?-81)7%+R%1-1IA4(HV:>].8U/T/\I;>#,8"24< 4#
MGM7#V#2B"_@]FF BN(%XN>'&P^3!%3'+KR*'MA9TLN6L51^B&<^ALG<)UU))
MG*U]8)S);B+*NY[H'J]S@1"-B7U9\V;(06$H*F77H_O'!P$U%IGHH6C!"R=5
M-;9+\"YV9LHH%<#<B* GS.G7XQEBM71]?1!5OK;25_-U&2I:7O,Y_2N)[AGD
M]]?]P>8@A^J'Q^"*_7\ENEUQ+UH?P6:U %^ &4FF^$VL\W\$V]3^4[!->-0*
M8)<3;VWM]IB;"_CX7YG*^0LB&5C3W@(VBIQ'$H8_8:B'(;ZJY/++5W>X.-I$
MBK?.G]O2?VW<;\"^+DGBTJ,P?D3+$\0+XJ!!4@B&9!UQB/E?-8KXEP:.J'S6
MF"/( Z1:!J?(1<TDH\Z+ZE;Z9!;^_@>7 S5PN[E05[<.*@!$\%U[;BB)D'G?
MR),-WU.D:90D.$Y_A)6VDQL4OF2(_46=JX0>K.S#W!]U22URJDJQJJJNL38B
MMQ8(;+)2DLR<%W9H-G70+[3E2VY-HWL8<'-'IS13:CSZ!4\ZS:8T#_\?T1/9
M[RA(P>Q(-[#6O4O0<L!9L=6CZMJME-DI 96ILJ>+&]L8"X.UQSJ)'VD4$?.)
M[9GLM4YFYO1_DVLL-Q<A*C-9/EHFTVAOGM@*?9+V#=YUFPJ CK# NX ZC""L
M$V1H(FAS^Z>'_=5[7#XV:)<-&[&O[I&"10#7'"N* XDFF3&9,/D_!=QR\EIV
M&)K-W<B_D+Y$5C+[7)\^NZINO/8MLP2:%YZ,B7%AX/NMHT&NAWM#>6&_@0(J
M[/RA+4M<IL1W;#J2+I#B.?9F^EM'@G8M]1==OB$D$1LZO+AZN>X54DZ)BD7#
M=!L5D$46]:F>]UK,3%VCB.#9!<'\P]FFW6^"*<?O4+#YMAVX#>V<Z2B'0H]B
M"0Z%A*'NFV_"D7&'FWX!GD^?E8O@K-_LU50QU^5;/V<H@5G2.!%!8TOF)H:8
MK+>$[)E7Z1AX2H$F'<P%?GW^;> H6FJ]RF_U>2<0>'LY\@_-!OJ?=LV:IW2C
M>( 8?KQ<+U*8A63MCYJ5,E$[4NDZH[_EI=3_3U7B.;M;HF\ % H5T%L_X,Q+
M!63+.1A,R<%_Y2\<+5B1K$='V[L8QE!2_9B \V='1.V35^XZ!+^7KP(?9Z.W
M9>UFR/PL\5U^OO?_6(]!8+C,AO0]>&(+,'WC<'<FX.@6GF&[BZB_#J/_F8E)
MW-#5*8<CI4OMK@@%;L^)//U 7GOBK)1V.+!-,T[TYPG9:%#*,1)^CJ0FF:3%
M4O-]^F(PWKF+IS_^N[]/,5>+;[*QIH#[,D#CM^)B40'.&$B0%$>0+A#1?''6
M)@Z(>!VI7P%8EB_Q07%\>]NBOOA^IF\423=MU><G:URA.=F/]N#5*Y/<&Q,V
MKWP1%X_]'6J<1T(@GN5_F_0ZU6>;"R;Q$[\]NQ;,9HWEWH =_GHC(K39/^@(
M$=B[4?4,77*:NF-3B[=QJ=$'*.G+GC>RFGY^E!=+"7]_+B3@FWC"!F20"G@B
M3)!&=@O/%?6%K\61&*J=YKU:KAE@'4R($HWI&W-/];3N+H;?^/YAC;5U6D91
M=@E.4,^F,'-H\:()'6=#;0@UU8C>['RI?*8;4TUA\SRENI@2$:74OZO<'#:6
MX*S%VL5MC2K80$%#R$N*R'KK\KO;+6Q!7@(5B[.H;UIL6_@LP'M,4Y/B61BD
M)Y_/>KC.JSE?PL*ZPFG<=K%Z)0JL.6?MN@L)V-G_H566[?9F[T3![(UW*3',
M8#:B,HKHZ3*%0B.H@-I+Y 2@MZ"#V=AVKC!#Z"?5Q@\<'PSI+13VY6(!=-\R
M_)]/&+A(9H"?T.2QFG*I#41PG!TWL 5E$"4&-=A)#9FPJ1T&8L57$'%IH>,T
M^6D ]J,%3.)FIS"ME9%T<8[PN9MEL3X7^FZR_I3X [TFGFR_R@&0E..P4SUO
M,E=XDOB3=D2C.AB W?($R?SL2B>';]"HI6&+-2<_D9XP#8=0.%I"G2[54VFA
M_=Y2$J6U<R?K"DUV<Y6+\X^35EN=_5(0[3]8D;&P\K[$ZK/$&CNKY*9)_\8]
M_]'@VN/3=A8Q!36G%0S_=L%@\"XX')W><DSBWD3OQES78B"GLO?*G_6R8 F9
MJ+%?8$G6P0#R)5S9]IFN/I]X[1='QY\,>S[J]$#+U5'.8[IP6VK+W?Z55]=X
M_G>:[XCE'IDMHI0C*=SL5$"_!\U?LP1ZI9Z4+A+N ZD /L0?K\03T.&T(F5W
M_K3!,[SVZ0(\C#1&.XG2!8V&9$LH24J8"G@UO6U(X@RAT<_OM)"-'*]<0+\)
M_C4>.F+5_F4JTC#@R:J1:\OK%W<,12X^0*=P_P"(VSWCK]R4D?WQ_4L27TK)
M%J1Q*&*]*O!1W8FR^,AI>T@$X\Y_U#9@X!ZH7V6=J$9$=[5A%Y S4JF44-9C
M7XAU<&C42&XUYD[4Z[M*!;"FU=4=76VMD/FH<?NN>3#D4ZZI7<$+820OZ;(V
MXL_-O*E:(I#0/V([_L3M=6A('Q<Y?^?,ON#G^<*_-#W$_%QFX/FW8)6_C?AZ
M"I,ET9 RPENGAQVA(7".:TOQ%R,J3:4/^57H$"?ZR!QV"A \(\YS.'-=><#<
ML=%'9:V(.+V1*M-D>ML7WQ:E"HQW<M=OP^V4J:1\] QR"?.=<T5^22C,$IUF
MK3K#L&F?3T>PPZ8FAM0YA+KTA!_'[UR5$9*3!V7A?S8%1XM:& 0W:0<7Z('G
M5'@V=(#9U]^H4 $TK0<Y>8^:D3D9 8$(DGM^Q-,$%D:@%V+V]NIHP^*+EN.X
MP,W2'B\AR;G"GG^6D[<R,G.R4]')"?0<C*LH$/Q1 4&YK*L#T%P[K:,56@<2
M  \T&>*.7CRI'YO\K%CG*%A/._4[C '/W^_)'LDDXOU^/WK[F/?:Y6C*#A40
M,;U3^TM/JF<\!+:_3W,2&3 %W;MLI$LX@P(,@G'='A1+ I887&D8/YBS0B*1
MYK_,;PD<2I9KO<^=F6B8BW(W^U)_&B,<VU"-#970%0L0_8?/#L1:S,6HQ>'E
M);OR_EU(1'Y9&H'F)IR]2SM<MKXJ[7 K/&IK7.75U>W9U:7.V9=?D2FJ(NG7
MK@NOW'>X%.MF[33 =98Y9D]MJ6Q+"9]QY(YJC1E L6KY88)JQ8P#(HKO-3TY
M;R+>:7D!031:CI@^<M*/@H'[0[]K\=PLMS+I2-W=W+?=UWIE #(H6DUMH0+8
MOU"$-L>U>(D722Z$UX8D4113AP1DK@7N'NI\L@D\WA'=D"6J%[;+O(]2PYF;
M3-F2.8<%8H%>\#C2A4Z:U<N"L>,E>U $2=LNU'E"JV$'C@I(T )B(DP5B:"V
M5X;:E9WY]VT [P4_L=<PCJCLOC$'T]D7E5M8"]LL+D2,IEZSLM7+)$SC]+KA
M#= >;=NN#O6?@;M<!'?[^)Z01Q%"A&7!MT(5&V&V%GQ&]!P&$-SN$4VIQ-QK
ML\-$.=S',VP=8EG %SSV>'.TY&M^5]<4^4S$?VCQUKLQ0C>LP*&0%9"%6-B0
M_3D4\,KF'\>9,(]CD!4%7#&QUHO^8VOSJ2,*M)1]VNHE=6FQD\T& N2-%":\
M+%9I/E-V4VQ_5M7LW%S\9"$L=+!YM<T&]>6N[*:GW^$=5)B^VHHL[-6>Z^M^
MRA85<%I'2+(FT!V%T?RUOE#1C.X%!GQ<@LN[JVIC#9!W?9&JXS&759_^]EM,
M/*8!\$6<'G1V:$F[L>T$U,5^Z4'/4YCMU)0@]Z=YI#A42((.968H*LI#]AJU
MLUGZKD?AD4+8+/[E98W-)10O8BANPCU200[PV 6A5.?DQ].BXW(T!/[:B M]
MI\.#5=U;9\?P'%*JL(-M8R>B+)<RB:J3[%F<<\$(KD7#Q C^([WV@J,+T;IU
M$=)/;^4R&0YSQTBR%C\UTJ"/(=@2 VEGZQ.<!\;EQ9N+[!*TG\9"XW3G+V9&
M:=E<7F;I['?P:9OYFX(>K:7[1S&<"M";L$5DKKUMHR/W-FSDE], RN" A.S9
MNRUD[#3*DC!,Z"*RDYZ0"W:@HGA$]Z)PJ*MW2-CXXKJM@@/@0]8CU1&YUV<E
M_6L=_PE(W)NE8*00E64#XR;';RQA%LCU$1D[5NC."$V<HE.Q2YWP.F0?>^)3
M/<E8'7["<:_?;YDV4 D!MH-WM>&S*%6?$TG1%81L"L\441BKB0["*<YG\'G9
M7:E<GJH=@M.!Y"??JH=]BMM,Z/'#WVT5!Z[#0*U(C:5$2LFG&F^0X&,9_6YN
M+*(4"5^&@$3+>,.,49U2A8D$ESEF1,4?FY:==W[N43[0,/<@OD0/R5?& E\-
MF.O>Q](_U45/)DK1[0./:( UQJF#'C9VG)T[W?-77N<\(7TI,E9;@M.O</A*
M/XN=@M#]2YT/A%3X)#W5$4.[LWH4MFCRIP[&Q>\4@=% X839N\U[.X%L9NIE
MOV;:V[\E](17P=S8_340?_H33[38>=S470=+OK>:@ ?@O?N;*Z'A+;,C0R "
M [YHB0J8 2VY=[<V?\1+=@LGY(K>6N%#:"F%<3^)>57Y]NBSY"49(XU+DE?;
M:CR<%]Q2]#V67V6Z/HJUN!DM2XPN;#^)C#*7AR7"TFDTU[%CA7VG*06"))X?
M SX'$;HYD3NB-Q8D]QAO.>QQS<<9>RN'SL^*?NE:D4YQ^'1S),W^1)M1QE "
M.R3$^4A.0K(B/F&W(2QPSB7_;>ZRH3!%NP_^D-MJ:FECA&!E<>A#,>81B&7!
MOB-64]SW>XBR\*YB%)^.Z! D"N_0E\]'@)1^,<SJ_TH%^'C%O&][8C#D&R?
M8%<,H *8Z JF=F<D*8Q('"^%:?FGES,[KGE*"RSP2+AW=K]ZIR1_5;3!$%IP
M\CC>")T!?F .5GGK=U[S4K/7C]&M!O JQ2<_2UC^H^$#N8CV4T/+L75J9!5T
MQ-=MA:0)?EBVZQ/2+32MG?1 3[#"">OJF-\C%@#^P4"ZG4.T@D^J4@'=SZD
MPC#<Q,JVEB;U[]N-'VWOVA_;SE(!J_Z//UOA+Q[EL:]F4Z[<(U< -][!,;>H
M ));*N&ETM$G*J#"APIX24<%X',I69\0#N2@[ZC68WB7!O!?T.)O$A5P;H]V
M^B1TKL&[%-OT\/9K6#!)5 ?\JOK@2P,5L)5W9UY@KG$T V8>3 74W L:T58
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M<L"W2#=2?Z5J <BJ!AX9) =MZ4?2!SPX82%=P@"CE(RD'9RLG-R["J:0^*>
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M-YH&3V!H#_)*_U2:'*"64#@)\([<DD7<&$EVF*!(3\ ,'>IHD,GEY51YX#F
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MF)[_6G_=U'[Y89W(YI9^H7EF@;&P?E*%WLOA6>F V=O#!3+&R4X77</?DM)
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M-;=JB]#WR(4DD77_S*_;.\L9C@Q";PQV=Z>-F#YH"W[CKCPCC/^GO>_;/>:
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M6Z@">.6BH0N%\_2K<=[JN6U%3JR<66$LC)WY;N< 9;Z$LH>H?^< ]5%<USF
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M=I^U)BU72;"W/CCU3<.CQ=O[:Q?I2TPC<% ;^.TU3I$_C]OT=2[11 J_XGX
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MPP[>KA=Y[(689Y*X.^M@_[2?/FSI=? O3:,R4TZED#NJ0A$<9%:1>P"_]2>
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M&[;[%"7))P_<_Y(R&>DB><1Z3FGU/N:M5/"WJVQSUZ/@1GXTW$PB'HNG*S6
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MI>Z:6R5QO'ZJ;E"_$2MRO*NT(Z&\I@NBR._0=[3UWGJ&J(H*[S[; 0=V<B5
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MK9LXBNER/OD1'V<\\^7S-DP0:,W+@>PM [_%EK^?0'5DAE=B6<\A6__C2"[
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MG\#]W<>;JYOK!S?F.&DH[8BFKP$*S$MUD^*9 FU#JE[&+5/ VA:P- 9\,>:
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M2J=\3"?KR.O+W\?EJ."X2'$L($K2%&*!,&0\93!/L:(XCO-<.97;V2-G:'/
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MYU_I=/P_5>SEE>:GV60LZD#,J;C7KY865/W8ROQ=90,[UW3T(6M 7TO;GJI
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M>@+>5_I$:'7[S;/H"?RMA(R^Y/9;\;K<4S:U)J(\)6G$"@&3 IM46%1 *K"
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MF'DQ?0W28FX&>M].335Z)U^MXJ.9 8?-D)O?'!WWR*:]TK]U'V.^^DFEI6V
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M.V=#OOC4P,@0VWZV_]ETJV_LT0:<[E?RX^?U9O>@-E]:<:@%2W7).62@1$0
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M\2[18BI_ZXNX"2;&X3)O"BV&DK]47"?OV6;WH]5QZO[[<KL@+.>*\APPD5*
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M]F.0"Z2+\(^Z4!H+ZJTNF+;)4?'DMRC9< ,0BWL%=5'R'*ZD^B!QO*+J?<7
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M4DL"5DH(N,P0SA!!##JUL.V1,3=S<& !K/5,K*))I:D_2^(IG/UF(!!(D2W
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M%"GL56U* %$L SH3DD&2Z4*7_J2+H8"_*4]B,P=Q<,<93Y'($"@+\P7'5):
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M[Z^+IM8KAT]\0)^X"5""*B2QH" :H\![Q8)F7"5L'5UM3-RX9<"# 6T8Y72
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ME_>_=3'7(J+RG-E""U(X6I"Z0%#:@^2,Q]KH0J;6_5U;TC^RJ6L!J'DGVNT
MV<_FB\_S!7FNO\PK\Y?^R\7P%).,QN(HCDNU*XO4L7;+LL <N7^.D14PK??8
M1PD:%WOCX>1.N_562NL @;^=S=8#U4\K,Y<\H(M>U''I4NI:ME$4^"R()11<
M&)Z2D-@8>/?1,>Z!7C=XVUM%'<#L7@?GU77K5"F80LO 1L%!*1G!2YL ,5D7
M'2M9-._J_RA%O8Q::NH.-E1"!Y"Z?4_DUBV23_/%:OK?M8/'<K6NJYPHRVU(
MP0")*(/B7$ (S ,J1W(K(5K7VO/;EL8.HY =\3$_H+)V!^-\%4X/ <;K"=:_
M+N;+Y>^S!8;3RG!-GOY2$UCX/OPY<=)DG2QM"SI(,NI.0Y!*00I2(-<F!=XZ
M'&Y">(?6\B"P'4"M_1O6!YFNAP#73".R$@(JB.@1E#42O!8%4K:Z"",5FEZP
M_ WAXQ;M=(CEW=7:^C2G':1O'A7<E$(]L$]>$5-6YD#N%0;P(GK(C@M76,JI
MM(Y\-J5MW#J= P*SB7)^F(L$YS>)PKTWB<+J^NSAL&>'6U(USJ'A/J([Q&EA
MRN086)Z *R1;FL@O<*K6\V)VJB27O&L]X.D@/6/VN/QV'N0:9T)69$VB-!3D
M)NW ::4!B\M&^L"#=D,)9E_B.SZ+W 9O0]QLW%ZY'7C#5XS_\O7JUW^9XH*(
M^OCU%7[!T_4)B'%*>99JY\]ZTXT5"8''5'._PN@0<LB#K>5'*>L$CX>%S4/@
M;:?#GI!Y(<>U2W:7OXL,M/<645@)$LDY4\&1XRY< !,*&07C2PF#V=1-".P$
MIPT1\A (FZNK)RRN6SPLUQ+C%T<5C)9N"B6#-/5P.$0'WF4!*%!BD-HY'*Q;
MW%UR.L%9>Q \!+<]-=(IN,0%*]+&Z&S=%E!1X*E+A! *!U0IJ!(+1:*#F;6[
MY'1R!7$4<.VBD4[!)2_/\ITMU@L%3-<A99F1I3>!1%1\-DHZK^Q@Y9QWR>GD
M.N$HX-I%(SV!:P_W]SK)ACS4X0((#&LOT2P$!,T\I"R4RE:;)'ML!M3)H7IG
MH<C!$='!<CCG^9X<Q76Y-$\QQ,0A^EP[?Z_O7]+Z5MXE9HI56;5NP/E=HCKQ
M& \/F-MY^J;:ZP&.FQX\8$J><<GK( T+2@4%OMZOHX4NA"RLCGGN^51HN![^
M;2&QZ\'0-OK9XU!RU01U-Y;O8X(K67(N? +CG"(W6B0(R!-HGCE+Q%*RK:/F
MS2A[^KMX&W,X@!X[L(F/7F>O8T*92K2Z8C&@!'H(#"/HB"AY$BRXUA-=]NXH
M,)CM&T+_V_06V$89/\QI^*70OUZ?XUZ.*,UCG85O1=,X)^&[B^T@MV8=1R>M
MA*R-K<F" I&9VA4M^F2EBMD-EL,;\AR\07?D=;PILRH>RWIITTHWUD T9$*8
MLK48W*#'UCU06_/020RU+_J&;(2]M:H[\!9N')M=F9AUXZ7U:1GW02?#(W"^
M3M9E3GN55!!$D$X6JZT?K 7G?01U L)1L/+PB?B>BNL)A?M+]K8X+M+9RA>3
M??9@=>2@9/0DZN(@YABLT\Y'H?JUP/<SU<EJV!^ P]GD!FCH8'E<M^.Y[X+B
M-U(ZOUIHK64RBCH0D82?2@+GI(0837"N" HZVO?VVHK$3J#;!\ >')K>7ML=
M@+FA\*_30")Z9%$Y8#(Q4$Y4<Z.0-E89+879"57K_.X0?'22F>O*OQD+)CTM
ME1LG]G^=KC[>X7?Y+</+M[>RI1<6:OU=$Q<Q8>U@1%MQJN-R-01>-' K;9(I
M8="#'4*W9.2'V4-VQ.<&U8F'!<O.*^8S[7CS_&X5%FT.:'85Q0.26'?_7TZ2
MDJB]R2 B0U#(+2F',T*[R5HR$U3S1OF#,/+#;#+CKIMV8'G".\T#0KCL*/IR
MED[/<IV<<1P6,_K8<F(]*\)*K/<,,P6&,D"HT:&)H@AMM,#0^2IZF+E.ZOM^
MT)75"%3]W&D>9L=F(:?,(]D;72CT=$E!M%)#"J9D5GC6OO41[WCNW?!3#9[Z
M8FH'ECW=N^-9[N@8^CK)<OMDM0KV7) '/H7>AJ1Q#J%W%MI!IMZ[:*0N"%)Z
M!4IP! *QHA^6EIRJXQH&<RPZO8O]T"#2">>.5K=D@%YCK>F3$#EAUQ9;/%<I
M,MGC]>R'^.DD$[ O*@\YBW8K"'00H-RV,[5AX_E!$\=26,U^*UL#+2$@RN*
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M& 7T"Z_+)7/9V7NB/0LNU I%%VP=LD-L22/!1)70II)IDV^$J]O/'K=$]&"
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M]WC[!VN9"!;ZRU_=D-TU4V+ +Y#7 ^E2<>B/N+L@P+N#K+C7Z[77*J'FOKI
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MN<I':U7N=._ZO3>]SD6_=W--;MZ0V[O>=:=W>W%%NK]W.^_ZO=^Z\!HDNG<
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M>0;C!1%+$E&41R0MZC#,(A,.Y8+"BX,3U[4[?;[,2;;1(Z=S5(>8PX(*.ML
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M,#(R,#8S,%]P<F4N>&UL4$L! A0#%     @ +4'\5&A[&KK4#P  G6   !X
M             ( !JZ8# &5X,3 R7V1I<F5C=&]R8V]M<&5N<V%T:6]N+FAT
M;5!+ 0(4 Q0    ( "U!_%2-F1[*>0@  +8J   8              "  ;NV
M P!E>#,Q,5]C96\S,#)C97)T<3(R,BYH=&U02P$"% ,4    "  M0?Q4?V*<
M:&\(  #-*@  &               @ %JOP, 97@S,3)?8V9O,S R8V5R='$R
M,C(N:'1M4$L! A0#%     @ +4'\5"INA./P!   (A8  !\
M ( !#\@# &5X,S(Q7V-E;W-E8W1I;VXY,#9C97)T<3(R,BYH=&U02P$"% ,4
M    "  M0?Q4#S25X><$   3%@  'P              @ $\S0, 97@S,C)?
M8V9O<V5C=&EO;CDP-F-E<G1Q,C(R+FAT;5!+!08     #  , '8#  !@T@,
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
